<SEC-DOCUMENT>0001104659-12-037471.txt : 20120515
<SEC-HEADER>0001104659-12-037471.hdr.sgml : 20120515
<ACCEPTANCE-DATETIME>20120515160249
ACCESSION NUMBER:		0001104659-12-037471
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120515
DATE AS OF CHANGE:		20120515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		12844508

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a12-9682_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended March&nbsp;31, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission file number 0-50626</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91-1707622</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other Jurisdiction<br> &nbsp;of Incorporation or Organization)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer<br> &nbsp;Identification No.)</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">200 Connell Drive, Suite&nbsp;1500</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Berkeley Heights, New Jersey</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">07922</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: (<b>908) 517-7330</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days. Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;"> No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;"> No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller reporting filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Do not check if a smaller reporting company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act). Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of May&nbsp;15, 2011 there were 59,003,301 shares of the registrant&#146;s common stock outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105627\12-9682-1\task5352916\9682-1-ba-01.htm',USER='105627',CD='May 14 20:19 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX</font></b><a name="TableOfContents"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="75%" valign="bottom" style="padding:0in 0in 0in 0in;width:75.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="75%" valign="bottom" style="padding:0in 0in 0in 0in;width:75.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="8%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:8.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Parti_FinancialInformation_081451">Part&nbsp;I.</a></font></p>    </td>
<td width="84%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Parti_FinancialInformation_081451">Financial   Information</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements__081452">Item 1.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements__081452">Financial   Statements (Unaudited)</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_074435">Item 2.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_074435">Management&#146;s   Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_072931">Item 3.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_072931">Quantitative   and Qualitative Disclosures About Market Risk</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_072945">Item 4.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_072945">Controls and   Procedures</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Partii_OtherInformation_072958">Part&nbsp;II.</a></font></p>    </td>
<td width="84%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Partii_OtherInformation_072958">Other Information</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_072959">Item 1.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_072959">Legal Proceedings</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_073003">Item 1A.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_073003">Risk Factors</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_073930">Item 2.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_073930">Unregistered   Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_073931">Item 3.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_073931">Defaults   upon Senior Securities</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_073933">Item 4.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_073933">Mine Safety   Disclosures</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_073934">Item 5.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_073934">Other Information</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_073935">Item 6.</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_073935">Exhibits</a></font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58</font></p>    </td>   </tr>
<tr>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="16%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:16.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Signatures_081127">SIGNATURE   PAGE</a></font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_080124_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105627\12-9682-1\task5352916\9682-1-ba-01.htm',USER='105627',CD='May 14 20:19 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I. FINANCIAL INFORMATION</font></b><a name="Parti_FinancialInformation_081451"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1. Financial Statements.</font></b><a name="Item1_FinancialStatements__081452"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> (A Development Stage Company)<br> CONDENSED CONSOLIDATED BALANCE SHEETS<br> (In $000s, except share amounts)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Unaudited)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ASSETS</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Current assets:</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,449</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,640</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Inventory </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">182</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">109</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,200</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,423</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total current assets</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,831</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,172</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Property, plant and equipment (net) </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">167</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">166</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total assets</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,998</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,338</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#146;   EQUITY</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Current liabilities:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,763</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,116</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued liabilities and other current liabilities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,664</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,504</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Economic rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,153</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liabilities measured at fair value </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total current liabilities</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,498</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,802</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total liabilities</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,498</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,802</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stockholders&#146; equity:</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock, $0.001 par value; 5,000,000   shares authorized at December&nbsp;31, 2011 and March&nbsp;31, 2012;   1,213,142 shares issued and outstanding at December&nbsp;31, 2011 and   March&nbsp;31, 2012. Aggregate preference in liquidation of $13,708,505 and   $13,890,476 at December&nbsp;31, 2011 and March&nbsp;31, 2012, respectively </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock, $0.001 par value; 100,000,000 shares   authorized at December&nbsp;31, 2011 and March&nbsp;31, 2012; 54,220,458 and   58,993,414 shares issued and outstanding at December&nbsp;31, 2011 and   March&nbsp;31, 2012, respectively </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in capital </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">276,452</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">278,430</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated other comprehensive loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">65</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deficit accumulated during the development stage </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(257,064</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(260,019</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total stockholders&#146; equity</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,500</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,536</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total liabilities and   stockholders&#146; equity</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,998</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,338</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_080513_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\jraja\12-9682-1\task5353029\9682-1-ba-03.htm',USER='105337',CD='May 14 21:08 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> &#160;(A Development Stage Company)<br> &#160;CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<br> &#160;(In $000s, except share and per share amounts)<br> &#160;(Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;from<br>   August&nbsp;13,&nbsp;1996<br>   (inception)&nbsp;to<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revenues:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration and research and development revenue   </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,100</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product revenue </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">161</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,182</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,648</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">161</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,930</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating expenses</font></b><font size="2" style="font-size:10.0pt;">:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cost of goods sold </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,846</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,080</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,347</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">187,146</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,806</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,996</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">91,483</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Goodwill and intangible impairment </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,934</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restructuring costs </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,634</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total operating expenses</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,992</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,437</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">291,043</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,800</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,276</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(281,113</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expense):</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Costs associated with aborted 2004 IPO </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,550</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment under guarantee </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,652</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of Economic Rights </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(56</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(56</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of other liabilities measured   at fair value </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,413</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Foreign exchange (losses)/gains</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(68</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">114</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,259</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,731</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,677</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other income (expense)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">153</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,997</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Loss before taxes</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,779</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,123</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(275,116</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Income tax benefit </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">191</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">168</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,612</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net loss</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,588</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,955</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(256,504</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dividends on preferred ordinary shares </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(38,123</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deemed dividend on convertible exchangeable   preferred shares </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,515</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dividend on convertible exchangeable preferred   shares </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(182</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(182</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,839</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net loss applicable to common   shareholders</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,770</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,137</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(301,981</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per share &#151; Basic and diluted </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.10</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.06</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average common shares outstanding </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">46,572,180</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">54,761,620</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_080701_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\jraja\12-9682-1\task5353029\9682-1-ba-03.htm',USER='105337',CD='May 14 21:08 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> &#160;(A Development Stage Company)<br> &#160;CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS<br> &#160;(In $000s, except share and per share amounts)<br> &#160;(Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;from<br>   August&nbsp;13,&nbsp;1996<br>   (inception)&nbsp;to<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Comprehensive loss</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,611</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,947</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">256,439</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_080838_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\jraja\12-9682-1\task5353029\9682-1-ba-03.htm',USER='105337',CD='May 14 21:08 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> (A Development Stage Company)<br> CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br> (In $000s)<br> (Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;from<br>   August&nbsp;13,&nbsp;1996<br>   (inception)&nbsp;to<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash flows from operating   activities:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,588</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,955</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(256,504</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to reconcile net loss to net cash used   in operating activities: </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accretion of interest on notes payable, net of   amortization of debt premium</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of investment premiums, net </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,297</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of Economic Rights </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of other liabilities measured   at fair value </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(78</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(42</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,413</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant re-pricing </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and amortization </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">86</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,570</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of intangible assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">886</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed asset impairment </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">221</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unrealized foreign exchange loss </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,747</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(98</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Compensation for warrants issued to non-employees </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,215</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares issued for IP rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">446</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Gain) loss on disposal of property, plant and   equipment </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(47</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Goodwill and intangibles impairment </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,934</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock based compensation </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">251</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">102</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,125</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Provision for restructuring </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,779</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of issuance costs of Preferred   Ordinary &#147;C&#148; shares </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,517</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Transaction costs on sale of economic rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in operating assets and liabilities: </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses, inventory and other current   assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(126</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(184</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable, accrued liabilities and other   current liabilities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">397</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(807</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,120</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net cash used in operating   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,892</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,771</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(216,890</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing activities:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of ALIGN</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,763</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of property, plant and equipment </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8,846</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from sale of property, plant and   equipment </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">187</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of short-term investments </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(156,657</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Redemptions of short-term investments, net of   maturities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">162,729</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by (used in) investing   activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,350</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financing activities:</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment of capital lease obligations </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,719</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from issuance of ordinary and preferred   ordinary shares, net of issuance costs </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121,678</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from issuance of common stock, warrants   and economic rights, net of issuance costs </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(80</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,911</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94,582</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net proceeds from stock options and warrants   exercised </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">207</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment of preferred stock dividend </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(182</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,898</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Repayment of government loan </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(455</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr height="0">
<td width="415" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_081224_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\jraja\12-9682-1\task5353029\9682-1-ba-03.htm',USER='105337',CD='May 14 21:08 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> (A Development Stage Company)<br> CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(In $000s)<br> (Unaudited)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;from<br>   August&nbsp;13,&nbsp;1996<br>   (inception)&nbsp;to<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government loan received </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">414</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loan received from Cyclacel Group Plc </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,103</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds of committable loan notes issued from   shareholders </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,883</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loans received from shareholders </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,645</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents assumed on stock   purchase </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,915</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Costs associated with stock purchase </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,951</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash (used in) provided by financing   activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(260</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,945</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">246,404</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effect of exchange rate changes on cash and cash   equivalents </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">476</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net increase (decrease) in cash and cash   equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,145</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(809</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,640</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents at beginning of period </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29,495</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,449</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash and cash equivalents at   end of period</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,350</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,640</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,640</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Supplemental disclosure of cash   flows information:</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash received during the period for: </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,751</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxes </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,207</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash paid during the period for: </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,914</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Schedule of non-cash transactions:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acquisitions of equipment purchased through   capital leases </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,470</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of common shares in connection with   license agreements </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">592</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of ordinary shares on conversion of   bridging loan </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,638</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of preferred ordinary &#147;C&#148; shares on   conversion of secured convertible loan notes and accrued interest </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,893</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of ordinary shares in lieu of cash bonus </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">164</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of other long term payable on ALIGN   acquisition </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,122</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="415" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_081311_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\jraja\12-9682-1\task5353029\9682-1-ba-03.htm',USER='105337',CD='May 14 21:08 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.<br> NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.&#160;&#160;&#160;&#160; NATURE OF OPERATIONS AND BASIS OF PRESENTATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Nature of Operations</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel Pharmaceuticals,&nbsp;Inc. (&#145;&#145;Cyclacel&#146;&#146; or the &#145;&#145;Company&#146;&#146;) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel&#146;s clinical development priorities are focused on sapacitabine, an orally available, cell cycle modulating nucleoside analogue.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sapacitabine is being evaluated in the SEAMLESS Phase 3 trial being conducted under a Special Protocol Assessment agreement with the US Food and Drug Administration (&#147;FDA&#148;) for the front-line treatment of acute myeloid leukemia in the elderly and in Phase 2 studies for myelodysplastic syndromes, non-small cell lung cancer (&#147;NSCLC&#148;) and chronic lymphocytic leukemia.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have ongoing clinical programs in development awaiting further data. Once data becomes available and is reviewed, we will determine the feasibility of pursuing further development and/or partnering these assets, including sapacitabine in combination with seliciclib, our second clinical candidate,&#160; and seliciclib in NSCLC and nasopharyngeal cancer (&#147;NPC&#148;). In addition, we market directly in the United States Xclair&#174; Cream for radiation dermatitis and Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia. However, these activities generate a small amount of revenues.&#160; As a development stage enterprise, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. We currently anticipate that our cash and cash equivalents of approximately $23.6 million at March&nbsp;31, 2012 are sufficient to meet our anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials for at least the next twelve months. However, we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The condensed consolidated balance sheet as of March&nbsp;31, 2012, the condensed consolidated statements of operations, comprehensive loss, and cash flows for the three months ended March&nbsp;31, 2012 and 2011 and the period from August&nbsp;13, 1996 (inception) to March&nbsp;31, 2012, and all related disclosures contained in the accompanying notes are unaudited. The condensed consolidated balance sheet as of December&nbsp;31, 2011 is derived from the audited consolidated financial statements included in the 2011 Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission (&#147;SEC&#148;). The condensed consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (&#147;GAAP&#148;) for interim financial information and in accordance with the rules&nbsp;and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the condensed consolidated balance sheet as of March&nbsp;31, 2012, and the results of operations, comprehensive loss and cash flows for the three months ended March&nbsp;31, 2012 and 2011, have been made. The interim results for the three months ended March&nbsp;31, 2012 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2012 or for any other year. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December&nbsp;31, 2011, included in the Company&#146;s Annual Report on Form&nbsp;10-K filed with the SEC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_081624_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-05.htm',USER='105939',CD='May 15 23:46 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sale of Common Stock and Economic Rights</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses involving specified Cyclacel intellectual property and for general corporate purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&#146;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&#146;s common stock for the period ending on Wednesday, March&nbsp;21, 2012. The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional shares or warrants. These collective contractual rights are referred to as &#147;Economic Rights&#148;.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See &#147;<i>Note 3, Fair Value Measurements&#148;</i> for further details.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred Stock Dividend</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;6, 2012, the Company&#146;s Board of Directors decided not to declare a quarterly cash dividend on the Company&#146;s 6% Convertible Exchangeable Preferred Stock (&#147;Preferred Stock&#148;) with respect to the first quarter of 2012 that would have otherwise been payable on May&nbsp;1, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Subsequent Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">NASDAQ Appeal</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Previously, the Company received a determination letter from NASDAQ, notifying the Company that it had not regained compliance with the minimum closing bid price requirements set forth in Listing Rule&nbsp;5450(a)(1)&nbsp;(the &#147;Rule&#148;) during the 180 calendar days allowed to regain compliance and that the Company&#146;s common stock was subject to delisting from the NASDAQ Global Market.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;26, 2012, the Company presented its plan to regain compliance with the Rule, which plan included the possibility of effectuating a reverse stock split,&nbsp;before a NASDAQ Listing Qualifications Panel (the &#147;Panel&#148;). On May 15, 2012, the Panel approved the Company&#146;s plan to regain compliance, and determined to continue the Company&#146;s listing pursuant to an exception to the Rule&nbsp;for a maximum of 180 calendar days from the date of the NASDAQ Staff&#146;s notification, or through September&nbsp;11, 2012, provided that the Company has evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days prior to such date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the Company is unable to provide evidence of compliance with the Rule, the Company may still transfer its listing to the NASDAQ Capital Market if it meets the initial listing criteria set forth in NASDAQ Marketplace Rule&nbsp;5505, except for the bid price requirement. In that case, it may have until September&nbsp;11, 2012 to comply with the minimum bid price requirement. The Company currently meets these initial listing criteria, except for the bid price requirement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Consolidation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany transactions and balances have been eliminated.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_081652_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-05.htm',USER='105939',CD='May 15 23:46 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Use of Estimates</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include estimated levels of product returns, and inputs used to determine stock-based compensation expense and the fair value of financial instruments, such as Economic Rights and other liabilities measured at fair value. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash equivalents are stated at cost, which is substantially the same as fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&#146;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&#146;s cash flow requirements and to attain a market rate of return.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Trade Accounts Receivable and Allowance for Doubtful Accounts</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An allowance for doubtful accounts is provided, as necessary, on trade receivables based on their respective aging categories and historical collection experience, taking into consideration the type of payer, historical and projected collection outcomes, and current economic and business conditions that could affect the collectability of the Company&#146;s receivables.&#160; The allowance for doubtful accounts is reviewed, at a minimum, on a quarterly basis.&#160; Changes in the allowance for doubtful accounts are recorded as an adjustment to bad debt expense within general and administrative expenses.&#160; Material revisions to reserve estimates may result from adverse changes in collection experience. The Company writes off accounts against the allowance for doubtful accounts when reasonable collection efforts have been unsuccessful and it is likely the receivable will not be recovered.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Trade accounts receivable are included in prepaid expenses and other current assets on the consolidated balance sheet and were $0.1 million and $0.2 million at December&nbsp;31, 2011 and March&nbsp;31, 2012, respectively. All trade accounts receivable were deemed collectible as of December&nbsp;31, 2011 and March&nbsp;31, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the three months ended March&nbsp;31, 2011 and 2012, approximately 90% and 86%, respectively, of our product sales in the United States were to three wholesalers.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Inventory</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel values inventories at the lower of cost or market. The Company determines cost using the first-in, first-out method. As of March&nbsp;31, 2012 and December&nbsp;31, 2011, all inventories were classified as finished goods. The Company analyzes its inventory levels at least quarterly to identify any items that may expire prior to sale, inventory that has a cost basis in excess of net realizable value, or inventory in excess of expected sales requirements.&#160; The determination of whether or not inventory costs will be realizable requires estimates by the Company&#146;s management.&#160; A critical input in this determination is future expected sales forecasts. The Company writes off inventory that is expected to expire before being sold.&#160; If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required in future periods.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no inventory write-downs during the three months ended March&nbsp;31, 2011 and 2012. In the future, reduced demand, quality issues or excess supply may result in write-downs, which would be recorded as adjustments to cost of sales.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, Economic Rights, and other liabilities measured at fair value. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. Economic Rights and other liabilities measured at fair value employ applicable inputs as described in &#147;<i>Note 3, Fair Value Measurements&#148;</i>.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_081736_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-05.htm',USER='105939',CD='May 15 23:46 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Product sales</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the selling price is fixed or determinable; and collectability is reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company offers a general right of return on product sales, and has considered the guidance in ASC Subtopic 605-15, &#147;<i>Revenue Recognition -Products</i>&#148; (&#147;ASC 605-15&#148;) and ASC Subtopic 605 &#151; 10 &#147;<i>Revenue Recognition - Overall</i>&#148; (&#147;ASC 605-10&#148;). Under these guidelines, the Company accounts for all product sales using the &#147;sell-through&#148; method. Under the sell-through method, revenue is not recognized upon shipment of product to distributors. Instead, the Company records deferred revenue at gross invoice sales price less 5% of the current wholesale acquisition price (in accordance with our returns policy) and deferred cost of sales at the cost at which those goods were held in inventory. The Company recognizes revenue and cost of sales when such inventory is sold through to pharmacies. To estimate product sold through to pharmacies, the Company relies on third-party information, including information obtained from significant distributors with respect to their inventory levels and sell-through to pharmacies. At the time of revenue recognition, the Company also estimates a provision for returned products based on historical data and future expectations; this provision is charged against revenues.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred revenue was $0.1 million at December&nbsp;31, 2011 and March 31, 2012. Deferred cost of goods sold was approximately $20,000 and $22,000 at December&nbsp;31, 2011 and March 31, 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Collaboration, research and development, and grant revenue</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain of the Company&#146;s revenues are earned from collaborative agreements. The Company recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether these criteria have been met is based on management&#146;s judgments regarding the nature of the research performed, the substance of the milestones met relative to those the Company must still perform, and the collectability of any related fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development revenues, which are earned under agreements with third parties for contract research and development activities, are recorded as the related services are performed. Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by achievement of the specified milestones and the absence of ongoing performance obligations. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues previously recognized are refundable if the relevant research effort is not successful.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. All grants earned and received are not refundable. The Company had deferred grant revenue of approximately $75,000 at March&nbsp;31, 2012.&#160; The Company had no such deferred revenue at December&nbsp;31, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Clinical Trial Accounting</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Data management and monitoring of the Company&#146;s clinical trials are performed with the assistance of contract research organizations (&#147;CROs&#148;) or clinical research associates (&#147;CRAs&#148;) in accordance with the Company&#146;s standard operating procedures. Typically, CROs and some CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into the trial and any initial payment made to the clinical trial site is recognized upon execution of the clinical trial agreements and expensed as research and development expenses.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_081836_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-05.htm',USER='105939',CD='May 15 23:46 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and Development Expenditures</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist primarily of costs associated with developing the Company&#146;s product candidates, including upfront fees and milestones paid to parties from whom the Company licenses certain intellectual property, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs, amortization of purchased technology and depreciation. Expenditures relating to research and development are expensed as incurred.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Foreign currency and currency translation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The assets and liabilities of the Company&#146;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date.&#160; Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from remeasurement of foreign-currency denominated intercompany loans that are </font><font size="2" style="font-size:10.0pt;">of a long-term-investment nature, </font><font size="2" style="font-size:10.0pt;">are recorded in other comprehensive income.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Inputs used to determine fair value of financial and non-financial assets and liabilities are categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least reliable (see <i>Note 3, Fair Value Measurements</i>). Management reviews the categorization of fair value inputs on a periodic basis and may determine that it is necessary to transfer an input from one level of the fair value hierarchy to another based on changes in events or circumstances, such as a change in the observability of an input. Any such transfer will be recognized at the end of the reporting period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Income Taxes</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&#146;s management has established a full valuation allowance against its deferred tax assets based on the determination that it is not more likely than not that the Company will recognize the benefits of those assets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company applies the guidance codified in ASC Topic 740, <i>&#147;Income taxes&#148; </i>(&#147;ASC 740&#148;) related to accounting for uncertainty in income taxes. ASC 740 specifies the accounting for uncertainty in income taxes recognized in a company&#146;s financial statements by prescribing a minimum probability threshold a tax position is required to meet before being recognized in the financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_081908_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-05.htm',USER='105939',CD='May 15 23:46 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company records income tax benefits related to research and development tax credits, which will be claimed from H. M. Revenue&nbsp;&amp; Customs, the United Kingdom&#146;s taxation and customs authority, with respect to qualifying research and development costs incurred in the same accounting period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company grants stock options, restricted stock units and restricted stock to officers, employees and directors under the Amended and Restated Equity Incentive Plan (&#147;2006 Plan&#148;), which was approved on March&nbsp;16, 2006, as amended on May&nbsp;21, 2007, and subsequently amended and restated on April&nbsp;14, 2008.&#160; The Company has granted various types of awards under the 2006 Plan, which is described more fully in <i>Note 6, Stock-Based Compensation Arrangements</i>. The Company accounts for these awards under ASC 718, &#147;<i>Compensation &#151; Stock Compensation</i>&#148; (&#147;ASC 718&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of awards granted and the quoted price of the Company&#146;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#146;s share price, the anticipated exercise behavior of its employees, interest rates, and dividend yields. These variables are projected based on the Company&#146;s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&#160; The Company considers many factors when estimating expected forfeitures, including type of awards granted employee class, and historical experience.&#160; Actual results and future estimates may differ substantially from current estimates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Segments</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has determined its reportable segments in accordance with ASC 280, &#147;<i>Segment Reporting</i>&#148; (&#147;ASC 280&#148;) and related disclosures about products, services, geographic areas and major customers.&#160; After considering its business activities and geographic reach, the Company has concluded that it operates in just one operating segment being the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_073020_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Net Loss per Common Share</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company calculates net loss per common share in accordance with ASC 260, &#147;<i>Earnings Per Share</i>&#148; (&#147;ASC 260&#148;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#146;s potentially dilutive shares, which include outstanding common stock options, restricted stock, restricted stock units, convertible preferred stock, and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="98%" style="border-collapse:collapse;margin-left:6.0pt;width:98.88%;">
<tr>
<td width="73%" valign="bottom" style="padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock options </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,347,033</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,438,679</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" style="padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted stock and restricted stock units</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52,070</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">344,784</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible preferred stock </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">516,228</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">516,228</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" style="padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contingently issuable common stock and common   stock warrants associated with economic rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,933,052</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options to purchase common stock and common stock   warrants issued in connection with the October&nbsp;2010 financing </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,242,398</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" style="padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock warrants </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,005,192</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,814,015</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="73%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:73.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total shares excluded from calculation </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,162,921</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21,046,758</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss)</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with ASC 220, &#147;<i>Comprehensive Income</i>&#148; (&#147;ASC 220&#148;) all components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. ASC 220 defines comprehensive income (loss) as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recognized in relation to items of other comprehensive income.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;2011, the FASB issued Accounting Standards ASU 2011-05 to amend the guidance on the presentation of comprehensive income in ASC 220. ASU 2011-05 requires companies to present a single statement of comprehensive income or two separate but consecutive statements, a statement of operations and a statement of comprehensive income. ASU 2011-05 eliminates the alternative to present comprehensive income within the statement of equity. ASU 2011-05 does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.&#160; The ASU should be applied retrospectively and is effective for annual periods beginning after December&nbsp;15, 2011.&#160; In December&nbsp;2011, the FASB issued ASU 2011-12, which deferred the changes in ASU 2011-05 that relate to the presentation of reclassifications out of accumulated other comprehensive income.&#160; The adoption of this guidance did not have a material impact on the Company&#146;s consolidated financial statements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May&nbsp;2011, the FASB issued ASU 2011-04, which amends the guidance on fair value measurement in ASC 820 to converge the fair value measurement and disclosure requirements under GAAP and International Financial Reporting Standards (&#147;IFRS&#148;) fair value measurement and disclosure requirements. The amendments change the wording used to describe the requirements for measuring fair value, changes certain fair value measurement principles and enhances disclosure requirements. This guidance is effective for annual periods beginning after December&nbsp;15, 2011, applied prospectively. The adoption of this guidance did not have a material impact on the Company&#146;s consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_073107_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As defined in ASC 820, <i>Fair Value Measurements and Disclosures</i> (&#147;ASC 820&#148;), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of the Company&#146;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December&nbsp;31, 2011:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="94%" style="border-collapse:collapse;margin-left:.2in;width:94.66%;">
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,894</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,894</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liabilities measured at fair value:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants liability </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scottish Enterprise Agreement </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liabilities measured at fair value </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,894</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,965</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value of the Company&#146;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of March&nbsp;31, 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="94%" style="border-collapse:collapse;margin-left:.2in;width:94.66%;">
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;1</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;2</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,498</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,498</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Economic rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,153</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,153</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liabilities measured at fair value:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants liability </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scottish Enterprise Agreement </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other liabilities measured at fair value </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,498</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,182</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,680</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_073238_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table reconciles the beginning and ending balances of Level 3 inputs for the three months ended March&nbsp;31, 2012:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="84%" valign="bottom" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Level&nbsp;3</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance as of December&nbsp;31, 2011 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">71</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sale of Economic Rights </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,097</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of Economic Rights </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" style="padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of warrants liability </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(42</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="84%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:84.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance as of March&nbsp;31, 2012 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,182</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Economic Rights</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, the Company entered into a financing agreement with certain existing institutional stockholders.&#160; Under the terms of the agreement, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional common shares or warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Economical Rights are accounted for as a derivative financial instrument under ASC 815, <i>Derivative financial instruments </i>(&#147;ASC 815&#148;), and are measured at fair value. Changes in fair value are recognized in earnings. &nbsp;The fair value of the Economical Rights has been estimated using a decision-tree analysis method.&#160; This is an income-based method that incorporates the expected benefits, costs and probabilities of contingent outcomes under varying scenarios.&#160; Each scenario within the decision-tree is discounted to the present value using the company&#146;s credit adjusted risk-free rate and ascribed a weighted probability to determine the fair value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has concluded the fair value of this liability was approximately $1.1 million and $1.2 million at March&nbsp;22, 2012, and March&nbsp;31, 2012, respectively.&#160; The fair value of the derivative increased approximately $56,000 from March&nbsp;22, 2012 to March&nbsp;31, 2012. The increase in fair value was recognized as a loss in the consolidated statement of operations for the three month period ended March&nbsp;31, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The most significant inputs in estimating the fair value of this liability are:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company&#146;s credit adjusted risk-free rate, which has been derived from the observable returns on debt for more developed pharmaceuticals companies, adjusted for the Company&#146;s risk profile.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The amount of the return to the investors, which will vary depending on:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The outcome of the litigation, including consideration of whether the litigation may be resolved in a jury trial or settled out of court;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The amount of the settlement or award, which the Company has estimated predominantly based on observable royalty rates arising from the settlement of other cases of intellectual property litigation; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The form of the settlement or award.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The projected timing of the cash flows to the investors, which could vary between several months to several years depending upon whether the litigation is settled, when the court may decide the case, whether any appeal is made on any court decision and the form of any settlement or award.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_073333_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The number of contingent warrants that could be issued, which is based on a formula.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The decision-tree analysis model used to calculate the fair value of the derivative requires the probability of alternative scenarios to be determined at a series of decision points.&#160; Each scenario may contain more than one decision point resulting in further scenarios.&#160; Therefore, the probability estimates made by management at each decision point are a significant input to the valuation model.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of these inputs are unobservable inputs, which have an interrelated effect on the fair value of the derivative.&#160; It is not possible to evaluate the impact on the fair value of each factor in combination.&#160; However, generally the fair value of the derivative liability will increase, (i)&nbsp;the higher the value of the expected settlement or award, (ii)&nbsp;the lower the discount rate employed and (iii)&nbsp;the more likely it is that a settlement or award will be made.&#160; The fair value of the derivative liability will decrease if the timing of settlement is delayed, the expected settlement decreases, or anticipated litigation costs increase.&#160;&#160; The impact on the fair value of the derivative liability related to the probability of whether the litigation is settled prior to the court hearing or whether a settlement award is made by the court and the form of the settlement will depend on the other factors above and cannot be estimated in isolation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The decision-tree analysis model has been performed by valuation specialists, based on inputs provided by the company and other sources. At each reporting period, the inputs to the model will be evaluated to determine whether any adjustments are appropriate, and to reflect changes in the time value of the expected cash flows.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company used the following assumptions to calculate the value of the Economic Rights:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.25in;width:93.34%;">
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;22,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Probability of unsuccessful/successful outcomes </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25% - 75%</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25% - 75%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amount of award or settlement (1) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$10.0 million - $20.0 million</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$10.0 million - $20.0 million</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Discount rate </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16%</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Timing of cash flows </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.75 &#150; 2.27 years</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.75 &#150; 2.27 years</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Royalty rate </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6%</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Litigation expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$1.0 million &#150; $3.0 million</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$1.0 million &#150; $3.0 million</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Assumptions take into consideration the cap on the amount that the Company would have to pay investors in the event of an award or settlement.</font></p>
<p style="margin:0in 0in .0001pt 31.5pt;text-indent:-13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other Liabilities Measured at Fair Value</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants Liability</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company issued warrants to purchase shares of common stock under the registered direct financing completed in February&nbsp;2007.&#160; These warrants are being accounted for as a liability in accordance with ASC 815.&#160; At the date of the transaction, the fair value of the warrants of $6.8&nbsp;million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#151; 4.68%, expected volatility &#151; 85%, expected dividend yield &#151; 0%, and a remaining contractual life of 7&nbsp;years. The fair value of the warrant is being remeasured each reporting period, with a gain or loss recognized in the consolidated statement of operations. Such gains or losses will continue to be reported until the warrants are exercised or expired. The Company used the Black-Scholes option-pricing model with the following assumptions to value the warrants:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_073554_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.25in;width:93.34%;">
<tr>
<td width="67%" valign="bottom" style="padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" style="padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercise price </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$8.44</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$8.44</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" style="padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.13 Yrs.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.88 Yrs.</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk free interest rate </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.25%</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.33%</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" style="padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected volatility </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121%</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">77%</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="67%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:67.88%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend yield over expected term </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognized the change in the value of warrants as a gain on the consolidated statement of operations of $0.1 million and approximately $42,000 for the three months ended March&nbsp;31, 2011 and 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scottish Enterprise Agreement</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;22, 2009, the Company amended the Agreement with Scottish Enterprise (&#147;SE&#148;) (the &#147;Amendment&#148;), in order to allow the Company to implement a reduction of the Company&#146;s research operations located in Scotland in exchange for the parties&#146; agreement to modify the payment terms of the Agreement in the principal amount of &#163;5&nbsp;million (approximately $8.0 million at December&nbsp;31, 2009), which SE had previously entered into with the Company. The Agreement provided for repayment of up to &#163;5 million in the event the Company significantly reduced its Scottish research operations. Pursuant to the terms of the Amendment, in association with Cyclacel&#146;s material reduction in staff at its Scottish research facility, the parties agreed to a modified payment of &#163;1&nbsp;million (approximately $1.7 million at June&nbsp;22, 2009) payable in two equal tranches. On July&nbsp;1, 2009, the first installment of &#163;0.5 million (approximately $0.8 million) was paid and the remaining amount of &#163;0.5 million (approximately $0.8 million) was paid on January&nbsp;6, 2010.&#160; In addition, should a further reduction below current minimum staff levels be effectuated before July&nbsp;2014 without SE&#146;s prior consent, the Company may be obligated to pay up to &#163;4&nbsp;million to SE, which will be calculated as a maximum of &#163;4&nbsp;million (approximately $6.2 million and $6.4 million at December&nbsp;31, 2011 and March&nbsp;31, 2012, respectively) less the market value of the shares held by SE at the time staffing levels in Scotland fall below the prescribed minimum levels. If the Company were to have reduced staffing levels below the prescribed levels, the amount potentially payable to SE would have been approximately &#163;3.8 million (approximately $5.9 million) and approximately &#163;3.8 million (approximately $6.1 million) at December&nbsp;31, 2011 and March&nbsp;31, 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This arrangement is accounted for as a liability under ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#147;ASC 480&#148;), and is measured at fair value. Changes in fair value are recognized in earnings. &nbsp;Due to the nature of the associated contingency and the likelihood of occurrence, the Company has concluded the fair value of this liability was approximately $20,000 at December&nbsp;31, 2011 and March&nbsp;31, 2012, respectively. The most significant inputs in estimating the fair value of this liability are the probabilities that staffing levels fall below the prescribed minimum and that the Company is unable or unwilling to replace such employees within the prescribed time period. At both December&nbsp;31, 2011 and March&nbsp;31, 2012, the Company used a scenario analysis model to arrive at the fair value of the Scottish Enterprise Agreement and assumed a 30% probability of falling below a minimum staffing level and a 1% probability that the occurrence of such an event would not be cured within the prescribed time period. At each reporting period, the inputs used to determine the fair value of the liability will be evaluated to determine whether adjustments are appropriate. Changes in the value of this liability are recorded in the consolidated statement of operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_073652_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">PREPAID EXPENSES AND OTHER CURRENT ASSETS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets consist of the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development tax credit receivable </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">541</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">734</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepayments </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">321</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">278</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts receivable </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">116</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">152</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deposits </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">153</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,200</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,423</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued and other current liabilities consisted of the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="94%" style="border-collapse:collapse;margin-left:.2in;width:94.66%;">
<tr>
<td width="68%" valign="bottom" style="padding:0in 0in 0in 0in;width:68.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="68%" valign="bottom" style="padding:0in 0in 0in 0in;width:68.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="28%" colspan="3" valign="bottom" style="padding:0in 0in 0in 0in;width:28.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued research and development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,471</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,334</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="68%" valign="bottom" style="padding:0in 0in 0in 0in;width:68.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other current liabilities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,193</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,170</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="68%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.3%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,664</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.68%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,504</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.&#160;&#160;&#160;&#160; STOCK BASED COMPENSATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March&nbsp;31, 2011 and 2012 as shown in the following table:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">For&nbsp;the&nbsp;three&nbsp;months<br>   ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="3" valign="bottom" style="padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">201</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation costs before income taxes   </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">251</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.02%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">102</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the Company&#146;s annual shareholder meeting on May&nbsp;14, 2008, the stockholders approved and amended the number of shares reserved under the 2006 Plan to 5,200,000 shares of the Company&#146;s common stock, up from 3,000,000 shares. The awards granted under the 2006 Plan have a maximum maturity of 10&nbsp;years and generally vest over a four-year period from the date of grant.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_073922_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A summary of activity for the options under the Company&#146;s 2006 Plan for the three months ended March&nbsp;31, 2012 is as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Options</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average<br>   Exercise&nbsp;Price</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted<br>   Average<br>   Remaining<br>   Contractual<br>   &nbsp;Term&nbsp;(years)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Aggregate<br>   Intrinsic<br>   Value</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(in&nbsp;$000s)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options outstanding at December&nbsp;31, 2011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,515,741</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.73</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.44</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">77,062</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.44</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expired </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cancelled / forfeited </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options outstanding at March&nbsp;31, 2012 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,438,679</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.80</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.18</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">233</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unvested at March&nbsp;31, 2012</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">556,177</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.72</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.59</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested and exercisable at March&nbsp;31, 2012 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,882,502</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.20</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.71</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">232</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of grant and 1/48 of the award vesting each month thereafter.&#160; However, certain awards made to executive officers vest over three to five years, depending on the terms of their employment with the Company. In addition, recent awards made to rank-in-file employees vest ratably over three to four years, with 1/36 to 1/48 of the award vesting each month.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company estimates grant date fair value for stock option awards using an option-pricing model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the forfeiture rate adjusted as necessary.&#160; Ultimately, the actual expense recognized over the requisite service period is based on only those shares that vest.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company estimates the expected term of stock option awards using past history of early exercise behavior and expectations about future behavior. Starting with the December&nbsp;2010 annual grants to the Company&#146;s employees, the Company relied exclusively on its historical volatility as an input to the option pricing model as the Company&#146;s management believes that this rate will be representative of future volatility over the expected term of the options.&#160; Prior to December&nbsp;2010, because the Company had been publicly traded for a limited period, the expected volatility assumption was based on the historical volatility of peer companies over the expected term of the option awards.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimates of pre-vesting option forfeitures are based on the Company&#146;s experience. For outstanding options, the Company uses a forfeiture rate of 0 &#151; 50% depending on when and to whom the options are granted. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and may impact the amount of compensation expense to be recognized in future periods.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_073952_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no options granted during either of the three month periods ending March&nbsp;31, 2011 and 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended March&nbsp;31, 2011, 5,131 stock options were exercised resulting in approximately $2,000 of cash proceeds to the Company.&#160; During the three months ended March&nbsp;31, 2012, there were 77,062 stock options exercised totaling approximately $34,000 in proceeds. As the Company presently has tax loss carry forwards from prior periods and expects to incur tax losses during the year ended December&nbsp;31, 2012, the Company is not able to benefit from the deduction for exercised stock options in the current reporting period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Restricted Stock</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November&nbsp;2008, the Company issued 50,000 shares of restricted common stock to an employee subject to certain forfeiture provisions. Specifically, one quarter of the award vests one year from the date of grant and 1/48 of the award effectively vests each month thereafter.&#160; This restricted stock grant was accounted for at fair value at the date of grant and an expense is recognized during the vesting term. Summarized information for the restricted stock grant for the three months ended March&nbsp;31, 2012 is as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="56%" valign="bottom" style="padding:0in 0in 0in 0in;width:56.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Restricted&nbsp;Stock</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average&nbsp;Grant<br>   Date&nbsp;Value&nbsp;Per&nbsp;Share</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="56%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-vested at December&nbsp;31, 2011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,450</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.44</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" valign="top" style="padding:0in 0in 0in 0in;width:56.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,126</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" style="padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.44</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-vested at March&nbsp;31, 2012</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,324</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.44</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Restricted Stock Units</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November&nbsp;2008 and December&nbsp;2011, respectively, the Company issued 91,700 and 238,000 restricted stock units to senior executives.&#160; Each unit entitles the holder to receive a share of the Company&#146;s common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the first quarter of 2012, the Company issued approximately 86,000 restricted stock units to employees as part of its annual grant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The 2008 grants vest over four years and the 2011 and 2012 grants vest over three years.&nbsp; A restricted stock unit grant is accounted for at fair value at the date of grant which is equivalent to the market price of a share of the Company&#146;s common stock, and an expense is recognized over the vesting term. Summarized information for restricted stock grants for the three months ended March&nbsp;31, 2012 is as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="51%" valign="bottom" style="padding:0in 0in 0in 0in;width:51.54%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Restricted&nbsp;Stock&nbsp;Units</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="23%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted&nbsp;Average&nbsp;Grant<br>   Date&nbsp;Value&nbsp;Per&nbsp;Share</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:51.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-vested at December&nbsp;31, 2011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:18.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">255,175</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.80</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85,974</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" style="padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.55</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:51.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vested</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,689</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.44</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.54%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-vested at March&nbsp;31, 2011</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.46%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">336,460</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="21%" valign="bottom" style="padding:0in 0in 0in 0in;width:21.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.74</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Licensing Agreements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_074136_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is required to pay royalties on future sales of product employing the technology or falling under claims of patent applications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#146;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial entering Phase 3 during the first quarter of 2011, a milestone payment of $1.6 million was paid in April&nbsp;2011. A further $10.0 million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones and the Company&#146;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six months&#146; notice, or upon twelve months&#146; notice after a launch of a sapacitabine-based product.&#160; The license also may be terminated by either party for material default. Effective July&nbsp;11, 2011, the license agreement was amended to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September&nbsp;2011, and releases the Company from all claims and liability of any kind arising under such provision. The amendment further provides that the royalty rate due from the Company to Daiichi Sankyo on future net sales of sapacitabine be increased between 1.25% and 1.50% depending on the level of net sales of sapacitabine realized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the asset acquisition of ALIGN on October&nbsp;5, 2007, the Company acquired distribution rights for the exclusive rights to sell and distribute three products in the United States. Each of the agreements covering the three products expires in June&nbsp;2015, after which the Company has no rights to distribute these products. The Company has a minimum purchase obligation equivalent to the value of product purchased in the previous year.&#160; For the year ended December&nbsp;31, 2012 this equates to $0.2 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Legal proceedings</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the United States District Court for the District of Delaware seeking a declaratory judgment that four of the Company&#146;s own patents (claiming the use of romidepsin injection in T-cell lymphomas) are invalid and not infringed by Celgene&#146;s products, but directly involve the use and administration of Celgene&#146;s ISTODAX&#174; (romidepsin for injection) product. On June&nbsp;17, 2010, the Company filed its answer and counterclaims to the declaratory judgment complaint. The Company has filed counterclaims charging Celgene with infringement of each of its four patents and seeking damages for Celgene&#146;s infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene&#146;s ISTODAX&#174; (romidepsin for injection) product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A Scheduling Order was entered February&nbsp;2, 2012, at which time the court set the following significant dates: March&nbsp;22, 2012 (amendment of pleadings/joinder of parties); September&nbsp;24, 2012 (teleconference with the court exploring possibility of Alternative Dispute Resolution); March&nbsp;14, 2013 (claim construction hearing); August&nbsp;14, 2013 (summary judgment briefing); and June&nbsp;2, 2014 (7 day jury trial start date). Discovery is currently ongoing.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_074140_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\105546\12-9682-1\task5355992\9682-1-ba-07.htm',USER='105546',CD='May 15 22:38 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.&nbsp;&nbsp;&nbsp;STOCKHOLDERS&#146; EQUITY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Preferred stock</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March&nbsp;31, 2012, there were 1,213,142 shares of Preferred Stock issued and outstanding at an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August&nbsp;and November, commencing February&nbsp;1, 2005. Any dividends must be declared by the Company&#146;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $10 per share, plus accrued and unpaid dividends.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Preferred Stock is convertible at the option of the holder at any time into the Company&#146;s shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for each share of Preferred Stock based on a price of $23.50. The Company has reserved 516,228 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at March&nbsp;31, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During 2010, 833,671 shares of Preferred Stock were converted into 1,655,599 shares of the Company&#146;s common stock. Since inception through March&nbsp;31, 2012, holders have voluntarily converted 1,776,858 shares of Preferred Stock into common stock. The converted shares of Preferred Stock have been retired and canceled and shall upon cancellation be restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#146;s common stock has exceeded $35.25, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#146;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&nbsp;2, 2010 and two directors were nominated and elected at the annual meeting held on May&nbsp;24, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From November&nbsp;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption prices per share stated below, plus an amount equal to accrued and unpaid dividends up to the date of redemption:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.1in;width:90.68%;">
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year from November&nbsp;1, 2011 to   October&nbsp;31, 2012</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.18</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year from November&nbsp;1, 2012 to   October&nbsp;31, 2013</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.12</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Year from November&nbsp;1, 2013 to   October&nbsp;31, 2014</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.06</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.92%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November&nbsp;1, 2014 and thereafter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.00</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&nbsp;1, 2005 (the &#147;Exchange Date&#148;) for the Company&#146;s 6% Convertible Subordinated Debentures (&#147;Debentures&#148;) at the rate of $10 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have terms substantially similar to those of the Preferred Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;6, 2012, the Company&#146;s Board of Directors decided not to declare a quarterly cash dividend on the Company&#146;s 6% Convertible Exchangeable Preferred Stock (&#147;Preferred Stock&#148;) with respect to the first quarter of 2012 that would have otherwise been payable on May&nbsp;1, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_074338_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Common Stock</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">March&nbsp;2012 Sale of Common Stock and Economic Rights</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders, raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses on certain intellectual property and for general corporate purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&#146;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&#146;s common stock for the period ending on Wednesday, March&nbsp;21, 2012. In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional shares or warrants.&#160; The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See <i>Note 3, Fair Value Measurements</i> for further details.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Common Stock Warrants</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes information about warrants outstanding at March&nbsp;31, 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="54%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Issued&nbsp;in&nbsp;Connection&nbsp;With&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Expiration</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Common&nbsp;Shares</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Issuable</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Average</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Exercise</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Price</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;2006 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,571,429</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.00</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">February&nbsp;2007 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2014</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,062,412</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.44</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2007 CEFF</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.40</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">July&nbsp;2009 Series&nbsp;II stock issuance</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2014</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">692,256</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.00</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">January&nbsp;2010 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">712,500</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.26</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">January&nbsp;2010 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">705,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.85</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">October&nbsp;2010 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,161,595</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.92</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">July&nbsp;2011 stock issuance</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,808,823</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.36</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="54%" valign="bottom" style="padding:0in 0in 0in 0in;width:54.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,814,015</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.28</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no exercises of warrants during the three months ended March&nbsp;31, 2011 and 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_074434_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</font></b><a name="Item2_ManagementsDiscussionAndAna_074435"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This Quarterly Report on Form&nbsp;10-Q, including, without limitation, Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). We intend that the forward-looking statements be covered by the safe harbor for forward-looking statements in the Exchange Act. The forward-looking information is based on various factors and was derived using numerous assumptions. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are usually accompanied by words such as &#147;believe,&#148;&#160; &#147;anticipate,&#148;&#160; &#147;plan,&#148;&#160; &#147;seek,&#148;&#160; &#147;expect,&#148;&#160; &#147;intend&#148; and similar expressions.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward looking statements due to a number of factors, including those set forth in Part&nbsp;I,&nbsp;Item 1A, entitled &#147;Risk Factors,&#148; of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011, as updated and supplemented by Part&nbsp;II,&nbsp;Item 1A, entitled &#147;Risk Factors,&#148; of our Quarterly Reports on Form&nbsp;10-Q, and elsewhere in this report. These factors as well as other cautionary statements made in this Quarterly Report on Form&nbsp;10-Q, should be read and understood as being applicable to all related forward-looking statements wherever they appear herein. The forward-looking statements contained in this Quarterly Report on Form&nbsp;10-Q represent our judgment as of the date hereof. We encourage you to read those descriptions carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements. In this report, &#147;Cyclacel,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Cyclacel Pharmaceuticals,&nbsp;Inc.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a development-stage biopharmaceutical company dedicated to the development and commercialization of small-molecule drugs that target the various phases of the cell cycle for the treatment of cancer and other serious diseases, particularly those of high unmet medical need.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our core area of expertise is in cell cycle biology and we focus primarily on the development of orally-available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors, and enhancing the quality of life and improving survival rates of cancer patients. We have generated several families of anticancer drugs that act on the cell cycle including nucleoside analogues, cyclin dependent kinase, or CDK, inhibitors and Aurora kinase/Vascular Endothelial Growth Factor Receptor 2 or AK/VEGFR 2 inhibitors and Plk inhibitors. Although a number of pharmaceutical and biotechnology companies are currently attempting to develop nucleoside analogues, CDK inhibitor and AK inhibitor drugs, we believe that our drug candidates are differentiated in that they are orally-available and interact with unique target profiles and mechanisms.&#160; For example we believe that our sapacitabine is the only orally-available nucleoside analogue presently being tested in a Phase 3 trial in AML and in Phase 2 for MDS and NSCLC and seliciclib is the most advanced orally-available CDK inhibitor currently in Phase 2 trials. Our resources are primarily directed towards advancing our lead drug candidate sapacitabine through in-house development activities although we are also progressing our earlier stage novel drug series through working with external collaborators but with limited investment by us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have worldwide rights to commercialize sapacitabine and seliciclib and our business strategy is to enter into selective partnership arrangements with these programs.&#160; Taken together, our pipeline covers all four phases of the cell cycle, which we believe will improve the chances of successfully developing and commercializing novel drugs that work on their own or in combination with approved conventional chemotherapies or with other targeted drugs to treat human cancers.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_074529_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sapacitabine is being evaluated in the SEAMLESS Phase 3 trial being conducted under a Special Protocol Assessment agreement with the US Food and Drug Administration for the front-line treatment of </font><font size="2" style="font-size:10.0pt;">acute myeloid leukemia in the elderly </font><font size="2" style="font-size:10.0pt;">and in Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukaemia.&#160; Additionally, sapacitabine has been shown to have increased activity in cancer cells with BRCA- or Homologous Recombinant repair-deficient backgrounds, including ovarian cancer cell lines.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have ongoing clinical programs in development awaiting further data. Once data becomes available and is reviewed, we will determine the feasibility of pursuing further development and/or partnering these assets, including sapacitabine in combination with seliciclib and seliciclib in NSCLC and nasopharyngeal cancer, or NPC. In addition, we market directly in the United States Xclair&#174; Cream for radiation dermatitis and Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From our inception in 1996 through March&nbsp;31, 2012, we have devoted substantially all our efforts and resources to our research and development activities. We have incurred significant net losses since inception. As of March&nbsp;31, 2012, our accumulated deficit during the development stage was $260.0 million. We expect to continue incurring substantial losses for the next several years as we continue to develop our clinical and pre-clinical drug candidates. Our operating expenses are comprised of research and development expenses and selling, general and administrative expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated significant product revenue but have financed our operations and internal growth through private placements, registered direct financings, licensing revenue, collaborations, interest on investments, government grants and research and development tax credits. We have recognized revenues from inception through March&nbsp;31, 2012, totaling $9.9 million, of which $3.1 million is derived from fees under collaborative agreements, $3.7 million of grant revenue from various United Kingdom and European government grant awards, and $3.2 million from product sales. We have also recognized $18.6 million in research and development tax credits, which are reported as income tax benefits on the consolidated statements of operations, from the United Kingdom&#146;s tax authority, H.M. Revenue&nbsp;&amp; Customs since inception.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenditures for the three months ended March&nbsp;31, 2012 decreased $1.7 million, or 56%, from $3.1 million for the three months ended March&nbsp;31, 2011 to $1.3 million for the three months ended March&nbsp;31, 2012.&#160; This is because during the three months ended March&nbsp;31, 2011, we incurred a contractual milestone amount of $1.6 million payable to Daiichi Sankyo under the sapacitabine licensing agreement. We expect that for the year ended December&nbsp;31, 2011, research and development expenses will increase compared to those incurred for the year ended December&nbsp;31, 2011, excluding the contractual obligation payment made to Daiichi Sankyo, as we continue to enroll the randomized portion of the SEAMLESS pivotal Phase 3 trial.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent Developments</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sale of Common Stock and Economic Rights</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, we entered into a purchase agreement with certain existing institutional stockholders, raising $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses involving specified intellectual property and for general corporate purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of our common stock at a price of $0.6476, which is equal to the 10-day average closing price of our common stock for the period ended on Wednesday, March&nbsp;21, 2012. The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_074536_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, we may have to issue either additional shares or warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred Stock Dividend</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;6, 2012, our Board of Directors decided not to declare a quarterly cash dividend on our 6% Convertible Exchangeable Preferred Stock (&#147;Preferred Stock&#148;) with respect to the first quarter of 2012 that would have otherwise been payable on May&nbsp;1, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Subsequent<i>  </i>Events</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">NASDAQ Appeal</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Previously, we received a determination letter from NASDAQ notifying us that we had not regained compliance with the minimum closing bid price requirements set forth in Listing Rule&nbsp;5450(a)(1)&nbsp;(the &#147;Rule&#148;) during the 180 calendar days allowed to regain compliance and that our common stock was subject to delisting from the NASDAQ Global Market.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;26, 2012, we presented our plan to regain compliance with the Rule, which plan included the possibility of effectuating a reverse stock split,&nbsp;before a NASDAQ Listing Qualifications Panel (the &#147;Panel&#148;). On May 15, 2012, the Panel approved our plan to regain compliance, and determined to continue our listing pursuant to an exception to the Rule&nbsp;for a maximum of 180 calendar days from the date of the NASDAQ Staff&#146;s notification, or through September&nbsp;11, 2012, provided that we have evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days prior to such date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are unable to provide evidence of compliance with the Rule, we may still transfer our listing to the NASDAQ Capital Market if we meet the initial listing criteria set forth in NASDAQ Marketplace Rule&nbsp;5505, except for the bid price requirement. In that case, we may have until September&nbsp;11, 2012 to comply with the minimum bid price requirement. We currently meet these initial listing criteria, except for the bid price requirement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Three Months Ended March&nbsp;31, 2011 and 2012</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenues</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the components of our revenues for the three months ended March&nbsp;31, 2011 and 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product revenue </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">161</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(31</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">192</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">161</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(31</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product revenue is derived from the sale of Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges. During each of the three months ended March&nbsp;31, 2011 and 2012, we recognized revenue of approximately $0.2 million in accordance with our revenue recognition policy.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may also recognize, from time to time, revenue from collaboration and research and development and from grant awards. We had no collaboration and research and development revenue or grant revenue for each of the three months periods ended March&nbsp;31, 2011 and 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The future</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:21.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to continue to maintain the sales of ALIGN products for the year ended December&nbsp;31, 2012 through the support of a small sales and marketing infrastructure. We also expect to recognize approximately $0.2 million in grant revenue over the next twelve to eighteen months in connection with an award from the European Union to study ovarian cancer therapies.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_074632_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Cost of goods sold</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cost of goods sold </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total cost of sales represented 55% and 58% of product revenue for the three months ended March&nbsp;31, 2011 and 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and development expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expense all research and development expenses as they are incurred. Research and development expenses primarily include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">clinical trial and regulatory-related costs;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">payroll and personnel-related expenses, including consultants and contract research;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">preclinical studies and laboratory supplies and materials;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">technology license costs; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">rent and facility expenses for our laboratories.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides information with respect to our research and development expenditure for the three months ended March&nbsp;31, 2011 and 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="98%" style="border-collapse:collapse;margin-left:6.0pt;width:98.88%;">
<tr>
<td width="38%" valign="bottom" style="padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="56%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:56.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="38%" valign="bottom" style="padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="38%" valign="bottom" style="padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:41.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="38%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sapacitabine </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,971</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,237</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,734</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(58</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="38%" valign="bottom" style="padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other research and development costs </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">109</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="38%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:38.82%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and development expenses </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,080</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,347</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,733</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(56</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and development expenses represented 62% and 40% of our operating expenses for the three months ended March&nbsp;31, 2011 and 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenditures decreased by $1.7 million to $1.3 million for the three month period ended March&nbsp;31, 2012 from $3.1 million for the three month period ended March&nbsp;31, 2011. The decrease was primarily due to $1.6 million of contractual expenses recognized during the three months ended March&nbsp;31, 2011, resulting from an achievement of a milestone triggered by the opening of enrollment in the lead-in portion our SEAMLESS trial, pursuant to the Daiichi-Sankyo license under which we license certain patent rights for sapacitabine, and a $0.2 million decrease in sapacitabine capsule manufacturing costs, partially offset by a $0.1 million increase in clinical trial costs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The future</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will continue to concentrate our resources on the development of sapacitabine. We anticipate that overall research and development expenditures for the year ended December&nbsp;31, 2012 will increase compared to the year ended December&nbsp;31, 2011, excluding the milestone payment to Daiichi-Sankyo, as we enroll the randomized portion of the SEAMLESS pivotal Phase 3 trial.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_074755_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Selling, general and administrative expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling, general and administrative expenses include costs for sales and marketing and administrative personnel, legal and other professional expenses and general corporate expenses. The following table summarizes the selling, general and administrative expenses for the three months ended March&nbsp;31, 2011 and 2012:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.1in;width:97.34%;">
<tr>
<td width="39%" valign="bottom" style="padding:0in 0in 0in 0in;width:39.38%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="57%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:57.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="39%" valign="bottom" style="padding:0in 0in 0in 0in;width:39.38%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="39%" valign="bottom" style="padding:0in 0in 0in 0in;width:39.38%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:42.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="39%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:39.38%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total selling, general and administrative expenses   </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,806</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,996</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">190</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total selling, general and administration expenses represented 36% and 58% of our operating expenses for the three months ended March&nbsp;31, 2011 and 2012, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our selling, general and administrative expenditure increased by approximately $0.2 million from $1.8 million for the three months ended March&nbsp;31, 2011, to $2.0 million for the three months ended March&nbsp;31, 2012. The increase in expenses was primarily attributable to a net increase in professional and consultancy costs of $0.2 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The future</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect our selling, general and administrative expenditures for the year ended December&nbsp;31, 2012 to remain at the same level as our expenditures for the year ended December&nbsp;31, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other income (expense)</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes other income (expense) for the three months ended March&nbsp;31, 2011 and 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.1in;width:97.34%;">
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="35%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:35.96%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of Economic Rights </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(56</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(56</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in valuation of other liabilities measured   at fair value </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(36</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(46</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Foreign exchange gains (losses) </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(68</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">114</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">182</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">268</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(45</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.6%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other income (expense) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">153</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">132</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.28%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">629</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other income and expense, net, increased by approximately $0.1 million, from income of approximately $21,000 for the three months ended March&nbsp;31, 2011, to income of $0.2 million for the three months ended March&nbsp;31, 2012.&#160; The increase was primarily because of the $0.2 million increase in foreign exchange gains, mostly due to the increase in exchange rate of the British Pound Sterling relative to the U.S. Dollar and an approximately $47,000 gain on sale of equipment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The change in valuation of Economic Rights related to the sale of Economic Rights in connection with the purchase agreement completed in March&nbsp;2012. These collective rights are classified as liabilities and will be marked to market each reporting period. For the three months ended March&nbsp;31, 2012, we recognized a loss of approximately $56,000 due to the change in the value of Economic Rights from the transaction date of March&nbsp;22, 2012 to March&nbsp;31, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The change in valuation of other liabilities measured at fair value relates to the issue of warrants to purchase shares of our common stock under the registered direct financing completed in February&nbsp;2007 and our liability under an agreement with the Scottish Enterprise, or SE, that would require us to make a payment to SE should staffing levels in Scotland fall below prescribed minimum levels. The warrants and agreement are classified as liabilities. The value of the warrants is being marked to market each reporting period as a gain or loss. Such gains or losses will continue to be reported for the warrants until they are exercised or expired. Gains of losses on the SE Agreement will be reported until the agreement expires in July&nbsp;2014. For the three months ended March&nbsp;31, 2011 and 2012, the change in the valuation of other liabilities measured at fair value was a decrease of $78,000 and $42,000, respectively.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_074901_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Foreign exchange gains (losses) increased by $0.2 million to a gain of $0.1 million for the three months ended March&nbsp;31, 2012 compared to a loss of approximately $68,000 for the three months ended March&nbsp;31, 2011. Foreign exchange gains (losses) are reported in the consolidated statement of operations as a separate line item within other income (expense).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognized approximately $47,000 in other income from the sale of laboratory equipment during the three months ended March&nbsp;31, 2012. We did not recognize any such income during the three months ended March&nbsp;31, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The future</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The valuation of the Economic Rights, warrants liability, and SE Agreement will continue to be re-measured at the end of each reporting period.&#160; The change in valuation of the Economic Rights is dependent on a number factors, including our stock price, and other management assumptions, including, the probability of success of the underlying litigation, amount of award or settlement, discount rate, royalty rate, and timing of cash flows, and may fluctuate significantly, which may have a significant impact on our statement of operations. The valuation of the warrant is dependent upon many factors, including our stock price, interest, and remaining term of the instrument and may fluctuate significantly, which may have a significant impact on our statement of operations. The valuation of the SE Agreement is dependent on a number of factors, including our stock price and the probability of the occurrence of certain events that would give rise to a payment.&#160; We do not expect the valuation of fair value of the SE Agreement to fluctuate significantly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As the nature of funding advanced through intercompany loans is that of a long-term investment in nature, future unrealized foreign exchange gains and losses on such funding will be recognized in other comprehensive income until repayment of the intercompany loan becomes foreseeable.&#160; This will minimize the future impact of unrealized foreign exchange fluctuations on earnings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Income tax benefit</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Credit is taken for research and development tax credits, which are claimed from the United Kingdom&#146;s revenue and customs authority, or HMRC, in respect of qualifying research and development costs incurred.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes research and development tax credits for the three months ended March&nbsp;31, 2011 and 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="7" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Difference</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total income tax benefit </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">191</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">168</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development tax credits recoverable decreased by $23,000 to $0.2 million for the three months ended March&nbsp;31, 2012 relative to the three-month period ended March&nbsp;31, 2011. The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year but is restricted to the payroll taxes paid by us to HMRC in that same year. The decrease is a consequence of lower payroll taxes in the period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The future</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to continue to be eligible to receive United Kingdom research and development tax credits for the foreseeable future and will elect to do so. If legislation is passed that eliminates the restriction of the amount recoverable to the payroll taxes paid in a period, we expect the amount of tax credits we will be able to recover to increase for the year ended December&nbsp;31, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_074934_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a summary of our key liquidity measures at December&nbsp;31, 2011 and March&nbsp;31, 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.1in;width:97.34%;">
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$&nbsp;Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%<br>   Difference</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="57%" colspan="10" valign="bottom" style="padding:0in 0in 0in 0in;width:57.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,449</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,640</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(809</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Working capital:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,831</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25,172</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(659</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current liabilities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,498</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,802</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(304</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Working capital </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,333</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,370</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(963</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 2.25pt 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At March&nbsp;31, 2012, we had cash and cash equivalents of $23.6 million as compared to $24.5&nbsp;million at December&nbsp;31, 2011. The decrease in balance was primarily due to normal cash outflows required to operate our business, offset by $2.9 million proceeds, net of certain expenses, received from a sale of common stock and Economic Rights completed in March&nbsp;2012. Since our inception, we have not generated any significant revenue and have relied primarily on the proceeds from sales of equity and preferred securities to finance our operations and internal growth. Additional funding has come through income on our investments, licensing revenue, government grants and research and development tax credits. We have incurred significant losses since our inception. As of March&nbsp;31, 2012, we had an accumulated deficit during the development stage of $260.0&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently anticipate that our cash and cash equivalents are sufficient to meet our anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials for at least the next twelve months. However, we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Cash provided by (used in) operating, investing and financing activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash provided by (used in) operating, investing and financing activities for the three months ended March&nbsp;31, 2011 and 2012, is summarized as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="3" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">($000s)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,892</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,771</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by investing activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash (used in) provided by financing   activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(260</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,945</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Operating activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities decreased slightly from $3.9 million for the three months ended March&nbsp;31, 2011 to $3.8 million for the three months ended March&nbsp;31, 2012. Net cash used in operating activities during the three months ended March&nbsp;31, 2012 resulted from our net operating loss of $2.9 million and a net decrease in working capital of $0.9 million due to an increase in prepaid expenses combined with a decrease in accounts payable and other current liabilities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investing activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by investing activities for the three months ended March&nbsp;31, 2012 was $15,000 as a result of the sale of laboratory equipment. There were no cash flows from investing activities during the three months ended March&nbsp;31, 2011.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_075203_2639"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\105939\12-9682-1\task5356211\9682-1-ba-09.htm',USER='105939',CD='May 15 23:47 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Financing activities</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in financing activities for the three months ended March&nbsp;31, 2011 was $0.3 million as a result of paying a cash dividend of approximately $0.2 million to our Preferred stockholders. Net cash provided by financing activities was $2.9 million for the three months ended March&nbsp;31, 2012. During the three months ended March&nbsp;31, 2012, we completed a sale of stock and Economic Rights for proceeds of approximately $2.9 million, net of certain expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Operating Capital and Capital Expenditure Requirements</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to continue to incur substantial operating losses in the future. Although we have generated a limited amount of product revenues from ALIGN product sales from October&nbsp;2007 through March&nbsp;31, 2012, we cannot guarantee that we will generate any significant product revenues until a product candidate has been approved by the US Food and Drug Administration, or FDA, or similar regulatory agencies in other countries and successfully commercialized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently anticipate that our cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months.&#160; We cannot be certain that any of our programs will be successful or that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in development, should they succeed. Additionally, we plan to continue to evaluate in-licensing and acquisition opportunities to gain access to new drugs or drug targets that would fit with our strategy. Any such transaction would likely increase our funding needs in the future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future funding requirements will depend on many factors, including but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs associated with establishing manufacturing and commercialization capabilities;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of acquiring or investing in businesses, product candidates and technologies;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs and timing of seeking and obtaining FDA and other regulatory approvals;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effect of competing technological and market developments; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations.&#160; Although we are not reliant on institutional credit finance and therefore not subject to debt covenant compliance requirements or potential withdrawal of credit by banks, the current economic climate has also impacted the availability of funds and activity in equity markets.&#160; We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes to our operating plan.&#160; In addition, we may have to partner one or more of our product candidate programs at an earlier stage of development, which would lower the economic value of those programs to us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.&#160; The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. We believe the judgments and estimates required by the following accounting policies to be critical in the preparation of our consolidated financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_080347_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Product sales</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have adopted the following revenue recognition policy related to the sales of Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges. We recognize revenue from these product sales when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We offer a general right of return on these product sales and account for all product sales using the &#147;sell-through&#148; method. Under the sell-through method, revenue is not recognized upon shipment of product to distributors. Instead, we record deferred revenue at gross invoice sales price less 5% of the current wholesale acquisition price in accordance with our returns policy and deferred cost of sales at the cost at which those goods were held in inventory. We recognize revenue when such inventory is sold through to pharmacies. To estimate product sold through to pharmacies, we rely on third-party information, including information obtained from significant distributors with respect to their inventory levels and sell-through to pharmacies. We also record against revenue a provision for product returns which is calculated based on the historical return rate for each product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We grant stock options, restricted stock units and restricted stock to officers, employees, directors and consultants under the Company&#146;s Amended and Restated Equity Incentive Plan, which was amended and restated as of April&nbsp;14, 2008. We measure compensation cost for all stock-based awards at fair value on date of grant and recognize compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of shares granted and the quoted price of our common stock on the date of grant.&#160; The determination of grant-date fair value for stock option awards is estimated using an option-pricing model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value is recognized as an expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Economic Rights</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Economic Rights are accounted for as a derivative financial instrument and measured at fair value. Changes in fair value are recognized in earnings. &nbsp;The fair value of the Economic Rights has been estimated using a decision-tree analysis method.&#160; This is an income-based method that incorporates the expected benefits, costs and probabilities of contingent outcomes under varying scenarios.&#160; Each scenario within the decision-tree is discounted to the present value using the company&#146;s credit adjusted risk-free rate and ascribed a weighted probability to determine the fair value. Changes in any of these assumptions could result in material adjustments to the expense recognized for changes in the valuation of the Economic Rights.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has concluded the fair value of this liability was approximately $1.1 million and $1.2 million at March&nbsp;22, 2012, and March&nbsp;31, 2012, respectively.&#160; We recognized approximately $56,000 as a loss on our consolidated statement of operations for the three months ended March&nbsp;31, 2012 as a result of an increase in the value of the Economic Rights from the transaction date to March&nbsp;31, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_080347_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other Liabilities Measured at Fair Value</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Warrants Liability</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accounting guidance on derivatives and hedging requires freestanding contracts that are settled in our own stock, including common stock warrants to be designated as equity instruments, assets or liabilities. Under the provisions of this guidance, a contract designated as an asset or a liability must be carried at fair value until exercised or expired, with any changes in fair value recorded in the results of operations. A contract designated as an equity instrument must be included within equity, and no subsequent fair value adjustments are required. We review the classification of the contracts at each balance sheet date. Since we are unable to control all the events or actions necessary to settle the warrants in registered shares the warrants have been recorded as a current liability at fair value. The fair value of the outstanding warrants is evaluated at each reporting period with any resulting change in the fair value being reflected in the consolidated statements of operations. We recorded income of approximately $78,000 and $42,000 to reflect the change in fair value for the years ended March&nbsp;31, 2011 and 2012, respectively. Fair value is estimated using an option-pricing model, which includes variables such as the expected volatility of our share price, interest rates, and dividend yields. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for changes in the valuation of the warrants liability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Scottish Enterprise Agreement</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accounting guidance on distinguishing liabilities and equity requires freestanding financial instruments that meet certain criteria to be accounted for as liabilities and carried at fair value until exercised or expired, with any changes in fair value recorded in the results of operations. We entered into an agreement with SE in 2009 that would require us to pay SE &#163;4&nbsp;million (approximately $6.4 million at March&nbsp;31, 2012) less the market value of the shares held by SE if staffing levels in Scotland fall below minimum levels stipulated in the Agreement. Due to the nature of the associated contingency and the likelihood of occurrence, we concluded the fair value of this liability was approximately $20,000 at March&nbsp;31, 2012. The most significant inputs in estimating the fair value of this liability are the probabilities that staffing levels fall below the prescribed minimum levels and that we are unable or unwilling to replace such employees within the prescribed time period. As of March&nbsp;31, 2012, we concluded the probability of the combination of these events occurring is minimal. We record changes in fair value in the consolidated statement of operations. There were no changes to the fair value for either the three months ended March&nbsp;31, 2012 or 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</font></b><a name="Item3_QuantitativeAndQualitativeD_072931"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to market risk related to fluctuations in foreign currency exchange rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Foreign Currency Risk</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to foreign currency rate fluctuations related to the operation of our subsidiary in the United Kingdom. At the end of each reporting period, income and expenses of the subsidiary are remeasured into U.S. dollars using the average currency rate in effect for the period and assets and liabilities are remeasured into U.S. dollars using either historical rates or the exchange rate in effect at the end of the period.&#160; From October&nbsp;1, 2008, foreign exchange gains and losses arising from U.S. dollar denominated intercompany loans with this subsidiary have been recorded have been recorded as a component of other comprehensive income.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently do not engage in foreign currency hedging. We enter into certain transactions denominated in foreign currencies in respect of underlying operations and, therefore, we are subject to currency exchange risks. &#160;We realized losses of approximately $68,000 and gains of $0.1 million for the three months ended March&nbsp;31, 2011 and 2012, respectively.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_080347_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock Price Risk</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In February&nbsp;2007, we issued common stock and warrants and recorded the fair value of the warrants as a current liability. The fair value of the outstanding warrants is evaluated at each reporting period with any resulting change in the fair value being reflected in the consolidated statements of operations.&nbsp;During the three months ended March&nbsp;31, 2012, we recognized the change in the value of warrants of approximately $42,000 as a gain on the consolidated statement of operations. During the three months ended March&nbsp;31, 2011, we recognized the change in the value of warrants as a gain of approximately $78,000 on the consolidated statement of operations. Fair value of the derivative instruments will be affected by estimates of various factors that may affect the respective instrument, including our stock price, the risk free rate of return and expected volatility in the fair value of our stock price. As the fair value of this derivative may fluctuate significantly from period to period, the resulting change in valuation may have a significant impact on our results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4. Controls and Procedures</font></b><a name="Item4_ControlsAndProcedures_072945"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the supervision and with the participation of our management, including our chief executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of March&nbsp;31, 2012, of our disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based upon such evaluation, our chief executive officer and principal financial and accounting officer have concluded that, as of March&nbsp;31, 2012, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i)&nbsp;is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules&nbsp;and forms and (ii)&nbsp;accumulated and communicated to our management, including our chief executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There have been no changes in our internal control over financial reporting during the quarter ended March&nbsp;31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Inherent Limitation on the Effectiveness of Internal Controls</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_080347_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II. </font></b><font size="2" style="font-size:10.0pt;">&#160;Other Information<a name="Partii_OtherInformation_072958"></a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1. Legal proceedings</font></b><a name="Item1_LegalProceedings_072959"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time, we may be involved in routine litigation incidental to the conduct of our business. On April&nbsp;27, 2010, we were served with a complaint filed by Celgene Corporation in the United States District Court for the District of Delaware seeking a declaratory judgment that four of our own patents, claiming the use of romidepsin injection in T-cell lymphomas, are invalid and not infringed by Celgene&#146;s products, but directly involve the use and administration of Celgene&#146;s ISTODAX</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(romidepsin for injection) product. On June&nbsp;17, 2010, we filed our answer and counterclaims to the declaratory judgment complaint. We have filed counterclaims charging Celgene with infringement of each of our four patents and seeking damages for Celgene&#146;s infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene&#146;s ISTODAX</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(romidepsin for injection) product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A scheduling Order was entered February&nbsp;2, 2012, at which time the court set the following significant dates: March&nbsp;22, 2012 (amendment of pleadings/joinder of parties); September&nbsp;24, 2012 (teleconference with the court exploring possibility of Alternative Dispute Resolution); March&nbsp;14, 2013 (claim construction hearing); August&nbsp;14, 2013 (summary judgment briefing); and June&nbsp;2, 2014 (7 day jury trial start date). Discovery is currently ongoing.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A. Risk Factors</font></b><a name="Item1a_RiskFactors_073003"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">In analyzing our company, you should consider carefully the following risk factors, together with all of the other information included in Part&nbsp;I, &#147;Item&nbsp;1A. Risk Factors&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011. Factors that could cause or contribute to differences in our actual results include those discussed in the following subsection, as well as those discussed above in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere throughout this Quarterly Report on Form&nbsp;10-Q. Each of the following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our common stock.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We have grouped risks into several categories in order of their potential impact on our results of operations, financial condition, and cash flows.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Associated with Development and Commercialization of Our Drug Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Clinical trial designs that were discussed with the authorities prior to their commencement may subsequently be considered insufficient for approval at the time of application for regulatory approval.&nbsp; Thus, our SPA regarding our SEAMLESS trial does not guarantee marketing approval or approval of our sapacitabine oral capsules for the treatment of AML.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;13, 2010, and as amended on October&nbsp;11, 2011, we reached agreement with the FDA regarding an SPA on the design of a pivotal Phase 3 trial for our sapacitabine oral capsules as a front-line treatment in elderly patients aged 70&nbsp;years or older with newly diagnosed AML,&nbsp;who are not candidates for intensive induction chemotherapy, or the SEAMLESS trial. An SPA provides trial sponsors with an agreement from the FDA that the design and analysis of the trial adequately address objectives in support of a submission for a marketing application if the trial is performed according to the SPA. The SPA may only be changed through a written agreement between the sponsor and the FDA or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. In January&nbsp;2011, we opened enrollment in the lead-in portion of the SEAMLESS trial and in October&nbsp;2011, we opened enrollment in the randomized portion of the trial.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An SPA, however, neither guarantees approval nor provides any assurance that a marketing application would be approved by the FDA. There are companies that have been granted SPAs but have ultimately failed to obtain final approval to market their drugs.&nbsp; The FDA may revise previous guidance or decide to ignore previous guidance at any time during the course of clinical activities or after the completion of clinical trials. The FDA may raise issues relating to, among other things,&nbsp;safety, study conduct, bias, deviation from the protocol, statistical power, patient completion rates, changes in scientific or medical parameters or internal inconsistencies in the data prior to making its final decision. The FDA may also seek the guidance of an outside advisory committee prior to making its final decision. Even with successful clinical safety and efficacy data, including such data from a clinical trial conducted pursuant to an SPA, we may be required to conduct additional, expensive clinical trials to obtain regulatory approval.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_080347_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate development or increase our expenditures.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances with pharmaceutical companies or other industry participants to advance our programs and enable us to maintain our financial and operational capacity.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all. In addition, these alliances may be unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our drug development or research programs. If we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Clinical trials are expensive, time consuming, subject to delay and may be required to continue beyond our available funding and we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Clinical trials are expensive, complex, can take many years to conduct and may have uncertain outcomes. We estimate that clinical trials of our most advanced drug candidates may be required to continue beyond our available funding and may take several more years to complete. The designs used in some of our trials have not been used widely by other pharmaceutical companies. Failure can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future drug candidates, including but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">delays in securing clinical investigators or trial sites for our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">delays in obtaining IRB and other regulatory approvals to commence a clinical trial;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">slower than anticipated rates of patient recruitment and enrollment, or not reaching the targeted number of patients because of competition for patients from other trials, or if there is limited or no availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payors for the use of agents used in our clinical trials, such as </font><font size="2" style="font-size:10.0pt;">Dacogen&#174; (decitabine)&#160; in SEAMLESS, or </font><font size="2" style="font-size:10.0pt;">other reasons;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">negative or inconclusive results from clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">unforeseen safety issues;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">uncertain dosing issues may or may not be related to suboptimal pharmacokinetic and pharmacodynamic behaviors;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">approval and introduction of new therapies or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications obsolete;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_080347_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">inability or unwillingness of medical investigators to follow our clinical protocols; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">unavailability of clinical trial supplies.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we suffer any significant delays, setbacks or negative results in, or termination of, our clinical trials, we may be unable to continue development of our drug candidates or generate revenue and our development costs could increase significantly. Adverse events have been observed in our clinical trials and may force us to stop development of our product candidates or prevent regulatory approval of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adverse or inconclusive results from our clinical trials may substantially delay, or halt entirely, any further development of our drug candidates. Many companies have failed to demonstrate the safety or effectiveness of drug candidates in later stage clinical trials notwithstanding favorable results in early stage clinical trials. Previously unforeseen and unacceptable side effects could interrupt, delay or halt clinical trials of our drug candidates and could result in the FDA or other regulatory authorities denying approval of our drug candidates. We will need to demonstrate safety and efficacy for specific indications of use, and monitor safety and compliance with clinical trial protocols throughout the development process. To date, long-term safety and efficacy has not been demonstrated in clinical trials for any of our drug candidates. Toxicity and &#147;serious adverse events&#148; as defined in trial protocols have been noted in preclinical and clinical trials involving certain of our drug candidates. For example, neutropenia and gastro-intestinal toxicity were observed in patients receiving sapacitabine and elevations of liver enzymes and decrease in potassium levels have been observed in patients receiving seliciclib.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we may pursue clinical trials for sapacitabine and seliciclib in more than one indication. There is a risk that severe toxicity observed in a trial for one indication could result in the delay or suspension of all trials involving the same drug candidate. Even if we believe the data collected from clinical trials of our drug candidates are promising with respect to safety and efficacy, such data may not be deemed sufficient by regulatory authorities to warrant product approval. Clinical data can be interpreted in different ways. Regulatory officials could interpret such data in different ways than we do which could delay, limit or prevent regulatory approval. The FDA, other regulatory authorities or we may suspend or terminate clinical trials at any time. Any failure or significant delay in completing clinical trials for our drug candidates, or in receiving regulatory approval for the commercialization of our drug candidates, may severely harm our business and reputation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are making use of biomarkers, which are not scientifically validated, and our reliance on biomarker data may thus lead us to direct our resources inefficiently.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are making use of biomarkers in an effort to facilitate our drug development and to optimize our clinical trials. Biomarkers are proteins or other substances whose presence in the blood can serve as an indicator of specific cell processes. We believe that these biological markers serve a useful purpose in helping us to evaluate whether our drug candidates are having their intended effects through their assumed mechanisms, and thus enable us to identify more promising drug candidates at an early stage and to direct our resources efficiently. We also believe that biomarkers may eventually allow us to improve patient selection in connection with clinical trials and monitor patient compliance with trial protocols.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For most purposes, however, biomarkers have not been scientifically validated. If our understanding and use of biomarkers is inaccurate or flawed, or if our reliance on them is otherwise misplaced, then we will not only fail to realize any benefits from using biomarkers, but may also be led to invest time and financial resources inefficiently in attempting to develop inappropriate drug candidates. Moreover, although the FDA has issued for comment a draft guidance document on the potential use of biomarker data in clinical development, such data are not currently accepted by the FDA or other regulatory agencies in the United States, the European Union or elsewhere in applications for regulatory approval of drug candidates and there is no guarantee that such data will ever be accepted by the relevant authorities in this connection. Our biomarker data should not be interpreted as evidence of efficacy.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_080347_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Due to our reliance on contract research organizations or other third parties to conduct clinical trials, we may be unable to directly control the timing, conduct and expense of our clinical trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have the ability to independently conduct clinical trials required to obtain regulatory approvals for our drug candidates. We must rely on third parties, such as contract research organizations, data management companies, contract clinical research associates, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. In addition, we rely on third parties to assist with our preclinical development of drug candidates. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we are not currently party to any collaboration arrangement or strategic alliance that is material to our business, in the future we expect to be dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of some of our drug candidates particularly after the Phase 2 stage of clinical testing. These arrangements may place the development of our drug candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dependence on collaborative arrangements or strategic alliances will subject us to a number of risks, including the risk that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may not be able to control the amount and timing of resources that our collaborators may devote to the drug candidates;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our collaborators may experience financial difficulties;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may be required to relinquish important rights such as marketing and distribution rights;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">business combinations or significant changes in a collaborator&#146;s business strategy may also adversely affect a collaborator&#146;s willingness or ability to complete our obligations under any arrangement;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have no manufacturing capacity and will rely on third party manufacturers for the late stage development and commercialization of any drugs or devices we may develop or sell.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not currently operate manufacturing facilities for clinical or commercial production of our drug candidates under development or our currently marketed ALIGN products. We currently lack the resources or the capacity to manufacture any of our products on a clinical or commercial scale. We anticipate future reliance on a limited number of third party manufacturers until we are able, or decide to, expand our operations to include manufacturing capacities. If the FDA or other regulatory agencies approve any of our drug candidates for commercial sale, or if we significantly expand our clinical trials, we will need to manufacture them in larger quantities and will be required to secure alternative third-party suppliers to our current suppliers. To date, our drug candidates have been manufactured in small quantities for preclinical testing and clinical trials and we may not be able to successfully increase the manufacturing capacity, whether in collaboration with our current or future third-party manufacturers or on our own, for any of our drug candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA and other regulatory bodies must review and approve. If we are unable to successfully increase the manufacturing capacity for a drug candidate whether for late stage clinical trials or for commercial sale or are unable to secure alternative third-party suppliers to our current suppliers, the drug development, regulatory approval or commercial launch of any related drugs may be delayed or blocked or there may be a shortage in supply. Even if any third party manufacturer makes improvements in the manufacturing process for our drug candidates, we may not own, or may have to share, the intellectual property rights to such innovation. Any performance failure on the part of manufacturers could delay late stage clinical development or regulatory approval of our drug, the commercialization of our drugs or our ability to sell our commercial products, producing additional losses and depriving us of potential product revenues. We depend upon a third party, Sinclair, to manufacture the commercial products sold by our ALIGN subsidiary and we cannot assure that Sinclair will be able to continue to supply the products.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_080347_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">As we evolve from a company primarily involved in discovery and development to one also involved in the commercialization of drugs and devices, we may encounter difficulties in managing our growth and expanding our operations successfully.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In order to execute our business strategy, we will need to expand our development, control and regulatory capabilities and develop financial, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. If our operations expand, we expect that we will need to manage additional relationships with various collaborative partners, suppliers and other third parties. Our ability to manage our operations and any growth will require us to make appropriate changes and upgrades, as necessary, to our operational, financial and management controls, reporting systems and procedures wherever we may operate. Any inability to manage growth could delay the execution of our business plan or disrupt our operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The failure to attract and retain skilled personnel and key relationships could impair our drug development and commercialization efforts.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are highly dependent on our senior management and key clinical development, scientific, technical and sales and marketing personnel. Competition for these types of personnel is intense. The loss of the services of any member of our senior management, clinical development, scientific, technical or sales and marketing staff may significantly delay or prevent the achievement of drug development and other business objectives and could have a material adverse effect on our business, operating results and financial condition. We also rely on consultants and advisors to assist us in formulating our strategy. All of our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, that may affect their ability to contribute to us. The success of the commercialization of the ALIGN products depends, in large part, on our continued ability to develop and maintain important relationships with distributors and research and medical institutions. Failure to do that could have a material adverse effect on our ability to commercialize the ALIGN products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We intend to expand and develop new drug candidates. We will need to hire additional employees in order to continue our clinical trials and market our drug candidates and medical devices. This strategy will require us to recruit additional executive management and clinical development, scientific and technical personnel. There is currently intense competition for skilled executives and employees with relevant clinical development, scientific and technical expertise, and this competition is likely to continue. The inability to attract and retain sufficient clinical development, scientific, technical and managerial personnel could limit or delay our product development efforts, which would adversely affect the development of our drug candidates and commercialization of our potential drugs and growth of our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_080347_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our drug candidates are subject to extensive regulation, which can be costly and time-consuming, and we may not obtain approvals for the commercialization of any of our drug candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The clinical development, manufacturing, selling and marketing of our drug candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States, the European Union and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA. We have not received an NDA approval from the FDA for any of our drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Obtaining an NDA approval is expensive and is a complex, lengthy and uncertain process. The FDA approval process for a new drug involves completion of preclinical studies and the submission of the results of these studies to the FDA, together with proposed clinical protocols, manufacturing information, analytical data and other information in an IND, which must become effective before human clinical trials may begin. Clinical development typically involves three phases of study: Phase 1, 2 and 3. The most significant costs associated with clinical development are the pivotal or suitable for registration late Phase 2 or Phase 3 clinical trials as they tend to be the longest and largest studies conducted during the drug development process. After completion of clinical trials, an NDA may be submitted to the FDA. In responding to an NDA, the FDA may refuse to file the application, or if accepted for filing, the FDA may grant marketing approval, request additional information or deny the application if it determines that the application does not provide an adequate basis for approval. In addition, failure to comply with the FDA and other applicable foreign and U.S. regulatory requirements may subject us to administrative or judicially imposed sanctions. These include warning letters, civil and criminal penalties, injunctions, product seizure or detention, product recalls, total or partial suspension of production and refusal to approve either pending NDAs, or supplements to approved NDAs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is substantial time and expense invested in preparation and submission of an NDA or equivalents in other jurisdictions and regulatory approval is never guaranteed. The FDA and other regulatory authorities in the United States, the European Union and elsewhere exercise substantial discretion in the drug approval process. The number, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the drug candidate, the disease or condition for which the drug candidate is intended to be used and the regulations and guidance documents applicable to any particular drug candidate. The FDA or other regulators can delay, limit or deny approval of a drug candidate for many reasons, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">those discussed in the risk factor which immediately follows;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the fact that the FDA or other regulatory officials may not approve our or our third party manufacturer&#146;s processes or facilities; or</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adoption of new regulations requiring new or different evidence of safety and efficacy for the intended use of a drug candidate.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">With regard to the ALIGN products, and following regulatory approval of any of our drug candidates, we are subject to ongoing regulatory obligations and restrictions, which may result in significant expense and limit our ability to commercialize our potential products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With regard to our ALIGN products and our drug candidates, if any, approved by the FDA or by another regulatory authority, we are held to extensive regulatory requirements over product manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the drug candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product or drug candidate, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the drug or device, and could include withdrawal of the drug or device from the market.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_080347_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\106461\12-9682-1\task5355996\9682-1-ba-11.htm',USER='106461',CD='May 15 22:29 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs and our business could suffer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our applications for regulatory approval could be delayed or denied due to problems with studies conducted before we in-licensed the rights to some of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently license some of the compounds and drug candidates used in our research programs from third parties. These include sapacitabine which was licensed from Daiichi Sankyo. Our present research involving these compounds relies upon previous research conducted by third parties over whom we had no control and before we in-licensed the drug candidates. In order to receive regulatory approval of a drug candidate, we must present all relevant data and information obtained during our research and development, including research conducted prior to our licensure of the drug candidate. Although we are not currently aware of any such problems, any problems that emerge with preclinical research and testing conducted prior to our in-licensing may affect future results or our ability to document prior research and to conduct clinical trials, which could delay, limit or prevent regulatory approval for our drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face intense competition and our competitors may develop drugs that are less expensive, safer, or more effective than our drug candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A large number of drug candidates are in development for the treatment of leukemia, lung cancer, lymphomas and nasopharyngeal cancer. Several pharmaceutical and biotechnology companies have nucleoside analogs or other products on the market or in clinical trials which may be competitive to sapacitabine in both hematological and oncology indications. See &#147;Competition&#148; under <i>Item 1. Business</i> for further details.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors, either alone or together with collaborators, may have substantially greater financial resources and research and development staff. Our competitors may also have more experience:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developing drug candidates;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conducting preclinical and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtaining regulatory approvals; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">commercializing product candidates.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors may succeed in obtaining patent protection and regulatory approval and may market drugs before we do. If our competitors market drugs that are less expensive, safer, more effective or more convenient to administer than our potential drugs, or that reach the market sooner than our potential drugs, we may not achieve commercial success. Scientific, clinical or technical developments by our competitors may render our drug candidates obsolete or noncompetitive. We anticipate that we will face increased competition in the future as new companies enter the markets and as scientific developments progress. If our drug candidates obtain regulatory approvals, but do not compete effectively in the marketplace, our business will suffer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The commercial success of our drug candidates and the ALIGN products depends upon their market acceptance among physicians, patients, healthcare providers and payors and the medical community.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If our drug candidates are approved, or approved in combination with another agent such as </font><u><font size="2" style="font-size:10.0pt;">Dacogen</font></u><font size="2" style="font-size:10.0pt;">&#174; (decitabine) in SEAMLESS, </font><font size="2" style="font-size:10.0pt;">by the FDA or by another regulatory authority, the resulting drugs, if any, must still gain market acceptance among physicians, healthcare providers and payors, patients and the medical community, as would our distribution partners&#146; products, including Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges. The degree of market acceptance of any of our approved drugs or devices will depend on a variety of factors, including:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_080446_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">timing of market introduction, number and clinical profile of competitive drugs;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to provide acceptable evidence of safety and efficacy;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">relative convenience and ease of administration;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">cost-effectiveness;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payors;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prevalence and severity of adverse side effects; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">other potential advantages over alternative treatment methods.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If our drug candidates or distribution partners&#146; products fail to achieve market acceptance, we may not be able to generate significant revenue and our business would suffer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to compete successfully in our market place, it will harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are existing products in the marketplace that compete with our products. Companies may develop new products that compete with our products. Certain of these competitors and potential competitors have longer operating histories, substantially greater product development capabilities and financial, scientific, marketing and sales resources. Competitors and potential competitors may also develop products that are safer, more effective or have other potential advantages compared to our products. In addition, research, development and commercialization efforts by others could render our products obsolete or non-competitive. Certain of our competitors and potential competitors have broader product offerings and extensive customer bases allowing them to adopt aggressive pricing policies that would enable them to gain market share. Competitive pressures could result in price reductions, reduced margins and loss of market share. We could encounter potential customers that, due to existing relationships with our competitors, are committed to products offered by those competitors. As a result, those potential customers may not consider purchasing our products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual property rights and distribution rights for our drug candidate seliciclib and ALIGN products are licensed from others, and any termination of these licenses could harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have in-licensed certain patent rights in connection with the development program of our drug candidate seliciclib. Pursuant to the CNRS and Institut Curie license under which we license seliciclib, we are obligated to pay license fees, milestone payments and royalties and provide regular progress reports. We are also obligated to use reasonable efforts to develop and commercialize products based on the licensed patents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have in-licensed from Sinclair the distribution rights to the ALIGN products. This license agreement imposes obligations on us and expires in 2015. Although we believe we are currently in compliance with all of our material obligations under these licenses, if we were to breach any such obligations our counterparties may be entitled to terminate the licenses. Any attempts to terminate our distribution rights could have adverse consequences on the ALIGN business. This could restrict our ability to sell the ALIGN products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be exposed to product liability claims that may damage our reputation and we may not be able to obtain adequate insurance.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we conduct clinical trials in humans, we face the risk that the use of our drug candidates will result in adverse effects. We believe that we have obtained reasonably adequate product liability insurance coverage for our trials. We cannot predict, however, the possible harm or side effects that may result from our clinical trials. Such claims may damage our reputation and we may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limit of, our insurance coverage or if the amount of the insurance coverage is insufficient to meet any liabilities resulting from any claims.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_080446_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As we market commercialized products through our ALIGN subsidiary we are exposed to additional risks of product liability claims. These risks exist even with respect to drugs and devices that are approved for commercial sale by the FDA or other regulatory authorities in the United States, the European Union or elsewhere and manufactured in facilities licensed and regulated by the FDA or other such regulatory authorities. We have secured limited product liability insurance coverage, but may not be able to maintain such insurance on acceptable terms with adequate coverage, or at a reasonable cost. There is also a risk that third parties that we have agreed to indemnify could incur liability. Even if we were ultimately successful in product liability litigation, the litigation would consume substantial amounts of our financial and managerial resources and may exceed insurance coverage creating adverse publicity, all of which would impair our ability to generate sales of the litigated product as well as our other potential drugs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be required to defend lawsuits or pay damages in connection with the alleged or actual violation of healthcare statutes such as fraud and abuse laws, and our corporate compliance programs can never guarantee that we are in compliance with all relevant laws and regulations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercialization efforts in the United States are subject to various federal and state laws pertaining to promotion and healthcare fraud and abuse, including federal and state anti-kickback, fraud and false claims laws. Anti-kickback laws make it illegal for a manufacturer to offer or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase of a product. The federal government has published many regulations relating to the anti-kickback statutes, including numerous safe harbors or exemptions for certain arrangements. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payers including Medicare and Medicaid, claims for reimbursed products or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our activities relating to the sale and marketing of our products will be subject to scrutiny under these laws and regulations. It may be difficult to determine whether or not our activities, comply with these complex legal requirements. Violations are punishable by significant criminal and/or civil fines and other penalties, as well as the possibility of exclusion of the product from coverage under governmental healthcare programs, including Medicare and Medicaid. If the government were to investigate or make allegations against us or any of our employees, or sanction or convict us or any of our employees, for violations of any of these legal requirements, this could have a material adverse effect on our business, including our stock price. Our activities could be subject to challenge for many reasons, including the broad scope and complexity of these laws and regulations, the difficulties in interpreting and applying these legal requirements, and the high degree of prosecutorial resources and attention being devoted to the biopharmaceutical industry and health care fraud by law enforcement authorities. During the last few years, numerous biopharmaceutical companies have paid multi-million dollar fines and entered into burdensome settlement agreements for alleged violation of these requirements, and other companies are under active investigation. Although we have developed and implemented corporate and field compliance programs as part of our commercialization efforts, we cannot assure you that we or our employees, directors or agents were, are or will be in compliance with all laws and regulations or that we will not come under investigation, allegation or sanction.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we may be required to prepare and report product pricing-related information to federal and state governmental authorities, such as the Department of Veterans Affairs and under the Medicaid program. The calculations used to generate the pricing-related information are complex and require the exercise of judgment. If we fail to accurately and timely report product pricing-related information or to comply with any of these or any other laws or regulations, various negative consequences could result, including criminal and/or civil prosecution, substantial criminal and/or civil penalties, exclusion of the approved product from coverage under governmental healthcare programs including Medicare and Medicaid, costly litigation and restatement of our financial statements. In addition, our efforts to comply with this wide range of laws and regulations are, and will continue to be, time-consuming and expensive.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_080446_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If our supplier upon whom we rely fails to produce on a timely basis the finished goods in the volumes that we require or fails to meet quality standards and maintain necessary licensure from regulatory authorities, we may be unable to meet demand for our products, potentially resulting in lost revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any third party manufacturer service providers do not meet our or our licensor&#146;s requirements for quality, quantity or timeliness, or do not achieve and maintain compliance with all applicable regulations, demand for our products or our ability to continue supplying such products could substantially decline. As the third party manufacturers are the sole supplier of the products any delays may impact our sales.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In all the countries where we sell or may sell our products, governmental regulations exist to define standards for manufacturing, packaging, labeling and storing. All of our suppliers of raw materials and contract manufacturers must comply with these regulations. Failure to do so could result in supply interruptions. In the United States, the FDA requires that all suppliers of pharmaceutical bulk material and all manufacturers of pharmaceuticals for sale in or from the United States achieve and maintain compliance with the FDA&#146;s cGMP regulations and guidelines. Failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on them or us, including fines, injunctions, civil penalties, disgorgement, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, before any product batch produced by our manufacturers can be shipped, it must conform to release specifications pre-approved by regulators for the content of the pharmaceutical product. If the operations of one or more of our manufacturers were to become unavailable for any reason, any required FDA review and approval of the operations of an alternative supplier could cause a delay in the manufacture of our products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our customer base is highly concentrated.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our principal customers are a small number of wholesale drug distributors. Sales to three wholesale distributors represented 90% and 86% of our product sales in the United States for the three months ended March&nbsp;31, 2011 and 2012, respectively. These customers comprise a significant part of the distribution network for pharmaceutical products in the United States. Three large wholesale distributors, AmerisourceBergen Corporation, Cardinal Health,&nbsp;Inc. and McKesson Corporation, control a significant share of the market in the United States. Our ability to distribute any product, including Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges and to recognize revenues on a timely basis is substantially dependent on our ability to maintain commercially reasonable agreements with each of these wholesale distributors and the extent to which these distributors, over whom we have no control, comply with such agreements. Our agreements with wholesaler distributors may contain terms that are not favorable, given our relative lack of market leverage as a company with only three approved products or other factors, which could adversely affect our commercialization of Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges. The loss of any of these customers could materially and adversely affect our ability to distribute our products, resulting in a negative impact on our operations and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be unable to accurately estimate demand and monitor wholesaler inventory of Xclair&#174; Cream, Numoisyn&#174; Liquid or Numoisyn&#174; Lozenges.&#160; Although we attempt to monitor wholesaler inventory, which is inherently uncertain and may not be accurate, to assist us in monitoring estimated inventory levels and prescription trends. Inaccurate estimates of the demand and inventory levels of the product may cause our revenues to fluctuate significantly from quarter to quarter and may cause our operating results for a particular quarter to be below expectations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Inventory levels of Xclair&#174; Cream, Numoisyn&#174; Liquid or Numoisyn&#174; Lozenges held by three wholesalers, Cardinal Health,&nbsp;Inc., McKesson Corporation and Amerisource Bergen, can cause our operating results to fluctuate unexpectedly if our sales to wholesalers do not match customer demand. We have entered into inventory management agreements with these U.S. wholesalers under which they provide us with data regarding inventory levels. However, these wholesalers may not be completely effective in matching inventory levels to customer demand, as they make estimates to determine customer demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations, for which we have no inventory management agreements and have no control in respect to their buying patterns. Also, the non-retail sector in the United States, which includes government institutions and large health maintenance organizations, tends to be less consistent in terms of buying patterns. Although we attempt to monitor inventory of Xclair&#174;, Numoisyn&#174; Liquid or Numoisyn&#174; Lozenges in the United States through the use of internal sales forecasts and the expiration dates of product shipped, among other factors, we may have quarter-over-quarter fluctuations in inventory and ordering patterns, which can cause our operating results for a particular quarter to be below expectations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45<a name="PB_45_080446_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The commercialization of our products is substantially dependent on our ability to develop effective sales and marketing capabilities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our successful commercialization of Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges in the United States will depend on our ability to establish and maintain effective sales and marketing initiatives in the United States. Although we launched the ALIGN products with a small specialty oncology sales force, we now sell and market our products via unique sales and marketing strategies in order to reduce costs. We contracted, trained and deployed additional telemarketing personnel to call on specialists who prescribe ALIGN products.&#160; We also utilize mailings, print advertising, sampling, trade show attendance and other unique marketing programs to reach our customer base. We may increase or decrease the size of our telemarketing sales force in the future, depending on many factors, including the effectiveness of the sales force, the level of market acceptance of Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges and the results of our clinical trials. Prior to our launches of these products, we had never sold or marketed any products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For our product candidates currently under development, our strategy is to develop compounds through the Phase 2 stage of clinical testing and market or co-promote certain of our drugs. We have limited sales, marketing or distribution capabilities. We will depend primarily on strategic alliances with third parties, which have established distribution systems and sales forces, to commercialize our drugs. To the extent that we are unsuccessful in commercializing any drugs or devices ourselves or through a strategic alliance, product revenues may suffer, we may incur significant additional losses and our share price will be negatively affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemical, radioactive or biological materials could be time consuming and expensive.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our research and development involves the controlled use of hazardous materials, including chemicals, radioactive and biological materials such as chemical solvents, phosphorus and bacteria. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from those materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Business and Financial Condition</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Raising additional capital in the future may not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing stockholders would experience further dilution. If we fail to obtain additional funding, we may be unable to complete the development and commercialization of our lead drug candidate, sapacitabine, or continue to fund our research and development programs.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have funded all of our operations and capital expenditures with proceeds from the issuance of public equity securities, private placements of our securities, interest on investments, licensing revenue, government grants, research and development tax credits and product revenue. In order to conduct the lengthy and expensive research, preclinical testing and clinical trials necessary to complete the development and marketing of our drug candidates, we will require substantial additional funds. We may have insufficient public equity available for issue to raise the required additional substantial funds to implement our operating plan and we may not be able to obtain the appropriate stockholder approvals necessary to increase our available public equity for issuance within a time that we may require additional funding. Based on our current operating plans of focusing on the advancement of sapacitabine, we expect our existing resources to be sufficient to fund our planned operations for at least the next twelve months. To meet our long-term financing requirements, we may raise funds through public or private equity offerings, debt financings or strategic alliances. Raising additional funds by issuing equity or convertible debt securities may cause our stockholders to experience substantial dilution in their ownership interests and new investors may have rights superior to the rights of our other stockholders. Raising additional funds through debt financing, if available, may involve covenants that restrict our business activities and options. To the extent that we raise additional funds through collaborations and licensing arrangements, we may have to relinquish valuable rights to our drug discovery and other technologies, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. Additional funding may not be available to us on favorable terms, or at all, particularly in light of the current economic conditions.&#160; If we are unable to obtain additional funds, we may be forced to delay or terminate our current clinical trials and the development and marketing of our drug candidates including sapacitabine.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46<a name="PB_46_080446_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Capital markets are currently experiencing a period of disruption and instability, which has had and could continue to have a negative impact on the availability and cost of capital.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The general disruption in the United States capital markets has impacted the broader worldwide financial and credit markets and reduced the availability of debt and equity capital for the market as a whole. These global conditions could persist for a prolonged period of time or worsen in the future. Our ability to access the capital markets may be restricted at a time when we would like, or need, to access those markets, which could have an impact on our flexibility to react to changing economic and business conditions. The resulting lack of available credit, lack of confidence in the financial sector, increased volatility in the financial markets could materially and adversely affect the cost of debt financing and the proceeds of equity financing may be materially adversely impacted by these market conditions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The current economic conditions and financial market turmoil could adversely affect our business and results of operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Economic conditions remain difficult with the continuing uncertainty in the global credit markets, the European Union, the financial services industry and the United States capital markets and with the United States economy as a whole experiencing a period of substantial turmoil and uncertainty characterized by unprecedented intervention by the United States federal government and the failure, bankruptcy, or sale of various financial and other institutions. We believe the current economic conditions and financial market turmoil could adversely affect our operations, business and prospects, as well as our ability to obtain funds. If these circumstances persist or continue to worsen, our future operating results could be adversely affected, particularly relative to our current expectations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are at an early stage of development as a company and we do not have, and may never have, any products that generate significant revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are at an early stage of development as a company and have a limited operating history on which to evaluate our business and prospects. While we have earned modest product revenues from the ALIGN business acquired in October&nbsp;2007, since beginning operations in 1996, we have not generated any product revenues from our product candidates currently in development. We cannot guarantee that any of our product candidates currently in development will ever become marketable products and we do not anticipate material revenues from the ALIGN products in the foreseeable future. We must demonstrate that our drug candidates satisfy rigorous standards of safety and efficacy for their intended uses before the FDA, and other regulatory authorities in the United States, the European Union and elsewhere. Significant additional research, preclinical testing and clinical testing is required before we can file applications with the FDA or other regulatory authorities for premarket approval of our drug candidates. In addition, to compete effectively, our drugs must be easy to administer, cost-effective and economical to manufacture on a commercial scale. We may not achieve any of these objectives. Sapacitabine, our most advanced drug candidates for the treatment of cancer, is currently in Phase 3 for AML and Phase 2 for MDS, NSCLC and CLL. A combination trial of sapacitabine and seliciclib is currently in a Phase 1 clinical trial. We cannot be certain that the clinical development of these or any other drug candidates in preclinical testing or clinical development will be successful, that we will receive the regulatory approvals required to commercialize them or that any of our other research and drug discovery programs will yield a drug candidate suitable for investigation through clinical trials. Our commercial revenues from our product candidates currently in development, if any, will be derived from sales of drugs that will not become marketable for several years, if at all.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47<a name="PB_47_080446_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have a history of operating losses and we may never become profitable. Our stock is a highly speculative investment.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred operating losses in each year since beginning operations in 1996 due to costs incurred in connection with our research and development activities and selling, general and administrative costs associated with our operations, and we may never achieve profitability.&#160; As of December&nbsp;31, 2011 and March&nbsp;31, 2012, our accumulated deficit was $257.1 million and $260.0 million, respectively.&#160; Our net loss for the three months ended March&nbsp;31, 2011 and 2012 was $4.6 million, $2.9 million, respectively. Our net loss applicable to common stockholders from inception through March&nbsp;31, 2012 was $302.0 million.&#160; Our drug candidates are in the mid-stages of clinical testing and we must conduct significant additional clinical trials before we can seek the regulatory approvals necessary to begin commercial sales of our drugs. We expect to incur continued losses for several years, as we continue our research and development of our drug candidates, seek regulatory approvals, commercialize any approved drugs and market and promote the ALIGN products: Xclair&#174; Cream, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges. If our drug candidates are unsuccessful in clinical trials or we are unable to obtain regulatory approvals, or if our drugs are unsuccessful in the market, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, particularly in light of the current economic conditions, you could lose all or part of your investment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with the continued listing requirements of the&nbsp;NASDAQ Global Market, our common stock may be delisted&nbsp;and the price&nbsp;of our common stock and our ability to access the capital markets could be negatively impacted.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our common stock is currently listed for trading on the NASDAQ Global Market. We must satisfy NASDAQ&#146;s continued listing requirements, including&nbsp;among other things,&nbsp;a minimum stockholders&#146; equity of $10.0 million and a minimum bid price for our common stock of $1.00 per share, or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from the NASDAQ Global Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In September&nbsp;2011, we received a NASDAQ Staff Deficiency Letter indicating that were not in compliance with the minimum bid price requirement for continued listing on the NASDAQ exchange because the bid price for the common stock had closed under $1.00 for 30 consecutive business days. On March&nbsp;15, 2012, we were notified by the NASDAQ Staff that we did not comply with the minimum bid price set forth in NASDAQ Listing Rule&nbsp;5450(a)(1)&nbsp;(the &#147;Rule&#148;) and that our securities are subject to delisting from The NASDAQ Global Market unless we request a hearing before a NASDAQ Listing Qualifications Panel (the &#147;Panel&#148;). We timely requested a hearing before the Panel, which automatically stays the delisting of our securities pending the issuance of the Panel&#146;s decision after a hearing.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;26, 2012, we presented our plan, which could include effectuating a reverse stock split, to regain compliance with the Rule&nbsp;before the Panel. On May 15, 2012, the Panel approved the Company&#146;s plan to regain compliance, and determined to continue our listing pursuant to an exception to the Rule&nbsp;for a maximum of 180 days from the date of the Staff&#146;s notification or through September&nbsp;11, 2012, provided that we have evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days prior to such date.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48<a name="PB_48_080446_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are unable to provide evidence of compliance with the Rule, we may transfer our listing to The NASDAQ Capital Market if we meet the initial listing requirements set forth in NASDAQ Marketplace Rule&nbsp;5505, except for the bid price requirement, which requirements include, among other things, the following criteria: (i)&nbsp;our stockholders&#146; equity must be at least $5,000,000; (ii)&nbsp;the market value of our publicly held shares must be at least $15,000,000; and (iii)&nbsp;the market value of our shares held by non-affiliates must be at least $1,000,000. In that case, we may have until September&nbsp;11, 2012 to regain compliance. The Company currently meets these initial listing criteria of the NASDAQ Capital Market, except for the bid price requirement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">To the extent we elect to fund the development of a drug candidate or the commercialization of a drug at our expense, we will need substantial additional funding.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We plan to market drugs on our own, with or without a partner, that can be effectively commercialized and sold in concentrated markets that do not require a large sales force to be competitive. To achieve this goal, we will need to establish our own specialized sales force, marketing organization and supporting distribution capabilities. The development and commercialization of our drug candidates is very expensive, including our Phase 3 clinical trials for sapacitabine. To the extent we elect to fund the full development of a drug candidate or the commercialization of a drug at our expense, we will need to raise substantial additional funding to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fund research and development and clinical trials connected with our research;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fund clinical trials and seek regulatory approvals;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">build or access manufacturing and commercialization capabilities;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">implement additional internal control systems and infrastructure;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">commercialize and secure coverage, payment and reimbursement of our drug candidates, if any such candidates receive regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, defend and expand the scope of our intellectual property; and</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire additional management, sales and scientific personnel.</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future funding requirements will depend on many factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, rate of progress and cost of our clinical trials and other research and development activities;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs and timing of seeking and obtaining regulatory approvals;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.15pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.15pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs associated with establishing sales and marketing capabilities;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of acquiring or investing in businesses, products and technologies;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effect of competing technological and market developments; and</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the payment, other terms and timing of any strategic alliance, licensing or other arrangements that we may establish.</font></p>
<p style="margin:0in 0in .0001pt 56.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are not able to secure additional funding when needed, especially in light of the current economic conditions and financial market turmoil, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or future commercialization efforts.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49<a name="PB_49_080446_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Any future workforce and expense reductions may have an adverse impact on our internal programs, strategic plans, and our ability to hire and retain key personnel, and may also be distracting to our management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further workforce and expense reductions in addition to those carried out in September&nbsp;2008 and June&nbsp;2009 could result in significant delays in implementing our strategic plans. In addition, employees, whether or not directly affected by such reduction, may seek future employment with our business partners or competitors. Although our employees are required to sign a confidentiality agreement at the time of hire, the confidential nature of certain proprietary information may not be maintained in the course of any such future employment. In addition, any additional workforce reductions or restructurings would be expected to involve significant expense as a result of contractual terms in certain of our existing agreements, including potential severance obligations as well as any payments that may, under certain circumstances, be required under our agreement with the Scottish Enterprise. Further, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled personnel. We may have difficulty retaining and attracting such personnel as a result of a perceived risk of future workforce and expense reductions. Finally, the implementation of expense reduction programs may result in the diversion of the time and attention of our executive management team and other key employees, which could adversely affect our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Funding constraints may negatively impact our research and development, forcing us to delay our efforts to develop certain product candidates in favor of developing others, which may prevent us from commercializing our product candidates as quickly as possible.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development is an expensive process. As part of our operating plan, we have decided to focus our clinical development priorities on sapacitabine, while still possibly continuing to progress additional programs pending the availability of clinical data and the availability of funds, at which time we will determine the feasibility of pursuing, if at all, further advanced development of seliciclib, or additional programs. Because we have had to prioritize our development candidates as a result of budget constraints, we may not be able to fully realize the value of our product candidates in a timely manner, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are exposed to risks related to foreign currency exchange rates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some of our costs and expenses are denominated in foreign currencies. Most of our foreign expenses are associated with our research and development operations of our United Kingdom-based wholly-owned subsidiary. When the United States dollar weakens against the British pound, the United States dollar value of the foreign currency denominated expense increases, and when the United States dollar strengthens against the British pound, the United States dollar value of the foreign currency denominated expense decreases. Consequently, changes in exchange rates, and in particular a weakening of the United States dollar, may adversely affect our results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain potential drugs, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50<a name="PB_50_080446_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\105948\12-9682-1\task5355994\9682-1-ba-13.htm',USER='105948',CD='May 15 22:32 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to enforce adequately or defend our intellectual property rights our business may be harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success depends in large part on obtaining and maintaining patent and trade secret protection for our drug candidates, the methods used to manufacture those drug candidates and the methods for treating patients using those drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specifically, sapacitabine is covered in granted, composition of matter patents that expire in 2014 in the United States and 2012 outside the United States. Sapacitabine is further protected by additional granted, composition of matter patents claiming certain, stable crystalline forms of sapacitabine and their pharmaceutical compositions and therapeutic uses that expire in 2022 (and may be eligible for a Hatch-Waxman term restoration of up to five years, which could extend the expiration date to 2027) and also patent applications claiming the combination of sapacitabine with hypomethylating agents, including decitabine, which is being tested as one of the arms of the SEAMLESS Phase 3 trial. In early development, amorphous sapacitabine was used. We have used one of the stable, crystalline forms of sapacitabine in nearly all our Phase 1 and in all of our Phase 2 clinical studies. We have also chosen this form for commercialization. Additional patents and applicants claim certain medical uses and formulations of sapacitabine which have emerged in our clinical trials. Seliciclib is protected by granted, composition of matter patents that expire in 2016. Additional patents claim certain medical uses which have emerged from our research programs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Failure to obtain, maintain or extend the patents could adversely affect our business. We will only be able to protect our drug candidates and our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to obtain patents is uncertain because legal means afford only limited protections and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Some legal principles remain unresolved and the breadth or interpretation of claims allowed in patents in the United States, the European Union or elsewhere can still be difficult to ascertain or predict. In addition, the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues. Changes in either patent laws or in interpretations of patent laws in the United States, the European Union or elsewhere may diminish the value of our intellectual property or narrow the scope of our patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products and technologies. In addition, we generally do not control the patent prosecution of subject matter that we license from others and have not controlled the earlier stages of the patent prosecution. Accordingly, we are unable to exercise the same degree of control over this intellectual property as we would over our own.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if patents are issued regarding our drug candidates or methods of using them, those patents can be challenged by our competitors who may argue such patents are invalid and/or unenforceable. Patents also will not protect our drug candidates if competitors devise ways of making or using these product candidates without legally infringing our patents. The U.S. Federal Food, Drug and Cosmetic Act and FDA regulations and policies and equivalents in other jurisdictions provide incentives to manufacturers to challenge patent validity or create modified, noninfringing versions of a drug in order to facilitate the approval of abbreviated new drug applications for generic substitutes. These same types of incentives encourage manufacturers to submit new drug applications that rely on literature and clinical data not prepared for or by the drug sponsor.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. We rely on trade secrets to protect our technology, especially where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third-party obtained illegally and is using trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51<a name="PB_51_080532_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Intellectual property rights of third parties may increase our costs or delay or prevent us from being able to commercialize our drug candidates and/or the ALIGN products.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There is a risk that we are infringing or will infringe the proprietary rights of third parties because patents and pending applications belonging to third parties exist in the United States, the European Union and elsewhere in the world in the areas of our research and/or the ALIGN products. Others might have been the first to make the inventions covered by each of our or our licensors&#146; pending patent applications and issued patents and might have been the first to file patent applications for these inventions. We are aware of several published patent applications, and understand that others may exist, that could support claims that, if granted and held valid, could cover various aspects of our developmental programs, including in some cases particular uses of our lead drug candidate sapacitabine, seliciclib or other therapeutic candidates, or gene sequences, substances, processes and techniques that we use in the course of our research and development and manufacturing processes. In addition, we understand that other applications and patents exist relating to potential uses of sapacitabine and seliciclib that are not part of our current clinical programs for these compounds. Numerous third-party United States and foreign issued patents and pending applications exist in the area of kinases, including CDK, AK and Plk for which we have research programs. For example, some pending patent applications contain broad claims that could represent freedom to operate limitations for some of our kinase programs should they be issued unchanged. Although we intend to continue to monitor these applications, we cannot predict what claims will ultimately be allowed and if allowed what their scope would be. In addition, because the patent application process can take several years to complete, there may be currently pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our drug candidates. If we wish to use the technology or compound claimed in issued and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge the validity of the patents or incur the risk of litigation in the event that the owner asserts that we infringe its patents. In one case we have opposed a European patent relating to human aurora kinase and the patent has been finally revoked (no appeal was filed). We are also aware of a corresponding U.S. patent containing method of treatment claims for specific cancers using aurora kinase modulators which, if held valid, could potentially restrict the use of our aurora kinase inhibitors once clinical trials are completed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. Defending against third party claims, including litigation in particular, would be costly and time consuming and would divert management&#146;s attention from our business, which could lead to delays in our development or commercialization efforts. If third parties are successful in their claims, we might have to pay substantial damages or take other actions that are adverse to our business. As a result of intellectual property infringement claims, or to avoid potential claims, we might:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be prohibited from selling or licensing any product that we may develop unless the patent holder licenses the patent to us, which it is not required to do;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be required to pay substantial royalties or grant a cross license to our patents to another patent holder;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">decide to move some of our screening work outside Europe;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be required to pay substantial damages for past infringement, which we may have to pay if a court determines that our product candidates or technologies infringe a competitor&#146;s patent or other proprietary rights; or</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be required to redesign the formulation of a drug candidate so it does not infringe, which may not be possible or could require substantial funds and time.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52<a name="PB_52_080532_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Securities Regulations and Investment in Our Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Failure to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we fail to maintain our internal controls or fail to implement required new or improved controls, as such control standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting. Effective internal controls are necessary for us to produce reliable financial reports and are important in the prevention of financial fraud. If we cannot produce reliable financial reports or prevent fraud, our business and operating results could be harmed. We have concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We incur increased costs and management resources as a result of being a public company, and we may fail to comply with public company obligations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, we face and will continue to face increased legal, accounting, administrative and other costs and expenses as a public company that we would not incur as a private company. Compliance with the Sarbanes Oxley Act of 2002, as well as other rules&nbsp;of the SEC, the Public Company Accounting Oversight Board and the NASDAQ Global Market resulted in a significant initial cost to us as well as an ongoing compliance cost. As a public company, we are subject to Section&nbsp;404 of the Sarbanes Oxley Act relating to internal control over financial reporting. We have completed a formal process to evaluate our internal controls for purposes of Section&nbsp;404, and we concluded that as of December&nbsp;31, 2011, our internal control over financial reporting was effective. As our business grows and changes, there can be no assurances that we can maintain the effectiveness of our internal controls over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed. We have completed a formal process to evaluate our internal control over financial reporting. However, guidance from regulatory authorities in the area of internal controls continues to evolve and substantial uncertainty exists regarding our on-going ability to comply by applicable deadlines. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our common stock may have a volatile public trading price.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An active public market for our common stock has not developed. Our stock can trade in small volumes which may make the price of our stock highly volatile. The last reported price of our stock may not represent the price at which you would be able to buy or sell the stock. The market prices for securities of companies comparable to us have been highly volatile. Often, these stocks have experienced significant price and volume fluctuations for reasons that are both related and unrelated to the operating performance of the individual companies. In addition, the stock market as a whole and biotechnology and other life science stocks in particular have experienced significant recent volatility. Like our common stock, these stocks have experienced significant price and volume fluctuations for reasons unrelated to the operating performance of the individual companies. Factors giving rise to this volatility may include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">disclosure of actual or potential clinical results with respect to product candidates we are developing;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory developments in both the United States and abroad;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developments concerning proprietary rights, including patents and litigation matters;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53<a name="PB_53_080532_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">public concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">public announcements by our competitors or others; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">general market conditions and comments by securities analysts and investors.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Fluctuations in our operating losses could adversely affect the price of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our operating losses may fluctuate significantly on a quarterly basis. Some of the factors that may cause our operating losses to fluctuate on a period-to-period basis include the status of our preclinical and clinical development programs, level of expenses incurred in connection with our preclinical and clinical development programs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, and compliance with regulatory requirements. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Our fluctuating losses may fail to meet the expectations of securities analysts or investors. Our failure to meet these expectations may cause the price of our common stock to decline.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about us, if they change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet their expectations, our stock price could decline.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are incorporated in Delaware. Anti-takeover provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws may make a change in control or efforts to remove management more difficult. Also, under Delaware law, our Board of Directors may adopt additional anti-takeover measures.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have the authority to issue up to 5 million shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If the Board of Directors exercises this power to issue preferred stock, it could be more difficult for a third party to acquire a majority of our outstanding voting stock and vote the stock they acquire to remove management or directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws also provides staggered terms for the members of our Board of Directors. Under Section&nbsp;141 of the Delaware General Corporation Law, our directors may be removed by stockholders only for cause and only by vote of the holders of a majority of voting shares then outstanding. These provisions may prevent stockholders from replacing the entire board in a single proxy contest, making it more difficult for a third-party to acquire control of us without the consent of our Board of Directors. These provisions could also delay the removal of management by the Board of Directors with or without cause. In addition, our directors may only be removed for cause and amended and restated bylaws limit the ability our stockholders to call special meetings of stockholders.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under Section&nbsp;203 of the Delaware General Corporation Law, a corporation may not engage in a business combination with any holder of 15% or more of its capital stock until the holder has held the stock for three years unless, among other possibilities, the Board of Directors approves the transaction. Our Board of Directors could use this provision to prevent changes in management. The existence of the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54<a name="PB_54_080532_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='54',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Certain severance-related agreements in our executive employment agreements may make an acquisition more difficult and could result in the entrenchment of management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In March&nbsp;2008 (as subsequently amended, most recently as of January&nbsp;1, 2011), we entered into employment agreements with our President and Chief Executive Officer and our Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer, which contain severance arrangements in the event that such executive&#146;s employment is terminated without &#147;cause&#148; or&nbsp;as a result of a &#147;change of control&#148; (as each such term is defined in each agreement).&#160; The financial obligations triggered by these provisions may prevent a business combination or acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">In the event of an acquisition of our common stock, we cannot assure our common stockholders that we will be able to negotiate terms that would provide for a price equivalent to, or more favorable than, the price at which our shares of common stock may be trading at such time.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:21.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not effect a consolidation or merger with another entity without the vote or consent of the holders of at least a majority of the shares of our preferred stock (in addition to the approval of our common stockholders), unless the preferred stock that remains outstanding and its rights, privileges and preferences are unaffected or are converted into or exchanged for preferred stock of the surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to our convertible preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, in the event a third party seeks to acquire our company or acquire control of our company by way of a merger, but the terms of such offer do not provide for our preferred stock to remain outstanding or be converted into or exchanged for preferred stock of the surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to our preferred stock, the terms of the Certificate of Designation of our preferred stock provide for an adjustment to the conversion ratio of our preferred stock such that, depending on the terms of any such transaction, preferred stockholders may be entitled, by their terms, to receive up to $10.00 per share in common stock, causing our common stockholders not to receive as favorable a price as the price at which such shares may be trading at the time of any such transaction. As of March&nbsp;31, 2012, there were 1,213,142 shares of our preferred stock issued and outstanding. If the transaction were one in which proceeds were received by the Company for distribution to stockholders, and the terms of the Certificate of Designation governing the preferred stock were strictly complied with, approximately $13.9 million would be paid to the preferred holders before any distribution to the common stockholders, although the form of transaction could affect how the holders of preferred stock are treated. In such an event, although such a transaction would be subject to the approval of our holders of common stock, we cannot assure our common stockholders that we will be able to negotiate terms that would provide for a price equivalent to, or more favorable than, the price at which our shares of common stock may be trading at such time.&#160; Thus, the terms of our preferred stock might hamper a third party&#146;s acquisition of our company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our certificate of incorporation and bylaws and certain provisions of Delaware law may delay or prevent a change in our management and make it more difficult for a third-party to acquire us.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our amended and restated certificate of incorporation and bylaws contain provisions that could delay or prevent a change in our Board of Directors and management teams. Some of these provisions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">authorize the issuance of preferred stock that can be created and issued by the Board of Directors without prior stockholder approval, commonly referred to as &#147;blank check&#148; preferred stock, with rights senior to those of our common stock;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provide for the Board of Directors to be divided into three classes; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55<a name="PB_55_080532_2639"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='55',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of large stockholders to complete a business combination with, or acquisition of, us. These provisions may prevent a business combination or acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These provisions also make it more difficult for our stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt to replace our current management team. Additionally, these provisions may prevent an acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may have limited ability to pay cash dividends on our preferred stock, and there is no assurance that future quarterly dividends will be declared.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delaware law may limit our ability to pay cash dividends on our preferred stock. Under Delaware law, cash dividends on our preferred stock may only be paid from surplus or, if there is no surplus, from the corporation&#146;s net profits for the current or preceding fiscal year. Delaware law defines &#147;surplus&#148; as the amount by which the total assets of a corporation, after subtracting its total liabilities, exceed the corporation&#146;s capital, as determined by its board of directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since we are not profitable, our ability to pay cash dividends will require the availability of adequate surplus. Even if adequate surplus is available to pay cash dividends on our preferred stock, we may not have sufficient cash to pay dividends on the preferred stock or we may choose not to declare the dividends.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our common and convertible preferred stock may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment in us less appealing.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market price of our common and convertible preferred stock may fluctuate substantially due to a variety of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">additions to or departures of our key personnel;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">announcements of technological innovations or new products or services by us or our competitors;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">announcements concerning our competitors or the biotechnology industry in general;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">new regulatory pronouncements and changes in regulatory guidelines;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">general and industry-specific economic conditions;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in financial estimates or recommendations by securities analysts;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">variations in our quarterly results;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">announcements about our collaborators or licensors; and</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in accounting principles.</font></p>
<p style="margin:0in 0in .0001pt 76.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market prices of the securities of biotechnology companies, particularly companies like us without product revenues and earnings, have been highly volatile and are likely to remain highly volatile in the future. This volatility has often been unrelated to the performance of particular companies. In the past, companies that experience volatility in the market price of their securities have often faced securities class action litigation. Moreover, market prices for stocks of biotechnology-related and technology companies frequently reach levels that bear no relationship to the performance of these companies. These market prices generally are not sustainable and are highly volatile. Whether or not meritorious, litigation brought against us could result in substantial costs, divert our management&#146;s attention and resources and harm our financial condition and results of operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56<a name="PB_56_080532_2794"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='56',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The future sale of our common and preferred stock and future issuances of our common stock upon conversion of our preferred stock could negatively affect our stock price and cause dilution to existing holders of our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If our common or preferred stockholders sell substantial amounts of our stock in the public market, or the market perceives that such sales may occur, the market price of our common and preferred stock could fall. If additional holders of preferred stock elect to convert their shares to shares of common stock at renegotiated prices, such conversion as well as the sale of substantial amounts of our common stock, could cause dilution to existing holders of our common stock, thereby also negatively affecting the price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we exchange the convertible preferred stock for debentures, the exchange will be taxable but we will not provide any cash to pay any tax liability that any convertible preferred stockholder may incur.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An exchange of convertible preferred stock for debentures, as well as any dividend make-whole or interest make-whole payments paid in our common stock, will be taxable events for United States federal income tax purposes, which may result in tax liability for the holder of convertible preferred stock without any corresponding receipt of cash by the holder. In addition, the debentures may be treated as having original issue discount, a portion of which would generally be required to be included in the holder&#146;s gross income even though the cash to which such income is attributable would not be received until maturity or redemption of the debenture. We will not distribute any cash to the holders of the securities to pay these potential tax liabilities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we automatically convert the convertible preferred stock, there is a substantial risk of fluctuation in the price of our common stock from the date we elect to automatically convert to the conversion date.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may automatically convert the convertible preferred stock into common stock if the closing price of our common stock has exceeded $35.30. There is a risk of fluctuation in the price of our common stock between the time when we may first elect to automatically convert the preferred and the automatic conversion date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We do not intend to pay cash dividends on our common stock in the foreseeable future.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend on our financial condition, results of operations, capital requirements, the outcome of the review of our strategic alternatives and other factors and will be at the discretion of our Board of Directors. Accordingly, investors will have to rely on capital appreciation, if any, to earn a return on their investment in our common stock. Furthermore, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The number of shares of common stock which are registered, including the shares to be issued upon exercise of our outstanding warrants, is significant in relation to our currently outstanding common stock and could cause downward pressure on the market price for our common stock.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The number of shares of common stock registered for resale, including those shares which are to be issued upon exercise of our outstanding warrants, is significant in relation to the number of shares of common stock currently outstanding. If the security holder determines to sell a substantial number of shares into the market at any given time, there may not be sufficient demand in the market to purchase the shares without a decline in the market price for our common stock. Moreover, continuous sales into the market of a number of shares in excess of the typical trading volume for our common stock, or even the availability of such a large number of shares, could depress the trading market for our common stock over an extended period of time.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57<a name="PB_57_080532_8299"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='57',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If persons engage in short sales of our common stock, including sales of shares to be issued upon exercise of our outstanding warrants, the price of our common stock may decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Selling short is a technique used by a stockholder to take advantage of an anticipated decline in the price of a security. In addition, holders of options and warrants will sometimes sell short knowing they can, in effect, cover through the exercise of an option or warrant, thus locking in a profit. A significant number of short sales or a large volume of other sales within a relatively short period of time can create downward pressure on the market price of a security. Further sales of common stock issued upon exercise of our outstanding warrants could cause even greater declines in the price of our common stock due to the number of additional shares available in the market upon such exercise, which could encourage short sales that could further undermine the value of our common stock. You could, therefore, experience a decline in the value of your investment as a result of short sales of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are exposed to risk related to the marketable securities we may purchase.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may invest cash not required to meet short term obligations in short term marketable securities. We may purchase securities in United States government, government-sponsored agencies and highly rated corporate and asset-backed securities subject to an approved investment policy. Historically, investment in these securities has been highly liquid and has experienced only very limited defaults. However, recent volatility in the financial markets has created additional uncertainty regarding the liquidity and safety of these investments. Although we believe our marketable securities investments are safe and highly liquid, we cannot guarantee that our investment portfolio will not be negatively impacted by recent or future market volatility or credit restrictions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></b><a name="Item2_UnregisteredSalesOfEquitySe_073930"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3. Defaults upon Senior Securities</font></b><a name="Item3_DefaultsUponSeniorSecuritie_073931"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4. Mine Safety Disclosure</font></b><a name="Item4_MineSafetyDisclosure_073933"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5. Other Information</font></b><a name="Item5_OtherInformation_073934"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6. Exhibits</font></b><a name="Item6_Exhibits_073935"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#134;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase   Agreement, dated as of March 22, 2012, by and among Cyclacel Pharmaceuticals,&nbsp;Inc.   and the investors signatory thereto</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer Pursuant to Securities Exchange Act   Rule&nbsp;13a-14(a)&nbsp;As Adopted Pursuant to Section&nbsp;302 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer Pursuant to Securities Exchange Act   Rule&nbsp;13a-14(a)&nbsp;As Adopted Pursuant to Section&nbsp;302 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer pursuant to Section&nbsp;906 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer pursuant to Section&nbsp;906 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#134;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Confidential   treatment has been requested with respect to certain portions of this   exhibit, which portions have been omitted and filed separately with the   Securities and Exchange Commission as part of an application for confidential   treatment pursuant to the Securities and Exchange Act of 1934, as amended.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58<a name="PB_58_080532_8247"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='58',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name="Signatures_081127"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL   PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;15, 2012</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Operating Officer, Chief Financial Officer and</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Vice President, Finance</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59<a name="PB_59_080532_5893"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='59',FILE='C:\JMS\106319\12-9682-1\task5353275\9682-1-ba-15.htm',USER='106319',CD='May 14 22:52 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a12-9682_1ex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTION VERSION</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURCHASE AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS PURCHASE AGREEMENT</font></b><font size="2" style="font-size:10.0pt;"> (this &#147;<b>Agreement</b>&#148;), dated as of March 22, 2012, by and among CYCLACEL PHARMACEUTICALS, INC., a Delaware corporation with headquarters located at 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922 (the &#147;<b>Company</b>&#148;), and each investor identified on the signature pages hereto (individually, an &#147;<b>Investor</b>&#148; and collectively, the &#147;<b>Investors</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BACKGROUND</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and each Investor are executing and delivering this Agreement in reliance upon the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the &#147;<b>Securities Act</b>&#148;), and Rule 506 of Regulation D (&#147;<b>Regulation D</b>&#148;), as promulgated by the United States Securities and Exchange Commission (the &#147;<b>SEC</b>&#148;) under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Investor, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions contained herein, (i) that aggregate number of shares of the common stock, par value $0.001 per share, of the Company (the &#147;<b>Common Stock</b>&#148;), set forth on such Investor&#146;s signature page to this Agreement (which aggregate amount for all Investors together shall be 4,688,079 shares of Common Stock and collectively referred to herein as the &#147;<b>Common Shares</b>&#148;) and (ii) its <i>Pro Rata </i>Portion of the Economic Rights (as each such term is defined below).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investors agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE I<br> DEFINITIONS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1 <u>Definitions</u>.&#160; In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Accredited Investor</b>&#148; has the meaning set forth in <u>Section 3.2(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;"> has the meaning set forth in <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Additional Shares</b>&#148; has the meaning set forth in <u>Section 3.1(e)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Affiliate</b>&#148; means any Person that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, a Person, as such terms are used in and construed under Rule 12b-2 under the Exchange Act.&#160; In the case of each Investor, Affiliate also means any Person that, directly or indirectly, through one or more intermediaries, manages, or is managed by, or is under common management with, such Investor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Agreement</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Business Day</b>&#148; means any day other than Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any day on which banking institutions in The State of New York are authorized or required by law or other governmental action to close.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Litigant</b>&#148; means the Company&#146;s adversary in the Litigation (including, for purposes of clarification, any successor-in-interest to such adversary by reason of acquisition, consolidation, merger, reverse merger or other combination of such adversary with or by another Person).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing</b>&#148; has the meaning set forth in <u>Section 2.2</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Date</b>&#148; has the meaning set forth in <u>Section 2.2</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Closing Price</b>&#148; means, for any date, the closing price per share of the Common Stock for such date (or, if not a Trading Day, the nearest preceding date that is a Trading Day) on the primary Eligible Market or exchange or quotation system on which the Common Stock is then listed or quoted.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Company</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&#148; </font></b><font size="2" style="font-size:10.0pt;">has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Common Shares</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Common Stock</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Contingent Obligation</b>&#148; has the meaning set forth in <u>Section 3.1(aa)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Convertible Securities</b>&#148; means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Demand Registration</b>&#148; has the meaning set forth in <u>Section 6.1(a)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Disclosure Materials</b>&#148; has the meaning set forth in <u>Section 3.1(g)</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Economic Rights</b>&#148; has the meaning set forth in <u>Section 4.1</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Effective Date</b>&#148; means the date that the Registration Statement is first declared effective by the SEC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Effectiveness Period</b>&#148; has the meaning set forth in <u>Section 6.1(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_204622_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>8-K Filing</b>&#148; has the meaning set forth in <u>Section 5.7</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Eligible Market</b>&#148; means any of the New York Stock Exchange, the NYSE Amex LLC, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market or the OTC Bulletin Board.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Environmental Laws</b>&#148; has the meaning set forth in <u>Section 3.1(dd)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Exchange Act</b>&#148; means the Securities Exchange Act of 1934, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Filing Date</b>&#148; means, (i) in the case of a Long-Form Registration, the date that is ninety (90) days after the receipt by the Company of a Demand Registration or, if such date is not a Business Day, the next date that is a Business Day and (ii) in the case of a Short-form Registration, the date that is thirty (30) days after the receipt by the Company of a Demand Registration or, if such date is not a Business Day, the next date that is a Business Day .</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>FINRA</b>&#148; has the meaning set forth in <u>Section 3.2(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>GAAP</b>&#148; has the meaning set forth in <u>Section 3.1(g)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Hazardous Materials</b>&#148; has the meaning set forth in <u>Section 3.1(dd)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Indebtedness</b>&#148; has the meaning set forth in <u>Section 3.1(aa)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Indemnified Party</b>&#148; has the meaning set forth in <u>Section 6.4(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Indemnifying Party</b>&#148; has the meaning set forth in <u>Section 6.4(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Insolvent</b>&#148; has the meaning set forth in <u>Section 3.1(h)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;"> has the meaning set forth in <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Intellectual Property Rights</b>&#148; has the meaning set forth in <u>Section 3.1(t)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Investor</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Knowledge</b>,&#148; when used in reference to the Company, means the actual knowledge of Spiro Rombotis and Paul McBarron after reasonable inquiry.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Litigation</b>&#148; means the Company&#146;s pending litigation, case number 1:10-cv-00348-GMS, currently pending in the United States District Court for the District of Delaware, as well as any appeals thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Lien</b>&#148; means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_204735_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Lock-Up Period</b>&#148; has the meaning set forth in <u>Section 5.1.</u></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Losses</b>&#148; means any and all losses, claims, damages, liabilities, settlement costs and expenses, including, without limitation, reasonable attorneys&#146; fees.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;"> has the meaning set forth in <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Material Adverse Effect</b>&#148; means any change, event, development or effect that is, has been or would reasonably be expected to be (i) a material adverse effect on the results of operations, assets, liabilities, business, financial condition or business prospects of the Company and the Subsidiaries taken as a whole on a consolidated basis or (ii) material and adverse impairment of the Company&#146;s ability to perform its obligations under this Agreement, provided, that none of the following alone shall be deemed, in and of itself, to constitute a Material Adverse Effect:&#160; (i) a change in the market price or trading volume of the Common Stock or (ii) changes in general economic conditions or changes affecting the industry in which the Company operates generally (as opposed to Company-specific changes) so long as such changes do not have a disproportionate effect on the Company and its Subsidiaries taken as a whole.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Material Permits</b>&#148; has the meaning set forth in <u>Section 3.1(v)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Options</b>&#148; means any outstanding rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;Person</font></b><font size="2" style="font-size:10.0pt;">&#148; has the meaning set forth in <u>Section 3.1(aa).</u></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Pro Rata</i> Portion</font></b><font size="2" style="font-size:10.0pt;">,</font><font size="2" style="font-size:10.0pt;">&#148; as to any Investor, means the percentage derived by (X) dividing the aggregate Purchase Price paid by such Investor (as set forth on such Investor&#146;s signature page to this Agreement) by (Y) the aggregate Purchase Price received by the Company from all Investors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Proceeding</b>&#148; means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition), whether commenced or threatened in writing.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Prospectus</b>&#148; means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_204809_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Purchase Price</b>&#148; means the average Closing Price per share of the Company&#146;s Common Stock on the Trading Market over the ten (10) consecutive Trading Days ending on the Trading Day prior to the public announcement of this Agreement, and shall be allocated 90% to the Common Shares and 10% to the Economic Rights.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>QIB</b>&#148;&#160; has the meaning set forth in <u>Section 3.2(c)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Registrable Securities</b>&#148; means the Common Shares and, if issued, the Additional Shares, together with any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing, until the earliest of (i) the effective registration under the Securities Act and the resale of all of the Registrable Securities in accordance with the Registration Statement or pursuant to Rule 144 or any similar provision then in force; (ii) the date on which the Registrable Security is distributed to the public pursuant to Rule 144; and (iii) the date on which the Registrable Securities cease to be outstanding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Registration Statement</b>&#148; means any registration statement required to be filed under <u>Article VI</u>, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Regulation D</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Required Effectiveness Date</b>&#148; means (i) if the Registration Statement does not become subject to review by the SEC, the date which is the earliest of (a) one hundred and twenty (120) days after the receipt by the Company of a Long-Form Demand Registration and ninety (90) days after the receipt by the Company of a Short-Form Demand Registration, to the extent the Company is eligible to use a Registration Statement on Form S-3, or (b) five (5) Trading Days after the Company receives notification from the SEC that the Registration Statement will not become subject to review, or (ii) if the Registration Statement becomes subject to review by the SEC, the date which is the earliest of (a) one hundred and eighty (180) days after the receipt by the Company of a Long-Form Demand Registration and one hundred and twenty (120) days after the receipt by the Company of a Short-Form Demand Registration or (b) five (5) Trading Days after the Company receives notification from the SEC that the SEC has no further comment to the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Right of First Refusal</b>&#148; has the meaning set forth in <u>Section 5.2</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Rule 144</b>,&#148; &#147;<b>Rule 415</b>,&#148; and &#147;<b>Rule 424</b>&#148; means Rule 144, Rule 415 and Rule 424, respectively, promulgated by the SEC pursuant to the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>SEC</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_204855_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>SEC Reports</b>&#148; has the meaning set forth in <u>Section 3.1(g)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Securities Act</b>&#148; has the meaning set forth in the preamble.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Settlement</b>&#148; has the meaning set forth in <u>Section 4.1(b)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:40.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;"> has the meaning set forth in <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Short Sales</b>&#148; has the meaning set forth in <u>Section 3.2(k)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Subsidiary</b>&#148; means any direct or indirect subsidiary of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Subject Intellectual Property</b>&#148; means all of the Company&#146;s and its Subsidiaries&#146; trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property that are at issue in the Litigation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Trading Day</b>&#148; means (i) a day on which the Common Stock is traded on a Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed or quoted on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not listed or quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink Sheets LLC (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Trading Market</b>&#148; means whichever of the New York Stock Exchange, the NYSE Amex LLC, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Transaction</b>&#148; has the meaning set forth in <u>Section 3.2(k)</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Transfer Agent</b>&#148; means American Stock Transfer &amp; Trust, located in Brooklyn, New York, or any successor transfer agent for the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Transfer Agent Instructions</b>&#148; means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the form of <u>Exhibit A</u>, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_204920_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE II<br> PURCHASE AND SALE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1 <u>Purchase and Sale</u>.&#160; Subject to the terms and conditions set forth in this Agreement, the Company hereby issues and sells the Common Shares and grants the Economic Rights to each Investor, and each Investor, severally and not jointly, hereby purchases from the Company, (i) such number of shares of Common Shares on such Investor&#146;s signature page to this Agreement at the Purchase Price and (ii) the Economic Rights equal to such Investor&#146;s P<i>ro Rata</i> Portion. The aggregate Purchase Price to be paid by all Investors hereunder shall be $3,036,000, and shall be allocated among and paid by the Investors as set forth on the signature pages hereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2 <u>Closing</u>.&#160; The closing of the transactions contemplated by this Agreement (the &#147;<b>Closing</b>&#148;) shall be held on the date of this Agreement (the &#147;<b>Closing Date</b>&#148;), at a location that is mutually acceptable to the parties or via .pdf, facsimile or a combination of the foregoing.&#160; The Closing shall be considered to have been effective on the Closing Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3 <u>Closing Deliveries</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a) At the Closing, the Company shall deliver or cause to be delivered to each Investor the following:</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160; a copy of the Company&#146;s irrevocable instructions to the Transfer Agent, instructing the Transfer Agent to deliver, on an expedited basis, one or more stock certificates containing the restrictive and other legends as provided in <u>Sections 5.1</u> and <u>5.3</u> hereof, evidencing such number of Common Shares set forth on such Investor&#146;s signature page to this Agreement, registered in the name of such Investor;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&#160;&#160; duly executed Transfer Agent Instructions acknowledged by the Company&#146;s transfer agent;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&#160; a certificate of the Secretary of the Company, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement, the issuance of the shares of Common Shares, the granting of the Economic Rights and the reservation of shares of Additional Shares;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&#160; certificates of good standing for the Company and each of its Subsidiaries from the respective jurisdictions of their organization; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)&#160;&#160; a draft of the Company&#146;s proposed public announcement and Form 8-K contemplated by <u>Section 5.7</u> (which draft has already been delivered to such Investor).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b) At the Closing, each Investor shall deliver or cause to be delivered to the Company the aggregate Purchase Price set forth on such Investor&#146;s signature page to this Agreement in United States dollars and in immediately available funds, by wire transfer to an account designated in writing to such Investor by the Company for such purpose.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_205014_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE III<br> REPRESENTATIONS AND WARRANTIES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1 <u>Representations and Warranties of the Company</u>.&#160; The Company hereby represents and warrants to the Investors (as defined in <u>Section 3.1(l)</u>) as follows (which representations and warranties shall be deemed to apply, where appropriate, to each Subsidiary of the Company):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a) <u>Subsidiaries</u>.&#160; The Company owns or controls, directly or indirectly, all of the capital stock or comparable equity interests of each Subsidiary, free and clear of any Lien, and all issued and outstanding shares of capital stock or comparable equity interest of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights.&#160; The Company only has two Subsidiaries: (i) Cyclacel Limited, a private limited company organized under the laws of England and Wales and (ii) ALIGN Pharmaceuticals, LLC, a Delaware limited liability corporation.&#160; Except as set forth in <u>Schedule 3.1(a) hereto</u>, no Subsidiary has outstanding any Options, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or entered into any agreement giving any Person any right to subscribe for or acquire, any equity interest in such Subsidiary, or securities or rights convertible or exchangeable into any equity interest in such Subsidiary.&#160; &#147;<b>Subsidiary&#148;</b> means any corporation, partnership, limited liability partnership, limited liability company, association, trust, joint venture, other entity or Person in which the Company owns, directly or indirectly, any equity interest.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b) <u>Organization and Qualification</u>. The Company and each Subsidiary is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, with the requisite legal authority to own and use its properties and assets and to carry on its business as currently conducted.&#160; Neither the Company nor any Subsidiary is in violation of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.&#160; The Company and each Subsidiary is duly qualified to do business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c) <u>Authorization; Enforcement</u>. The Company has the requisite corporate authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder.&#160; The execution and delivery of this Agreement and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of the Company.&#160; This Agreement has been (or upon delivery will be) duly executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute, the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_205041_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d) <u>No Conflicts</u>.&#160; The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not, and will not, (i) conflict with or violate any provision of the Company&#146;s or any Subsidiary&#146;s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound, or affected, or (iii) result in a material violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any Subsidiary is subject (including, assuming the accuracy of the representations and warranties of the Investors set forth in <u>Section 3.2</u> hereof, federal and state securities laws and regulations and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company or any Subsidiary are bound or affected.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e) <u>The Securities</u>.&#160; The Common Shares and the shares of Common Stock issuable pursuant to the Economic Rights <b>[***]</b> (the &#147;<b>Additional Shares</b>&#148; and, with the Common Shares, the &#147;<b>Securities</b>&#148;) are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and non-assessable, free and clear of all Liens and transfer taxes, and will not be subject to preemptive or similar rights of stockholders (other than those affirmatively imposed by the Investors).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_205130_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f) <u>Capitalization</u>.&#160; The aggregate number of shares and type of all authorized, issued and outstanding classes of capital stock, options and other securities of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company) is set forth in <u>Schedule 3.1(f</u>) hereto.&#160; All outstanding shares of capital stock are duly authorized, validly issued, fully paid and non-assessable, and have been issued in compliance in all material respects with all applicable securities laws.&#160; Except as disclosed in <u>Schedule 3.1(f</u>) hereto, the Company did not have outstanding as of the date hereof any other Options, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or entered into any agreement giving any Person any right to subscribe for or acquire, any shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock.&#160; Except as set forth on <u>Schedule 3.1(f</u>) hereto, and except for customary adjustments as a result of stock dividends, stock splits, combinations of shares, reorganizations, recapitalizations, reclassifications or other similar events, there are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders), and the issuance and sale of the Securities and the granting of the Economic Rights will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investors) and will not result in a right of any holder of securities to adjust the exercise, conversion, exchange or reset price under such securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g) <u>SEC Reports; Financial Statements</u>.&#160; The Company has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.&#160; Such reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports were required being collectively referred to herein as the &#147;<b>SEC Reports</b>&#148; and, together with this Agreement and the Schedules to this Agreement, the &#147;<b>Disclosure Materials</b>.&#148;&#160; As of their respective dates, the SEC Reports filed by the Company complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder.&#160; The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing.&#160; Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#147;<b>GAAP</b>&#148;), except as may be otherwise specified in such financial statements, the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP or may be condensed or summary statements, and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments.&#160; All agreements to which the Company or any Subsidiary is a party or to which the property or assets of the Company or any Subsidiary are subject are included as part of or identified in the SEC Reports, to the extent such agreements are required to be included or identified pursuant to the rules and regulations of the SEC.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_205201_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\C901169\12-9682-1\task5352973\9682-1-ke-01.htm',USER='C901169',CD='May 14 21:10 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">  </font><font size="2" style="font-size:10.0pt;">&#160;<u>Material Changes; Undisclosed Events, Liabilities or Developments; Solvency</u>.&#160; Since the date of the latest audited financial statements included within the SEC Reports, except as disclosed in <u>Schedule 3.1(h)</u>&nbsp;hereto, (i)&nbsp;there has been no event, occurrence or development that, individually or in the aggregate, has had or that would be reasonably expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any material liabilities or obligations other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#146;s financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii)&nbsp;the Company has not altered its method of accounting or changed its auditors, (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders, in their capacities as such, or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, except as disclosed in its SEC Reports, and (v)&nbsp;the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based plans.&#160; The Company has not taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any Knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any Knowledge of any fact which would reasonably lead a creditor to do so.&#160; The Company is not, as of the date hereof, and after giving effect to the transactions contemplated hereby, will not be Insolvent (as defined below).&#160; For purposes of this <u>Section&nbsp;3.1(h)</u>, <b>&#147;Insolvent&#148;</b> means (i)&nbsp;the present fair saleable value of the Company&#146;s assets is less than the amount required to pay the Company&#146;s total Indebtedness (as defined in <u>Section&nbsp;3.1(aa)</u>), (ii)&nbsp;the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii)&nbsp;the Company intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv) the Company has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i) <u>Absence of Litigation</u>.&#160; Except for the Litigation and as disclosed in <u>Schedule 3.1(i)</u>, there is no action, suit, claim, or Proceeding, or, to the Company&#146;s Knowledge, inquiry or investigation, before or by any court, public board, government or other regulatory agency, self-regulatory organization or body pending or, to the Knowledge of the Company, threatened against or affecting the Company or any Subsidiary that could, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j) <u>Compliance</u>.&#160; Neither the Company nor any Subsidiary is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived) involving Indebtedness, individually or in the aggregate, in excess of $1,000,000.&#160; Neither the Company nor any Subsidiary is in violation of, and the issuance of the Common Shares and Additional Shares hereunder will not violate (i)&nbsp;any order of any court, arbitrator or governmental body, or (ii)&nbsp;any material statute, rule&nbsp;or regulation of any governmental authority. This Section does not relate to matters with respect to tax status, which are the subject of <u>Section&nbsp;3.1(ff)</u>, employee relations, which are the subject of <u>Section 3.1(bb)</u>, labor matters, which are the subject of <u>Section&nbsp;3.1(cc)</u>, and environmental laws, which are the subject of <u>Section 3.1(dd)</u>.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_204449_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k) <u>Title to Assets</u>.&#160; Neither the Company nor any Subsidiary owns real property.&#160; The Company and each Subsidiary has good and marketable title in all personal property owned by them that is material to the business of the Company and each Subsidiary, in each case, free and clear of all Liens, except for Liens that do not, individually or in the aggregate, have or result in a Material Adverse Effect.&#160; Any real property and facilities held under lease by the Company or any Subsidiary is held by it, to the Company&#146;s Knowledge, under valid, subsisting and enforceable leases of which the Company and each Subsidiary is in material compliance.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l) <u>No General Solicitation</u>.&#160; Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m) <u>Brokers</u>.&#160; No agent, broker, finder or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission payable by the Company in connection with the transactions contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n) <u>Private Placement; Investment Company; U.S. Real Property Holding Corporation</u>.&#160; Neither the Company nor any of its Affiliates nor, any Person acting on the Company&#146;s behalf has, directly or indirectly, at any time within the past six months, made any offer or sale of any security or solicitation of any offer to buy any security under circumstances that would (i)&nbsp;eliminate the availability of the exemption from registration under Regulation&nbsp;D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii)&nbsp;cause the offering of the Securities pursuant hereto to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules&nbsp;and regulations of any Trading Market.&#160; Assuming the accuracy of the representations and warranties of the Investors set forth in <u>Section&nbsp;3.2</u>, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Investors as contemplated hereby. The sale and issuance of the Securities hereunder does not contravene the rules&nbsp;and regulations of any Trading Market on which the Common Stock is listed or quoted.&#160; The Company is not required to be registered as, and is not an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended.&#160; The Company is not required to be registered as a United States real property holding corporation within the meaning of the Foreign Investment in Real Property Tax Act of 1980.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_204552_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o) <u>Form&nbsp;S-1 Eligibility</u>.&#160; The Company is eligible to register the Common Shares and, if and when issued, the Additional Shares for resale by the Investors using a Registration Statement on Form&nbsp;S-1 promulgated under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(p) <u>Registration Rights</u>.&#160; Except as described in <u>Schedule 3.1(p)</u>, the Company has not granted or agreed to grant to any Person any rights (including &#147;piggy-back&#148; registration rights) to have any securities of the Company registered with the SEC or any other governmental authority that have not expired or been satisfied or waived as of the Closing Date (the rights described on <u>Schedule 3.1(p)</u>, the &#147;<b>Prior Holders</b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(q) <u>Application of Takeover Protections</u>.&#160; The Company and its Board of Directors have taken all necessary action, if any, to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company&#146;s charter documents or the laws of its state of incorporation that is or could become applicable to any of the Investors as a result of the Investors and the Company fulfilling their obligations or exercising their rights hereunder, including, without limitation, as a result of the Company&#146;s issuance, and the Investors&#146; ownership, of the Securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(r) <u>Disclosure</u>.&#160; Neither the Company nor any officers, directors or Affiliates, has provided any of the Investors (other than those certain investors who signed a confidentiality agreement with the Company) or an Investor&#146;s agents or counsel with any information that constitutes or might constitute material, nonpublic information (other than the existence and terms of the issuance of the Securities, as contemplated by this Agreement).&#160; The Company understands and confirms that each of the Investors (other than those certain investors who signed a confidentiality agreement with the Company) will rely on the foregoing representations in effecting transactions in securities of the Company.&#160; All disclosure provided by the Company to the Investors regarding the Company, its business and the transactions contemplated hereby, including the Schedules to this Agreement furnished by or on behalf of the Company, are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.&#160; To the Company&#146;s Knowledge, except for the transactions contemplated by this Agreement, no event or circumstance has occurred or information exists with respect to the Company or any Subsidiary or their businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed.&#160; The Company acknowledges and agrees that no Investor makes or has made any statements, representations or warranties, express or implied, with respect to the transactions contemplated hereby other than those specifically set forth herein, and that the Company is not relying upon any statements, representations or warranties of any Investor, other than those representations and warranties in <u>Section&nbsp;3.2</u> hereof,<i>  </i>in connection with this Agreement and the transactions contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_204621_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(s) <u>Acknowledgment Regarding Investors&#146; Purchase of the Common Shares and Economic Rights</u>.&#160; Based upon the assumption that the transactions contemplated by this Agreement are consummated in all material respects in conformity with this Agreement, the Company acknowledges and agrees that each of the Investors is acting solely in the capacity of an arm&#146;s length purchaser with respect to this Agreement and the transactions contemplated hereby.&#160; The Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement, and the transactions contemplated hereby and any advice given by any Investor or any of their respective representatives or agents in connection herewith and the transactions contemplated hereby is merely incidental to the Investors&#146; purchase of the Common Shares and the Economic Rights.&#160; The Company further represents to each Investor that the Company&#146;s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its advisors and representatives.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(t) <u>Patents and Trademarks</u>.&#160; Except as disclosed in <u>Schedule 3.1(t)(i)</u>, the Company and each Subsidiary owns, or possesses adequate rights or licenses to use, all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights necessary to conduct their respective businesses as now conducted (&#147;<b>Intellectual Property Rights</b>&#148;).&#160; Except as disclosed in <u>Schedule 3.1(t)</u>(ii), none of the Company&#146;s or any Subsidiary&#146;s Intellectual Property Rights have expired or terminated, or are expected to expire or terminate within three years from the date of this Agreement. The Company does not have any Knowledge of any infringement by the Company or any Subsidiary of Intellectual Property Rights of others.&#160; Except as disclosed in S<u>chedule 3.1(t)(iii)</u>, there is no claim, action or proceeding being made or brought, or to the Knowledge of the Company, being threatened, against the Company or any Subsidiary regarding its Intellectual Property Rights.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(u) <u>Insurance</u>.&#160; The Company and each Subsidiary is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses and locations in which the Company and each Subsidiary conducts business.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v) <u>Regulatory Permits</u>.&#160; The Company and each Subsidiary possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as presently conducted and described in the SEC Reports (&#147;<b>Material Permits</b>&#148;), except where the failure to possess such permits does not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, and neither the Company nor any Subsidiary has received any written notice of proceedings relating to the revocation or modification of any Material Permit.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_204658_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(w) <u>Transactions With Affiliates and Employees</u>.&#160; Except as set forth or incorporated by reference in the Company&#146;s SEC Reports, none of the officers, directors or employees of the Company is presently a party to any transaction with the Company that would be required to be reported on Form&nbsp;10-K by Item 12 thereof pursuant to Regulation S-K Item 404 (other than for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the Company&#146;s Knowledge, any corporation, partnership, trust or other entity in which any such officer, director, or employee has a substantial interest or is an officer, director, trustee or partner.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x) <u>Internal Accounting Controls</u>.&#160; The Company and each Subsidiary maintains a system of internal accounting controls sufficient, the Company&#146;s Knowledge, to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(y) <u>Sarbanes-Oxley Act</u>. The Company is in compliance in all material respects with applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules&nbsp;and regulations promulgated by the SEC thereunder.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(z) <u>Foreign Corrupt Practices</u>.&#160; Neither the Company nor any Subsidiary nor, to the Knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf of the Company or any Subsidiary has, in the course of its actions for, or on behalf of, the Company (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee or to any foreign or domestic political parties or campaigns from corporate funds; (iii)&nbsp;violated or is in violation in any material respect of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_205032_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Indebtedness</u>.&#160; Except as disclosed in Schedule 3.1(aa), neither the Company nor any Subsidiary (i) has any outstanding Indebtedness (as defined below), (ii)&nbsp;is in violation of any term of or is in default under any contract, agreement or instrument relating to any Indebtedness in excess of $1,000,000, and (iii)&nbsp;is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, to the Knowledge of the Company, has or could reasonably be expected to have a Material Adverse Effect.&#160; For purposes of this Agreement:&#160; (x)&nbsp;&#147;Indebtedness&#148; of any Person means, without duplication (A)&nbsp;all indebtedness for borrowed money, (B)&nbsp;all obligations issued, undertaken or assumed as the deferred purchase price of property or services (other than trade payables entered into in the ordinary course of business), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds, guarantees and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E)&nbsp;all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case, with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F)&nbsp;all monetary obligations under any leasing or similar arrangement which, in connection with generally accepted accounting principles, consistently applied for the periods covered thereby, is classified as a capital lease, (G)&nbsp;all indebtedness referred to in clauses (A)&nbsp;through (F)&nbsp;above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H)&nbsp;all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A)&nbsp;through (G)&nbsp;above; (y)&nbsp;&#147;<b>Contingent Obligation</b>&#148; means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, lease, dividend or other obligation of another Person, if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto; and (z)&nbsp;<b>&#147;Person&#148;</b> means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, a government or any department or agency thereof and any other legal entity.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Employee Relations</u>.&#160; Neither the Company nor any Subsidiary is a party to any collective bargaining agreement or employs any member of a union.&#160; The Company believes that its relations with its employees are as disclosed in the SEC Reports.&#160; Except as disclosed in the SEC Reports, during the period covered by the SEC Reports, no executive officer of the Company or any Subsidiary has notified the Company or any Subsidiary that such officer intends to leave the Company or a Subsidiary, as applicable, or otherwise terminate such officer&#146;s employment with the Company or a Subsidiary, as applicable.&#160; To the Knowledge of the Company and each Subsidiary, no executive officer of the Company or any Subsidiary is in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer does not subject the Company or any Subsidiary to any liability with respect to any of the foregoing matters.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_205056_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Labor Matters</u>.&#160; The Company and each Subsidiary is in compliance in all material respects with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Environmental Laws</u>.&#160; The Company and each Subsidiary (i)&nbsp;is in compliance in all material respects with any and all Environmental Laws (as hereinafter defined), (ii)&nbsp;has received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;is in compliance in all material respects with all terms and conditions of any such permit, license or approval.&#160; The term <b>&#147;Environmental Laws&#148;</b> means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, <b>&#147;Hazardous Materials&#148;</b>) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all codes, decrees, injunctions, judgments, licenses, orders, permits or regulations issued, entered, promulgated or approved thereunder.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Subsidiary Rights</u>.&#160; The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.35pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Tax Status.</u>&#160; The Company and each Subsidiary (i)&nbsp;has made or filed all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith, and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.&#160; There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and to the Company&#146;s Knowledge, there is no basis for any such claim.</font></p>
<p style="margin:0in 0in .0001pt 27.35pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2 <u>Representations and Warranties of the Investors</u>.&#160; Each Investor hereby, as to itself only and for no other Investor, represents and warrants to the Company (and, as a condition, and with respect, to the Company&#146;s issuance of the Additional Shares, shall, as to itself only and for no other Investor, represents and warrants to the Company in a letter, other than with respect to those representations and warranties in <u>Sections 3.2(h)</u>&nbsp;and <u>3.2(k)</u>, as of the date of such issuance) as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_205208_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a) <u>Organization; Authority</u>.&#160; Such Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite corporate, partnership or other power and authority to enter into and to consummate the transactions contemplated herby and otherwise to carry out its obligations hereunder and thereunder.&#160; The purchase by such Investor of the Common Shares and the Economic Rights hereunder has been duly authorized by all necessary corporate, partnership or other action on the part of such Investor.&#160; This Agreement has been duly executed and delivered by such Investor and constitutes the valid and binding obligation of such Investor, enforceable against it in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b) <u>No Public Sale or Distribution</u>.&#160; Such Investor is&nbsp;acquiring the Common Shares for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws, and such Investor does not have a present arrangement to effect any distribution of such securities to or through any person or entity except pursuant to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c) <u>Investor Status</u>.&#160; At the time such Investor was offered the Common Shares, it was, and at the date hereof, it is, an &#147;accredited investor&#148; as defined in Rule&nbsp;501(a)&nbsp;of Regulation&nbsp;D promulgated under the Securities Act (&#147;<b>Accredited Investor</b>&#148;) or a &#147;qualified institutional buyer&#148; as defined in Rule&nbsp;144A(a)&nbsp;under the Securities Act (&#147;<b>QIB</b>&#148;).&#160; Such Investor is not a registered broker dealer registered under Section&nbsp;15(a)&nbsp;of the Exchange Act, or a member of Financial Industry Regulatory Authority,&nbsp;Inc. (&#147;<b>FINRA</b>&#148;) or an entity engaged in the business of being a broker dealer.&#160; On or prior to the date of this Agreement, such Investor is not affiliated with any broker dealer registered under Section&nbsp;15(a)&nbsp;of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker dealer.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d) <u>General Solicitation</u>.&#160; Such Investor is not purchasing the Common Shares as a result of any advertisement, article, notice or other communication regarding the Common Shares published in any newspaper, magazine or similar media, broadcast over television or radio, disseminated over the Internet or presented at any seminar or any other general solicitation or general advertisement.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_205240_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e) <u>Beneficial Ownership</u>. The purchase by such Investor of the Common Shares hereunder will not result in such Investor (individually or together with any other Person with whom such Investor has identified, or will have identified, itself as part of a &#147;group&#148; in a public filing made with the SEC involving the Company&#146;s securities) acquiring, or obtaining the right to acquire, in excess of 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that the Closing shall have occurred. As of the date of this Agreement, such Investor does not intend to, alone or together with others, make a public filing with the SEC to disclose that it has (or that it together with such other Persons have) acquired, or obtained the right to acquire, as a result of the purchase by such Investor of the Common Shares hereunder (when added to any Additional Shares, if issued, and any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.9% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that the Closing has occurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f) <u>Brokers</u>.&#160; No agent, broker, finder or investment banker is entitled to any brokerage, finder&#146;s or other fee or commission payable by each of the Investors, jointly or severally, in connection with the transactions contemplated hereby.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g) <u>Experience of Such Investor</u>.&#160; Such Investor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Common Shares, and has so evaluated the merits and risks of such investment.&#160; Such Investor understands that it must bear the economic risk of this investment in the Common Shares indefinitely, and is able to bear such risk and is able to afford a complete loss of such investment.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h) <u>Access to Information</u>.&#160; Such Investor acknowledges that it has reviewed the Disclosure Materials and has been afforded:&#160; (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Common Shares and the merits and risks of investing in the Common Shares; (ii)&nbsp;access to information (other than material non-public information for those certain investors who did not enter into a confidentiality agreement with the Company) about the Company and each Subsidiary and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&#160; Neither such inquiries nor any other investigation conducted by or on behalf of such Investor or its representatives or counsel shall modify, amend or affect such Investor&#146;s right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company&#146;s representations and warranties contained herein (including, without limitation, the Company&#146;s representations and warranties in <u>Section&nbsp;3.1(r</u>), <i>provided</i>, <i>however</i>, that such Investor acknowledges and agrees that the Company does not make or has not made any statements, representations or warranties, express or implied, with respect to the transactions contemplated hereby other than those specifically set forth in <u>Section&nbsp;3.1</u> hereof, and that such Investor is not relying upon any statements, representations or warranties of the Company, other than those representations and warranties in <u>Section 3.1</u> hereof,<i>  </i>in connection with this Agreement and the transactions contemplated hereby). Such Investor acknowledges that it has reviewed the SEC Reports.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_205412_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i) <u>No Governmental Review</u>.&#160; Such Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Common Shares or the Additional Shares or the fairness or suitability of the investment in the Common Shares or the Additional Shares nor have such authorities passed upon or endorsed the merits of the offering of the Common Shares or the Additional Shares.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j) <u>No Conflicts</u>.&#160; The execution, delivery and performance by such Investor of this Agreement and the consummation by such Investor of the transactions contemplated hereby will not (i)&nbsp;result in a violation of the organizational documents of such Investor or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree applicable to such Investor, except in the case of (X)&nbsp;clauses (ii)&nbsp;and (iii)&nbsp;above, for such that are not material and do not otherwise affect the ability of such Investor to consummate the transactions contemplated hereby and (Y)&nbsp;clause (iii)&nbsp;above, for any federal and state securities laws and regulations applicable to the offer and sale of the Common Shares and Additional Shares, assuming the accuracy of the representations and warranties of the Investors set forth in <u>Section 3.2</u> hereof.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k) <u>Prohibited Transactions; Confidentiality</u>.&#160; No Investor, directly or indirectly, and to the actual knowledge of such Investor, no Person acting on behalf of or pursuant to any understanding with any Investor, has engaged in any purchases or sales in the securities, including derivatives, of the Company (including, without limitation, any Short Sales (a &#147;<b>Transaction</b>&#148;) involving any of the Company&#146;s securities) since the time that such Investor was first contacted by the Company or any other Person regarding an investment by such Investor in the Common Shares for the specific use set forth in <u>Section 5.8</u> hereto.&#160; Provided that the Company files the Form&nbsp;8-K contemplated by <u>Section&nbsp;5.7</u> of this Agreement within the time set forth in such section, such Investor covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with such Investor will engage, directly or indirectly, in any Transactions in the securities of the Company (including Short Sales) prior to the filing of the Form&nbsp;8-K contemplated by <u>Section&nbsp;5.7</u>, or if earlier, the time that the transactions contemplated by this Agreement are publicly disclosed.&#160; <b>&#147;Short Sales&#148;</b> include, without limitation, all &#147;short sales&#148; as defined in Rule&nbsp;200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated brokers.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_205439_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\C901156\12-9682-1\task5353080\9682-1-ke-03.htm',USER='c901156',CD='May 14 21:24 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)&#160;&#160;&#160; <u>Restricted Securities</u>.&#160; The Investors understand that the Common Shares and, if issued, the Additional Shares, are characterized as &#147;restricted securities&#148; under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that, under such laws and applicable regulations, such securities may be resold without registration under the Securities Act only in certain limited circumstances.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)&#160; <u>Legends</u>.&#160; It is understood that, except as provided in <u>Section&nbsp;5.1</u> and <u>Section&nbsp;5.3</u> of this Agreement, certificates evidencing the Common Shares may bear the legend set forth in <u>Section&nbsp;5.1</u> and <u>Section&nbsp;5.3</u>, and, if issued, the Additional Shares may bear the legend set forth in <u>Section&nbsp;5.3</u>.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)&#160;&#160; <u>No Legal, Tax or Investment Advice</u>.&#160; Such Investor understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice.&#160; Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IV<br> GRANT OF ECONOMIC RIGHTS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1&nbsp;<u>Economic Rights</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Investor is hereby granted an economic right (the &#147;<b>Economic Right</b>&#148;) to receive such Investor&#146;s <i>Pro Rata Portion</i> of (i)&nbsp;<b>[***]</b> or (ii)&nbsp;the Additional Shares, in accordance with the terms and conditions set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The <b>[***]</b> means an amount equal to ten percent (10%) of a <b>[***]</b> (&#147;<b>Settlement</b>&#148;) <b>[***].</b>&#160; Furthermore, in the event that the Company organizes, forms or otherwise acquires an equity interest in any Subsidiary after the date of this Agreement, the Company shall provide each of the Investors with reasonably prompt written notice thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Without the prior written consent of each holder of an Economic Right, neither the Company nor any of its Subsidiaries, prior to any Settlement <b>[***]</b> that includes a provision which would prohibit or otherwise limit the Company from being able to notify such holders of Economic Rights of all of the terms of such Settlement, provided that such holders agree to maintain confidential any such information provided to them.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as may be required by law, and subject to <u>Sections 4.1(c</u>)&nbsp;and <u>4.(e)</u>, neither the Company nor any Subsidiary shall, nor shall any of their respective officers, directors, employees and agents, provide any Investor with any material nonpublic information regarding the Litigation, any proposed Settlement, <b>[***]</b> without the express written consent of such Investor.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_204552_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Following any final Settlement, <b>[***]</b> the Company shall, subject to <u>Section&nbsp;4.1(f)</u>&nbsp;below, use its good-faith efforts to promptly issue a public statement announcing such event to the extent permitted by law and the terms of such Settlement, <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as prohibited by law, the Company shall provide the Investors with prior written notice in advance of any public statement by the Company announcing any Settlement, <b>[***]</b> to permit the Investors and their Affiliates sufficient time to cease trading the Company&#146;s common stock until after such public announcement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that the Company or any of its Subsidiaries are awarded <b>[***]</b> the Company shall as promptly as practicable <b>[***]</b>&#160; By way of example, <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Investor shall receive its <i>Pro Rata</i> Portion of <b>[***]</b> The Company shall be entitled to deduct and withhold, or cause to be deducted or withheld <b>[***]</b> such amounts as it is required to deduct and withhold with respect to the making of such payment under the Internal Revenue Code of 1986, as amended, or any provision of state, local or foreign tax law. To the extent that amounts are so withheld or paid over to or deposited with the relevant governmental entity, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Investor in respect of which such deduction and withholding was made.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the extent any portion of a Settlement <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2&nbsp;<u>Economic Rights are Contractual; No Certificates</u>.&#160; The Economic Right hereby granted is a contractual right, and shall not be evidenced by a certificate or other instrument.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3&nbsp;<u>No Rights as a Stockholder</u>. Nothing contained in this Agreement shall be construed as conferring upon any Investor, solely by virtue of being a holder of an Economic Right, the right to vote any of the Economic Rights or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company or any other matter, or any rights of any kind or nature whatsoever as a stockholder of the Company, either at law or in equity. The rights of a holder of Economic Rights are limited to those expressed in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4&nbsp;<b>[***]</b>&#160; In the event that the Company <b>[***] </b>the Company shall issue to each Investor <b>[***]</b> its <i>Pro Rata </i>Portion of <b>[***]</b> Additional Shares, as adjusted to account for any stock dividends, stock splits, reverse stock splits and similar events affecting the Company&#146;s Common Stock.&#160; In no event shall the Company issue more than <b>[***]</b> Additional Shares, as adjusted to account for any stock dividends, stock splits, reverse stock splits and similar events affecting the Company&#146;s Common Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5&nbsp;<u>Extinguishment of Economic Rights</u>.&#160; The Economic Rights granted hereunder shall be extinguished <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6&nbsp;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;"> the Company shall issue to each Investor, <b>[***]</b> stock purchase warrants representing the right for such Investor to purchase its <i>Pro Rata</i> Portion <b>[***]</b> as adjusted to account for any stock dividends, stock splits, reverse stock splits and similar events affecting the Company&#146;s Common Stock</font><font size="2" style="font-size:10.0pt;">  <b>[***]</b>&#160; For purposes hereof, <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_204628_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;V<br> OTHER AGREEMENTS OF THE PARTIES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1&nbsp;<u>Lock-Up</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160; Each Investor agrees that, for a period of one (1)&nbsp;year from the Closing Date (the &#147;<b>Lock-Up Period</b>&#148;), such Investor will not, directly or indirectly, sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option with respect to, make any short sale or otherwise dispose of or agree to dispose of, any of the Common Shares or any interest therein.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160; The Investors agree to the imprinting, until no longer required by <u>Section&nbsp;5.1(a</u>), of the following legend on any certificate evidencing any of the Common Shares:</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO, AND IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF THAT CERTAIN PURCHASE AGREEMENT, DATED AS OF MARCH&nbsp;22, 2012, BY AND BETWEEN CYCLACEL PHARMACEUTICALS,&nbsp;INC. (THE &#147;<b>COMPANY</b>&#148;) AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160; Notwithstanding the foregoing, each Investor may, at its own option, except as prohibited by law and subject to any applicable federal or state securities laws and the rules&nbsp;and regulations promulgated thereunder, transfer any or all of the Common Shares, the Economic Rights (or the Additional Shares, if issued), to any of its Affiliates during the Lock-Up Period<i>, provided, however,</i> that such Affiliate transferee is an Accredited Investor or a QIB and shall agree in writing to be bound by the provisions of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2&nbsp;<u>Right of First Refusal</u>.&#160; So long as the Economic Rights remain outstanding, the Company shall be given not less than thirty (30) days&#146; prior written notice of any proposed sale, transfer or other disposition by any transferring Investor or third-party (a &#147;<b>Transferor</b>&#148;) of its Economic Rights.&nbsp;&nbsp;The Company shall have the right, during such thirty (30) days following receipt of the notice pursuant to this Section, to purchase all, but not less than all, of the Economic Rights being offered by a Transferor in accordance with the same terms and conditions as those being offered by such Transferor and as set forth in the notice of sale (the &#147;<b>Right of First Refusal</b>&#148;).&nbsp;&nbsp;In the event such terms and conditions are modified during the notice period provided for in this Section, the Company shall be given prompt notice of such modification and shall have an additional five (5)&nbsp;days during which to exercise such Right of First Refusal.&nbsp;&nbsp;In no event shall any Economic Right be sold or transferred to Litigant or any competitor of the Company without the Company&#146;s prior written consent. The Right of First Refusal shall not apply to any transfer of Economic Rights by an Investor to any of its Affiliates, <i>provided, however,</i> that such Affiliate transferee agrees in writing to be bound by the provisions of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_204653_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3&nbsp;<u>Transfer Restrictions</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160; Subject to <u>Section&nbsp;5.1</u>, the Investors covenant that the Common Shares and, if issued, the Additional Shares will only be disposed of pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act, and in compliance with any applicable state securities laws.&#160; In connection with any transfer of the Common Shares and, if issued, the Additional Shares other than pursuant to an effective registration statement or pursuant to Rule&nbsp;144, or to the Company, the Company may require the transferor to provide to the Company an opinion of counsel selected by the transferor who is reasonably satisfactory to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act.&#160; Notwithstanding the foregoing, the Company hereby consents to and agrees to register on the books of the Company and with its Transfer Agent, without any such legal opinion, except to the extent that the Transfer Agent requests such legal opinion, any transfer of Securities by an Investor to an Affiliate of such Investor, provided that the transferee certifies to the Company that it is an Accredited Investor or QIB and provided that such Affiliate does not request any removal of any existing legends on any certificate evidencing the Common Shares and, if issued, the Additional Shares.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160; The Investors agree to the imprinting, until no longer required by this <u>Section&nbsp;5.3(b</u>), of the following legend on any certificate evidencing any of the Common Shares and, if issued, the Additional Shares:</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<b>SECURITIES ACT</b>&#148;), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_204717_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificates evidencing the Common Shares and, if issued, the Additional Shares, shall not be required to contain such legend or any other legend (i)&nbsp;while a registration statement (including the Registration Statement) covering the resale of the Common Shares and/or, if issued, the Additional Shares is effective under the Securities Act so long as the beneficial owner of such Securities is not an Affiliate of the Company, (ii)&nbsp;following any sale of such Securities pursuant to Rule&nbsp;144 if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably acceptable to the Company from counsel who is reasonably acceptable to the Company to the effect that the Securities can be sold under Rule&nbsp;144, or (iii)&nbsp;if the holder provides the Company with a legal opinion reasonably acceptable to the Company from counsel who is reasonably acceptable to the Company to the effect that the legend is not required under applicable requirements of the Securities Act (including controlling judicial interpretations and pronouncements issued by the Staff of the SEC).&#160; Following the Effective Date</font><font size="2" style="font-size:10.0pt;"> and provided the registration statement referred to in clause (i)&nbsp;above is then in effect,</font><font size="2" style="font-size:10.0pt;"> or at such earlier time as a legend is no longer required for certain of such securities, the Company will, as promptly as practicable following the delivery by an Investor to the Company or the Transfer Agent (if delivery is made to the Transfer Agent a copy shall be contemporaneously delivered to the Company) of (i)&nbsp;a legended certificate representing such Securities (and, in the case of a requested transfer, endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect transfer), and (ii)&nbsp;an opinion of counsel to the extent required by <u>Section&nbsp;5.3(a)</u>, deliver or cause to be delivered to such Investor a certificate representing such Securities that is free from all restrictive and other legends.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4&nbsp;<u>Furnishing of Information</u>.&#160; Until the third anniversary of the date hereof, the Company covenants to use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5&nbsp;<u>Integration</u>.&#160; The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate thereof shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Common Shares (and, if issued, the Additional Shares) in a manner that would require the registration under the Securities Act of the sale of such Securities to the Investors or that would be integrated with the offer or sale of such Securities for purposes of the rules&nbsp;and regulations of any Trading Market.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.6&nbsp;<u>Reservation of Securities</u>.&#160; The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant hereto in such amount as may be required to fulfill its obligations to issue the Common Shares and, if issued, the Additional Shares.&#160; In the event that at any time the then authorized shares of Common Stock are insufficient for the Company to satisfy its obligations to issue such shares, the Company shall promptly notify the Investors thereof and as promptly as practicable take all such actions as may be required to increase the number of authorized shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_204747_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7&nbsp;<u>Securities Laws Disclosure; Publicity</u>.&#160; The Company shall, at or before 9:00&nbsp;a.m., New York time, on the first Trading Day following execution of this Agreement, issue a press release disclosing all material terms of the transactions contemplated hereby. The Company shall also file a Current Report on Form&nbsp;8-K with the SEC (the &#147;<b>8-K Filing</b>&#148;) describing the terms of the transactions contemplated hereby and including as exhibits to such Current Report on Form&nbsp;8-K this Agreement and the schedules and the names and addresses of the Investors and the amount(s)&nbsp;of the Securities and Economic Rights respectively purchased, in the form required by the Exchange Act.&#160; One counsel on behalf of all Investors has had the opportunity to review and comment on the 8-K Filing prior to filing.&#160; Thereafter, the Company shall timely file any filings and notices required by the SEC or applicable law with respect to the transactions contemplated hereby.&#160; Except as herein provided, neither the Company nor any Subsidiary shall publicly disclose the name of any Investor, or include the name of any Investor in any press release without the prior written consent of such Investor (which consent shall not be unreasonably withheld, delayed or conditioned), unless otherwise required by law, regulatory authority or Trading Market. &#160;Neither the Company nor any Subsidiary shall, nor shall any of their respective officers, directors, employees and agents, provide any Investor with any material nonpublic information regarding the Company or any Subsidiary from and after the issuance of the above referenced press release without the express written consent of such Investor.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.8&nbsp;<u>Use of Proceeds</u>.&#160; The Company intends to use the net proceeds from the sale of the Common Shares and Economic Rights to fund the Litigation and for general corporate purposes after due consideration has been given to the funding needs of the Litigation.&#160; Pending these uses, the Company intends to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade securities, or as otherwise pursuant to the Company&#146;s customary investment policies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.9&nbsp;<u>Limitation on Issuance of Securities</u>.&#160; Notwithstanding anything to the contrary contained in this Agreement, the Company shall not effect any issuance of Securities that, if, after giving effect to such issuance, such Securities are in excess of 19.9% of the total issued and outstanding shares of Common Stock of the Company as of the Closing Date or otherwise compel the Company to seek the approval of its stockholders under the applicable NASDAQ Global Market rules&nbsp;and regulations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 31.5pt;text-indent:3.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b><font size="2" style="font-size:10.0pt;">&#160; The Company agrees that neither it nor any Subsidiary <b>[***]</b></font></p>
<p style="margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VI</font></b><font size="2" style="font-size:10.0pt;"><br>  <b>REGISTRATION RIGHTS</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1&nbsp;<u>Demand Registration</u>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160; <u>Request for Registration</u>.&#160; Commencing three (3)&nbsp;months prior to the expiration of the Lock-Up Period, a majority of the Investors may make a written demand for registration under the Securities Act of all or part of their Registrable Securities on Form&nbsp;S-1 or any similar long-form registration statement (&#147;<u>Long-Form Registration</u>&#148;) or, if available, on Form&nbsp;S-3 or any similar short-form registration statement (&#147;<u>Short-Form Registrations</u>&#148;) (all registrations requested pursuant to this <u>Section 6.1(a)</u> are referred to herein as &#147;<b>Demand Registration</b>s&#148;). Any demand for a Demand Registration shall specify the number and type of Registrable Securities proposed to be sold by such Investors. Upon any such request, the Investors shall be entitled to have their Registrable Securities included in the Demand Registration in accordance with this <u>Article&nbsp;VI</u>.&#160; A majority of the Investors shall be entitled to request one (1)&nbsp;Long-Form&nbsp;Registration, which shall not count as the permitted Long-Form Registration until it has become effective.&#160; In addition to the Long-Form&nbsp;Registration, a majority of the Investors shall be entitled to request an unlimited number of Short-Form&nbsp;Registrations, provided that the Company is eligible to use a Short-Form Registration.&#160; Demand Registrations shall be Short-Form&nbsp;Registrations whenever the Company is permitted to use any applicable short form and if the managing underwriters (if any) agree to the use of a Short-Form&nbsp;Registration Statement.&#160; Demand Registrations may be underwritten registrations or resale registrations pursuant to Rule&nbsp;415 under the Securities Act (&#147;<u>Shelf Registrations</u>&#148;) or otherwise, in each case at the sole discretion of the requesting Investors.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_204821_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160; As promptly as possible, and in any event on or prior to the Filing Date, the Company shall prepare and file with the SEC a Registration Statement covering the resale of all Registrable Securities for an offering to be made on a continuous basis pursuant to Rule&nbsp;415; <i>provided</i>, <i>however</i>, that, in the event that such Registration Statement only covers the Registrable Securities, if at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&nbsp;415 as a result of a characterization by the SEC of the transaction described by the Registration Statement as a primary offering by the Company, the Company shall, upon obtaining consent of the Investors, (i)&nbsp;remove from the Registration Statement such portion of the Registrable Securities (the &#147;<b>Cut Back Shares</b>&#148;), in which case, if such registration was a Long-Form&nbsp;Registration, the Company shall grant the Investors the right to request one (1)&nbsp;additional Long-Form&nbsp;Registration notwithstanding any limit on the number of Long-Form&nbsp;Registrations under this <u>Section&nbsp;6.1</u>, and/or (ii)&nbsp;agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&#146;s compliance with the requirements of Rule&nbsp;415. Any Registrable Securities not able to be included in the Registration Statement shall reduce the number of Registrable Securities of each Investor covered by such Registration Statement on a <i>pro rata</i> basis based on the number of Registrable Securities purchased by each Investor, and the Company shall have no liability to any Investor as a result of the Registration Statement covering less than all of the Registrable Shares under the circumstances described in this proviso. The Registration Statement shall be on an appropriate form in accordance with the Securities Act and the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC as promptly as possible after the filing thereof, but in any event prior to the Required Effectiveness Date, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act for such period as will terminate, at the earlier of six (6)&nbsp;months in the case of underwritten registrations, twenty four (24) months in the case of Shelf Registrations or, in any event, when all of the securities covered by such Registration Statement (but, in any event, not before the expiration of any longer period required under the Securities Act, or, if such Registration Statement relates to an underwritten offering, such longer period as in the opinion of counsel for the underwriters a prospectus is required by law to be delivered in connection with sales of Registrable Securities by an underwriter or dealer) (the <b>&#147;Effectiveness Period</b>&#148;); provided that, upon notification by the SEC that a Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company shall request acceleration of such Registration Statement within five&nbsp;(5)&nbsp;Trading Days after receipt of such notice and request that it become effective on 4:00&nbsp;p.m. New York City time on the Effective Date and, if applicable, file a prospectus supplement for any Registration Statement, whether or not required under Rule&nbsp;424 (or otherwise), by 9:00&nbsp;a.m. New York City time the day after the Effective Date.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_204844_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160; The Company shall notify the Investors in writing promptly (and in any event within two Trading Days) after receiving notification from the SEC that the Registration Statement has been declared effective.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160; Notwithstanding anything in this Agreement to the contrary, after sixty (60) consecutive Trading Days of continuous effectiveness of the initial Registration Statement filed and declared effective pursuant to this Agreement, the Company may, by written notice to the Investors, suspend sales under a Registration Statement after the Effective Date thereof and/or require that the Investors immediately cease the sale of shares of Common Stock pursuant thereto and/or defer the filing of any subsequent Registration Statement if the Company is engaged in a material merger, acquisition or sale and the Board of Directors determines in good faith, by appropriate resolutions, that, as a result of such activity, (A)&nbsp;it would be materially detrimental to the Company (other than as relating solely to the price of the Common Stock) to maintain<b>  </b>a Registration Statement at such time or (B)&nbsp;it is in the best interests of the Company to suspend sales under such registration at such time.&#160; Upon receipt of such notice, each Investor shall immediately discontinue any sales of Registrable Securities pursuant to such registration until such Investor is advised in writing by the Company that the current Prospectus or amended Prospectus, as applicable, may be used.&#160; In no event, however, shall this right be exercised to suspend sales beyond the period during which (in the good faith determination of the Company&#146;s Board of Directors) the failure to require such suspension would be materially detrimental to the Company.&#160; The Company&#146;s rights under this <u>Section&nbsp;6(e)</u>&nbsp;may be exercised for a period of no more than twenty (20) Trading Days at a time and not more than three times in any twelve-month period.&#160; Immediately after the end of any suspension period under this <u>Section&nbsp;6(e)</u>, the Company shall take all necessary actions (including filing any required supplemental prospectus) to restore the effectiveness of the applicable Registration Statement and the ability of the Investors to publicly resell their Registrable Securities pursuant to such effective Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_204904_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&#160;&#160;&#160; The Company shall not, from the date hereof until the Effective Date of the Registration Statement, prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than any registration statement or post-effective amendment to a registration statement (or supplement thereto) relating to the Company&#146;s employee benefit plans registered on Form&nbsp;S-8 or as may be demanded by any Prior Holder.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2&nbsp;<u>Registration Procedures</u>.&#160; In connection with the Company&#146;s registration obligations hereunder, the Company shall:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160; Not less than three (3)&nbsp;Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement thereto, furnish to the Investors copies of all such documents proposed to be filed, which documents (other than any document that is incorporated or deemed to be incorporated by reference therein) will be subject to the review of such Investors.&#160; The Company shall reflect in each such document when so filed with the SEC such comments regarding the Investors and the plan of distribution as the Investors may reasonably and promptly propose no later than two (2)&nbsp;Trading Days after the Investors have been so furnished with copies of such documents as aforesaid.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160; (i)&nbsp;Subject to <u>Section&nbsp;6.1(e)</u>, prepare and file with the SEC such amendments, including post-effective amendments, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective, as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the SEC such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii)&nbsp;cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule&nbsp;424; (iii)&nbsp;respond as promptly as reasonably possible to any comments received from the SEC with respect to the Registration Statement or any amendment thereto; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by the Registration Statement during the applicable period in accordance with the intended methods of disposition by the Investors thereof set forth in the Registration Statement as so amended or in such Prospectus as so supplemented.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160; Notify the Investors as promptly as reasonably possible, and (if requested by the Investors confirm such notice in writing no later than two (2)&nbsp;Trading Days thereafter), of any of the following events:&#160; (i)&nbsp;the SEC notifies the Company whether there will be a &#147;review&#148; of any Registration Statement; (ii)&nbsp;the SEC comments in writing on any Registration Statement; (iii)&nbsp;any Registration Statement or any post-effective amendment is declared effective; (iv)&nbsp;the SEC or any other Federal or state governmental authority requests any amendment or supplement to any Registration Statement or Prospectus or requests additional information related thereto; (v)&nbsp;the SEC issues any stop order suspending the effectiveness of any Registration Statement or initiates any Proceedings for that purpose; (vi)&nbsp;the Company receives notice of any suspension of the qualification or exemption from qualification of any Registrable Securities for sale in any jurisdiction, or the initiation or threat of any Proceeding for such purpose; or (vii)&nbsp;the financial statements included in any Registration Statement become ineligible for inclusion therein or any Registration Statement or Prospectus or other document contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_204923_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160; Use its commercially reasonable efforts to avoid the issuance of or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of any Registration Statement, or (ii)&nbsp;any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as possible.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160; If requested by an Investor, provide such Investor without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial statements and schedules, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the SEC.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)&#160;&#160;&#160; Promptly deliver to each Investor, without charge, as many copies of the Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request. The Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Investors in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto to the extent permitted by federal and state securities laws and regulations.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)&#160;&#160; (i)&nbsp;In the time and manner required by each Trading Market, prepare and file with such Trading Market an additional shares listing application covering all of the Registrable Securities; (ii)&nbsp;take all steps necessary to cause such Common Shares to be approved for listing on each Trading Market as soon as possible thereafter; (iii)&nbsp;provide to each Investor evidence of such listing; and (iv)&nbsp;during the Effectiveness Period, maintain the listing of such Common Shares on each such Trading Market or another Eligible Market.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)&#160;&#160; Prior to any public offering of Registrable Securities, use its commercially reasonable efforts to register or qualify or cooperate with the selling Investors in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions within the United States as any Investor requests in writing, to keep each such registration or qualification (or exemption therefrom) effective for so long as required, but not to exceed the duration of the Effectiveness Period, and to do any and all other acts or things reasonably necessary or advisable to enable the disposition in such jurisdictions of the Registrable Securities covered by a Registration Statement; <i>provided, however,</i> that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_205033_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\106781\12-9682-1\task5354233\9682-1-ke-05.htm',USER='106781',CD='May 15 04:15 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160; Cooperate with the Investors to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by this Agreement and under law, of all restrictive legends, and to enable such certificates to be in such denominations and registered in such names as any such Investors may reasonably request.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)&#160;&#160;&#160; Upon the occurrence of any event described in <u>Section&nbsp;6.2(c)(vii</u>), as promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)&#160;&#160; Cooperate with any reasonable due diligence investigation undertaken by the Investors, any underwriter participating in any sale of Registrable Securities, and any attorney, accountant, or other agent retained by any Investor or underwriter in connection with the sale of Registrable Securities, including, without limitation, by making available documents and information; <i>provided</i> that the Company will not deliver or make available any material, nonpublic information unless requested to do so in advance in writing; <i>provided further</i> that the recipient thereof agrees to keep such information confidential.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(l)&#160;&#160;&#160; Comply with all rules&nbsp;and regulations of the SEC applicable to the registration of the Securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(m)&#160; It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of any particular Investor that such Investor furnish to the Company information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required by the Company to effect the registration of such Registrable Securities and shall complete and execute such documents in connection with such registration as the Company may reasonably request.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(n)&#160;&#160; The Company shall comply with all applicable rules&nbsp;and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule&nbsp;172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule&nbsp;424 under the Securities Act, promptly inform the Investors in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule&nbsp;172 and, as a result thereof, the Investors are required to make available a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_204627_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(o)&#160;&#160; Enter into such customary agreements (including underwriting agreements in customary form) and take all such other actions as the holders of a majority of the Registrable Securities being sold or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Registrable Securities.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3&nbsp;<u>Registration Expenses</u>.&#160; The Company shall pay all fees and expenses incident to the performance of or compliance with <u>Article&nbsp;VI</u> of this Agreement by the Company, including without limitation (a)&nbsp;all registration and filing fees and expenses, including without limitation those related to filings with the SEC, any Trading Market and in connection with applicable state securities or Blue Sky laws, (b)&nbsp;printing expenses (including without limitation expenses of printing certificates for Registrable Securities), (c)&nbsp;messenger, telephone and delivery expenses, (d)&nbsp;fees and disbursements of counsel for the Company, (e)&nbsp;fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement, and (f)&nbsp;all listing fees to be paid by the Company to the Trading Market.&#160; In addition, in connection with each Demand Registration, the Company shall reimburse the holders of Registrable Securities included in such registration for the reasonable fees and disbursements of one counsel chosen by the holders of a majority of the Registrable Securities included in such registration.&#160; The Company&#146;s obligation to bear or pay all Registration Expenses is absolute and shall not depend on whether or not any offering contemplated hereby is completed or whether any Registration Statement is declared effective.&#160; Notwithstanding the foregoing, the Company shall have no obligation to pay any underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling commissions shall be borne by such holders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_204726_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4&nbsp;<u>Indemnification</u></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160; <u>Indemnification by the Company</u>.&#160; The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Investor, the officers, directors, partners, members, agents and employees of each of them, each Person who controls any such Investor (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) and the officers, directors, partners, members, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (i)&nbsp;any misrepresentation or breach of any representation or warranty made by the Company herein or any other certificate, instrument or document contemplated hereby</font><font size="2" style="font-size:10.0pt;">,</font><font size="2" style="font-size:10.0pt;"> (ii)&nbsp;any breach of any covenant, agreement or obligation of the Company contained herein or any other certificate, instrument or document contemplated hereby, (iii)&nbsp;any cause of action, suit or claim brought or made against such Indemnified Party (as defined in <u>Section&nbsp;6.4(c)</u>&nbsp;below) by a third party (including for these purposes a derivative action brought on behalf of the Company), arising out of or resulting from (x)&nbsp;the execution, delivery, performance or enforcement of this Agreement or any other certificate, instrument or document contemplated hereby, (y)&nbsp;litigation or any other transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Common Shares, or (z)&nbsp;the status of Indemnified Party as holder of Registrable Securities (unless, and only to the extent that, such action, suit or claim is based, including in part, upon a breach of such Investor&#146;s representations, warranties or covenants hereunder or any conduct by such Investor that constitutes fraud or willful misconduct) or (iv)&nbsp;any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or any form of Company prospectus or in any amendment or supplement thereto or in any Company preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (A)&nbsp;such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such Investor that has been expressly approved in writing by such Investor or furnished in writing to the Company by such Investor for use therein, or to the extent that such information relates to such Investor or such Investor&#146;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved by such Investor in writing expressly for use in the Registration Statement, or (B)&nbsp;with respect to any prospectus, if the untrue statement or omission of material fact contained in such prospectus was corrected on a timely basis in the prospectus, as then amended or supplemented, if such corrected prospectus was timely made available by the Company to the Investor through the EDGAR filing system, and the Investor seeking indemnity hereunder was advised in writing by the Company not to use the incorrect prospectus prior to the use giving rise to Losses.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160; <u>Indemnification by Investors</u>.&#160; Each Investor shall, severally and not jointly, indemnify and hold harmless the Company and its directors, officers, agents and employees to the fullest extent permitted by applicable law, from and against all Losses (as determined by a court of competent jurisdiction in a final judgment not subject to appeal or review) arising solely out of any untrue statement of a material fact contained in the Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, but only to the extent that (i)&nbsp;such untrue statements or omissions are based solely upon information regarding such Investor that has been approved in writing by such Investor or furnished to the Company by such Investor in writing expressly for use therein, or to the extent that such information relates to such Investor or such Investor&#146;s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Investor expressly for use in the Registration Statement (it being understood that the information provided by the Investor to the Company, as the same may be modified by such Investor and other information provided by the Investor to the Company in or pursuant hereto, constitutes information reviewed and expressly approved by such Investor in writing expressly for use in the Registration Statement), such Prospectus or such form of prospectus or in any amendment or supplement thereto.&#160; In no event shall the liability of any selling Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_204814_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160; <u>Conduct of Indemnification Proceedings</u>.&#160; If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#147;<b>Indemnified Party</b>&#148;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#147;<b>Indemnifying Party</b>&#148;) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless:&#160; (i)&nbsp;the Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii)&nbsp;the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii)&nbsp;the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of separate counsel shall be at the expense of the Indemnifying Party).&#160; It shall be understood, however, that the Indemnifying Party shall not, in connection with any one such Proceeding (including separate Proceedings that have been or will be consolidated before a single judge) be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties, which firm shall be appointed by a majority of the Indemnified Parties.&#160; The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. &#160;No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_204849_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within twenty (20) Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160; <u>Contribution</u>.&#160; If a claim for indemnification under <u>Section&nbsp;6.4(a</u>)&nbsp;or&nbsp; <u>(b</u>)&nbsp;is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.&#160; The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission.&#160; The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in <u>Section&nbsp;6.4(c</u>), any reasonable attorneys&#146; or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section&nbsp;was available to such party in accordance with its terms.</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties hereto agree that it would not be just and equitable if contribution pursuant to this <u>Section&nbsp;6.4(c</u>)&nbsp;were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph.&#160; Notwithstanding the provisions of this <u>Section&nbsp;6.4(c</u>), no Investor shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Investor from the sale of the Registrable Securities subject to the Proceeding exceed the amount of any damages that such Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.&#160; No Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_204926_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The indemnity and contribution agreements contained in this Section&nbsp;are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5&nbsp;<u>Dispositions</u>.&#160; Each Investor agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement and shall sell its Registrable Securities in accordance with the Plan of Distribution set forth in the Prospectus.&#160; Each Investor further agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in <u>Sections 6.2(c)(v</u>), <u>(vi</u>)&nbsp;or <u>(vii</u>), such Investor will discontinue disposition of such Registrable Securities under the Registration Statement until such Investor is advised in writing by the Company that the use of the Prospectus, or amended Prospectus, as applicable, may be resumed.&#160; The Company may provide appropriate stop orders to enforce the provisions of this paragraph. Each Investor, severally and not jointly with the other Investors, agrees that the removal of the restrictive legend from certificates representing the Common Shares and, if issued, the Additional Shares, as set forth in <u>Section&nbsp;4.4</u> is predicated upon the Company&#146;s reliance that the Investor will comply with the provisions of this subsection. Both the Company and the Transfer Agent, and their respective directors, officers, employees and agents, may rely on this subsection.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6&nbsp;<u>Piggy-Back Registrations</u>.&#160; If, at any time the Company shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than pursuant to a Demand Registration or on Form&nbsp;S-4 or Form&nbsp;S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock options or other employee benefit plans, and the registration form to be used may be used for the registration of Registrable Securities, then the Company shall send to each Investor, written notice of such determination and if, within ten (10)&nbsp;days after receipt of such notice, any such Investor shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Investor requests to be registered.&#160; Notwithstanding the foregoing, in the event that, in connection with any underwritten public offering, the managing underwriter(s)&nbsp;thereof shall impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)&#146; judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which such Investor has requested inclusion hereunder as the underwriter shall permit; <i>provided</i>, <i>however</i>, that (i)&nbsp;the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not contractually entitled to inclusion of such securities in such Registration Statement or are not contractually entitled to <i>pro rata</i> inclusion with the Registrable Securities and, (ii)&nbsp;after giving effect to the immediately preceding proviso, any such exclusion of Registrable Securities shall be made <i>pro rata</i> among the Investors seeking to include Registrable Securities and the holders of other securities having the contractual right to inclusion of their securities in such Registration Statement by reason of demand registration rights, in proportion to the number of Registrable Securities or other securities, as applicable, sought to be included by each such Investor or other holder.&#160; If an offering in connection with which an Investor is entitled to registration under this <u>Section&nbsp;6.6</u> is an underwritten offering, then each Investor whose Registrable Securities are included in such Registration Statement shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering and shall enter into an underwriting agreement in form and substance reasonably satisfactory to the Company and the underwriter or underwriters.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_205024_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VII<br> MISCELLANEOUS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1&nbsp;<u>Fees and Expenses</u>.&#160; Except as expressly set forth herein to the contrary, the Company shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses it incurs incident to the negotiation, preparation, execution, delivery and performance of this Agreement. Further, the Company shall reimburse the Investors for the fees and expenses of one counsel to the Investors incident to the negotiation, preparation, execution, delivery and performance of this Agreement in an aggregate amount of up to $36,000.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2&nbsp;<u>Entire Agreement</u>.&#160; This Agreement, together with the exhibits and schedules hereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.&#160; At or after the Closing, and without further consideration, each party will execute and deliver to such other party such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3&nbsp;<u>Notices</u>.&#160; Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section&nbsp;prior to 6:30&nbsp;p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section&nbsp;on a day that is not a Trading Day or later than 6:30&nbsp;p.m. (New York City time) on any Trading Day, (c)&nbsp;the Trading Day following the date of deposit with a nationally recognized overnight courier service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The addresses, facsimile numbers and email addresses for such notices and communications are those set forth on the signature pages&nbsp;hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same manner, by any such Person.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4&nbsp;<u>Amendments; Waivers</u>.&#160; No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and each of the Investors or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.&#160; No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_205100_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5&nbsp;<u>Construction</u>.&#160; The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. &#160;The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules&nbsp;of strict construction will be applied against any party.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.6&nbsp;<u>Successors and Assigns</u>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.&#160; The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investors.&#160; Except as otherwise provided in this Agreement, including, without limitation, <u>Sections 5.2</u> and <u>5.3</u>, any Investor may assign its rights under this Agreement to any Person to whom such Investor assigns or transfers any Common Shares or Economic Rights (or Additional Shares, if issued), provided (i)&nbsp;such transferor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company after such assignment, (ii)&nbsp;the Company is furnished with written notice of (x)&nbsp;the name and address of such transferee or assignee and (y)&nbsp;the Registrable Securities with respect to which such registration rights are being transferred or assigned, (iii)&nbsp;following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws, (iv)&nbsp;such transferee agrees in writing to be bound, with respect to the transferred Common Shares or Economic Rights (or Additional Shares, if issued), by the provisions hereof that apply to the &#147;Investors,&#148; (v)&nbsp;such transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto, and (vi)&nbsp;the Company has approved in writing any transfer to a Person who is not an Affiliate of such transferor.&#160; For purposes of clarification, subject to the preceding sentence, the Economic Rights may be transferred and/or assigned by an Investor separately from any transfer or assignment of Common Shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.7&nbsp;<u>No Third-Party Beneficiaries</u>.&#160; This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that each Indemnified Party is an intended third party beneficiary of <u>Section&nbsp;6.4</u> and (in each case) may enforce the provisions of such Section&nbsp;directly against the parties with obligations thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_205134_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.8&nbsp;<u>Governing Law; Venue</u>.&#160; THE CORPORATE LAWS OF THE STATE OF DELAWARE SHALL GOVERN ALL ISSUES CONCERNING THE RELATIVE RIGHTS OF THE COMPANY AND ITS STOCKHOLDERS.&#160; ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.&#160; THE COMPANY AND INVESTORS HEREBY IRREVOCABLY SUBMIT TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY INVESTOR HEREUNDER,&nbsp;IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF THIS AGREEMENT), AND HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY INVESTOR, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER.&#160; EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.&#160; NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9&nbsp;<u>Execution</u>.&#160; This Agreement may be executed in two or more counterparts, all of which, when taken together, shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.&#160; In the event that any signature is delivered by facsimile transmission or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or email-attached signature page&nbsp;were an original thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.10&nbsp;<u>Severability</u>.&#160; If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.11&nbsp;<u>Replacement of Securities</u>.&#160; If any certificate or instrument evidencing any securities issued hereunder is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company for any losses in connection therewith.&#160; The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_205205_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.12&nbsp;<u>Remedies</u>.&#160; In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Investors and the Company will be entitled to seek specific performance hereunder.&#160; The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.13&nbsp;<u>Adjustments in Share Numbers and Prices</u>.&#160; In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference herein to a number of shares or a price per share shall be amended to account appropriately for such event.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.14&nbsp;<u>Independent Nature of Investors&#146; Obligations and Rights</u>.&#160; The obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor hereunder.&#160; The decision of each Investor to purchase securities pursuant to this Agreement has been made by such Investor independently of any other Investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations or condition (financial or otherwise) of the Company which may have been made or given by any other Investor or by any agent or employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor (or any other Person) relating to or arising from any such information, materials, statements or opinions.&#160; Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement.&#160; Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no other Investor will be acting as agent of such Investor in connection with monitoring its investment hereunder.&#160; Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any Proceeding for such purpose.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;[SIGNATURE PAGES TO FOLLOW]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_205232_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\105924\12-9682-1\task5353160\9682-1-ke-07.htm',USER='105924',CD='May 14 21:58 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address   for Notice:</font></u></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel   Pharmaceuticals,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">200   Connell Drive</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;1500,   Berkeley Heights,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New   Jersey 07922</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel:   (908) 517-7330</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:   866-271-3466</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:   Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With   a copy to:</font></u></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mintz,   Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The   Chrysler Center</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">666   Third Avenue</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New   York, NY 10017</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:   Joel I. Papernik,&nbsp;Esq.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tel:   (212) 935-3000</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fax:   (212) 983-3115</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY SIGNATURE PAGE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor Signature Page</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the Purchase Agreement dated as of March&nbsp;22, 2012 (the &#147;<b>Purchase Agreement</b>&#148;) by and between Cyclacel Pharmaceuticals,&nbsp;Inc. and each of the Investors (as defined therein), as to the number of Common Shares and the <i>Pro Rata </i>Portion of the Economic Rights set forth below, and authorizes this signature page&nbsp;to be attached to the Purchase Agreement or counterparts thereof.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name   of Investor:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address   for Notice: <b>[***]</b></font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone   No.: <b>[***]</b></font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile   No.: <b>[***]</b></font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Email   Address: <b>[***]</b></font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number   of Common Shares:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Pro   Rata</font></i><font size="2" style="font-size:10.0pt;"> Portion of Economic Rights:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aggregate   Purchase Price: $</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delivery   Instructions (if different than above):</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c/o:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone   No.:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile   No.&nbsp;:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other   Special Instructions:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMPANY TRANSFER AGENT INSTRUCTIONS</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">American Stock Transfer&nbsp;&amp; Trust Company</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6201 15th Avenue</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brooklyn, NY 11219</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention</font></u><font size="2" style="font-size:10.0pt;">: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reference is made to that certain Purchase Agreement, dated as of March&nbsp;22, 2012 (the &#147;<b>Agreement&#148;</b>), by and among Cyclacel Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &#147;<b>Company</b>&#148;), and the investors named on the Schedule of Investors attached thereto (collectively, the &#147;<b>Holders&#148;</b>), pursuant to which the Company is issuing to the Holders shares (the &#147;<b>Common Shares</b>&#148;)</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">1</font><font size="2" style="font-size:10.0pt;">/ of common stock of the Company, par value $0.001 per share (the &#147;<b>Common Stock</b>&#148;), and Economic Rights (as defined in the Agreement) pursuant to the terms and conditions set forth in the Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the consummation of the transactions contemplated by the Agreement, this letter shall serve as our irrevocable authorization and direction to you:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;&#160; to issue an aggregate of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of our Common Stock in the names and denominations set forth on <u>Annex I</u> attached hereto. The certificates should bear the legends set forth on <u>Annex II</u> attached hereto and &#147;stop transfer&#148; instructions should be placed against their subsequent transfer.&#160; Kindly deliver the certificates to the respective delivery addresses set forth on <u>Annex I</u> via hand delivery or overnight courier.&#160; We confirm that these shares will be validly issued, fully paid and non-assessable upon issuance; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp; to issue (provided that you are the transfer agent of the Company at such time) certificates for shares of Common Stock upon transfer or resale of the Common Shares</font><font size="2" style="font-size:10.0pt;"> and receipt by you of certificate(s)&nbsp;for the Common Shares so transferred or sold (duly endorsed or accompanied by stock powers duly endorsed, in each case with signatures guaranteed and otherwise in form eligible for transfer)</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You acknowledge and agree that so long as you have previously received (a)&nbsp;written confirmation from the Company or the Company&#146;s legal counsel that either (i)&nbsp;a registration statement covering resales of the Common Shares has been declared effective by the Securities and Exchange Commission (the &#147;<b>SEC</b>&#148;) under the Securities Act of 1933, as amended (the &#147;<b>Securities Act</b>&#148;), or (ii)&nbsp;the Common Shares are eligible for sale in conformity with Rule&nbsp;144 under the Securities Act (&#147;<b>Rule&nbsp;144</b>&#148;) and (b)&nbsp;if applicable, a copy of such registration statement, then, unless otherwise required by law, within three (3)&nbsp;business days of your receipt of certificates representing the Common Shares, you shall issue the certificates representing the Common Shares to the Holders or their permissible transferees, as the case may be, registered in the names of such Holders or transferees, as the case may be, and such certificates shall not bear any legend restricting transfer of the Common Shares thereby and should not be subject to any stop-transfer restriction.&#160; Any certificates tendered for transfer shall be endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect transfer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please be advised that the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a third party beneficiary to these instructions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please execute this letter in the space indicated to acknowledge your agreement to act in accordance with these instructions.&#160; Should you have any questions concerning this matter, please contact </font><font size="2" style="font-size:10.0pt;">our counsel, Joel I. Papernik,&nbsp;Esq., at (212) 935-3000.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THE   FOREGOING INSTRUCTIONS ARE</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ACKNOWLEDGED   AND AGREED TO</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">this   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of [Month],   20[&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[TRANSFER   AGENT]</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:46.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="40%" valign="top" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enclosures</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_205619_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_205635_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_205943_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_205955_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">***</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_210003_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_210010_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_210018_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Portions of this Exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Company&#146;s application requesting confidential treatment pursuant to Rule&nbsp;24b-2 of the Securities Exchange Act of 1934, as amended.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_210025_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\C901040\12-9682-1\task5352985\9682-1-ke-09.htm',USER='C901040',CD='May 14 21:13 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a12-9682_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;31.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certification of Principal Executive Officer<br> Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Spiro Rombotis, certify that:</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this Quarterly Report on Form&nbsp;10-Q for the three months ended March&nbsp;31, 2012 of Cyclacel Pharmaceuticals,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting: and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;15, 2012</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Spiro Rombotis</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Spiro Rombotis</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp; Chief Executive Officer<br>  <i>(Principal Executive Officer)</i></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105542\12-9682-1\task5351040\9682-1-ma.htm',USER='105542',CD='May 12 07:57 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a12-9682_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;31.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certification of Principal Financial Officer<br> Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Paul McBarron, certify that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this Quarterly Report on Form&nbsp;10-Q for the three months ended March&nbsp;31, 2012 of Cyclacel Pharmaceuticals,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;15, 2012</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul McBarron</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Operating Officer, Chief Financial Officer<br> and Executive Vice President, Finance<br>  <i>(Principal Financial Officer)</i></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105542\12-9682-1\task5351040\9682-1-mc.htm',USER='105542',CD='May 12 07:59 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a12-9682_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;32.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certification of Principal Executive Officer<br> Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to 18 U.S.C. s 1350, as created by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cyclacel Pharmaceuticals,&nbsp;Inc. ( the &#147;Company&#148;) hereby certifies, to such officer&#146;s knowledge, that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Quarterly Report on Form10-Q of the Company for the three months ended March&nbsp;31, 2012 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;15, 2012</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Spiro Rombotis</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Spiro   Rombotis</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;   Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 192.0pt;text-indent:-192.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jmathew\12-9682-1\task5351290\9682-1-me.htm',USER='105205',CD='May 12 11:56 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a12-9682_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;32.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Certification of Principal Financial Officer<br> Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to 18 U.S.C. s 1350, as created by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cyclacel Pharmaceuticals,&nbsp;Inc. ( the &#147;Company&#148;) hereby certifies, to such officer&#146;s knowledge, that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the Quarterly Report on Form10-Q of the Company for the three months ended March&nbsp;31, 2012 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;15, 2012</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Operating Officer, Chief Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and   Executive Vice President, Finance</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 192.0pt;text-indent:-192.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105542\12-9682-1\task5351040\9682-1-mg.htm',USER='105542',CD='May 12 08:02 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>cycc-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cycc="http://cyclacel.com/20120331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="cycc-20120331.xsd" />
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012ITD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>1996-08-13</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-05-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag1" decimals="-3" contextRef="I2011" unitRef="USD">24449000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag2" decimals="-3" contextRef="I2012Q1" unitRef="USD">23640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag3" decimals="-3" contextRef="I2011" unitRef="USD">182000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="Tag4" decimals="-3" contextRef="I2012Q1" unitRef="USD">109000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag5" decimals="-3" contextRef="I2011" unitRef="USD">1200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag6" decimals="-3" contextRef="I2012Q1" unitRef="USD">1423000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag7" decimals="-3" contextRef="I2011" unitRef="USD">25831000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag8" decimals="-3" contextRef="I2012Q1" unitRef="USD">25172000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag9" decimals="-3" contextRef="I2011" unitRef="USD">167000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag10" decimals="-3" contextRef="I2012Q1" unitRef="USD">166000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets id="Tag11" decimals="-3" contextRef="I2011" unitRef="USD">25998000</us-gaap:Assets>
  <us-gaap:Assets id="Tag12" decimals="-3" contextRef="I2012Q1" unitRef="USD">25338000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag13" decimals="-3" contextRef="I2011" unitRef="USD">1763000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag14" decimals="-3" contextRef="I2012Q1" unitRef="USD">1116000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag15" decimals="-3" contextRef="I2011" unitRef="USD">4664000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag16" decimals="-3" contextRef="I2012Q1" unitRef="USD">4504000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:WarrantsAndRightsOutstanding id="Tag18" decimals="-3" contextRef="I2012Q1" unitRef="USD">1153000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:LiabilitiesCurrent id="Tag19" decimals="-3" contextRef="I2011" unitRef="USD">6498000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag20" decimals="-3" contextRef="I2012Q1" unitRef="USD">6802000</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities id="Tag21" decimals="-3" contextRef="I2011" unitRef="USD">6498000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Tag22" decimals="-3" contextRef="I2012Q1" unitRef="USD">6802000</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue id="Tag23" decimals="-3" contextRef="I2011" unitRef="USD">1000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="Tag24" decimals="-3" contextRef="I2012Q1" unitRef="USD">1000</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue id="Tag25" decimals="-3" contextRef="I2011" unitRef="USD">54000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="Tag26" decimals="-3" contextRef="I2012Q1" unitRef="USD">59000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag27" decimals="-3" contextRef="I2011" unitRef="USD">276452000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="Tag28" decimals="-3" contextRef="I2012Q1" unitRef="USD">278430000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Tag29" decimals="-3" contextRef="I2011" unitRef="USD">57000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Tag30" decimals="-3" contextRef="I2012Q1" unitRef="USD">65000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag31" decimals="-3" contextRef="I2011" unitRef="USD">-257064000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag32" decimals="-3" contextRef="I2012Q1" unitRef="USD">-260019000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag33" decimals="-3" contextRef="I2011" unitRef="USD">19500000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag34" decimals="-3" contextRef="I2012Q1" unitRef="USD">18536000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag35" decimals="-3" contextRef="I2011" unitRef="USD">25998000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag36" decimals="-3" contextRef="I2012Q1" unitRef="USD">25338000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Tag37" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Tag38" decimals="INF" contextRef="I2012Q1" unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="Tag39" decimals="INF" contextRef="I2011" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="Tag40" decimals="INF" contextRef="I2012Q1" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="Tag41" decimals="INF" contextRef="I2011" unitRef="Shares">1213142</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="Tag42" decimals="INF" contextRef="I2011" unitRef="Shares">1213142</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="Tag43" decimals="INF" contextRef="I2012Q1" unitRef="Shares">1213142</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="Tag44" decimals="INF" contextRef="I2012Q1" unitRef="Shares">1213142</us-gaap:PreferredStockSharesOutstanding>
  <cycc:PreferredStockLiquidationPreferenceValue id="Tag45" decimals="0" contextRef="I2011" unitRef="USD">13708505</cycc:PreferredStockLiquidationPreferenceValue>
  <cycc:PreferredStockLiquidationPreferenceValue id="Tag46" decimals="0" contextRef="I2012Q1" unitRef="USD">13890476</cycc:PreferredStockLiquidationPreferenceValue>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag47" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag48" decimals="INF" contextRef="I2012Q1" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag49" decimals="INF" contextRef="I2011" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Tag50" decimals="INF" contextRef="I2012Q1" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag51" decimals="INF" contextRef="I2011" unitRef="Shares">54220458</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag52" decimals="INF" contextRef="I2011" unitRef="Shares">54220458</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued id="Tag53" decimals="INF" contextRef="I2012Q1" unitRef="Shares">58993414</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag54" decimals="INF" contextRef="I2012Q1" unitRef="Shares">58993414</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:LicenseAndServicesRevenue id="Tag55" decimals="-3" contextRef="D2012ITD" unitRef="USD">3100000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:SalesRevenueGoodsNet id="Tag56" decimals="-3" contextRef="D2011Q1" unitRef="USD">192000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag57" decimals="-3" contextRef="D2012Q1" unitRef="USD">161000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet id="Tag58" decimals="-3" contextRef="D2012ITD" unitRef="USD">3182000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RevenueFromGrants id="Tag59" decimals="-3" contextRef="D2012ITD" unitRef="USD">3648000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueNet id="Tag60" decimals="-3" contextRef="D2011Q1" unitRef="USD">192000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet id="Tag61" decimals="-3" contextRef="D2012Q1" unitRef="USD">161000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet id="Tag62" decimals="-3" contextRef="D2012ITD" unitRef="USD">9930000</us-gaap:SalesRevenueNet>
  <us-gaap:CostOfGoodsSold id="Tag63" decimals="-3" contextRef="D2011Q1" unitRef="USD">106000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Tag64" decimals="-3" contextRef="D2012Q1" unitRef="USD">94000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Tag65" decimals="-3" contextRef="D2012ITD" unitRef="USD">1846000</us-gaap:CostOfGoodsSold>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag66" decimals="-3" contextRef="D2011Q1" unitRef="USD">3080000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag67" decimals="-3" contextRef="D2012Q1" unitRef="USD">1347000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag68" decimals="-3" contextRef="D2012ITD" unitRef="USD">187146000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag69" decimals="-3" contextRef="D2011Q1" unitRef="USD">1806000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag70" decimals="-3" contextRef="D2012Q1" unitRef="USD">1996000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag71" decimals="-3" contextRef="D2012ITD" unitRef="USD">91483000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:AccretionExpense id="Tag72" decimals="-3" contextRef="D2012ITD" unitRef="USD">100000</us-gaap:AccretionExpense>
  <us-gaap:OtherRestructuringCosts id="Tag73" decimals="-3" contextRef="D2012ITD" unitRef="USD">2634000</us-gaap:OtherRestructuringCosts>
  <us-gaap:CostsAndExpenses id="Tag74" decimals="-3" contextRef="D2011Q1" unitRef="USD">4992000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="Tag75" decimals="-3" contextRef="D2012Q1" unitRef="USD">3437000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="Tag76" decimals="-3" contextRef="D2012ITD" unitRef="USD">291043000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag77" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4800000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag78" decimals="-3" contextRef="D2012Q1" unitRef="USD">-3276000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag79" decimals="-3" contextRef="D2012ITD" unitRef="USD">-281113000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsOfFinancingCosts id="Tag80" decimals="-3" contextRef="D2012ITD" unitRef="USD">-3550000</us-gaap:PaymentsOfFinancingCosts>
  <cycc:PaymentUnderGuarantee id="Tag81" decimals="-3" contextRef="D2012ITD" unitRef="USD">1652000</cycc:PaymentUnderGuarantee>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax id="Tag82" decimals="-3" contextRef="D2012ITD" unitRef="USD">6413000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Tag86" decimals="-3" contextRef="D2011Q1" unitRef="USD">-68000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Tag87" decimals="-3" contextRef="D2012Q1" unitRef="USD">114000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Tag88" decimals="-3" contextRef="D2012ITD" unitRef="USD">-4259000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:InvestmentIncomeInterest id="Tag89" decimals="-3" contextRef="D2011Q1" unitRef="USD">11000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="Tag90" decimals="-3" contextRef="D2012Q1" unitRef="USD">6000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="Tag91" decimals="-3" contextRef="D2012ITD" unitRef="USD">13731000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="Tag92" decimals="-3" contextRef="D2012ITD" unitRef="USD">4677000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag93" decimals="-3" contextRef="D2012Q1" unitRef="USD">47000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Tag94" decimals="-3" contextRef="D2012ITD" unitRef="USD">47000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NonoperatingIncomeExpense id="Tag95" decimals="-3" contextRef="D2011Q1" unitRef="USD">21000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag96" decimals="-3" contextRef="D2012Q1" unitRef="USD">153000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag97" decimals="-3" contextRef="D2012ITD" unitRef="USD">5997000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag98" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag99" decimals="-3" contextRef="D2012Q1" unitRef="USD">-3123000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag100" decimals="-3" contextRef="D2012ITD" unitRef="USD">-275116000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag101" decimals="-3" contextRef="D2011Q1" unitRef="USD">-191000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag102" decimals="-3" contextRef="D2012Q1" unitRef="USD">-168000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag103" decimals="-3" contextRef="D2012ITD" unitRef="USD">-18612000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="Tag104" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4588000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag105" decimals="-3" contextRef="D2012Q1" unitRef="USD">-2955000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag106" decimals="-3" contextRef="D2012ITD" unitRef="USD">-256504000</us-gaap:NetIncomeLoss>
  <cycc:DividendsOnPreferredOrdinaryShares id="Tag107" decimals="-3" contextRef="D2012ITD" unitRef="USD">38123000</cycc:DividendsOnPreferredOrdinaryShares>
  <cycc:RedeemablePreferredStocksDividends id="Tag108" decimals="-3" contextRef="D2012ITD" unitRef="USD">3515000</cycc:RedeemablePreferredStocksDividends>
  <cycc:DividendsPreferredStocks id="Tag109" decimals="-3" contextRef="D2011Q1" unitRef="USD">182000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks id="Tag110" decimals="-3" contextRef="D2012Q1" unitRef="USD">182000</cycc:DividendsPreferredStocks>
  <cycc:DividendsPreferredStocks id="Tag111" decimals="-3" contextRef="D2012ITD" unitRef="USD">3839000</cycc:DividendsPreferredStocks>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag112" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4770000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag113" decimals="-3" contextRef="D2012Q1" unitRef="USD">-3137000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag114" decimals="-3" contextRef="D2012ITD" unitRef="USD">-301981000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag115" decimals="2" contextRef="D2011Q1" unitRef="USDPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag116" decimals="2" contextRef="D2012Q1" unitRef="USDPerShare">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag117" decimals="0" contextRef="D2011Q1" unitRef="Shares">46572180</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag118" decimals="0" contextRef="D2012Q1" unitRef="Shares">54761620</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag119" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4611000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag120" decimals="-3" contextRef="D2012Q1" unitRef="USD">-2947000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag121" decimals="-3" contextRef="D2012ITD" unitRef="USD">256439000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeAmortizationOfPremium id="Tag122" decimals="-3" contextRef="D2012ITD" unitRef="USD">-2297000</us-gaap:InvestmentIncomeAmortizationOfPremium>
  <us-gaap:GainLossOnPriceRiskDerivativesNet id="Tag127" decimals="-3" contextRef="D2012ITD" unitRef="USD">-44000</us-gaap:GainLossOnPriceRiskDerivativesNet>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag128" decimals="-3" contextRef="D2011Q1" unitRef="USD">86000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag129" decimals="-3" contextRef="D2012Q1" unitRef="USD">15000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag130" decimals="-3" contextRef="D2012ITD" unitRef="USD">12570000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfIntangibleAssets id="Tag131" decimals="-3" contextRef="D2012ITD" unitRef="USD">886000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="Tag132" decimals="-3" contextRef="D2012ITD" unitRef="USD">221000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Tag133" decimals="-3" contextRef="D2012ITD" unitRef="USD">-7747000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:RecognitionOfDeferredRevenue id="Tag134" decimals="-3" contextRef="D2012ITD" unitRef="USD">98000</us-gaap:RecognitionOfDeferredRevenue>
  <cycc:StockOptionPlanExpenses id="Tag135" decimals="-3" contextRef="D2012ITD" unitRef="USD">1215000</cycc:StockOptionPlanExpenses>
  <cycc:IssuanceOfStocksAndWarrantsForServicesOrClaims id="Tag136" decimals="-3" contextRef="D2012ITD" unitRef="USD">446000</cycc:IssuanceOfStocksAndWarrantsForServicesOrClaims>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag137" decimals="-3" contextRef="D2012Q1" unitRef="USD">47000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag138" decimals="-3" contextRef="D2012ITD" unitRef="USD">-53000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GoodwillAndIntangibleAssetImpairment id="Tag139" decimals="-3" contextRef="D2012ITD" unitRef="USD">7934000</us-gaap:GoodwillAndIntangibleAssetImpairment>
  <us-gaap:ShareBasedCompensation id="Tag140" decimals="-3" contextRef="D2011Q1" unitRef="USD">251000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag141" decimals="-3" contextRef="D2012Q1" unitRef="USD">102000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag142" decimals="-3" contextRef="D2012ITD" unitRef="USD">19125000</us-gaap:ShareBasedCompensation>
  <us-gaap:PaymentsForRestructuring id="Tag143" decimals="-3" contextRef="D2012ITD" unitRef="USD">-1779000</us-gaap:PaymentsForRestructuring>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Tag144" decimals="-3" contextRef="D2012ITD" unitRef="USD">2517000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag145" decimals="-3" contextRef="D2011Q1" unitRef="USD">-40000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag146" decimals="-3" contextRef="D2012Q1" unitRef="USD">126000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag147" decimals="-3" contextRef="D2012ITD" unitRef="USD">184000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities id="Tag148" decimals="-3" contextRef="D2011Q1" unitRef="USD">397000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities id="Tag149" decimals="-3" contextRef="D2012Q1" unitRef="USD">-807000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities id="Tag150" decimals="-3" contextRef="D2012ITD" unitRef="USD">-6120000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag151" decimals="-3" contextRef="D2011Q1" unitRef="USD">-3892000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag152" decimals="-3" contextRef="D2012Q1" unitRef="USD">-3771000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag153" decimals="-3" contextRef="D2012ITD" unitRef="USD">-216890000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="Tag154" decimals="-3" contextRef="D2012ITD" unitRef="USD">3763000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag155" decimals="-3" contextRef="D2012Q1" unitRef="USD">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag156" decimals="-3" contextRef="D2012ITD" unitRef="USD">8846000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag157" decimals="-3" contextRef="D2012ITD" unitRef="USD">187000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireShortTermInvestments id="Tag158" decimals="-3" contextRef="D2012ITD" unitRef="USD">156657000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:ProceedsFromSaleOfShortTermInvestments id="Tag160" decimals="-3" contextRef="D2012ITD" unitRef="USD">162729000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag161" decimals="-3" contextRef="D2012Q1" unitRef="USD">15000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag162" decimals="-3" contextRef="D2012ITD" unitRef="USD">-6350000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="Tag163" decimals="-3" contextRef="D2012ITD" unitRef="USD">3719000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="Tag164" decimals="-3" contextRef="D2012ITD" unitRef="USD">121678000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag165" decimals="-3" contextRef="D2011Q1" unitRef="USD">-80000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag166" decimals="-3" contextRef="D2012Q1" unitRef="USD">2911000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag167" decimals="-3" contextRef="D2012ITD" unitRef="USD">94582000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag168" decimals="-3" contextRef="D2011Q1" unitRef="USD">2000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag169" decimals="-3" contextRef="D2012Q1" unitRef="USD">34000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag170" decimals="-3" contextRef="D2012ITD" unitRef="USD">207000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock id="Tag171" decimals="-3" contextRef="D2011Q1" unitRef="USD">182000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock id="Tag172" decimals="-3" contextRef="D2012ITD" unitRef="USD">1898000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
  <us-gaap:RepaymentsOfNotesPayable id="Tag173" decimals="-3" contextRef="D2012ITD" unitRef="USD">455000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromNotesPayable id="Tag174" decimals="-3" contextRef="D2012ITD" unitRef="USD">414000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromLoans id="Tag175" decimals="-3" contextRef="D2012ITD" unitRef="USD">9103000</us-gaap:ProceedsFromLoans>
  <cycc:ProceedsOfCommittableLoanNotesIssuedFromShareholders id="Tag176" decimals="-3" contextRef="D2012ITD" unitRef="USD">8883000</cycc:ProceedsOfCommittableLoanNotesIssuedFromShareholders>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesCollections id="Tag177" decimals="-3" contextRef="D2012ITD" unitRef="USD">-1645000</us-gaap:LoansAndLeasesReceivableRelatedPartiesCollections>
  <us-gaap:CashAcquiredFromAcquisition id="Tag178" decimals="-3" contextRef="D2012ITD" unitRef="USD">17915000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:PaymentsForRepurchaseOfEquity id="Tag179" decimals="-3" contextRef="D2012ITD" unitRef="USD">1951000</us-gaap:PaymentsForRepurchaseOfEquity>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag180" decimals="-3" contextRef="D2011Q1" unitRef="USD">-260000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag181" decimals="-3" contextRef="D2012Q1" unitRef="USD">2945000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag182" decimals="-3" contextRef="D2012ITD" unitRef="USD">246404000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations id="Tag183" decimals="-3" contextRef="D2011Q1" unitRef="USD">7000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations id="Tag184" decimals="-3" contextRef="D2012Q1" unitRef="USD">2000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations id="Tag185" decimals="-3" contextRef="D2012ITD" unitRef="USD">476000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag186" decimals="-3" contextRef="D2011Q1" unitRef="USD">-4145000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag187" decimals="-3" contextRef="D2012Q1" unitRef="USD">-809000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag188" decimals="-3" contextRef="D2012ITD" unitRef="USD">23640000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:ProceedsFromInterestReceived id="Tag189" decimals="-3" contextRef="D2011Q1" unitRef="USD">3000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromInterestReceived id="Tag190" decimals="-3" contextRef="D2012Q1" unitRef="USD">5000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromInterestReceived id="Tag191" decimals="-3" contextRef="D2012ITD" unitRef="USD">11751000</us-gaap:ProceedsFromInterestReceived>
  <us-gaap:ProceedsFromIncomeTaxRefunds id="Tag192" decimals="-3" contextRef="D2012ITD" unitRef="USD">18207000</us-gaap:ProceedsFromIncomeTaxRefunds>
  <us-gaap:InterestPaidNet id="Tag193" decimals="-3" contextRef="D2012ITD" unitRef="USD">-1914000</us-gaap:InterestPaidNet>
  <cycc:AcquisitionsOfEquipmentPurchasedThroughCapitalLeases id="Tag194" decimals="-3" contextRef="D2012ITD" unitRef="USD">3470000</cycc:AcquisitionsOfEquipmentPurchasedThroughCapitalLeases>
  <cycc:IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements id="Tag195" decimals="-3" contextRef="D2012ITD" unitRef="USD">592000</cycc:IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements>
  <cycc:IssuanceOfOrdinarySharesOnConversionOfBridgingLoan id="Tag196" decimals="-3" contextRef="D2012ITD" unitRef="USD">1638000</cycc:IssuanceOfOrdinarySharesOnConversionOfBridgingLoan>
  <cycc:IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest id="Tag197" decimals="-3" contextRef="D2012ITD" unitRef="USD">8893000</cycc:IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest>
  <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 id="Tag198" decimals="-3" contextRef="D2012ITD" unitRef="USD">1122000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag199" decimals="-3" contextRef="I2011Q1" unitRef="USD">25350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag200" decimals="-3" contextRef="I2010" unitRef="USD">29495000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Tag201" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160; NATURE OF OPERATIONS AND BASIS OF PRESENTATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Nature of Operations&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cyclacel Pharmaceuticals,&amp;#160;Inc. (&amp;#8216;&amp;#8216;Cyclacel&amp;#8217;&amp;#8217; or the &amp;#8216;&amp;#8216;Company&amp;#8217;&amp;#8217;) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&amp;#8217;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cyclacel&amp;#8217;s clinical development priorities are focused on sapacitabine, an orally available, cell cycle modulating nucleoside analogue.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Sapacitabine is being evaluated in the SEAMLESS Phase 3 trial being conducted under a Special Protocol Assessment agreement with the US Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) for the front-line treatment of acute myeloid leukemia in the elderly and in Phase 2 studies for myelodysplastic syndromes, non-small cell lung cancer (&amp;#8220;NSCLC&amp;#8221;) and chronic lymphocytic leukemia.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;We have ongoing clinical programs in development awaiting further data. Once data becomes available and is reviewed, we will determine the feasibility of pursuing further development and/or partnering these assets, including sapacitabine in combination with seliciclib, our second clinical candidate,&amp;#160; and seliciclib in NSCLC and nasopharyngeal cancer (&amp;#8220;NPC&amp;#8221;). In addition, we market directly in the United States Xclair&amp;#174; Cream for radiation dermatitis and Numoisyn&amp;#174; Liquid and Numoisyn&amp;#174; Lozenges for xerostomia. However, these activities generate a small amount of revenues.&amp;#160; As a development stage enterprise, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. We currently anticipate that our cash and cash equivalents of approximately $23.6 million at March&amp;#160;31, 2012 are sufficient to meet our anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials for at least the next twelve months. However, we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The condensed consolidated balance sheet as of March&amp;#160;31, 2012, the condensed consolidated statements of operations, comprehensive loss, and cash flows for the three months ended March&amp;#160;31, 2012 and 2011 and the period from August&amp;#160;13, 1996 (inception) to March&amp;#160;31, 2012, and all related disclosures contained in the accompanying notes are unaudited. The condensed consolidated balance sheet as of December&amp;#160;31, 2011 is derived from the audited consolidated financial statements included in the 2011 Annual Report on Form&amp;#160;10-K filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). The condensed consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the rules&amp;#160;and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the condensed consolidated balance sheet as of March&amp;#160;31, 2012, and the results of operations, comprehensive loss and cash flows for the three months ended March&amp;#160;31, 2012 and 2011, have been made. The interim results for the three months ended March&amp;#160;31, 2012 are not necessarily indicative of the results to be expected for the year ending December&amp;#160;31, 2012 or for any other year. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December&amp;#160;31, 2011, included in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K filed with the SEC.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Recent Developments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;u&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Sale of Common Stock and Economic Rights&lt;/font&gt;&lt;/u&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses involving specified Cyclacel intellectual property and for general corporate purposes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&amp;#8217;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&amp;#8217;s common stock for the period ending on Wednesday, March&amp;#160;21, 2012. The shares issued at closing are subject to a lock-up period of one year from the date of issuance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&amp;#160; In certain defined situations, the Company may have to issue either additional shares or warrants. These collective contractual rights are referred to as &amp;#8220;Economic Rights&amp;#8221;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;See &amp;#8220;&lt;i&gt;Note 3, Fair Value Measurements&amp;#8221;&lt;/i&gt; for further details.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;u&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Preferred Stock Dividend&lt;/font&gt;&lt;/u&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;6, 2012, the Company&amp;#8217;s Board of Directors decided not to declare a quarterly cash dividend on the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;) with respect to the first quarter of 2012 that would have otherwise been payable on May&amp;#160;1, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Subsequent Developments&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;u&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;NASDAQ Appeal&lt;/font&gt;&lt;/u&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Previously, the Company received a determination letter from NASDAQ, notifying the Company that it had not regained compliance with the minimum closing bid price requirements set forth in Listing Rule&amp;#160;5450(a)(1)&amp;#160;(the &amp;#8220;Rule&amp;#8221;) during the 180 calendar days allowed to regain compliance and that the Company&amp;#8217;s common stock was subject to delisting from the NASDAQ Global Market.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On April&amp;#160;26, 2012, the Company presented its plan to regain compliance with the Rule, which plan included the possibility of effectuating a reverse stock split,&amp;#160;before a NASDAQ Listing Qualifications Panel (the &amp;#8220;Panel&amp;#8221;). On May 15, 2012, the Panel approved the Company&amp;#8217;s plan to regain compliance, and determined to continue the Company&amp;#8217;s listing pursuant to an exception to the Rule&amp;#160;for a maximum of 180 calendar days from the date of the NASDAQ Staff&amp;#8217;s notification, or through September&amp;#160;11, 2012, provided that the Company has evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days prior to such date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;If the Company is unable to provide evidence of compliance with the Rule, the Company may still transfer its listing to the NASDAQ Capital Market if it meets the initial listing criteria set forth in NASDAQ Marketplace Rule&amp;#160;5505, except for the bid price requirement. In that case, it may have until September&amp;#160;11, 2012 to comply with the minimum bid price requirement. The Company currently meets these initial listing criteria, except for the bid price requirement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Tag202" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Consolidation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany transactions and balances have been eliminated.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include estimated levels of product returns, and inputs used to determine stock-based compensation expense and the fair value of financial instruments, such as Economic Rights and other liabilities measured at fair value. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents are stated at cost, which is substantially the same as fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&amp;#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&amp;#8217;s cash flow requirements and to attain a market rate of return.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;An allowance for doubtful accounts is provided, as necessary, on trade receivables based on their respective aging categories and historical collection experience, taking into consideration the type of payer, historical and projected collection outcomes, and current economic and business conditions that could affect the collectability of the Company&amp;#8217;s receivables.&amp;#160; The allowance for doubtful accounts is reviewed, at a minimum, on a quarterly basis.&amp;#160; Changes in the allowance for doubtful accounts are recorded as an adjustment to bad debt expense within general and administrative expenses.&amp;#160; Material revisions to reserve estimates may result from adverse changes in collection experience. The Company writes off accounts against the allowance for doubtful accounts when reasonable collection efforts have been unsuccessful and it is likely the receivable will not be recovered.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Trade accounts receivable are included in prepaid expenses and other current assets on the consolidated balance sheet and were $0.1 million and $0.2 million at December&amp;#160;31, 2011 and March&amp;#160;31, 2012, respectively. All trade accounts receivable were deemed collectible as of December&amp;#160;31, 2011 and March&amp;#160;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;For the three months ended March&amp;#160;31, 2011 and 2012, approximately 90% and 86%, respectively, of our product sales in the United States were to three wholesalers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Inventory&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cyclacel values inventories at the lower of cost or market. The Company determines cost using the first-in, first-out method. As of March&amp;#160;31, 2012 and December&amp;#160;31, 2011, all inventories were classified as finished goods. The Company analyzes its inventory levels at least quarterly to identify any items that may expire prior to sale, inventory that has a cost basis in excess of net realizable value, or inventory in excess of expected sales requirements.&amp;#160; The determination of whether or not inventory costs will be realizable requires estimates by the Company&amp;#8217;s management.&amp;#160; A critical input in this determination is future expected sales forecasts. The Company writes off inventory that is expected to expire before being sold.&amp;#160; If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required in future periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;There were no inventory write-downs during the three months ended March&amp;#160;31, 2011 and 2012. In the future, reduced demand, quality issues or excess supply may result in write-downs, which would be recorded as adjustments to cost of sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, Economic Rights, and other liabilities measured at fair value. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. Economic Rights and other liabilities measured at fair value employ applicable inputs as described in &amp;#8220;&lt;i&gt;Note 3, Fair Value Measurements&amp;#8221;&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Product sales&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the selling price is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company offers a general right of return on product sales, and has considered the guidance in ASC Subtopic 605-15, &amp;#8220;&lt;i&gt;Revenue Recognition -Products&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 605-15&amp;#8221;) and ASC Subtopic 605 &amp;#8212; 10 &amp;#8220;&lt;i&gt;Revenue Recognition - Overall&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 605-10&amp;#8221;). Under these guidelines, the Company accounts for all product sales using the &amp;#8220;sell-through&amp;#8221; method. Under the sell-through method, revenue is not recognized upon shipment of product to distributors. Instead, the Company records deferred revenue at gross invoice sales price less 5% of the current wholesale acquisition price (in accordance with our returns policy) and deferred cost of sales at the cost at which those goods were held in inventory. The Company recognizes revenue and cost of sales when such inventory is sold through to pharmacies. To estimate product sold through to pharmacies, the Company relies on third-party information, including information obtained from significant distributors with respect to their inventory levels and sell-through to pharmacies. At the time of revenue recognition, the Company also estimates a provision for returned products based on historical data and future expectations; this provision is charged against revenues.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deferred revenue was $0.1 million at December&amp;#160;31, 2011 and March 31, 2012. Deferred cost of goods sold was approximately $20,000 and $22,000 at December&amp;#160;31, 2011 and March 31, 2012, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Collaboration, research and development, and grant revenue&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Certain of the Company&amp;#8217;s revenues are earned from collaborative agreements. The Company recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether these criteria have been met is based on management&amp;#8217;s judgments regarding the nature of the research performed, the substance of the milestones met relative to those the Company must still perform, and the collectability of any related fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Research and development revenues, which are earned under agreements with third parties for contract research and development activities, are recorded as the related services are performed. Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by achievement of the specified milestones and the absence of ongoing performance obligations. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues previously recognized are refundable if the relevant research effort is not successful.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. All grants earned and received are not refundable. The Company had deferred grant revenue of approximately $75,000 at March&amp;#160;31, 2012.&amp;#160; The Company had no such deferred revenue at December&amp;#160;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Clinical Trial Accounting&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Data management and monitoring of the Company&amp;#8217;s clinical trials are performed with the assistance of contract research organizations (&amp;#8220;CROs&amp;#8221;) or clinical research associates (&amp;#8220;CRAs&amp;#8221;) in accordance with the Company&amp;#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into the trial and any initial payment made to the clinical trial site is recognized upon execution of the clinical trial agreements and expensed as research and development expenses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Research and Development Expenditures&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Research and development expenses consist primarily of costs associated with developing the Company&amp;#8217;s product candidates, including upfront fees and milestones paid to parties from whom the Company licenses certain intellectual property, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs, amortization of purchased technology and depreciation. Expenditures relating to research and development are expensed as incurred.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Foreign currency and currency translation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date.&amp;#160; Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from remeasurement of foreign-currency denominated intercompany loans that are &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;of a long-term-investment nature, &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;are recorded in other comprehensive income.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Fair Value Measurements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Inputs used to determine fair value of financial and non-financial assets and liabilities are categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least reliable (see &lt;i&gt;Note 3, Fair Value Measurements&lt;/i&gt;). Management reviews the categorization of fair value inputs on a periodic basis and may determine that it is necessary to transfer an input from one level of the fair value hierarchy to another based on changes in events or circumstances, such as a change in the observability of an input. Any such transfer will be recognized at the end of the reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Income Taxes&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&amp;#8217;s management has established a full valuation allowance against its deferred tax assets based on the determination that it is not more likely than not that the Company will recognize the benefits of those assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company applies the guidance codified in ASC Topic 740, &lt;i&gt;&amp;#8220;Income taxes&amp;#8221; &lt;/i&gt;(&amp;#8220;ASC 740&amp;#8221;) related to accounting for uncertainty in income taxes. ASC 740 specifies the accounting for uncertainty in income taxes recognized in a company&amp;#8217;s financial statements by prescribing a minimum probability threshold a tax position is required to meet before being recognized in the financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company records income tax benefits related to research and development tax credits, which will be claimed from H. M. Revenue&amp;#160;&amp;amp; Customs, the United Kingdom&amp;#8217;s taxation and customs authority, with respect to qualifying research and development costs incurred in the same accounting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company grants stock options, restricted stock units and restricted stock to officers, employees and directors under the Amended and Restated Equity Incentive Plan (&amp;#8220;2006 Plan&amp;#8221;), which was approved on March&amp;#160;16, 2006, as amended on May&amp;#160;21, 2007, and subsequently amended and restated on April&amp;#160;14, 2008.&amp;#160; The Company has granted various types of awards under the 2006 Plan, which is described more fully in &lt;i&gt;Note 6, Stock-Based Compensation Arrangements&lt;/i&gt;. The Company accounts for these awards under ASC 718, &amp;#8220;&lt;i&gt;Compensation &amp;#8212; Stock Compensation&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 718&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of awards granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&amp;#8217;s share price, the anticipated exercise behavior of its employees, interest rates, and dividend yields. These variables are projected based on the Company&amp;#8217;s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&amp;#160; The Company considers many factors when estimating expected forfeitures, including type of awards granted employee class, and historical experience.&amp;#160; Actual results and future estimates may differ substantially from current estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Segments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has determined its reportable segments in accordance with ASC 280, &amp;#8220;&lt;i&gt;Segment Reporting&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 280&amp;#8221;) and related disclosures about products, services, geographic areas and major customers.&amp;#160; After considering its business activities and geographic reach, the Company has concluded that it operates in just one operating segment being the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Net Loss per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company calculates net loss per common share in accordance with ASC 260, &amp;#8220;&lt;i&gt;Earnings Per Share&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company&amp;#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock, restricted stock units, convertible preferred stock, and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 6pt; WIDTH: 98.88%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="98%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;br /&gt;
2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;br /&gt;
2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Stock options &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,347,033&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,438,679&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Restricted stock and restricted stock units&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;52,070&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;344,784&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Convertible preferred stock &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;516,228&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;516,228&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Contingently issuable common stock and common stock warrants associated with economic rights &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,933,052&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Options to purchase common stock and common stock warrants issued in connection with the October&amp;#160;2010 financing &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6,242,398&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Common stock warrants &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10,005,192&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;13,814,015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total shares excluded from calculation &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;20,162,921&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;21,046,758&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In accordance with ASC 220, &amp;#8220;&lt;i&gt;Comprehensive Income&lt;/i&gt;&amp;#8221; (&amp;#8220;ASC 220&amp;#8221;) all components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. ASC 220 defines comprehensive income (loss) as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recognized in relation to items of other comprehensive income.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In June&amp;#160;2011, the FASB issued Accounting Standards ASU 2011-05 to amend the guidance on the presentation of comprehensive income in ASC 220. ASU 2011-05 requires companies to present a single statement of comprehensive income or two separate but consecutive statements, a statement of operations and a statement of comprehensive income. ASU 2011-05 eliminates the alternative to present comprehensive income within the statement of equity. ASU 2011-05 does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.&amp;#160; The ASU should be applied retrospectively and is effective for annual periods beginning after December&amp;#160;15, 2011.&amp;#160; In December&amp;#160;2011, the FASB issued ASU 2011-12, which deferred the changes in ASU 2011-05 that relate to the presentation of reclassifications out of accumulated other comprehensive income.&amp;#160; The adoption of this guidance did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In May&amp;#160;2011, the FASB issued ASU 2011-04, which amends the guidance on fair value measurement in ASC 820 to converge the fair value measurement and disclosure requirements under GAAP and International Financial Reporting Standards (&amp;#8220;IFRS&amp;#8221;) fair value measurement and disclosure requirements. The amendments change the wording used to describe the requirements for measuring fair value, changes certain fair value measurement principles and enhances disclosure requirements. This guidance is effective for annual periods beginning after December&amp;#160;15, 2011, applied prospectively. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag203" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As defined in ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt; (&amp;#8220;ASC 820&amp;#8221;), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December&amp;#160;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other liabilities measured at fair value:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Warrants liability &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;51&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;51&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Scottish Enterprise Agreement &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other liabilities measured at fair value &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19,894&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19,965&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of March&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,498&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,498&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Economic rights &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,153&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,153&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other liabilities measured at fair value:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Warrants liability &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Scottish Enterprise Agreement &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other liabilities measured at fair value &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,498&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,182&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;18,680&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 9pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table reconciles the beginning and ending balances of Level 3 inputs for the three months ended March&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;$000&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Balance as of December&amp;#160;31, 2011 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Sale of Economic Rights &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,097&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation of Economic Rights &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;56&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Change in valuation of warrants liability &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(42&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Balance as of March&amp;#160;31, 2012 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,182&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Economic Rights&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;22, 2012, the Company entered into a financing agreement with certain existing institutional stockholders.&amp;#160; Under the terms of the agreement, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&amp;#160; In certain defined situations, the Company may have to issue either additional common shares or warrants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Economical Rights are accounted for as a derivative financial instrument under ASC 815, &lt;i&gt;Derivative financial instruments &lt;/i&gt;(&amp;#8220;ASC 815&amp;#8221;), and are measured at fair value. Changes in fair value are recognized in earnings. &amp;#160;The fair value of the Economical Rights has been estimated using a decision-tree analysis method.&amp;#160; This is an income-based method that incorporates the expected benefits, costs and probabilities of contingent outcomes under varying scenarios.&amp;#160; Each scenario within the decision-tree is discounted to the present value using the company&amp;#8217;s credit adjusted risk-free rate and ascribed a weighted probability to determine the fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has concluded the fair value of this liability was approximately $1.1 million and $1.2 million at March&amp;#160;22, 2012, and March&amp;#160;31, 2012, respectively.&amp;#160; The fair value of the derivative increased approximately $56,000 from March&amp;#160;22, 2012 to March&amp;#160;31, 2012. The increase in fair value was recognized as a loss in the consolidated statement of operations for the three month period ended March&amp;#160;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The most significant inputs in estimating the fair value of this liability are:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(i)&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The Company&amp;#8217;s credit adjusted risk-free rate, which has been derived from the observable returns on debt for more developed pharmaceuticals companies, adjusted for the Company&amp;#8217;s risk profile.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(ii)&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The amount of the return to the investors, which will vary depending on:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;a.&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The outcome of the litigation, including consideration of whether the litigation may be resolved in a jury trial or settled out of court;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;b.&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The amount of the settlement or award, which the Company has estimated predominantly based on observable royalty rates arising from the settlement of other cases of intellectual property litigation; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;c.&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The form of the settlement or award.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(iii)&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The projected timing of the cash flows to the investors, which could vary between several months to several years depending upon whether the litigation is settled, when the court may decide the case, whether any appeal is made on any court decision and the form of any settlement or award.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(iv)&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;The number of contingent warrants that could be issued, which is based on a formula.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The decision-tree analysis model used to calculate the fair value of the derivative requires the probability of alternative scenarios to be determined at a series of decision points.&amp;#160; Each scenario may contain more than one decision point resulting in further scenarios.&amp;#160; Therefore, the probability estimates made by management at each decision point are a significant input to the valuation model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;All of these inputs are unobservable inputs, which have an interrelated effect on the fair value of the derivative.&amp;#160; It is not possible to evaluate the impact on the fair value of each factor in combination.&amp;#160; However, generally the fair value of the derivative liability will increase, (i)&amp;#160;the higher the value of the expected settlement or award, (ii)&amp;#160;the lower the discount rate employed and (iii)&amp;#160;the more likely it is that a settlement or award will be made.&amp;#160; The fair value of the derivative liability will decrease if the timing of settlement is delayed, the expected settlement decreases, or anticipated litigation costs increase.&amp;#160;&amp;#160; The impact on the fair value of the derivative liability related to the probability of whether the litigation is settled prior to the court hearing or whether a settlement award is made by the court and the form of the settlement will depend on the other factors above and cannot be estimated in isolation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The decision-tree analysis model has been performed by valuation specialists, based on inputs provided by the company and other sources. At each reporting period, the inputs to the model will be evaluated to determine whether any adjustments are appropriate, and to reflect changes in the time value of the expected cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company used the following assumptions to calculate the value of the Economic Rights:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.25in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;22,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="bottom" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Probability of unsuccessful/successful outcomes &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;25% - 75%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;25% - 75%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Amount of award or settlement (1) &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$10.0 million - $20.0 million&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$10.0 million - $20.0 million&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Discount rate &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;16%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;16%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Timing of cash flows &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.75 &amp;#8211; 2.27 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.75 &amp;#8211; 2.27 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Royalty rate &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Litigation expenses &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$1.0 million &amp;#8211; $3.0 million&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$1.0 million &amp;#8211; $3.0 million&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(1)&lt;/font&gt;&lt;font style="FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Assumptions take into consideration the cap on the amount that the Company would have to pay investors in the event of an award or settlement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 31.5pt; TEXT-INDENT: -13.5pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Other Liabilities Measured at Fair Value&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;u&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Warrants Liability&lt;/font&gt;&lt;/u&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company issued warrants to purchase shares of common stock under the registered direct financing completed in February&amp;#160;2007.&amp;#160; These warrants are being accounted for as a liability in accordance with ASC 815.&amp;#160; At the date of the transaction, the fair value of the warrants of $6.8&amp;#160;million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &amp;#8212; 4.68%, expected volatility &amp;#8212; 85%, expected dividend yield &amp;#8212; 0%, and a remaining contractual life of 7&amp;#160;years. The fair value of the warrant is being remeasured each reporting period, with a gain or loss recognized in the consolidated statement of operations. Such gains or losses will continue to be reported until the warrants are exercised or expired. The Company used the Black-Scholes option-pricing model with the following assumptions to value the warrants:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.25in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Exercise price &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$8.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$8.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Expected term &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2.13 Yrs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.88 Yrs.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Risk free interest rate &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.25%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.33%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Expected volatility &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;121%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;77%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Expected dividend yield over expected term &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company recognized the change in the value of warrants as a gain on the consolidated statement of operations of $0.1 million and approximately $42,000 for the three months ended March&amp;#160;31, 2011 and 2012, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;u&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Scottish Enterprise Agreement&lt;/font&gt;&lt;/u&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On June&amp;#160;22, 2009, the Company amended the Agreement with Scottish Enterprise (&amp;#8220;SE&amp;#8221;) (the &amp;#8220;Amendment&amp;#8221;), in order to allow the Company to implement a reduction of the Company&amp;#8217;s research operations located in Scotland in exchange for the parties&amp;#8217; agreement to modify the payment terms of the Agreement in the principal amount of &amp;#163;5&amp;#160;million (approximately $8.0 million at December&amp;#160;31, 2009), which SE had previously entered into with the Company. The Agreement provided for repayment of up to &amp;#163;5 million in the event the Company significantly reduced its Scottish research operations. Pursuant to the terms of the Amendment, in association with Cyclacel&amp;#8217;s material reduction in staff at its Scottish research facility, the parties agreed to a modified payment of &amp;#163;1&amp;#160;million (approximately $1.7 million at June&amp;#160;22, 2009) payable in two equal tranches. On July&amp;#160;1, 2009, the first installment of &amp;#163;0.5 million (approximately $0.8 million) was paid and the remaining amount of &amp;#163;0.5 million (approximately $0.8 million) was paid on January&amp;#160;6, 2010.&amp;#160; In addition, should a further reduction below current minimum staff levels be effectuated before July&amp;#160;2014 without SE&amp;#8217;s prior consent, the Company may be obligated to pay up to &amp;#163;4&amp;#160;million to SE, which will be calculated as a maximum of &amp;#163;4&amp;#160;million (approximately $6.2 million and $6.4 million at December&amp;#160;31, 2011 and March&amp;#160;31, 2012, respectively) less the market value of the shares held by SE at the time staffing levels in Scotland fall below the prescribed minimum levels. If the Company were to have reduced staffing levels below the prescribed levels, the amount potentially payable to SE would have been approximately &amp;#163;3.8 million (approximately $5.9 million) and approximately &amp;#163;3.8 million (approximately $6.1 million) at December&amp;#160;31, 2011 and March&amp;#160;31, 2012, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;This arrangement is accounted for as a liability under ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt; (&amp;#8220;ASC 480&amp;#8221;), and is measured at fair value. Changes in fair value are recognized in earnings. &amp;#160;Due to the nature of the associated contingency and the likelihood of occurrence, the Company has concluded the fair value of this liability was approximately $20,000 at December&amp;#160;31, 2011 and March&amp;#160;31, 2012, respectively. The most significant inputs in estimating the fair value of this liability are the probabilities that staffing levels fall below the prescribed minimum and that the Company is unable or unwilling to replace such employees within the prescribed time period. At both December&amp;#160;31, 2011 and March&amp;#160;31, 2012, the Company used a scenario analysis model to arrive at the fair value of the Scottish Enterprise Agreement and assumed a 30% probability of falling below a minimum staffing level and a 1% probability that the occurrence of such an event would not be cured within the prescribed time period. At each reporting period, the inputs used to determine the fair value of the liability will be evaluated to determine whether adjustments are appropriate. Changes in the value of this liability are recorded in the consolidated statement of operations.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock id="Tag204" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Prepaid expenses and other current assets consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;br /&gt;
2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 26.5%; PADDING-TOP: 0in" valign="bottom" width="26%" colspan="3"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;($000s)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Research and development tax credit receivable &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;541&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;734&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Prepayments &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;321&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;278&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accounts receivable &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;116&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;152&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Deposits &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;13&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;153&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other current assets &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;209&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;106&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total prepaid expenses and other current assets &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,200&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,423&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="Tag205" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accrued and other current liabilities consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;March&amp;#160;31,&lt;br /&gt;
2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 28%; PADDING-TOP: 0in" valign="bottom" width="28%" colspan="3"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;($000s)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Accrued research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.68%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,471&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.68%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Other current liabilities &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,193&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,170&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,664&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,504&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag206" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6.&amp;#160;&amp;#160;&amp;#160;&amp;#160; STOCK BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March&amp;#160;31, 2011 and 2012 as shown in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.75in; WIDTH: 80%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="80%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 33.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;For&amp;#160;the&amp;#160;three&amp;#160;months&lt;br /&gt;
ended&amp;#160;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.12%; PADDING-TOP: 0in" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;($000s)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Research and development &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;50&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.02%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;General and administrative &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;201&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;85&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Stock-based compensation costs before income taxes &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="15%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;251&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="15%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;102&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;At the Company&amp;#8217;s annual shareholder meeting on May&amp;#160;14, 2008, the stockholders approved and amended the number of shares reserved under the 2006 Plan to 5,200,000 shares of the Company&amp;#8217;s common stock, up from 3,000,000 shares. The awards granted under the 2006 Plan have a maximum maturity of 10&amp;#160;years and generally vest over a four-year period from the date of grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;A summary of activity for the options under the Company&amp;#8217;s 2006 Plan for the three months ended March&amp;#160;31, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
&amp;#160;Term&amp;#160;(years)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;(in&amp;#160;$000s)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Options outstanding at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,515,741&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;140&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Granted &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Exercised &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;77,062&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Expired &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Cancelled / forfeited &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Options outstanding at March&amp;#160;31, 2012 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,438,679&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.80&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;233&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Unvested at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;556,177&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.72&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8.59&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Vested and exercisable at March&amp;#160;31, 2012 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,882,502&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4.20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5.71&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;232&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of grant and 1/48 of the award vesting each month thereafter.&amp;#160; However, certain awards made to executive officers vest over three to five years, depending on the terms of their employment with the Company. In addition, recent awards made to rank-in-file employees vest ratably over three to four years, with 1/36 to 1/48 of the award vesting each month.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company estimates grant date fair value for stock option awards using an option-pricing model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the forfeiture rate adjusted as necessary.&amp;#160; Ultimately, the actual expense recognized over the requisite service period is based on only those shares that vest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company estimates the expected term of stock option awards using past history of early exercise behavior and expectations about future behavior. Starting with the December&amp;#160;2010 annual grants to the Company&amp;#8217;s employees, the Company relied exclusively on its historical volatility as an input to the option pricing model as the Company&amp;#8217;s management believes that this rate will be representative of future volatility over the expected term of the options.&amp;#160; Prior to December&amp;#160;2010, because the Company had been publicly traded for a limited period, the expected volatility assumption was based on the historical volatility of peer companies over the expected term of the option awards.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Estimates of pre-vesting option forfeitures are based on the Company&amp;#8217;s experience. For outstanding options, the Company uses a forfeiture rate of 0 &amp;#8212; 50% depending on when and to whom the options are granted. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and may impact the amount of compensation expense to be recognized in future periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;There were no options granted during either of the three month periods ending March&amp;#160;31, 2011 and 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During the three months ended March&amp;#160;31, 2011, 5,131 stock options were exercised resulting in approximately $2,000 of cash proceeds to the Company.&amp;#160; During the three months ended March&amp;#160;31, 2012, there were 77,062 stock options exercised totaling approximately $34,000 in proceeds. As the Company presently has tax loss carry forwards from prior periods and expects to incur tax losses during the year ended December&amp;#160;31, 2012, the Company is not able to benefit from the deduction for exercised stock options in the current reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Restricted Stock&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In November&amp;#160;2008, the Company issued 50,000 shares of restricted common stock to an employee subject to certain forfeiture provisions. Specifically, one quarter of the award vests one year from the date of grant and 1/48 of the award effectively vests each month thereafter.&amp;#160; This restricted stock grant was accounted for at fair value at the date of grant and an expense is recognized during the vesting term. Summarized information for the restricted stock grant for the three months ended March&amp;#160;31, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="86%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="bottom" width="56%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Restricted&amp;#160;Stock&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted&amp;#160;Average&amp;#160;Grant&lt;br /&gt;
Date&amp;#160;Value&amp;#160;Per&amp;#160;Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Non-vested at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;11,450&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="21%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(3,126&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Non-vested at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8,324&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Restricted Stock Units&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In November&amp;#160;2008 and December&amp;#160;2011, respectively, the Company issued 91,700 and 238,000 restricted stock units to senior executives.&amp;#160; Each unit entitles the holder to receive a share of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During the first quarter of 2012, the Company issued approximately 86,000 restricted stock units to employees as part of its annual grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The 2008 grants vest over four years and the 2011 and 2012 grants vest over three years.&amp;#160; A restricted stock unit grant is accounted for at fair value at the date of grant which is equivalent to the market price of a share of the Company&amp;#8217;s common stock, and an expense is recognized over the vesting term. Summarized information for restricted stock grants for the three months ended March&amp;#160;31, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="86%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="bottom" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Restricted&amp;#160;Stock&amp;#160;Units&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted&amp;#160;Average&amp;#160;Grant&lt;br /&gt;
Date&amp;#160;Value&amp;#160;Per&amp;#160;Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Non-vested at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="18%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;255,175&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="21%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 18.46%; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;85,974&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.55&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;(4,689&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Non-vested at March&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="18%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;336,460&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.74&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Tag207" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Licensing Agreements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of product employing the technology or falling under claims of patent applications.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&amp;#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial entering Phase 3 during the first quarter of 2011, a milestone payment of $1.6 million was paid in April&amp;#160;2011. A further $10.0 million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones and the Company&amp;#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six months&amp;#8217; notice, or upon twelve months&amp;#8217; notice after a launch of a sapacitabine-based product.&amp;#160; The license also may be terminated by either party for material default. Effective July&amp;#160;11, 2011, the license agreement was amended to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September&amp;#160;2011, and releases the Company from all claims and liability of any kind arising under such provision. The amendment further provides that the royalty rate due from the Company to Daiichi Sankyo on future net sales of sapacitabine be increased between 1.25% and 1.50% depending on the level of net sales of sapacitabine realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In connection with the asset acquisition of ALIGN on October&amp;#160;5, 2007, the Company acquired distribution rights for the exclusive rights to sell and distribute three products in the United States. Each of the agreements covering the three products expires in June&amp;#160;2015, after which the Company has no rights to distribute these products. The Company has a minimum purchase obligation equivalent to the value of product purchased in the previous year.&amp;#160; For the year ended December&amp;#160;31, 2012 this equates to $0.2 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Legal proceedings&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On April&amp;#160;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the United States District Court for the District of Delaware seeking a declaratory judgment that four of the Company&amp;#8217;s own patents (claiming the use of romidepsin injection in T-cell lymphomas) are invalid and not infringed by Celgene&amp;#8217;s products, but directly involve the use and administration of Celgene&amp;#8217;s ISTODAX&amp;#174; (romidepsin for injection) product. On June&amp;#160;17, 2010, the Company filed its answer and counterclaims to the declaratory judgment complaint. The Company has filed counterclaims charging Celgene with infringement of each of its four patents and seeking damages for Celgene&amp;#8217;s infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene&amp;#8217;s ISTODAX&amp;#174; (romidepsin for injection) product.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;A Scheduling Order was entered February&amp;#160;2, 2012, at which time the court set the following significant dates: March&amp;#160;22, 2012 (amendment of pleadings/joinder of parties); September&amp;#160;24, 2012 (teleconference with the court exploring possibility of Alternative Dispute Resolution); March&amp;#160;14, 2013 (claim construction hearing); August&amp;#160;14, 2013 (summary judgment briefing); and June&amp;#160;2, 2014 (7 day jury trial start date). Discovery is currently ongoing.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <dei:EntityRegistrantName contextRef="D2012Q1">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="D2012Q1">0001130166</dei:EntityCentralIndexKey>
  <dei:DocumentType contextRef="D2012Q1">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="D2012Q1">2012-03-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="D2012Q1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="D2012Q1">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus contextRef="D2012Q1">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="D2012Q1">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="D2012Q1">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="D2012Q1">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCommonStockSharesOutstanding decimals="INF" contextRef="I2012Q1SO" unitRef="Shares">59003301</dei:EntityCommonStockSharesOutstanding>
  <cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus decimals="-3" contextRef="D2012ITD" unitRef="USD">164000</cycc:IssuanceOfOrdinarySharesInLieuOfCashBonus>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8.&amp;#160;&amp;#160;&amp;#160;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Preferred stock&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As of March&amp;#160;31, 2012, there were 1,213,142 shares of Preferred Stock issued and outstanding at an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August&amp;#160;and November, commencing February&amp;#160;1, 2005. Any dividends must be declared by the Company&amp;#8217;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $10 per share, plus accrued and unpaid dividends.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Preferred Stock is convertible at the option of the holder at any time into the Company&amp;#8217;s shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for each share of Preferred Stock based on a price of $23.50. The Company has reserved 516,228 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at March&amp;#160;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During 2010, 833,671 shares of Preferred Stock were converted into 1,655,599 shares of the Company&amp;#8217;s common stock. Since inception through March&amp;#160;31, 2012, holders have voluntarily converted 1,776,858 shares of Preferred Stock into common stock. The converted shares of Preferred Stock have been retired and canceled and shall upon cancellation be restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&amp;#8217;s common stock has exceeded $35.25, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&amp;#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&amp;#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&amp;#160;24, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;From November&amp;#160;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption prices per share stated below, plus an amount equal to accrued and unpaid dividends up to the date of redemption:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.1in; WIDTH: 90.68%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Year from November&amp;#160;1, 2011 to October&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10.18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Year from November&amp;#160;1, 2012 to October&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10.12&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Year from November&amp;#160;1, 2013 to October&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;November&amp;#160;1, 2014 and thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10.00&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&amp;#160;1, 2005 (the &amp;#8220;Exchange Date&amp;#8221;) for the Company&amp;#8217;s 6% Convertible Subordinated Debentures (&amp;#8220;Debentures&amp;#8221;) at the rate of $10 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have terms substantially similar to those of the Preferred Stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;6, 2012, the Company&amp;#8217;s Board of Directors decided not to declare a quarterly cash dividend on the Company&amp;#8217;s 6% Convertible Exchangeable Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;) with respect to the first quarter of 2012 that would have otherwise been payable on May&amp;#160;1, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Common Stock&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;March&amp;#160;2012 Sale of Common Stock and Economic Rights&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On March&amp;#160;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders, raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses on certain intellectual property and for general corporate purposes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&amp;#8217;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&amp;#8217;s common stock for the period ending on Wednesday, March&amp;#160;21, 2012. In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&amp;#160; In certain defined situations, the Company may have to issue either additional shares or warrants.&amp;#160; The shares issued at closing are subject to a lock-up period of one year from the date of issuance.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;See &lt;i&gt;Note 3, Fair Value Measurements&lt;/i&gt; for further details.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Common Stock Warrants&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The following table summarizes information about warrants outstanding at March&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 54.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Issued&amp;#160;in&amp;#160;Connection&amp;#160;With&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Expiration&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Date&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Common&amp;#160;Shares&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Issuable&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"&gt;Exercise&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 54.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="54%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;April&amp;#160;2006 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2,571,429&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7.00&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;February&amp;#160;2007 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1,062,412&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8.44&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;December&amp;#160;2007 CEFF&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;100,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.40&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;July&amp;#160;2009 Series&amp;#160;II stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;692,256&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.00&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;January&amp;#160;2010 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;712,500&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.26&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;January&amp;#160;2010 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;705,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2.85&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;October&amp;#160;2010 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4,161,595&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.92&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;July&amp;#160;2011 stock issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3,808,823&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.36&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;13,814,015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.28&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;There were no exercises of warrants during the three months ended March&amp;#160;31, 2011 and 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesCurrent decimals="-3" contextRef="I2012Q1" unitRef="USD">29000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent decimals="-3" contextRef="I2011" unitRef="USD">71000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax decimals="-3" contextRef="D2011Q1" unitRef="USD">78000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax decimals="-3" contextRef="D2012Q1" unitRef="USD">42000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <cycc:TransactionCostsOnSaleOfEconomicRights decimals="-3" contextRef="D2012Q1" unitRef="USD">33000</cycc:TransactionCostsOnSaleOfEconomicRights>
  <cycc:TransactionCostsOnSaleOfEconomicRights decimals="-3" contextRef="D2012ITD" unitRef="USD">33000</cycc:TransactionCostsOnSaleOfEconomicRights>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment decimals="-3" contextRef="D2012Q1" unitRef="USD">24000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <cycc:ChangeInValuationOfEconomicRights decimals="-3" contextRef="D2012Q1" unitRef="USD">56000</cycc:ChangeInValuationOfEconomicRights>
  <cycc:ChangeInValuationOfEconomicRights decimals="-3" contextRef="D2012ITD" unitRef="USD">56000</cycc:ChangeInValuationOfEconomicRights>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cycc-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<xsd:schema targetNamespace="http://cyclacel.com/20120331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cycc="http://cyclacel.com/20120331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20120331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://cyclacel.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementOfComprehensiveIncome" id="StatementOfComprehensiveIncome">
        <link:definition>0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/CashFlows" id="CashFlows">
        <link:definition>0040 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation" id="DisclosureNatureOfOperationsAndBasisOfPresentation">
        <link:definition>1010 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>1020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1030 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>1040 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities" id="DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities">
        <link:definition>1050 - Disclosure - ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>1060 - Disclosure - STOCK BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>1070 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>1080 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
        <link:definition>8000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/StatementOfStockholdersEquityCalc2" id="StatementOfStockholdersEquityCalc2">
        <link:definition>8010 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) CALC 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureSignificantContracts" id="DisclosureSignificantContracts">
        <link:definition>8020 - Disclosure - Significant Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureCashAndCashEquivalents" id="DisclosureCashAndCashEquivalents">
        <link:definition>8030 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosurePropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipment">
        <link:definition>8040 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>8050 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>8060 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureTaxes" id="DisclosureTaxes">
        <link:definition>8070 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureGeographicInformation" id="DisclosureGeographicInformation">
        <link:definition>8080 - Disclosure - Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureSelectedQuarterlyInformation" id="DisclosureSelectedQuarterlyInformation">
        <link:definition>8090 - Disclosure - Selected Quarterly Information (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cyclacel.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>8100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="cycc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockLiquidationPreferenceValue" id="cycc_PreferredStockLiquidationPreferenceValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PaymentUnderGuarantee" id="cycc_PaymentUnderGuarantee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ChangeInValuationOfWarrants" id="cycc_ChangeInValuationOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ChangeInValuationOfEconomicRights" id="cycc_ChangeInValuationOfEconomicRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DividendsOnPreferredOrdinaryShares" id="cycc_DividendsOnPreferredOrdinaryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RedeemablePreferredStocksDividends" id="cycc_RedeemablePreferredStocksDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DividendsPreferredStocks" id="cycc_DividendsPreferredStocks" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CashReceivedDuringPeriodForAbstract" id="cycc_CashReceivedDuringPeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfNonCashTransactionsAbstract" id="cycc_ScheduleOfNonCashTransactionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" id="cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" id="cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" id="cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" id="cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfOrdinarySharesInLieuOfCashBonus" id="cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionPlanExpenses" id="cycc_StockOptionPlanExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfStocksAndWarrantsForServicesOrClaims" id="cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsOfCommittableLoanNotesIssuedFromShareholders" id="cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpensesAndOtherCurrentAssetsAbstract" id="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" id="cycc_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" id="cycc_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" id="cycc_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cycc_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="cycc_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValuePrivatePlacement" id="cycc_StockIssuedDuringPeriodValuePrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesPrivatePlacement" id="cycc_StockIssuedDuringPeriodSharesPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" id="cycc_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodValue" id="cycc_StockAndWarrantsIssuedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodShares" id="cycc_StockAndWarrantsIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuedForServices" id="cycc_StockIssuedDuringPeriodValueIssuedForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesIssuedForServices" id="cycc_StockIssuedDuringPeriodSharesIssuedForServices" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" id="cycc_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesContractualAgreements" id="cycc_StockIssuedDuringPeriodSharesContractualAgreements" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" id="cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesConversionOfDebt" id="cycc_StockIssuedDuringPeriodSharesConversionOfDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueReverseAcquisition" id="cycc_StockIssuedDuringPeriodValueReverseAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesReverseAcquisition" id="cycc_StockIssuedDuringPeriodSharesReverseAcquisition" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmortizationOfDeferredStockBasedCompensation" id="cycc_AmortizationOfDeferredStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SignificantContractsDisclosureAbstract" id="cycc_SignificantContractsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantContractsDisclosureTextBlock" id="cycc_SignificantContractsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TransactionCostsOnSaleOfEconomicRights" id="cycc_TransactionCostsOnSaleOfEconomicRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cycc-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://cyclacel.com/role/BalanceSheet" xlink:type="simple" xlink:href="cycc-20120331.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://cyclacel.com/role/CashFlows" xlink:type="simple" xlink:href="cycc-20120331.xsd#CashFlows" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfStockholdersEquityCalc2" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfStockholdersEquityCalc2" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryFinishedGoodsNetOfReserves" xlink:title="calculation: AssetsCurrent to InventoryFinishedGoodsNetOfReserves" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="WarrantsAndRightsOutstanding" xlink:title="calculation: LiabilitiesCurrent to WarrantsAndRightsOutstanding" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherLiabilitiesCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" use="optional" order="5.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to OperatingIncomeLoss" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="SalesRevenueNet" xlink:title="calculation: OperatingIncomeLoss to SalesRevenueNet" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="LicenseAndServicesRevenue" xlink:title="calculation: SalesRevenueNet to LicenseAndServicesRevenue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="SalesRevenueGoodsNet" xlink:title="calculation: SalesRevenueNet to SalesRevenueGoodsNet" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RevenueFromGrants" xlink:title="calculation: SalesRevenueNet to RevenueFromGrants" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="CostsAndExpenses" xlink:title="calculation: OperatingIncomeLoss to CostsAndExpenses" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="CostOfGoodsSold" xlink:title="calculation: CostsAndExpenses to CostOfGoodsSold" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: CostsAndExpenses to ResearchAndDevelopmentExpense" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: CostsAndExpenses to SellingGeneralAndAdministrativeExpense" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="calculation: CostsAndExpenses to GoodwillAndIntangibleAssetImpairment" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="OtherRestructuringCosts" xlink:title="OtherRestructuringCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="OtherRestructuringCosts" xlink:title="calculation: CostsAndExpenses to OtherRestructuringCosts" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to NonoperatingIncomeExpense" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="PaymentsOfFinancingCosts" xlink:title="calculation: NonoperatingIncomeExpense to PaymentsOfFinancingCosts" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PaymentUnderGuarantee" xlink:label="PaymentUnderGuarantee" xlink:title="PaymentUnderGuarantee" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="PaymentUnderGuarantee" xlink:title="calculation: NonoperatingIncomeExpense to PaymentUnderGuarantee" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="calculation: NonoperatingIncomeExpense to GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="calculation: NonoperatingIncomeExpense to ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" use="optional" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpense" use="optional" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncome" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncome" use="optional" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="calculation: NonoperatingIncomeExpense to ChangeInValuationOfEconomicRights" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="DividendsOnPreferredOrdinaryShares" xlink:title="DividendsOnPreferredOrdinaryShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="DividendsOnPreferredOrdinaryShares" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to DividendsOnPreferredOrdinaryShares" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="RedeemablePreferredStocksDividends" xlink:title="RedeemablePreferredStocksDividends" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="RedeemablePreferredStocksDividends" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to RedeemablePreferredStocksDividends" use="optional" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsPreferredStocks" xlink:label="DividendsPreferredStocks" xlink:title="DividendsPreferredStocks" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="DividendsPreferredStocks" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to DividendsPreferredStocks" use="optional" order="4.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLoss" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="AccretionExpense" xlink:title="AccretionExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AccretionExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AccretionExpense" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="InvestmentIncomeAmortizationOfPremium" xlink:title="InvestmentIncomeAmortizationOfPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="InvestmentIncomeAmortizationOfPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to InvestmentIncomeAmortizationOfPremium" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnPriceRiskDerivativesNet" xlink:label="GainLossOnPriceRiskDerivativesNet" xlink:title="GainLossOnPriceRiskDerivativesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnPriceRiskDerivativesNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnPriceRiskDerivativesNet" order="6.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DepreciationDepletionAndAmortization" order="7.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfIntangibleAssets" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ImpairmentOfLongLivedAssetsHeldForUse" order="9.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ForeignCurrencyTransactionGainLossUnrealized" order="10.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="RecognitionOfDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to RecognitionOfDeferredRevenue" order="11.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockOptionPlanExpenses" xlink:label="StockOptionPlanExpenses" xlink:title="StockOptionPlanExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="StockOptionPlanExpenses" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to StockOptionPlanExpenses" order="12.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IssuanceOfStocksAndWarrantsForServicesOrClaims" order="13.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnSaleOfPropertyPlantEquipment" order="14.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GoodwillAndIntangibleAssetImpairment" order="15.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" order="16.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="PaymentsForRestructuring" xlink:title="PaymentsForRestructuring" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="PaymentsForRestructuring" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to PaymentsForRestructuring" order="17.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfFinancingCostsAndDiscounts" order="18.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="20.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="21.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_TransactionCostsOnSaleOfEconomicRights" xlink:label="TransactionCostsOnSaleOfEconomicRights" xlink:title="TransactionCostsOnSaleOfEconomicRights" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="TransactionCostsOnSaleOfEconomicRights" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to TransactionCostsOnSaleOfEconomicRights" use="optional" order="19.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ChangeInValuationOfEconomicRights" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnDerivativeInstrumentsNetPretax" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquireBusinessesNetOfCashAcquired" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfPropertyPlantAndEquipment" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquireShortTermInvestments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquireShortTermInvestments" order="4.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfShortTermInvestments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfShortTermInvestments" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfLongTermCapitalLeaseObligations" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStock" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromStockOptionsExercised" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="5.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfNotesPayable" order="6.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromNotesPayable" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="ProceedsFromLoans" xlink:title="ProceedsFromLoans" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromLoans" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromLoans" order="9.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsOfCommittableLoanNotesIssuedFromShareholders" order="10.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="LoansAndLeasesReceivableRelatedPartiesCollections" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to LoansAndLeasesReceivableRelatedPartiesCollections" order="11.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="CashAcquiredFromAcquisition" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to CashAcquiredFromAcquisition" order="12.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="PaymentsForRepurchaseOfEquity" xlink:title="PaymentsForRepurchaseOfEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="PaymentsForRepurchaseOfEquity" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to PaymentsForRepurchaseOfEquity" order="13.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="4.0" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cycc-20120331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://cyclacel.com/role/BalanceSheet" xlink:type="simple" xlink:href="cycc-20120331.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfComprehensiveIncome" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfComprehensiveIncome" />
  <link:roleRef roleURI="http://cyclacel.com/role/CashFlows" xlink:type="simple" xlink:href="cycc-20120331.xsd#CashFlows" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfStockholdersEquity" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="definition: StatementLineItems to AssetsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="definition: AssetsAbstract to AssetsCurrentAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryFinishedGoodsNetOfReserves" xlink:title="definition: AssetsCurrentAbstract to InventoryFinishedGoodsNetOfReserves" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to AssetsCurrent" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="definition: AssetsAbstract to Assets" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccountsPayableCurrent" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: LiabilitiesCurrentAbstract to WarrantsAndRightsOutstanding" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LiabilitiesCurrent" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to Liabilities" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="definition: StockholdersEquityAbstract to PreferredStockValue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="definition: StockholdersEquityAbstract to CommonStockValue" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="definition: StockholdersEquityAbstract to AdditionalPaidInCapital" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="definition: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="definition: StockholdersEquityAbstract to StockholdersEquity" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" use="optional" order="8000.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SalesRevenueNetAbstract" xlink:title="definition: StatementLineItems to SalesRevenueNetAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SalesRevenueNetAbstract" xlink:to="LicenseAndServicesRevenue" xlink:title="definition: SalesRevenueNetAbstract to LicenseAndServicesRevenue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueGoodsNet" xlink:title="definition: SalesRevenueNetAbstract to SalesRevenueGoodsNet" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SalesRevenueNetAbstract" xlink:to="RevenueFromGrants" xlink:title="definition: SalesRevenueNetAbstract to RevenueFromGrants" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueNet" xlink:title="definition: SalesRevenueNetAbstract to SalesRevenueNet" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="definition: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="CostOfGoodsSold" xlink:title="definition: CostsAndExpensesAbstract to CostOfGoodsSold" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="definition: CostsAndExpensesAbstract to GoodwillAndIntangibleAssetImpairment" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="OtherRestructuringCosts" xlink:title="OtherRestructuringCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherRestructuringCosts" xlink:title="definition: CostsAndExpensesAbstract to OtherRestructuringCosts" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="definition: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: StatementLineItems to OperatingIncomeLoss" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpenseAbstract" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="PaymentsOfFinancingCosts" xlink:title="definition: NonoperatingIncomeExpenseAbstract to PaymentsOfFinancingCosts" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PaymentUnderGuarantee" xlink:label="PaymentUnderGuarantee" xlink:title="PaymentUnderGuarantee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="PaymentUnderGuarantee" xlink:title="definition: NonoperatingIncomeExpenseAbstract to PaymentUnderGuarantee" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="definition: NonoperatingIncomeExpenseAbstract to GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="ChangeInValuationOfWarrants" xlink:title="ChangeInValuationOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInValuationOfWarrants" xlink:title="definition: NonoperatingIncomeExpenseAbstract to ChangeInValuationOfWarrants" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="definition: NonoperatingIncomeExpenseAbstract to ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="definition: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="definition: NonoperatingIncomeExpenseAbstract to InterestExpense" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="definition: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="definition: NonoperatingIncomeExpenseAbstract to ChangeInValuationOfEconomicRights" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="definition: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: StatementLineItems to IncomeTaxExpenseBenefit" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="DividendsOnPreferredOrdinaryShares" xlink:title="DividendsOnPreferredOrdinaryShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsOnPreferredOrdinaryShares" xlink:title="definition: StatementLineItems to DividendsOnPreferredOrdinaryShares" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="RedeemablePreferredStocksDividends" xlink:title="RedeemablePreferredStocksDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RedeemablePreferredStocksDividends" xlink:title="definition: StatementLineItems to RedeemablePreferredStocksDividends" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsPreferredStocks" xlink:label="DividendsPreferredStocks" xlink:title="DividendsPreferredStocks" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStocks" xlink:title="definition: StatementLineItems to DividendsPreferredStocks" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareBasicAndDiluted" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="140.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfComprehensiveIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="definition: StatementLineItems to ComprehensiveIncomeNetOfTax" use="optional" order="20.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLoss" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLoss" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="AccretionExpense" xlink:title="AccretionExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionExpense" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="InvestmentIncomeAmortizationOfPremium" xlink:title="InvestmentIncomeAmortizationOfPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InvestmentIncomeAmortizationOfPremium" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to InvestmentIncomeAmortizationOfPremium" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnPriceRiskDerivativesNet" xlink:label="GainLossOnPriceRiskDerivativesNet" xlink:title="GainLossOnPriceRiskDerivativesNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnPriceRiskDerivativesNet" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnPriceRiskDerivativesNet" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ForeignCurrencyTransactionGainLossUnrealized" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RecognitionOfDeferredRevenue" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to RecognitionOfDeferredRevenue" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockOptionPlanExpenses" xlink:label="StockOptionPlanExpenses" xlink:title="StockOptionPlanExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="StockOptionPlanExpenses" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to StockOptionPlanExpenses" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStocksAndWarrantsForServicesOrClaims" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GoodwillAndIntangibleAssetImpairment" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="150.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="PaymentsForRestructuring" xlink:title="PaymentsForRestructuring" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaymentsForRestructuring" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaymentsForRestructuring" order="160.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="170.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="190.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_TransactionCostsOnSaleOfEconomicRights" xlink:label="TransactionCostsOnSaleOfEconomicRights" xlink:title="TransactionCostsOnSaleOfEconomicRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="TransactionCostsOnSaleOfEconomicRights" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to TransactionCostsOnSaleOfEconomicRights" use="optional" order="180.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ChangeInValuationOfEconomicRights" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="definition: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDerivativeInstrumentsNetPretax" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireBusinessesNetOfCashAcquired" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireShortTermInvestments" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireShortTermInvestments" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfShortTermInvestments" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfShortTermInvestments" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfLongTermCapitalLeaseObligations" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromStockOptionsExercised" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfNotesPayable" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromNotesPayable" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="ProceedsFromLoans" xlink:title="ProceedsFromLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromLoans" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromLoans" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsOfCommittableLoanNotesIssuedFromShareholders" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="LoansAndLeasesReceivableRelatedPartiesCollections" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to LoansAndLeasesReceivableRelatedPartiesCollections" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="PaymentsForRepurchaseOfEquity" xlink:title="PaymentsForRepurchaseOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsForRepurchaseOfEquity" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsForRepurchaseOfEquity" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="definition: StatementLineItems to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="definition: StatementLineItems to SupplementalCashFlowInformationAbstract" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="CashReceivedDuringPeriodForAbstract" xlink:title="CashReceivedDuringPeriodForAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="CashReceivedDuringPeriodForAbstract" xlink:title="definition: SupplementalCashFlowInformationAbstract to CashReceivedDuringPeriodForAbstract" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="ProceedsFromInterestReceived" xlink:title="ProceedsFromInterestReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="ProceedsFromInterestReceived" xlink:title="definition: CashReceivedDuringPeriodForAbstract to ProceedsFromInterestReceived" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="ProceedsFromIncomeTaxRefunds" xlink:title="ProceedsFromIncomeTaxRefunds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="ProceedsFromIncomeTaxRefunds" xlink:title="definition: CashReceivedDuringPeriodForAbstract to ProceedsFromIncomeTaxRefunds" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="PaymentsForOperatingActivitiesAbstract" xlink:title="PaymentsForOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="PaymentsForOperatingActivitiesAbstract" xlink:title="definition: SupplementalCashFlowInformationAbstract to PaymentsForOperatingActivitiesAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="InterestPaidNet" xlink:title="definition: PaymentsForOperatingActivitiesAbstract to InterestPaidNet" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ScheduleOfNonCashTransactionsAbstract" xlink:label="ScheduleOfNonCashTransactionsAbstract" xlink:title="ScheduleOfNonCashTransactionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="ScheduleOfNonCashTransactionsAbstract" xlink:title="definition: PaymentsForOperatingActivitiesAbstract to ScheduleOfNonCashTransactionsAbstract" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:label="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:label="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:label="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:label="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:label="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesInLieuOfCashBonus" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="definition: ScheduleOfNonCashTransactionsAbstract to NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="60.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:label="DeferredCompensationShareBasedPaymentsMember" xlink:title="DeferredCompensationShareBasedPaymentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="DeferredCompensationShareBasedPaymentsMember" xlink:title="definition: EquityComponentDomain to DeferredCompensationShareBasedPaymentsMember" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="ComprehensiveIncomeMember" xlink:title="ComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="ComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to ComprehensiveIncomeMember" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:label="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StockIssuedDuringPeriodValueNewIssues to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:to="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="definition: StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility to StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueWarrantsExercised" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="definition: StockIssuedDuringPeriodValueWarrantsExercised to StockIssuedDuringPeriodSharesWarrantsExercised" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValuePrivatePlacement" xlink:label="StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValuePrivatePlacement" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValuePrivatePlacement" xlink:to="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="definition: StockIssuedDuringPeriodValuePrivatePlacement to StockIssuedDuringPeriodSharesPrivatePlacement" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueShareBasedCompensation" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StockIssuedDuringPeriodValueShareBasedCompensation to StockIssuedDuringPeriodSharesShareBasedCompensation" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="definition: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to StockIssuedDuringPeriodSharesConversionOfDebt" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueReverseAcquisition" xlink:label="StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="StockIssuedDuringPeriodValueReverseAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueReverseAcquisition" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesReverseAcquisition" xlink:label="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="StockIssuedDuringPeriodSharesReverseAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueReverseAcquisition" xlink:to="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="definition: StockIssuedDuringPeriodValueReverseAcquisition to StockIssuedDuringPeriodSharesReverseAcquisition" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:label="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="StockAndWarrantsIssuedDuringPeriodValue" xlink:title="StockAndWarrantsIssuedDuringPeriodValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockAndWarrantsIssuedDuringPeriodValue" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockAndWarrantsIssuedDuringPeriodValue" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="StockAndWarrantsIssuedDuringPeriodShares" xlink:title="StockAndWarrantsIssuedDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockAndWarrantsIssuedDuringPeriodValue" xlink:to="StockAndWarrantsIssuedDuringPeriodShares" xlink:title="definition: StockAndWarrantsIssuedDuringPeriodValue to StockAndWarrantsIssuedDuringPeriodShares" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueIssuedForServices" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: StockIssuedDuringPeriodValueIssuedForServices to StockIssuedDuringPeriodSharesIssuedForServices" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:label="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalContractualAgreements" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesContractualAgreements" xlink:label="StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:to="StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="definition: AdjustmentsToAdditionalPaidInCapitalContractualAgreements to StockIssuedDuringPeriodSharesContractualAgreements" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" order="150.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StockIssuedDuringPeriodValueStockOptionsExercised to StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" order="160.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendsPreferredStock" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to DividendsPreferredStock" use="optional" order="170.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="180.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AmortizationOfDeferredStockBasedCompensation" xlink:label="AmortizationOfDeferredStockBasedCompensation" xlink:title="AmortizationOfDeferredStockBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AmortizationOfDeferredStockBasedCompensation" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AmortizationOfDeferredStockBasedCompensation" use="optional" order="190.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to ComprehensiveIncomeNetOfTaxAbstract" use="optional" order="200.0" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="definition: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="definition: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="definition: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssued" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssued" use="optional" order="220.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" use="optional" order="230.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="definition: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cycc-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label: DocumentAndEntityInformationAbstract to label_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockLiquidationPreferenceValue" xml:lang="en-US" id="label_PreferredStockLiquidationPreferenceValue">Preferred Stock, Liquidation Preference Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="label_PreferredStockLiquidationPreferenceValue" xlink:title="label: PreferredStockLiquidationPreferenceValue to label_PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockLiquidationPreferenceValue_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockLiquidationPreferenceValue" xml:lang="en-US" id="label_PreferredStockLiquidationPreferenceValue_4">Preferred stock, liquidation preference value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="label_PreferredStockLiquidationPreferenceValue_4" xlink:title="label: PreferredStockLiquidationPreferenceValue to label_PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockLiquidationPreferenceValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PreferredStockLiquidationPreferenceValue" xml:lang="en-US" id="label_PreferredStockLiquidationPreferenceValue_2">The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="label_PreferredStockLiquidationPreferenceValue_2" xlink:title="label: PreferredStockLiquidationPreferenceValue to label_PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockLiquidationPreferenceValue_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockLiquidationPreferenceValue" xml:lang="en-US" id="label_PreferredStockLiquidationPreferenceValue_3">Preferred stock, liquidation preference value (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="label_PreferredStockLiquidationPreferenceValue_3" xlink:title="label: PreferredStockLiquidationPreferenceValue to label_PreferredStockLiquidationPreferenceValue" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PaymentUnderGuarantee" xlink:label="PaymentUnderGuarantee" xlink:title="PaymentUnderGuarantee" />
    <link:label xlink:type="resource" xlink:label="label_PaymentUnderGuarantee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentUnderGuarantee" xml:lang="en-US" id="label_PaymentUnderGuarantee">Payment Under Guarantee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentUnderGuarantee" xlink:to="label_PaymentUnderGuarantee" xlink:title="label: PaymentUnderGuarantee to label_PaymentUnderGuarantee" />
    <link:label xlink:type="resource" xlink:label="label_PaymentUnderGuarantee_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PaymentUnderGuarantee" xml:lang="en-US" id="label_PaymentUnderGuarantee_3">The cash outflow form a repayment of an unsecured loan facility agreement with the Scottish Enterprise having terms of repayment due if the Company significantly reduced its Scottish research operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentUnderGuarantee" xlink:to="label_PaymentUnderGuarantee_3" xlink:title="label: PaymentUnderGuarantee to label_PaymentUnderGuarantee" />
    <link:label xlink:type="resource" xlink:label="label_PaymentUnderGuarantee_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentUnderGuarantee" xml:lang="en-US" id="label_PaymentUnderGuarantee_2">Payment under guarantee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentUnderGuarantee" xlink:to="label_PaymentUnderGuarantee_2" xlink:title="label: PaymentUnderGuarantee to label_PaymentUnderGuarantee" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="ChangeInValuationOfWarrants" xlink:title="ChangeInValuationOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ChangeInValuationOfWarrants" xml:lang="en-US" id="label_ChangeInValuationOfWarrants">Change in Valuation of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfWarrants" xlink:to="label_ChangeInValuationOfWarrants" xlink:title="label: ChangeInValuationOfWarrants to label_ChangeInValuationOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfWarrants_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ChangeInValuationOfWarrants" xml:lang="en-US" id="label_ChangeInValuationOfWarrants_3">Change in valuation of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfWarrants" xlink:to="label_ChangeInValuationOfWarrants_3" xlink:title="label: ChangeInValuationOfWarrants to label_ChangeInValuationOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfWarrants_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ChangeInValuationOfWarrants" xml:lang="en-US" id="label_ChangeInValuationOfWarrants_2">Change in valuation of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfWarrants" xlink:to="label_ChangeInValuationOfWarrants_2" xlink:title="label: ChangeInValuationOfWarrants to label_ChangeInValuationOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="DividendsOnPreferredOrdinaryShares" xlink:title="DividendsOnPreferredOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="label_DividendsOnPreferredOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsOnPreferredOrdinaryShares" xml:lang="en-US" id="label_DividendsOnPreferredOrdinaryShares">Dividends on Preferred Ordinary Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsOnPreferredOrdinaryShares" xlink:to="label_DividendsOnPreferredOrdinaryShares" xlink:title="label: DividendsOnPreferredOrdinaryShares to label_DividendsOnPreferredOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="label_DividendsOnPreferredOrdinaryShares_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DividendsOnPreferredOrdinaryShares" xml:lang="en-US" id="label_DividendsOnPreferredOrdinaryShares_3">Dividends on preferred ordinary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsOnPreferredOrdinaryShares" xlink:to="label_DividendsOnPreferredOrdinaryShares_3" xlink:title="label: DividendsOnPreferredOrdinaryShares to label_DividendsOnPreferredOrdinaryShares" />
    <link:label xlink:type="resource" xlink:label="label_DividendsOnPreferredOrdinaryShares_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DividendsOnPreferredOrdinaryShares" xml:lang="en-US" id="label_DividendsOnPreferredOrdinaryShares_2">Dividends on preferred ordinary shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsOnPreferredOrdinaryShares" xlink:to="label_DividendsOnPreferredOrdinaryShares_2" xlink:title="label: DividendsOnPreferredOrdinaryShares to label_DividendsOnPreferredOrdinaryShares" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="RedeemablePreferredStocksDividends" xlink:title="RedeemablePreferredStocksDividends" />
    <link:label xlink:type="resource" xlink:label="label_RedeemablePreferredStocksDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RedeemablePreferredStocksDividends" xml:lang="en-US" id="label_RedeemablePreferredStocksDividends">Redeemable Preferred Stocks Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemablePreferredStocksDividends" xlink:to="label_RedeemablePreferredStocksDividends" xlink:title="label: RedeemablePreferredStocksDividends to label_RedeemablePreferredStocksDividends" />
    <link:label xlink:type="resource" xlink:label="label_RedeemablePreferredStocksDividends_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RedeemablePreferredStocksDividends" xml:lang="en-US" id="label_RedeemablePreferredStocksDividends_3">The amount of dividends deemed declared in the period to preferred shareholders as a result of the preferred shares being converted into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemablePreferredStocksDividends" xlink:to="label_RedeemablePreferredStocksDividends_3" xlink:title="label: RedeemablePreferredStocksDividends to label_RedeemablePreferredStocksDividends" />
    <link:label xlink:type="resource" xlink:label="label_RedeemablePreferredStocksDividends_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RedeemablePreferredStocksDividends" xml:lang="en-US" id="label_RedeemablePreferredStocksDividends_2">Deemed dividend on convertible exchangeable preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemablePreferredStocksDividends" xlink:to="label_RedeemablePreferredStocksDividends_2" xlink:title="label: RedeemablePreferredStocksDividends to label_RedeemablePreferredStocksDividends" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsPreferredStocks" xlink:label="DividendsPreferredStocks" xlink:title="DividendsPreferredStocks" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStocks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsPreferredStocks" xml:lang="en-US" id="label_DividendsPreferredStocks">Dividends Preferred Stocks</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStocks" xlink:to="label_DividendsPreferredStocks" xlink:title="label: DividendsPreferredStocks to label_DividendsPreferredStocks" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStocks_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DividendsPreferredStocks" xml:lang="en-US" id="label_DividendsPreferredStocks_3">The amount of dividends declared in the period to preferred shareholders even if not paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStocks" xlink:to="label_DividendsPreferredStocks_3" xlink:title="label: DividendsPreferredStocks to label_DividendsPreferredStocks" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStocks_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DividendsPreferredStocks" xml:lang="en-US" id="label_DividendsPreferredStocks_2">Dividend on convertible exchangeable preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStocks" xlink:to="label_DividendsPreferredStocks_2" xlink:title="label: DividendsPreferredStocks to label_DividendsPreferredStocks" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="CashReceivedDuringPeriodForAbstract" xlink:title="CashReceivedDuringPeriodForAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashReceivedDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashReceivedDuringPeriodForAbstract" xml:lang="en-US" id="label_CashReceivedDuringPeriodForAbstract">Cash Received During Period for [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="label_CashReceivedDuringPeriodForAbstract" xlink:title="label: CashReceivedDuringPeriodForAbstract to label_CashReceivedDuringPeriodForAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashReceivedDuringPeriodForAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashReceivedDuringPeriodForAbstract" xml:lang="en-US" id="label_CashReceivedDuringPeriodForAbstract_2">Cash received during the period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="label_CashReceivedDuringPeriodForAbstract_2" xlink:title="label: CashReceivedDuringPeriodForAbstract to label_CashReceivedDuringPeriodForAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ScheduleOfNonCashTransactionsAbstract" xlink:label="ScheduleOfNonCashTransactionsAbstract" xlink:title="ScheduleOfNonCashTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfNonCashTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfNonCashTransactionsAbstract" xml:lang="en-US" id="label_ScheduleOfNonCashTransactionsAbstract">Schedule of Non Cash Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="label_ScheduleOfNonCashTransactionsAbstract" xlink:title="label: ScheduleOfNonCashTransactionsAbstract to label_ScheduleOfNonCashTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfNonCashTransactionsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfNonCashTransactionsAbstract" xml:lang="en-US" id="label_ScheduleOfNonCashTransactionsAbstract_2">Schedule of non-cash transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="label_ScheduleOfNonCashTransactionsAbstract_2" xlink:title="label: ScheduleOfNonCashTransactionsAbstract to label_ScheduleOfNonCashTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:label="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:label xlink:type="resource" xlink:label="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xml:lang="en-US" id="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases">Acquisitions of Equipment Purchased Through Capital Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:to="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="label: AcquisitionsOfEquipmentPurchasedThroughCapitalLeases to label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:label xlink:type="resource" xlink:label="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xml:lang="en-US" id="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_3">Assets acquired under capital leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:to="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_3" xlink:title="label: AcquisitionsOfEquipmentPurchasedThroughCapitalLeases to label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:label xlink:type="resource" xlink:label="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xml:lang="en-US" id="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_2">Acquisitions of equipment purchased through capital leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:to="label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases_2" xlink:title="label: AcquisitionsOfEquipmentPurchasedThroughCapitalLeases to label_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label: AmendmentDescription to label_AmendmentDescription" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:label="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements">Issuance of Ordinary Shares in Connection with License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:to="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="label: IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements to label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_3">Issuance of ordinary shares through issuance of license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:to="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_3" xlink:title="label: IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements to label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_2">Issuance of common shares in connection with license agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:to="label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements_2" xlink:title="label: IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements to label_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label: AmendmentFlag to label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:label="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan">Issuance of Ordinary Shares on Conversion of Bridging Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:to="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="label: IssuanceOfOrdinarySharesOnConversionOfBridgingLoan to label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_3">Issuance of ordinary shares through conversion of bridge loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:to="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_3" xlink:title="label: IssuanceOfOrdinarySharesOnConversionOfBridgingLoan to label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_2">Issuance of ordinary shares on conversion of bridging loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:to="label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan_2" xlink:title="label: IssuanceOfOrdinarySharesOnConversionOfBridgingLoan to label_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:label="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xml:lang="en-US" id="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest">Issuance of Preferred Ordinary Class C Shares on Conversion of Secured Convertible Loan Notes and Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:to="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="label: IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest to label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xml:lang="en-US" id="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_3">Issuance of Preferred shares on conversion of secured convertible loan notes and accrued interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:to="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_3" xlink:title="label: IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest to label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xml:lang="en-US" id="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_2">Issuance of preferred ordinary "C" shares on conversion of secured convertible loan notes and accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:to="label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest_2" xlink:title="label: IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest to label_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:label="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfOrdinarySharesInLieuOfCashBonus" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInLieuOfCashBonus">Issuance of Ordinary Shares in Lieu of Cash Bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:to="label_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="label: IssuanceOfOrdinarySharesInLieuOfCashBonus to label_IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfOrdinarySharesInLieuOfCashBonus" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_3">Issuance of ordinary shares in lieu of cash bonuses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:to="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_3" xlink:title="label: IssuanceOfOrdinarySharesInLieuOfCashBonus to label_IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfOrdinarySharesInLieuOfCashBonus" xml:lang="en-US" id="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_2">Issuance of ordinary shares in lieu of cash bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:to="label_IssuanceOfOrdinarySharesInLieuOfCashBonus_2" xlink:title="label: IssuanceOfOrdinarySharesInLieuOfCashBonus to label_IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockOptionPlanExpenses" xlink:label="StockOptionPlanExpenses" xlink:title="StockOptionPlanExpenses" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionPlanExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockOptionPlanExpenses" xml:lang="en-US" id="label_StockOptionPlanExpenses">Stock Option Plan Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanExpenses" xlink:to="label_StockOptionPlanExpenses" xlink:title="label: StockOptionPlanExpenses to label_StockOptionPlanExpenses" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionPlanExpenses_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockOptionPlanExpenses" xml:lang="en-US" id="label_StockOptionPlanExpenses_3">The aggregate amount of noncash, equity-based issued to non-employees for services rendered. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanExpenses" xlink:to="label_StockOptionPlanExpenses_3" xlink:title="label: StockOptionPlanExpenses to label_StockOptionPlanExpenses" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionPlanExpenses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockOptionPlanExpenses" xml:lang="en-US" id="label_StockOptionPlanExpenses_2">Compensation for warrants issued to non-employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlanExpenses" xlink:to="label_StockOptionPlanExpenses_2" xlink:title="label: StockOptionPlanExpenses to label_StockOptionPlanExpenses" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfStocksAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStocksAndWarrantsForServicesOrClaims">Issuance of Stocks and Warrants for Services or Claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="label: IssuanceOfStocksAndWarrantsForServicesOrClaims to label_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfStocksAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_3">The aggregate amount of noncash, equity-based issued intellectual property rights. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_3" xlink:title="label: IssuanceOfStocksAndWarrantsForServicesOrClaims to label_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfStocksAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_2">Shares issued for IP rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStocksAndWarrantsForServicesOrClaims_2" xlink:title="label: IssuanceOfStocksAndWarrantsForServicesOrClaims to label_IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xml:lang="en-US" id="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders">Proceeds of Committable Loan Notes Issued from Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:to="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="label: ProceedsOfCommittableLoanNotesIssuedFromShareholders to label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xml:lang="en-US" id="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_3">Cash received from a loan issued by shareholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:to="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_3" xlink:title="label: ProceedsOfCommittableLoanNotesIssuedFromShareholders to label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xml:lang="en-US" id="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_2">Proceeds of committable loan notes issued from shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:to="label_ProceedsOfCommittableLoanNotesIssuedFromShareholders_2" xlink:title="label: ProceedsOfCommittableLoanNotesIssuedFromShareholders to label_ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:title="PrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsAbstract" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsAbstract">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsAbstract to label_PrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsTextBlock to label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_3">This element represent as Prepaid Expenses and Other Current Assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_3" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsTextBlock to label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" xlink:title="label: PrepaidExpensesAndOtherCurrentAssetsTextBlock to label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:label="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing">Adjustments to Additional Paid in Capital Effect of Warrant Pricing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing to label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_3">The adjustment to additional paid in capital for warrant re-pricing during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_3" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing to label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_2">Warrant re-pricing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing to label_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility">Stock Issued During Period, Value, Draw Down of Committed Equity Finance Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="label: StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_3">Value of shares of common stock issued during the period upon draw down of committed equity finance facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_3" xlink:title="label: StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_2">Issue of common stock upon draw down of Committed Equity Finance Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility_2" xlink:title="label: StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility">Stock Issued During Period, Shares, Draw Down of Committed Equity Finance Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="label: StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_3">Number of shares of stock issued during the reporting period upon draw down of committed equity finance facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_3" xlink:title="label: StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_2">Issue of common stock upon draw down of Committed Equity Finance Facility (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:to="label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility_2" xlink:title="label: StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility to label_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised_3">Value stock issued during the current period as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised_3" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised_2">Warrant exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised_3">Number of warrant options (or warrant units) exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised_3" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised_2">Warrant exercise (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValuePrivatePlacement" xlink:label="StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValuePrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValuePrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodValuePrivatePlacement">Stock Issued During Period, Value, Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivatePlacement" xlink:to="label_StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="label: StockIssuedDuringPeriodValuePrivatePlacement to label_StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValuePrivatePlacement_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValuePrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodValuePrivatePlacement_3">Value of shares of stock issued during the period on private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivatePlacement" xlink:to="label_StockIssuedDuringPeriodValuePrivatePlacement_3" xlink:title="label: StockIssuedDuringPeriodValuePrivatePlacement to label_StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValuePrivatePlacement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValuePrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodValuePrivatePlacement_2">Issue of common stock on private placement, net of expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValuePrivatePlacement" xlink:to="label_StockIssuedDuringPeriodValuePrivatePlacement_2" xlink:title="label: StockIssuedDuringPeriodValuePrivatePlacement to label_StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesPrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPrivatePlacement">Stock Issued During Period, Shares, Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="label_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to label_StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPrivatePlacement_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesPrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPrivatePlacement_3">Number of shares issued during the reporting period on private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="label_StockIssuedDuringPeriodSharesPrivatePlacement_3" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to label_StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPrivatePlacement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesPrivatePlacement" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPrivatePlacement_2">Issue of common stock on private placement, net of expenses (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="label_StockIssuedDuringPeriodSharesPrivatePlacement_2" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to label_StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:label="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived">Adjustments to Additional Paid in Capital, Loans Payable Waived</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived to label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_3">Increase in additional paid in capital due to loans payable waived during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_3" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived to label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_2">Loan from Cyclacel Group plc waived</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived to label_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="StockAndWarrantsIssuedDuringPeriodValue" xlink:title="StockAndWarrantsIssuedDuringPeriodValue" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockAndWarrantsIssuedDuringPeriodValue" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodValue">Stock and Warrants Issued During Period, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodValue" xlink:to="label_StockAndWarrantsIssuedDuringPeriodValue" xlink:title="label: StockAndWarrantsIssuedDuringPeriodValue to label_StockAndWarrantsIssuedDuringPeriodValue" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodValue_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockAndWarrantsIssuedDuringPeriodValue" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodValue_3">Value of shares of common stock and warrants issued during the period for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodValue" xlink:to="label_StockAndWarrantsIssuedDuringPeriodValue_3" xlink:title="label: StockAndWarrantsIssuedDuringPeriodValue to label_StockAndWarrantsIssuedDuringPeriodValue" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockAndWarrantsIssuedDuringPeriodValue" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodValue_2">Issue of common stock and warrants for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodValue" xlink:to="label_StockAndWarrantsIssuedDuringPeriodValue_2" xlink:title="label: StockAndWarrantsIssuedDuringPeriodValue to label_StockAndWarrantsIssuedDuringPeriodValue" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="StockAndWarrantsIssuedDuringPeriodShares" xlink:title="StockAndWarrantsIssuedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockAndWarrantsIssuedDuringPeriodShares" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodShares">Stock and Warrants Issued During Period, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodShares" xlink:to="label_StockAndWarrantsIssuedDuringPeriodShares" xlink:title="label: StockAndWarrantsIssuedDuringPeriodShares to label_StockAndWarrantsIssuedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodShares_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockAndWarrantsIssuedDuringPeriodShares" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodShares_3">Number of shares or units of common stock and warrants issued during the period for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodShares" xlink:to="label_StockAndWarrantsIssuedDuringPeriodShares_3" xlink:title="label: StockAndWarrantsIssuedDuringPeriodShares to label_StockAndWarrantsIssuedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_StockAndWarrantsIssuedDuringPeriodShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockAndWarrantsIssuedDuringPeriodShares" xml:lang="en-US" id="label_StockAndWarrantsIssuedDuringPeriodShares_2">Issue of common stock and warrants for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockAndWarrantsIssuedDuringPeriodShares" xlink:to="label_StockAndWarrantsIssuedDuringPeriodShares_2" xlink:title="label: StockAndWarrantsIssuedDuringPeriodShares to label_StockAndWarrantsIssuedDuringPeriodShares" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuedForServices">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="label_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to label_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuedForServices_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuedForServices_3">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="label_StockIssuedDuringPeriodValueIssuedForServices_3" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to label_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuedForServices_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuedForServices_2">Issue of shares in lieu of cash bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="label_StockIssuedDuringPeriodValueIssuedForServices_2" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to label_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices_3">Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices_3" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices_2">Issue of shares in lieu of cash bonus (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices_2" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:label="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements">Adjustments to Additional Paid-in Capital, Contractual Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalContractualAgreements to label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_3">Increase in additional paid in capital due to stock issued for IP rights agreement, research and development agreement and license agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_3" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalContractualAgreements to label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_2">Issue of shares for IP rights agreement, research &amp; development agreement and license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalContractualAgreements to label_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesContractualAgreements" xlink:label="StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesContractualAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesContractualAgreements" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesContractualAgreements">Number of shares of stock issued for IP rights agreement, research and development agreement and license agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesContractualAgreements" xlink:to="label_StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="label: StockIssuedDuringPeriodSharesContractualAgreements to label_StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesContractualAgreements_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesContractualAgreements" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesContractualAgreements_3">Issue of shares for IP rights agreement, research &amp; development agreement and license agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesContractualAgreements" xlink:to="label_StockIssuedDuringPeriodSharesContractualAgreements_3" xlink:title="label: StockIssuedDuringPeriodSharesContractualAgreements to label_StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesContractualAgreements_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesContractualAgreements" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesContractualAgreements_2">Stock Issued During Period, Shares, Contractual Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesContractualAgreements" xlink:to="label_StockIssuedDuringPeriodSharesContractualAgreements_2" xlink:title="label: StockIssuedDuringPeriodSharesContractualAgreements to label_StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="AccretionExpense" xlink:title="AccretionExpense" />
    <link:label xlink:type="resource" xlink:label="label_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccretionExpense" xml:lang="en-US" id="label_AccretionExpense">Accretion of interest on notes payable, net of amortization of debt premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionExpense" xlink:to="label_AccretionExpense" xlink:title="label: AccretionExpense to label_AccretionExpense" />
    <link:label xlink:type="resource" xlink:label="label_AccretionExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccretionExpense" xml:lang="en-US" id="label_AccretionExpense_2">Accretion Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionExpense" xlink:to="label_AccretionExpense_2" xlink:title="label: AccretionExpense to label_AccretionExpense" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent">Other Comprehensive Income, Unrealized Foreign Exchange on Inter-company Loans, Net Of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="label: OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_3">Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_3" xlink:title="label: OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_2">Unrealized foreign exchange on intercompany loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent_2" xlink:title="label: OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfDebt" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfDebt">Stock Issued During Period, Shares, Conversion of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfDebt to label_StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfDebt_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfDebt" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfDebt_3">Number of shares of stock issued during the reporting period on conversion of bridging loan and loan note instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfDebt_3" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfDebt to label_StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfDebt" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfDebt_2">Issue of shares on conversion of bridging loan and Loan Note Instrument (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfDebt_2" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfDebt to label_StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueReverseAcquisition" xlink:label="StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="StockIssuedDuringPeriodValueReverseAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueReverseAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueReverseAcquisition">Stock Issued During Period, Value, Reverse Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="label: StockIssuedDuringPeriodValueReverseAcquisition to label_StockIssuedDuringPeriodValueReverseAcquisition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueReverseAcquisition_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueReverseAcquisition_3">Value of shares of stock issued during the period on reverse acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodValueReverseAcquisition_3" xlink:title="label: StockIssuedDuringPeriodValueReverseAcquisition to label_StockIssuedDuringPeriodValueReverseAcquisition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueReverseAcquisition_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueReverseAcquisition_2">Reverse Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodValueReverseAcquisition_2" xlink:title="label: StockIssuedDuringPeriodValueReverseAcquisition to label_StockIssuedDuringPeriodValueReverseAcquisition" use="optional" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesReverseAcquisition" xlink:label="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="StockIssuedDuringPeriodSharesReverseAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesReverseAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesReverseAcquisition">Stock Issued During Period, Shares, Reverse Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="label: StockIssuedDuringPeriodSharesReverseAcquisition to label_StockIssuedDuringPeriodSharesReverseAcquisition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesReverseAcquisition_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesReverseAcquisition_3">Number of shares issued during the reporting period on reverse acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodSharesReverseAcquisition_3" xlink:title="label: StockIssuedDuringPeriodSharesReverseAcquisition to label_StockIssuedDuringPeriodSharesReverseAcquisition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesReverseAcquisition_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesReverseAcquisition" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesReverseAcquisition_2">Reverse Acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:to="label_StockIssuedDuringPeriodSharesReverseAcquisition_2" xlink:title="label: StockIssuedDuringPeriodSharesReverseAcquisition to label_StockIssuedDuringPeriodSharesReverseAcquisition" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AmortizationOfDeferredStockBasedCompensation" xlink:label="AmortizationOfDeferredStockBasedCompensation" xlink:title="AmortizationOfDeferredStockBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDeferredStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfDeferredStockBasedCompensation" xml:lang="en-US" id="label_AmortizationOfDeferredStockBasedCompensation">Amortization of Deferred Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredStockBasedCompensation" xlink:to="label_AmortizationOfDeferredStockBasedCompensation" xlink:title="label: AmortizationOfDeferredStockBasedCompensation to label_AmortizationOfDeferredStockBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDeferredStockBasedCompensation_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AmortizationOfDeferredStockBasedCompensation" xml:lang="en-US" id="label_AmortizationOfDeferredStockBasedCompensation_3">Amortization of deferred stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredStockBasedCompensation" xlink:to="label_AmortizationOfDeferredStockBasedCompensation_3" xlink:title="label: AmortizationOfDeferredStockBasedCompensation to label_AmortizationOfDeferredStockBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDeferredStockBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AmortizationOfDeferredStockBasedCompensation" xml:lang="en-US" id="label_AmortizationOfDeferredStockBasedCompensation_2">Represents the equity impact of amortization of deferred stock based compensation during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDeferredStockBasedCompensation" xlink:to="label_AmortizationOfDeferredStockBasedCompensation_2" xlink:title="label: AmortizationOfDeferredStockBasedCompensation to label_AmortizationOfDeferredStockBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_SignificantContractsDisclosureAbstract" xlink:label="SignificantContractsDisclosureAbstract" xlink:title="SignificantContractsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SignificantContractsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantContractsDisclosureAbstract" xml:lang="en-US" id="label_SignificantContractsDisclosureAbstract">Significant Contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantContractsDisclosureAbstract" xlink:to="label_SignificantContractsDisclosureAbstract" xlink:title="label: SignificantContractsDisclosureAbstract to label_SignificantContractsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_SignificantContractsDisclosureTextBlock" xlink:label="SignificantContractsDisclosureTextBlock" xlink:title="SignificantContractsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantContractsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantContractsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantContractsDisclosureTextBlock">Significant Contracts Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantContractsDisclosureTextBlock" xlink:to="label_SignificantContractsDisclosureTextBlock" xlink:title="label: SignificantContractsDisclosureTextBlock to label_SignificantContractsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantContractsDisclosureTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SignificantContractsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantContractsDisclosureTextBlock_3">The entire disclosure of significant contracts pursuant to distribution, licensing and research agreements entered by the reporting entity during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantContractsDisclosureTextBlock" xlink:to="label_SignificantContractsDisclosureTextBlock_3" xlink:title="label: SignificantContractsDisclosureTextBlock to label_SignificantContractsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantContractsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantContractsDisclosureTextBlock" xml:lang="en-US" id="label_SignificantContractsDisclosureTextBlock_2">Significant Contracts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantContractsDisclosureTextBlock" xlink:to="label_SignificantContractsDisclosureTextBlock_2" xlink:title="label: SignificantContractsDisclosureTextBlock to label_SignificantContractsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to label_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to label_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to label_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label: EntityFilerCategory to label_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label: EntityPublicFloat to label_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label: EntityRegistrantName to label_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to label_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to label_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US" id="label_PaymentsToAcquireBusinessesNetOfCashAcquired">Purchase of ALIGN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="label_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="label: PaymentsToAcquireBusinessesNetOfCashAcquired to label_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireBusinessesNetOfCashAcquired_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US" id="label_PaymentsToAcquireBusinessesNetOfCashAcquired_2">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="label_PaymentsToAcquireBusinessesNetOfCashAcquired_2" xlink:title="label: PaymentsToAcquireBusinessesNetOfCashAcquired to label_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to label_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to label_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label: DocumentType to label_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to label_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital_2">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital_2" xlink:title="label: AdditionalPaidInCapital to label_AdditionalPaidInCapital" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts">Amortization of issuance costs of Preferred Ordinary "C" shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to label_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts_2">Amortization of Financing Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts_2" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to label_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets" xlink:title="label: AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets_2">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets_2" xlink:title="label: AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to label_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition">Cash and cash equivalents assumed on stock purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition_2">Cash Acquired from Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition_2" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_4">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="PaymentsForRestructuring" xlink:title="PaymentsForRestructuring" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsForRestructuring" xml:lang="en-US" id="label_PaymentsForRestructuring">Provision for restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRestructuring" xlink:to="label_PaymentsForRestructuring" xlink:title="label: PaymentsForRestructuring to label_PaymentsForRestructuring" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForRestructuring_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsForRestructuring" xml:lang="en-US" id="label_PaymentsForRestructuring_2">Payments for Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRestructuring" xlink:to="label_PaymentsForRestructuring_2" xlink:title="label: PaymentsForRestructuring to label_PaymentsForRestructuring" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="ProceedsFromLoans" xlink:title="ProceedsFromLoans" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromLoans" xml:lang="en-US" id="label_ProceedsFromLoans">Loan received from Cyclacel Group Plc</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLoans" xlink:to="label_ProceedsFromLoans" xlink:title="label: ProceedsFromLoans to label_ProceedsFromLoans" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromLoans_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromLoans" xml:lang="en-US" id="label_ProceedsFromLoans_2">Proceeds from Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLoans" xlink:to="label_ProceedsFromLoans_2" xlink:title="label: ProceedsFromLoans to label_ProceedsFromLoans" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPaidNet" xml:lang="en-US" id="label_InterestPaidNet">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="label_InterestPaidNet" xlink:title="label: InterestPaidNet to label_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaidNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaidNet" xml:lang="en-US" id="label_InterestPaidNet_2">Interest Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="label_InterestPaidNet_2" xlink:title="label: InterestPaidNet to label_InterestPaidNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses, inventory and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_2">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock_2">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock_2" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_2">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_2" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label: CommonStockValue to label_CommonStockValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue_2">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2011 and March 31, 2012; 54,220,458 and 58,993,414 shares issued and outstanding at December 31, 2011 and March 31, 2012, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_2" xlink:title="label: CommonStockValue to label_CommonStockValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax_2">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax_2" xlink:title="label: ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:label xlink:type="resource" xlink:label="label_CostOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostOfGoodsSold" xml:lang="en-US" id="label_CostOfGoodsSold">Cost of goods sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsSold" xlink:to="label_CostOfGoodsSold" xlink:title="label: CostOfGoodsSold to label_CostOfGoodsSold" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostOfGoodsSold_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostOfGoodsSold" xml:lang="en-US" id="label_CostOfGoodsSold_2">Cost of Goods Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsSold" xlink:to="label_CostOfGoodsSold_2" xlink:title="label: CostOfGoodsSold to label_CostOfGoodsSold" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent_2">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_2" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_2">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_2" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="CashAndCashEquivalentsDisclosureTextBlock" xlink:title="CashAndCashEquivalentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US" id="label_CashAndCashEquivalentsDisclosureTextBlock">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsDisclosureTextBlock" xlink:to="label_CashAndCashEquivalentsDisclosureTextBlock" xlink:title="label: CashAndCashEquivalentsDisclosureTextBlock to label_CashAndCashEquivalentsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US" id="label_CashAndCashEquivalentsDisclosureTextBlock_2">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsDisclosureTextBlock" xlink:to="label_CashAndCashEquivalentsDisclosureTextBlock_2" xlink:title="label: CashAndCashEquivalentsDisclosureTextBlock to label_CashAndCashEquivalentsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations to label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_2" xlink:title="label: EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations to label_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation_2">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_2" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfFinancingCosts" xml:lang="en-US" id="label_PaymentsOfFinancingCosts">Costs associated with aborted 2004 IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts" xlink:title="label: PaymentsOfFinancingCosts to label_PaymentsOfFinancingCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfFinancingCosts" xml:lang="en-US" id="label_PaymentsOfFinancingCosts_2">Payments of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts_2" xlink:title="label: PaymentsOfFinancingCosts to label_PaymentsOfFinancingCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US" id="label_GainLossOnDerivativeInstrumentsNetPretax">Change in valuation of other liabilities measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="label_GainLossOnDerivativeInstrumentsNetPretax" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to label_GainLossOnDerivativeInstrumentsNetPretax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDerivativeInstrumentsNetPretax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US" id="label_GainLossOnDerivativeInstrumentsNetPretax_2">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="label_GainLossOnDerivativeInstrumentsNetPretax_2" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to label_GainLossOnDerivativeInstrumentsNetPretax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDerivativeInstrumentsNetPretax_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US" id="label_GainLossOnDerivativeInstrumentsNetPretax_3">Change in valuation of other liabilities measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="label_GainLossOnDerivativeInstrumentsNetPretax_3" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to label_GainLossOnDerivativeInstrumentsNetPretax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnPriceRiskDerivativesNet" xlink:label="GainLossOnPriceRiskDerivativesNet" xlink:title="GainLossOnPriceRiskDerivativesNet" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnPriceRiskDerivativesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnPriceRiskDerivativesNet" xml:lang="en-US" id="label_GainLossOnPriceRiskDerivativesNet">Gain (Loss) on Price Risk Derivatives, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnPriceRiskDerivativesNet" xlink:to="label_GainLossOnPriceRiskDerivativesNet" xlink:title="label: GainLossOnPriceRiskDerivativesNet to label_GainLossOnPriceRiskDerivativesNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnPriceRiskDerivativesNet_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GainLossOnPriceRiskDerivativesNet" xml:lang="en-US" id="label_GainLossOnPriceRiskDerivativesNet_3">Warrant re-pricing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnPriceRiskDerivativesNet" xlink:to="label_GainLossOnPriceRiskDerivativesNet_3" xlink:title="label: GainLossOnPriceRiskDerivativesNet to label_GainLossOnPriceRiskDerivativesNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnPriceRiskDerivativesNet_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnPriceRiskDerivativesNet" xml:lang="en-US" id="label_GainLossOnPriceRiskDerivativesNet_2">Warrant re-pricing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnPriceRiskDerivativesNet" xlink:to="label_GainLossOnPriceRiskDerivativesNet_2" xlink:title="label: GainLossOnPriceRiskDerivativesNet to label_GainLossOnPriceRiskDerivativesNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment">(Gain) loss on disposal of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment_2">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="label_ImpairmentOfLongLivedAssetsHeldForUse">Fixed asset impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to label_ImpairmentOfLongLivedAssetsHeldForUse" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfLongLivedAssetsHeldForUse_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="label_ImpairmentOfLongLivedAssetsHeldForUse_2">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_ImpairmentOfLongLivedAssetsHeldForUse_2" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to label_ImpairmentOfLongLivedAssetsHeldForUse" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to label_IncomeStatementAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_2">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_2" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="ProceedsFromIncomeTaxRefunds" xlink:title="ProceedsFromIncomeTaxRefunds" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIncomeTaxRefunds" xml:lang="en-US" id="label_ProceedsFromIncomeTaxRefunds">Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIncomeTaxRefunds" xlink:to="label_ProceedsFromIncomeTaxRefunds" xlink:title="label: ProceedsFromIncomeTaxRefunds to label_ProceedsFromIncomeTaxRefunds" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIncomeTaxRefunds_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIncomeTaxRefunds" xml:lang="en-US" id="label_ProceedsFromIncomeTaxRefunds_2">Proceeds from Income Tax Refunds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIncomeTaxRefunds" xlink:to="label_ProceedsFromIncomeTaxRefunds_2" xlink:title="label: ProceedsFromIncomeTaxRefunds to label_ProceedsFromIncomeTaxRefunds" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense" xlink:title="label: InterestExpense to label_InterestExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense_2">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_2" xlink:title="label: InterestExpense to label_InterestExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="ProceedsFromInterestReceived" xlink:title="ProceedsFromInterestReceived" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromInterestReceived" xml:lang="en-US" id="label_ProceedsFromInterestReceived">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromInterestReceived" xlink:to="label_ProceedsFromInterestReceived" xlink:title="label: ProceedsFromInterestReceived to label_ProceedsFromInterestReceived" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromInterestReceived_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromInterestReceived" xml:lang="en-US" id="label_ProceedsFromInterestReceived_2">Proceeds from Interest Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromInterestReceived" xlink:to="label_ProceedsFromInterestReceived_2" xlink:title="label: ProceedsFromInterestReceived to label_ProceedsFromInterestReceived" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities" xlink:title="label: Liabilities to label_Liabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities_2">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities_2" xlink:title="label: Liabilities to label_Liabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_2">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_2" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_2">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="LoansAndLeasesReceivableRelatedPartiesCollections" />
    <link:label xlink:type="resource" xlink:label="label_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_LoansAndLeasesReceivableRelatedPartiesCollections" xml:lang="en-US" id="label_LoansAndLeasesReceivableRelatedPartiesCollections">Loans received from shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:to="label_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="label: LoansAndLeasesReceivableRelatedPartiesCollections to label_LoansAndLeasesReceivableRelatedPartiesCollections" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LoansAndLeasesReceivableRelatedPartiesCollections_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LoansAndLeasesReceivableRelatedPartiesCollections" xml:lang="en-US" id="label_LoansAndLeasesReceivableRelatedPartiesCollections_2">Loans and Leases Receivable, Related Parties, Collections</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:to="label_LoansAndLeasesReceivableRelatedPartiesCollections_2" xlink:title="label: LoansAndLeasesReceivableRelatedPartiesCollections to label_LoansAndLeasesReceivableRelatedPartiesCollections" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss_4">Loss for the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_4" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss_2">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_2" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss_3">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_3" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net loss applicable to common shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_2">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to label_NonoperatingIncomeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpense" xml:lang="en-US" id="label_NonoperatingIncomeExpense_2">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="label_NonoperatingIncomeExpense_2" xlink:title="label: NonoperatingIncomeExpense to label_NonoperatingIncomeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to label_NonoperatingIncomeExpenseAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract_2">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract_2" xlink:title="label: NonoperatingIncomeExpenseAbstract to label_NonoperatingIncomeExpenseAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss_2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_2" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">Change in unrealized loss on investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to label_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncome" xml:lang="en-US" id="label_OtherNonoperatingIncome">Other Nonoperating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="label_OtherNonoperatingIncome" xlink:title="label: OtherNonoperatingIncome to label_OtherNonoperatingIncome" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncome_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNonoperatingIncome" xml:lang="en-US" id="label_OtherNonoperatingIncome_2">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="label_OtherNonoperatingIncome_2" xlink:title="label: OtherNonoperatingIncome to label_OtherNonoperatingIncome" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="OtherRestructuringCosts" xlink:title="OtherRestructuringCosts" />
    <link:label xlink:type="resource" xlink:label="label_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherRestructuringCosts" xml:lang="en-US" id="label_OtherRestructuringCosts">Other Restructuring Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherRestructuringCosts" xlink:to="label_OtherRestructuringCosts" xlink:title="label: OtherRestructuringCosts to label_OtherRestructuringCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherRestructuringCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherRestructuringCosts" xml:lang="en-US" id="label_OtherRestructuringCosts_2">Restructuring costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherRestructuringCosts" xlink:to="label_OtherRestructuringCosts_2" xlink:title="label: OtherRestructuringCosts to label_OtherRestructuringCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US" id="label_PaymentsOfDividendsPreferredStockAndPreferenceStock">Payment of preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="label_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to label_PaymentsOfDividendsPreferredStockAndPreferenceStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfDividendsPreferredStockAndPreferenceStock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US" id="label_PaymentsOfDividendsPreferredStockAndPreferenceStock_2">Payments of Dividends, Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="label_PaymentsOfDividendsPreferredStockAndPreferenceStock_2" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to label_PaymentsOfDividendsPreferredStockAndPreferenceStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="PaymentsForRepurchaseOfEquity" xlink:title="PaymentsForRepurchaseOfEquity" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsForRepurchaseOfEquity" xml:lang="en-US" id="label_PaymentsForRepurchaseOfEquity">Costs associated with stock purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfEquity" xlink:to="label_PaymentsForRepurchaseOfEquity" xlink:title="label: PaymentsForRepurchaseOfEquity to label_PaymentsForRepurchaseOfEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForRepurchaseOfEquity_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsForRepurchaseOfEquity" xml:lang="en-US" id="label_PaymentsForRepurchaseOfEquity_2">Payments for Repurchase of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfEquity" xlink:to="label_PaymentsForRepurchaseOfEquity_2" xlink:title="label: PaymentsForRepurchaseOfEquity to label_PaymentsForRepurchaseOfEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="PaymentsForOperatingActivitiesAbstract" xlink:title="PaymentsForOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsForOperatingActivitiesAbstract" xml:lang="en-US" id="label_PaymentsForOperatingActivitiesAbstract">Cash paid during the period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="label_PaymentsForOperatingActivitiesAbstract" xlink:title="label: PaymentsForOperatingActivitiesAbstract to label_PaymentsForOperatingActivitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsForOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsForOperatingActivitiesAbstract" xml:lang="en-US" id="label_PaymentsForOperatingActivitiesAbstract_2">Payments for Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="label_PaymentsForOperatingActivitiesAbstract_2" xlink:title="label: PaymentsForOperatingActivitiesAbstract to label_PaymentsForOperatingActivitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Employee Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_2">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_2" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to label_PreferredStockSharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued_2">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_2" xlink:title="label: PreferredStockSharesIssued to label_PreferredStockSharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_2">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_2" xlink:title="label: PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_2">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_2" xlink:title="label: PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock, warrants and economic rights, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock_2">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock_2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="label: ProceedsFromIssuanceOfPreferredStockAndPreferenceStock to label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2" xlink:title="label: ProceedsFromIssuanceOfPreferredStockAndPreferenceStock to label_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromNotesPayable" xml:lang="en-US" id="label_ProceedsFromNotesPayable">Government loan received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable" xlink:title="label: ProceedsFromNotesPayable to label_ProceedsFromNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromNotesPayable_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromNotesPayable" xml:lang="en-US" id="label_ProceedsFromNotesPayable_2">Proceeds from Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="label_ProceedsFromNotesPayable_2" xlink:title="label: ProceedsFromNotesPayable to label_ProceedsFromNotesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds from sale of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_ProceedsFromSaleOfShortTermInvestments">Redemptions of short-term investments, net of maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfShortTermInvestments" xlink:to="label_ProceedsFromSaleOfShortTermInvestments" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfShortTermInvestments_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_ProceedsFromSaleOfShortTermInvestments_2">Proceeds from Sale of Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfShortTermInvestments" xlink:to="label_ProceedsFromSaleOfShortTermInvestments_2" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised">Net proceeds from stock options and warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to label_ProceedsFromStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised_2">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised_2" xlink:title="label: ProceedsFromStockOptionsExercised to label_ProceedsFromStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property, plant and equipment (net)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_PropertyPlantAndEquipmentAbstract">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="label_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to label_PropertyPlantAndEquipmentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_2">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments">Purchase of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments_2">Payments to Acquire Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments_2" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US" id="label_RepaymentsOfLongTermCapitalLeaseObligations">Payment of capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="label_RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to label_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermCapitalLeaseObligations_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US" id="label_RepaymentsOfLongTermCapitalLeaseObligations_2">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="label_RepaymentsOfLongTermCapitalLeaseObligations_2" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to label_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfNotesPayable" xml:lang="en-US" id="label_RepaymentsOfNotesPayable">Repayments of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="label_RepaymentsOfNotesPayable" xlink:title="label: RepaymentsOfNotesPayable to label_RepaymentsOfNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfNotesPayable_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfNotesPayable" xml:lang="en-US" id="label_RepaymentsOfNotesPayable_2">Repayment of government loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="label_RepaymentsOfNotesPayable_2" xlink:title="label: RepaymentsOfNotesPayable to label_RepaymentsOfNotesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US" id="label_RestructuringAndRelatedActivitiesDisclosureTextBlock">Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="label_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to label_RestructuringAndRelatedActivitiesDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RestructuringAndRelatedActivitiesDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US" id="label_RestructuringAndRelatedActivitiesDisclosureTextBlock_2">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="label_RestructuringAndRelatedActivitiesDisclosureTextBlock_2" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to label_RestructuringAndRelatedActivitiesDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Deficit accumulated during the development stage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_2">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_2" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants_2">Revenue from Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants_2" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_SalesRevenueNet" xml:lang="en-US" id="label_SalesRevenueNet">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="label_SalesRevenueNet" xlink:title="label: SalesRevenueNet to label_SalesRevenueNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesRevenueNet" xml:lang="en-US" id="label_SalesRevenueNet_2">Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="label_SalesRevenueNet_2" xlink:title="label: SalesRevenueNet to label_SalesRevenueNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SalesRevenueNetAbstract" xml:lang="en-US" id="label_SalesRevenueNetAbstract">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="label_SalesRevenueNetAbstract" xlink:title="label: SalesRevenueNetAbstract to label_SalesRevenueNetAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNetAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesRevenueNetAbstract" xml:lang="en-US" id="label_SalesRevenueNetAbstract_2">Revenue, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetAbstract" xlink:to="label_SalesRevenueNetAbstract_2" xlink:title="label: SalesRevenueNetAbstract to label_SalesRevenueNetAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueGoodsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SalesRevenueGoodsNet" xml:lang="en-US" id="label_SalesRevenueGoodsNet">Product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueGoodsNet" xlink:to="label_SalesRevenueGoodsNet" xlink:title="label: SalesRevenueGoodsNet to label_SalesRevenueGoodsNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueGoodsNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesRevenueGoodsNet" xml:lang="en-US" id="label_SalesRevenueGoodsNet_2">Sales Revenue, Goods, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueGoodsNet" xlink:to="label_SalesRevenueGoodsNet_2" xlink:title="label: SalesRevenueGoodsNet to label_SalesRevenueGoodsNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="label_SegmentReportingDisclosureTextBlock">Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="label_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to label_SegmentReportingDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SegmentReportingDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="label_SegmentReportingDisclosureTextBlock_2">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="label_SegmentReportingDisclosureTextBlock_2" xlink:title="label: SegmentReportingDisclosureTextBlock to label_SegmentReportingDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="label_SellingGeneralAndAdministrativeExpense">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="label_SellingGeneralAndAdministrativeExpense" xlink:title="label: SellingGeneralAndAdministrativeExpense to label_SellingGeneralAndAdministrativeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SellingGeneralAndAdministrativeExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="label_SellingGeneralAndAdministrativeExpense_2">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="label_SellingGeneralAndAdministrativeExpense_2" xlink:title="label: SellingGeneralAndAdministrativeExpense to label_SellingGeneralAndAdministrativeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock_2">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock_2" xlink:title="label: SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to label_StatementOfCashFlowsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US" id="label_StatementOfIncomeAndComprehensiveIncomeAbstract">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="label_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="label: StatementOfIncomeAndComprehensiveIncomeAbstract to label_StatementOfIncomeAndComprehensiveIncomeAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to label_StatementOfStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract_2">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_2" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to label_StockholdersEquityNoteAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock_2">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract">Supplemental disclosure of cash flows information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract_2">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract_2" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent_2">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_2" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract_2">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_2" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding">Economic rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding" xlink:title="label: WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding_2">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding_2" xlink:title="label: WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic_2">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label: CommonStockMember to label_CommonStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember_2">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_2" xlink:title="label: CommonStockMember to label_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock_2">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_2">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_2" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockMember" xml:lang="en-US" id="label_PreferredStockMember">Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember" xlink:title="label: PreferredStockMember to label_PreferredStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockMember" xml:lang="en-US" id="label_PreferredStockMember_2">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember_2" xlink:title="label: PreferredStockMember to label_PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Assets_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets_2">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_2" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentIncomeInterest" xml:lang="en-US" id="label_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to label_InvestmentIncomeInterest" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentIncomeInterest" xml:lang="en-US" id="label_InvestmentIncomeInterest_2">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest_2" xlink:title="label: InvestmentIncomeInterest to label_InvestmentIncomeInterest" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="InvestmentIncomeAmortizationOfPremium" xlink:title="InvestmentIncomeAmortizationOfPremium" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentIncomeAmortizationOfPremium" xml:lang="en-US" id="label_InvestmentIncomeAmortizationOfPremium">Amortization of investment premiums, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeAmortizationOfPremium" xlink:to="label_InvestmentIncomeAmortizationOfPremium" xlink:title="label: InvestmentIncomeAmortizationOfPremium to label_InvestmentIncomeAmortizationOfPremium" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeAmortizationOfPremium_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentIncomeAmortizationOfPremium" xml:lang="en-US" id="label_InvestmentIncomeAmortizationOfPremium_2">Investment Income, Amortization of Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeAmortizationOfPremium" xlink:to="label_InvestmentIncomeAmortizationOfPremium_2" xlink:title="label: InvestmentIncomeAmortizationOfPremium to label_InvestmentIncomeAmortizationOfPremium" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">STOCK BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to label_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label: StatementTable to label_StatementTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Statement, Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to label_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract_2">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_2" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label: StatementLineItems to label_StatementLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems_2">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems_2" xlink:title="label: StatementLineItems to label_StatementLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_2">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_2" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock">Selected Quarterly Information (unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock_2">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock_2" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2">Investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2">Financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward_2">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockholdersEquityPeriodIncreaseDecrease">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="label_StockholdersEquityPeriodIncreaseDecrease" xlink:title="label: StockholdersEquityPeriodIncreaseDecrease to label_StockholdersEquityPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Issue of warrants in connection with registered direct offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_RecognitionOfDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RecognitionOfDeferredRevenue" xml:lang="en-US" id="label_RecognitionOfDeferredRevenue">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="label_RecognitionOfDeferredRevenue" xlink:title="label: RecognitionOfDeferredRevenue to label_RecognitionOfDeferredRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RecognitionOfDeferredRevenue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RecognitionOfDeferredRevenue" xml:lang="en-US" id="label_RecognitionOfDeferredRevenue_2">Recognition of Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="label_RecognitionOfDeferredRevenue_2" xlink:title="label: RecognitionOfDeferredRevenue to label_RecognitionOfDeferredRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">Loss before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_4">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_4" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_2">Balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_3" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_2" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossBeforeTax">Foreign exchange (losses)/gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="label_ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to label_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossBeforeTax_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossBeforeTax_2">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="label_ForeignCurrencyTransactionGainLossBeforeTax_2" xlink:title="label: ForeignCurrencyTransactionGainLossBeforeTax to label_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossUnrealized">Unrealized foreign exchange loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_ForeignCurrencyTransactionGainLossUnrealized" xlink:title="label: ForeignCurrencyTransactionGainLossUnrealized to label_ForeignCurrencyTransactionGainLossUnrealized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossUnrealized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossUnrealized_2">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealized" xlink:to="label_ForeignCurrencyTransactionGainLossUnrealized_2" xlink:title="label: ForeignCurrencyTransactionGainLossUnrealized to label_ForeignCurrencyTransactionGainLossUnrealized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2011 and March 31, 2012; 1,213,142 shares issued and outstanding at December 31, 2011 and March 31, 2012. Aggregate preference in liquidation of $13,708,505 and $13,890,476 at December 31, 2011 and March 31, 2012, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue" xlink:title="label: PreferredStockValue to label_PreferredStockValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue_2">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue_2" xlink:title="label: PreferredStockValue to label_PreferredStockValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAbstract">Comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_ComprehensiveIncomeNetOfTaxAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAbstract_2">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="label_ComprehensiveIncomeNetOfTaxAbstract_2" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to label_ComprehensiveIncomeNetOfTaxAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Statement, Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to label_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember_2">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember_2" xlink:title="label: AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember">Deficit accumulated during development stage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember_2">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember_2" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember">Accumulated other comprehensive income/(loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember_2">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember_2" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label: EquityComponentDomain to label_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:label="DeferredCompensationShareBasedPaymentsMember" xlink:title="DeferredCompensationShareBasedPaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredCompensationShareBasedPaymentsMember" xml:lang="en-US" id="label_DeferredCompensationShareBasedPaymentsMember">Deferred compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationShareBasedPaymentsMember" xlink:to="label_DeferredCompensationShareBasedPaymentsMember" xlink:title="label: DeferredCompensationShareBasedPaymentsMember to label_DeferredCompensationShareBasedPaymentsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCompensationShareBasedPaymentsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredCompensationShareBasedPaymentsMember" xml:lang="en-US" id="label_DeferredCompensationShareBasedPaymentsMember_2">Deferred Compensation, Share-based Payments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationShareBasedPaymentsMember" xlink:to="label_DeferredCompensationShareBasedPaymentsMember_2" xlink:title="label: DeferredCompensationShareBasedPaymentsMember to label_DeferredCompensationShareBasedPaymentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues">Issue of common stock for cash on registered direct offering, net of expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues_2">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueShareBasedCompensation">Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="label_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to label_StockIssuedDuringPeriodValueShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueShareBasedCompensation_2">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="label_StockIssuedDuringPeriodValueShareBasedCompensation_2" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to label_StockIssuedDuringPeriodValueShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised">Issue of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised_2">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">Preferred stock conversions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2" xlink:title="label: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Issue of common stock for cash on registered direct offering, net of expenses (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_2">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesShareBasedCompensation">Issue of common stock to certain directors and officers upon exercise of stock options, stock-based awards exercised, restricted stock units and restricted stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="label_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to label_StockIssuedDuringPeriodSharesShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesShareBasedCompensation_2">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="label_StockIssuedDuringPeriodSharesShareBasedCompensation_2" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to label_StockIssuedDuringPeriodSharesShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised">Issue of common stock upon exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">Preferred stock conversions (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:label xlink:type="resource" xlink:label="label_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US" id="label_InventoryFinishedGoodsNetOfReserves">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="label_InventoryFinishedGoodsNetOfReserves" xlink:title="label: InventoryFinishedGoodsNetOfReserves to label_InventoryFinishedGoodsNetOfReserves" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InventoryFinishedGoodsNetOfReserves_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US" id="label_InventoryFinishedGoodsNetOfReserves_2">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoodsNetOfReserves" xlink:to="label_InventoryFinishedGoodsNetOfReserves_2" xlink:title="label: InventoryFinishedGoodsNetOfReserves to label_InventoryFinishedGoodsNetOfReserves" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="label: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="ComprehensiveIncomeMember" xlink:title="ComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeMember" xml:lang="en-US" id="label_ComprehensiveIncomeMember">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeMember" xlink:to="label_ComprehensiveIncomeMember" xlink:title="label: ComprehensiveIncomeMember to label_ComprehensiveIncomeMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeMember" xml:lang="en-US" id="label_ComprehensiveIncomeMember_2">Comprehensive Income [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeMember" xlink:to="label_ComprehensiveIncomeMember_2" xlink:title="label: ComprehensiveIncomeMember to label_ComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract_2">Costs and Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract_2" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses_2">Costs and Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses_2" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAndServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LicenseAndServicesRevenue" xml:lang="en-US" id="label_LicenseAndServicesRevenue">Collaboration and research and development revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndServicesRevenue" xlink:to="label_LicenseAndServicesRevenue" xlink:title="label: LicenseAndServicesRevenue to label_LicenseAndServicesRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAndServicesRevenue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicenseAndServicesRevenue" xml:lang="en-US" id="label_LicenseAndServicesRevenue_2">License and Services Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndServicesRevenue" xlink:to="label_LicenseAndServicesRevenue_2" xlink:title="label: LicenseAndServicesRevenue to label_LicenseAndServicesRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DividendsPreferredStock" xml:lang="en-US" id="label_DividendsPreferredStock">Preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStock" xlink:to="label_DividendsPreferredStock" xlink:title="label: DividendsPreferredStock to label_DividendsPreferredStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsPreferredStock" xml:lang="en-US" id="label_DividendsPreferredStock_2">Dividends, Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStock" xlink:to="label_DividendsPreferredStock_2" xlink:title="label: DividendsPreferredStock to label_DividendsPreferredStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_SharesIssued" xml:lang="en-US" id="label_SharesIssued">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="label_SharesIssued" xlink:title="label: SharesIssued to label_SharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssued_3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_SharesIssued" xml:lang="en-US" id="label_SharesIssued_3">Balances (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="label_SharesIssued_3" xlink:title="label: SharesIssued to label_SharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesIssued" xml:lang="en-US" id="label_SharesIssued_2">Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="label_SharesIssued_2" xlink:title="label: SharesIssued to label_SharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization_2">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization_2" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies_2">Commitments and Contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_2" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent_2">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent_2" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent">Accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent" xlink:title="label: AccruedLiabilitiesCurrent to label_AccruedLiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_2" xlink:title="label: AccruedLiabilitiesCurrent to label_AccruedLiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2">Comprehensive loss for the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">Translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US" id="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent to label_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities to label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2">Accounts payable, accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2" xlink:title="label: IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities to label_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations_2">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAbstract" xml:lang="en-US" id="label_CashAndCashEquivalentsAbstract">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="label_CashAndCashEquivalentsAbstract" xlink:title="label: CashAndCashEquivalentsAbstract to label_CashAndCashEquivalentsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PayablesAndAccrualsAbstract" xml:lang="en-US" id="label_PayablesAndAccrualsAbstract">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="label_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to label_PayablesAndAccrualsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US" id="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="label: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock to label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US" id="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2" xlink:title="label: AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock to label_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to label_CommitmentsAndContingenciesDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to label_IncomeTaxDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to label_FairValueDisclosuresAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock_2">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_2" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="label_CompensationAndRetirementDisclosureAbstract">Employee Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="label_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to label_CompensationAndRetirementDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US" id="label_QuarterlyFinancialInformationDisclosureAbstract">Selected Quarterly Information (unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="label: QuarterlyFinancialInformationDisclosureAbstract to label_QuarterlyFinancialInformationDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">STOCK BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US" id="label_RestructuringAndRelatedActivitiesAbstract">Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="label_RestructuringAndRelatedActivitiesAbstract" xlink:title="label: RestructuringAndRelatedActivitiesAbstract to label_RestructuringAndRelatedActivitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetImpairment">Goodwill and Intangible Asset Impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetImpairment" xlink:to="label_GoodwillAndIntangibleAssetImpairment" xlink:title="label: GoodwillAndIntangibleAssetImpairment to label_GoodwillAndIntangibleAssetImpairment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetImpairment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetImpairment_2">Goodwill and intangibles impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetImpairment" xlink:to="label_GoodwillAndIntangibleAssetImpairment_2" xlink:title="label: GoodwillAndIntangibleAssetImpairment to label_GoodwillAndIntangibleAssetImpairment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GoodwillAndIntangibleAssetImpairment_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US" id="label_GoodwillAndIntangibleAssetImpairment_3">Goodwill and intangible impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetImpairment" xlink:to="label_GoodwillAndIntangibleAssetImpairment_3" xlink:title="label: GoodwillAndIntangibleAssetImpairment to label_GoodwillAndIntangibleAssetImpairment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to label_AccountingPoliciesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SegmentReportingAbstract" xml:lang="en-US" id="label_SegmentReportingAbstract">Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="label_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to label_SegmentReportingAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to label_SubsequentEventsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2">Issuance of other long term payable on ALIGN acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Net loss per share - Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2">Issue of shares on conversion of bridging loan and Loan Note Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to label_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherLiabilitiesCurrent" xml:lang="en-US" id="label_OtherLiabilitiesCurrent_2">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="label_OtherLiabilitiesCurrent_2" xlink:title="label: OtherLiabilitiesCurrent to label_OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherLiabilitiesCurrent" xml:lang="en-US" id="label_OtherLiabilitiesCurrent">Other liabilities measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="label_OtherLiabilitiesCurrent" xlink:title="label: OtherLiabilitiesCurrent to label_OtherLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_TransactionCostsOnSaleOfEconomicRights" xlink:label="TransactionCostsOnSaleOfEconomicRights" xlink:title="TransactionCostsOnSaleOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_TransactionCostsOnSaleOfEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TransactionCostsOnSaleOfEconomicRights" xml:lang="en-US" id="label_TransactionCostsOnSaleOfEconomicRights">Transaction Costs on Sale of Economic Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionCostsOnSaleOfEconomicRights" xlink:to="label_TransactionCostsOnSaleOfEconomicRights" xlink:title="label: TransactionCostsOnSaleOfEconomicRights to label_TransactionCostsOnSaleOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_TransactionCostsOnSaleOfEconomicRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TransactionCostsOnSaleOfEconomicRights" xml:lang="en-US" id="label_TransactionCostsOnSaleOfEconomicRights_2">Transaction costs on sale of economic rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionCostsOnSaleOfEconomicRights" xlink:to="label_TransactionCostsOnSaleOfEconomicRights_2" xlink:title="label: TransactionCostsOnSaleOfEconomicRights to label_TransactionCostsOnSaleOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_TransactionCostsOnSaleOfEconomicRights_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TransactionCostsOnSaleOfEconomicRights" xml:lang="en-US" id="label_TransactionCostsOnSaleOfEconomicRights_3">This element represents the transaction cost on sale of economic rights incurred during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionCostsOnSaleOfEconomicRights" xlink:to="label_TransactionCostsOnSaleOfEconomicRights_3" xlink:title="label: TransactionCostsOnSaleOfEconomicRights to label_TransactionCostsOnSaleOfEconomicRights" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfEconomicRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ChangeInValuationOfEconomicRights" xml:lang="en-US" id="label_ChangeInValuationOfEconomicRights">Change in valuation of Economic Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfEconomicRights" xlink:to="label_ChangeInValuationOfEconomicRights" xlink:title="label: ChangeInValuationOfEconomicRights to label_ChangeInValuationOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfEconomicRights_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ChangeInValuationOfEconomicRights" xml:lang="en-US" id="label_ChangeInValuationOfEconomicRights_2">Change in Valuation of Economic Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfEconomicRights" xlink:to="label_ChangeInValuationOfEconomicRights_2" xlink:title="label: ChangeInValuationOfEconomicRights to label_ChangeInValuationOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfEconomicRights_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ChangeInValuationOfEconomicRights" xml:lang="en-US" id="label_ChangeInValuationOfEconomicRights_3">This element represents the change in the valuation of economic rights during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfEconomicRights" xlink:to="label_ChangeInValuationOfEconomicRights_3" xlink:title="label: ChangeInValuationOfEconomicRights to label_ChangeInValuationOfEconomicRights" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInValuationOfEconomicRights_4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ChangeInValuationOfEconomicRights" xml:lang="en-US" id="label_ChangeInValuationOfEconomicRights_4">Change in valuation of Economic Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInValuationOfEconomicRights" xlink:to="label_ChangeInValuationOfEconomicRights_4" xlink:title="label: ChangeInValuationOfEconomicRights to label_ChangeInValuationOfEconomicRights" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cycc-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://cyclacel.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cycc-20120331.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://cyclacel.com/role/BalanceSheet" xlink:type="simple" xlink:href="cycc-20120331.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://cyclacel.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="cycc-20120331.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfIncome" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfComprehensiveIncome" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfComprehensiveIncome" />
  <link:roleRef roleURI="http://cyclacel.com/role/CashFlows" xlink:type="simple" xlink:href="cycc-20120331.xsd#CashFlows" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureNatureOfOperationsAndBasisOfPresentation" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureFairValueMeasurements" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://cyclacel.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="cycc-20120331.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureSignificantContracts" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureSignificantContracts" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureCashAndCashEquivalents" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureCashAndCashEquivalents" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosurePropertyPlantAndEquipment" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosurePropertyPlantAndEquipment" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureRestructuring" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureRestructuring" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureEmployeeBenefitPlans" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureEmployeeBenefitPlans" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureTaxes" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureTaxes" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureGeographicInformation" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureGeographicInformation" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureSelectedQuarterlyInformation" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureSelectedQuarterlyInformation" />
  <link:roleRef roleURI="http://cyclacel.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="cycc-20120331.xsd#DisclosureSubsequentEvents" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentDescription" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentDescription" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="150.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="InventoryFinishedGoodsNetOfReserves" xlink:title="InventoryFinishedGoodsNetOfReserves" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryFinishedGoodsNetOfReserves" xlink:title="presentation: AssetsCurrentAbstract to InventoryFinishedGoodsNetOfReserves" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: LiabilitiesCurrentAbstract to WarrantsAndRightsOutstanding" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockParOrStatedValuePerShare" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesAuthorized" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesIssued" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesOutstanding" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockLiquidationPreferenceValue" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockParOrStatedValuePerShare" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesAuthorized" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesIssued" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesOutstanding" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="SalesRevenueNetAbstract" xlink:title="SalesRevenueNetAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SalesRevenueNetAbstract" xlink:title="presentation: StatementLineItems to SalesRevenueNetAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="LicenseAndServicesRevenue" xlink:title="LicenseAndServicesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="LicenseAndServicesRevenue" xlink:title="presentation: SalesRevenueNetAbstract to LicenseAndServicesRevenue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="SalesRevenueGoodsNet" xlink:title="SalesRevenueGoodsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueGoodsNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueGoodsNet" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="RevenueFromGrants" xlink:title="presentation: SalesRevenueNetAbstract to RevenueFromGrants" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesRevenueNetAbstract" xlink:to="SalesRevenueNet" xlink:title="presentation: SalesRevenueNetAbstract to SalesRevenueNet" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="CostOfGoodsSold" xlink:title="CostOfGoodsSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostOfGoodsSold" xlink:title="presentation: CostsAndExpensesAbstract to CostOfGoodsSold" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="presentation: CostsAndExpensesAbstract to GoodwillAndIntangibleAssetImpairment" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="OtherRestructuringCosts" xlink:title="OtherRestructuringCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherRestructuringCosts" xlink:title="presentation: CostsAndExpensesAbstract to OtherRestructuringCosts" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="presentation: StatementLineItems to OperatingIncomeLoss" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: StatementLineItems to NonoperatingIncomeExpenseAbstract" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="PaymentsOfFinancingCosts" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to PaymentsOfFinancingCosts" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PaymentUnderGuarantee" xlink:label="PaymentUnderGuarantee" xlink:title="PaymentUnderGuarantee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="PaymentUnderGuarantee" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to PaymentUnderGuarantee" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfWarrants" xlink:label="ChangeInValuationOfWarrants" xlink:title="ChangeInValuationOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInValuationOfWarrants" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to ChangeInValuationOfWarrants" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ForeignCurrencyTransactionGainLossBeforeTax" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to ChangeInValuationOfEconomicRights" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="presentation: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: StatementLineItems to IncomeTaxExpenseBenefit" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsOnPreferredOrdinaryShares" xlink:label="DividendsOnPreferredOrdinaryShares" xlink:title="DividendsOnPreferredOrdinaryShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DividendsOnPreferredOrdinaryShares" xlink:title="presentation: StatementLineItems to DividendsOnPreferredOrdinaryShares" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_RedeemablePreferredStocksDividends" xlink:label="RedeemablePreferredStocksDividends" xlink:title="RedeemablePreferredStocksDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RedeemablePreferredStocksDividends" xlink:title="presentation: StatementLineItems to RedeemablePreferredStocksDividends" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_DividendsPreferredStocks" xlink:label="DividendsPreferredStocks" xlink:title="DividendsPreferredStocks" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStocks" xlink:title="presentation: StatementLineItems to DividendsPreferredStocks" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: StatementLineItems to EarningsPerShareBasicAndDiluted" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="130.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfComprehensiveIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: StatementLineItems to ComprehensiveIncomeNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccretionExpense" xlink:label="AccretionExpense" xlink:title="AccretionExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="InvestmentIncomeAmortizationOfPremium" xlink:title="InvestmentIncomeAmortizationOfPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InvestmentIncomeAmortizationOfPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to InvestmentIncomeAmortizationOfPremium" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnPriceRiskDerivativesNet" xlink:label="GainLossOnPriceRiskDerivativesNet" xlink:title="GainLossOnPriceRiskDerivativesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnPriceRiskDerivativesNet" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnPriceRiskDerivativesNet" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="ForeignCurrencyTransactionGainLossUnrealized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ForeignCurrencyTransactionGainLossUnrealized" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ForeignCurrencyTransactionGainLossUnrealized" order="90.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RecognitionOfDeferredRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to RecognitionOfDeferredRevenue" order="100.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockOptionPlanExpenses" xlink:label="StockOptionPlanExpenses" xlink:title="StockOptionPlanExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="StockOptionPlanExpenses" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to StockOptionPlanExpenses" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStocksAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStocksAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStocksAndWarrantsForServicesOrClaims" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" order="130.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="GoodwillAndIntangibleAssetImpairment" xlink:title="GoodwillAndIntangibleAssetImpairment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GoodwillAndIntangibleAssetImpairment" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GoodwillAndIntangibleAssetImpairment" order="140.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="150.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="PaymentsForRestructuring" xlink:title="PaymentsForRestructuring" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaymentsForRestructuring" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaymentsForRestructuring" order="160.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="170.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="190.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_TransactionCostsOnSaleOfEconomicRights" xlink:label="TransactionCostsOnSaleOfEconomicRights" xlink:title="TransactionCostsOnSaleOfEconomicRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="TransactionCostsOnSaleOfEconomicRights" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to TransactionCostsOnSaleOfEconomicRights" order="180.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ChangeInValuationOfEconomicRights" xlink:label="ChangeInValuationOfEconomicRights" xlink:title="ChangeInValuationOfEconomicRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInValuationOfEconomicRights" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ChangeInValuationOfEconomicRights" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDerivativeInstrumentsNetPretax" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireBusinessesNetOfCashAcquired" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireShortTermInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireShortTermInvestments" order="40.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfShortTermInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfShortTermInvestments" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfLongTermCapitalLeaseObligations" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromStockOptionsExercised" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfNotesPayable" order="60.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromNotesPayable" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="ProceedsFromLoans" xlink:title="ProceedsFromLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromLoans" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromLoans" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:label="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="ProceedsOfCommittableLoanNotesIssuedFromShareholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsOfCommittableLoanNotesIssuedFromShareholders" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsOfCommittableLoanNotesIssuedFromShareholders" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections" xlink:label="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="LoansAndLeasesReceivableRelatedPartiesCollections" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="LoansAndLeasesReceivableRelatedPartiesCollections" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to LoansAndLeasesReceivableRelatedPartiesCollections" order="100.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="PaymentsForRepurchaseOfEquity" xlink:title="PaymentsForRepurchaseOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsForRepurchaseOfEquity" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsForRepurchaseOfEquity" order="120.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="130.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:title="presentation: StatementLineItems to EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementLineItems to SupplementalCashFlowInformationAbstract" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="CashReceivedDuringPeriodForAbstract" xlink:title="CashReceivedDuringPeriodForAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="CashReceivedDuringPeriodForAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to CashReceivedDuringPeriodForAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="ProceedsFromInterestReceived" xlink:title="ProceedsFromInterestReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="ProceedsFromInterestReceived" xlink:title="presentation: CashReceivedDuringPeriodForAbstract to ProceedsFromInterestReceived" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="ProceedsFromIncomeTaxRefunds" xlink:title="ProceedsFromIncomeTaxRefunds" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashReceivedDuringPeriodForAbstract" xlink:to="ProceedsFromIncomeTaxRefunds" xlink:title="presentation: CashReceivedDuringPeriodForAbstract to ProceedsFromIncomeTaxRefunds" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="PaymentsForOperatingActivitiesAbstract" xlink:title="PaymentsForOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="PaymentsForOperatingActivitiesAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to PaymentsForOperatingActivitiesAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: PaymentsForOperatingActivitiesAbstract to InterestPaidNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_ScheduleOfNonCashTransactionsAbstract" xlink:label="ScheduleOfNonCashTransactionsAbstract" xlink:title="ScheduleOfNonCashTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsForOperatingActivitiesAbstract" xlink:to="ScheduleOfNonCashTransactionsAbstract" xlink:title="presentation: PaymentsForOperatingActivitiesAbstract to ScheduleOfNonCashTransactionsAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:label="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to AcquisitionsOfEquipmentPurchasedThroughCapitalLeases" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:label="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:label="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesOnConversionOfBridgingLoan" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:label="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:label="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="IssuanceOfOrdinarySharesInLieuOfCashBonus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="IssuanceOfOrdinarySharesInLieuOfCashBonus" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to IssuanceOfOrdinarySharesInLieuOfCashBonus" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashTransactionsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="presentation: ScheduleOfNonCashTransactionsAbstract to NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureFairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets">
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:title="PrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="presentation: PrepaidExpensesAndOtherCurrentAssetsAbstract to PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureStockBasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssued" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued_2" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssued_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssued" order="240.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:label="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEffectOfWarrantPricing" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: StockIssuedDuringPeriodValueNewIssues to StockIssuedDuringPeriodSharesNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:label="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility" xlink:to="StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" xlink:title="presentation: StockIssuedDuringPeriodValueDrawDownOfCommittedEquityFinanceFacility to StockIssuedDuringPeriodSharesDrawDownOfCommittedEquityFinanceFacility" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueWarrantsExercised" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="presentation: StockIssuedDuringPeriodValueWarrantsExercised to StockIssuedDuringPeriodSharesWarrantsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValuePrivatePlacement" xlink:label="StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="StockIssuedDuringPeriodValuePrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValuePrivatePlacement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValuePrivatePlacement" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValuePrivatePlacement" xlink:to="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="presentation: StockIssuedDuringPeriodValuePrivatePlacement to StockIssuedDuringPeriodSharesPrivatePlacement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueShareBasedCompensation" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: StockIssuedDuringPeriodValueShareBasedCompensation to StockIssuedDuringPeriodSharesShareBasedCompensation" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="100.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="StockIssuedDuringPeriodSharesConversionOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="StockIssuedDuringPeriodSharesConversionOfDebt" xlink:title="presentation: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to StockIssuedDuringPeriodSharesConversionOfDebt" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueReverseAcquisition" xlink:label="StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="StockIssuedDuringPeriodValueReverseAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueReverseAcquisition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueReverseAcquisition" order="110.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesReverseAcquisition" xlink:label="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="StockIssuedDuringPeriodSharesReverseAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueReverseAcquisition" xlink:to="StockIssuedDuringPeriodSharesReverseAcquisition" xlink:title="presentation: StockIssuedDuringPeriodValueReverseAcquisition to StockIssuedDuringPeriodSharesReverseAcquisition" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:label="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalLoansPayableWaived" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="StockAndWarrantsIssuedDuringPeriodValue" xlink:title="StockAndWarrantsIssuedDuringPeriodValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockAndWarrantsIssuedDuringPeriodValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockAndWarrantsIssuedDuringPeriodValue" order="130.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="StockAndWarrantsIssuedDuringPeriodShares" xlink:title="StockAndWarrantsIssuedDuringPeriodShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockAndWarrantsIssuedDuringPeriodValue" xlink:to="StockAndWarrantsIssuedDuringPeriodShares" xlink:title="presentation: StockAndWarrantsIssuedDuringPeriodValue to StockAndWarrantsIssuedDuringPeriodShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="140.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueIssuedForServices" order="150.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: StockIssuedDuringPeriodValueIssuedForServices to StockIssuedDuringPeriodSharesIssuedForServices" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:label="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalContractualAgreements" order="160.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_StockIssuedDuringPeriodSharesContractualAgreements" xlink:label="StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="StockIssuedDuringPeriodSharesContractualAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToAdditionalPaidInCapitalContractualAgreements" xlink:to="StockIssuedDuringPeriodSharesContractualAgreements" xlink:title="presentation: AdjustmentsToAdditionalPaidInCapitalContractualAgreements to StockIssuedDuringPeriodSharesContractualAgreements" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="170.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: StockIssuedDuringPeriodValueStockOptionsExercised to StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="180.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendsPreferredStock" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DividendsPreferredStock" order="190.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="200.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_AmortizationOfDeferredStockBasedCompensation" xlink:label="AmortizationOfDeferredStockBasedCompensation" xlink:title="AmortizationOfDeferredStockBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AmortizationOfDeferredStockBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AmortizationOfDeferredStockBasedCompensation" order="210.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ComprehensiveIncomeNetOfTaxAbstract" order="220.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTaxPortionAttributableToParent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" use="optional" order="250.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="presentation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="presentation: EquityComponentDomain to PreferredStockMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: EquityComponentDomain to AdditionalPaidInCapitalMember" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:label="DeferredCompensationShareBasedPaymentsMember" xlink:title="DeferredCompensationShareBasedPaymentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="DeferredCompensationShareBasedPaymentsMember" xlink:title="presentation: EquityComponentDomain to DeferredCompensationShareBasedPaymentsMember" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="presentation: EquityComponentDomain to RetainedEarningsMember" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="ComprehensiveIncomeMember" xlink:title="ComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="ComprehensiveIncomeMember" xlink:title="presentation: EquityComponentDomain to ComprehensiveIncomeMember" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureSignificantContracts">
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_SignificantContractsDisclosureAbstract" xlink:label="SignificantContractsDisclosureAbstract" xlink:title="SignificantContractsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="cycc-20120331.xsd#cycc_SignificantContractsDisclosureTextBlock" xlink:label="SignificantContractsDisclosureTextBlock" xlink:title="SignificantContractsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantContractsDisclosureAbstract" xlink:to="SignificantContractsDisclosureTextBlock" xlink:title="presentation: SignificantContractsDisclosureAbstract to SignificantContractsDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureCashAndCashEquivalents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="CashAndCashEquivalentsDisclosureTextBlock" xlink:title="CashAndCashEquivalentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsDisclosureTextBlock" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosurePropertyPlantAndEquipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureRestructuring">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to RestructuringAndRelatedActivitiesDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureEmployeeBenefitPlans">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureGeographicInformation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureSelectedQuarterlyInformation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="QuarterlyFinancialInformationTextBlock" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to QuarterlyFinancialInformationTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">FAIR VALUE MEASUREMENTS</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">As defined in ASC 820, <i>Fair Value Measurements and Disclosures</i> (&#8220;ASC 820&#8221;), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2">&#183;</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2">&#183;</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol" size="2">&#183;</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The fair value of the Company&#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December&#160;31, 2011:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Total</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cash equivalents </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,894</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,894</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other liabilities measured at fair value:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Warrants liability </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">51</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">51</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Scottish Enterprise Agreement </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">20</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">20</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other liabilities measured at fair value </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">71</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">71</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,894</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">71</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19,965</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The fair value of the Company&#8217;s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of March&#160;31, 2012:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;1</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;2</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Total</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cash equivalents </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,498</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,498</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Economic rights </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,153</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,153</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other liabilities measured at fair value:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Warrants liability </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">9</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.56%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">9</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Scottish Enterprise Agreement </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">20</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">20</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other liabilities measured at fair value </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">29</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">29</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.12%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,498</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,182</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.56%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">18,680</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The following table reconciles the beginning and ending balances of Level 3 inputs for the three months ended March&#160;31, 2012:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Level&#160;3</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">$000</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Balance as of December&#160;31, 2011 </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">71</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Sale of Economic Rights </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,097</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation of Economic Rights </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">56</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Change in valuation of warrants liability </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(42</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 84.5%; PADDING-TOP: 0in" valign="bottom" width="84%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Balance as of March&#160;31, 2012 </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,182</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Economic Rights</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On March&#160;22, 2012, the Company entered into a financing agreement with certain existing institutional stockholders.&#160; Under the terms of the agreement, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional common shares or warrants.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Economical Rights are accounted for as a derivative financial instrument under ASC 815, <i>Derivative financial instruments </i>(&#8220;ASC 815&#8221;), and are measured at fair value. Changes in fair value are recognized in earnings. &#160;The fair value of the Economical Rights has been estimated using a decision-tree analysis method.&#160; This is an income-based method that incorporates the expected benefits, costs and probabilities of contingent outcomes under varying scenarios.&#160; Each scenario within the decision-tree is discounted to the present value using the company&#8217;s credit adjusted risk-free rate and ascribed a weighted probability to determine the fair value.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has concluded the fair value of this liability was approximately $1.1 million and $1.2 million at March&#160;22, 2012, and March&#160;31, 2012, respectively.&#160; The fair value of the derivative increased approximately $56,000 from March&#160;22, 2012 to March&#160;31, 2012. The increase in fair value was recognized as a loss in the consolidated statement of operations for the three month period ended March&#160;31, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The most significant inputs in estimating the fair value of this liability are:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(i)</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The Company&#8217;s credit adjusted risk-free rate, which has been derived from the observable returns on debt for more developed pharmaceuticals companies, adjusted for the Company&#8217;s risk profile.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(ii)</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The amount of the return to the investors, which will vary depending on:</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">a.</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The outcome of the litigation, including consideration of whether the litigation may be resolved in a jury trial or settled out of court;</font></p>
<p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">b.</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The amount of the settlement or award, which the Company has estimated predominantly based on observable royalty rates arising from the settlement of other cases of intellectual property litigation; and</font></p>
<p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 1in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">c.</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The form of the settlement or award.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(iii)</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The projected timing of the cash flows to the investors, which could vary between several months to several years depending upon whether the litigation is settled, when the court may decide the case, whether any appeal is made on any court decision and the form of any settlement or award.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(iv)</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">The number of contingent warrants that could be issued, which is based on a formula.</font></p>
<p style="MARGIN: 0in 0in 0pt 0.75in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The decision-tree analysis model used to calculate the fair value of the derivative requires the probability of alternative scenarios to be determined at a series of decision points.&#160; Each scenario may contain more than one decision point resulting in further scenarios.&#160; Therefore, the probability estimates made by management at each decision point are a significant input to the valuation model.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">All of these inputs are unobservable inputs, which have an interrelated effect on the fair value of the derivative.&#160; It is not possible to evaluate the impact on the fair value of each factor in combination.&#160; However, generally the fair value of the derivative liability will increase, (i)&#160;the higher the value of the expected settlement or award, (ii)&#160;the lower the discount rate employed and (iii)&#160;the more likely it is that a settlement or award will be made.&#160; The fair value of the derivative liability will decrease if the timing of settlement is delayed, the expected settlement decreases, or anticipated litigation costs increase.&#160;&#160; The impact on the fair value of the derivative liability related to the probability of whether the litigation is settled prior to the court hearing or whether a settlement award is made by the court and the form of the settlement will depend on the other factors above and cannot be estimated in isolation.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The decision-tree analysis model has been performed by valuation specialists, based on inputs provided by the company and other sources. At each reporting period, the inputs to the model will be evaluated to determine whether any adjustments are appropriate, and to reflect changes in the time value of the expected cash flows.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company used the following assumptions to calculate the value of the Economic Rights:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.25in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;22,</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="bottom" width="46%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Probability of unsuccessful/successful outcomes </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">25% - 75%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">25% - 75%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Amount of award or settlement (1) </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$10.0 million - $20.0 million</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$10.0 million - $20.0 million</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Discount rate </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">16%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">16%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Timing of cash flows </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.75 &#8211; 2.27 years</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.75 &#8211; 2.27 years</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Royalty rate </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 46.42%; PADDING-TOP: 0in" valign="top" width="46%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Litigation expenses </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$1.0 million &#8211; $3.0 million</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 23.58%; PADDING-TOP: 0in" valign="bottom" width="23%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$1.0 million &#8211; $3.0 million</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1)</font><font style="FONT-SIZE: 8.5pt" size="1">&#160;&#160; </font><font style="FONT-SIZE: 10pt" size="2">Assumptions take into consideration the cap on the amount that the Company would have to pay investors in the event of an award or settlement.</font></p>
<p style="MARGIN: 0in 0in 0pt 31.5pt; TEXT-INDENT: -13.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Other Liabilities Measured at Fair Value</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><u><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Warrants Liability</font></u></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company issued warrants to purchase shares of common stock under the registered direct financing completed in February&#160;2007.&#160; These warrants are being accounted for as a liability in accordance with ASC 815.&#160; At the date of the transaction, the fair value of the warrants of $6.8&#160;million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate &#8212; 4.68%, expected volatility &#8212; 85%, expected dividend yield &#8212; 0%, and a remaining contractual life of 7&#160;years. The fair value of the warrant is being remeasured each reporting period, with a gain or loss recognized in the consolidated statement of operations. Such gains or losses will continue to be reported until the warrants are exercised or expired. The Company used the Black-Scholes option-pricing model with the following assumptions to value the warrants:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.25in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">December&#160;31,</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Exercise price </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$8.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.86%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$8.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected term </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2.13 Yrs.</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.88 Yrs.</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Risk free interest rate </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.25%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.33%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected volatility </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">121%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">77%</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 67.88%; PADDING-TOP: 0in" valign="bottom" width="67%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expected dividend yield over expected term </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.86%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company recognized the change in the value of warrants as a gain on the consolidated statement of operations of $0.1 million and approximately $42,000 for the three months ended March&#160;31, 2011 and 2012, respectively.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><u><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Scottish Enterprise Agreement</font></u></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On June&#160;22, 2009, the Company amended the Agreement with Scottish Enterprise (&#8220;SE&#8221;) (the &#8220;Amendment&#8221;), in order to allow the Company to implement a reduction of the Company&#8217;s research operations located in Scotland in exchange for the parties&#8217; agreement to modify the payment terms of the Agreement in the principal amount of &#163;5&#160;million (approximately $8.0 million at December&#160;31, 2009), which SE had previously entered into with the Company. The Agreement provided for repayment of up to &#163;5 million in the event the Company significantly reduced its Scottish research operations. Pursuant to the terms of the Amendment, in association with Cyclacel&#8217;s material reduction in staff at its Scottish research facility, the parties agreed to a modified payment of &#163;1&#160;million (approximately $1.7 million at June&#160;22, 2009) payable in two equal tranches. On July&#160;1, 2009, the first installment of &#163;0.5 million (approximately $0.8 million) was paid and the remaining amount of &#163;0.5 million (approximately $0.8 million) was paid on January&#160;6, 2010.&#160; In addition, should a further reduction below current minimum staff levels be effectuated before July&#160;2014 without SE&#8217;s prior consent, the Company may be obligated to pay up to &#163;4&#160;million to SE, which will be calculated as a maximum of &#163;4&#160;million (approximately $6.2 million and $6.4 million at December&#160;31, 2011 and March&#160;31, 2012, respectively) less the market value of the shares held by SE at the time staffing levels in Scotland fall below the prescribed minimum levels. If the Company were to have reduced staffing levels below the prescribed levels, the amount potentially payable to SE would have been approximately &#163;3.8 million (approximately $5.9 million) and approximately &#163;3.8 million (approximately $6.1 million) at December&#160;31, 2011 and March&#160;31, 2012, respectively.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">This arrangement is accounted for as a liability under ASC 480, <i>Distinguishing Liabilities from Equity</i> (&#8220;ASC 480&#8221;), and is measured at fair value. Changes in fair value are recognized in earnings. &#160;Due to the nature of the associated contingency and the likelihood of occurrence, the Company has concluded the fair value of this liability was approximately $20,000 at December&#160;31, 2011 and March&#160;31, 2012, respectively. The most significant inputs in estimating the fair value of this liability are the probabilities that staffing levels fall below the prescribed minimum and that the Company is unable or unwilling to replace such employees within the prescribed time period. At both December&#160;31, 2011 and March&#160;31, 2012, the Company used a scenario analysis model to arrive at the fair value of the Scottish Enterprise Agreement and assumed a 30% probability of falling below a minimum staffing level and a 1% probability that the occurrence of such an event would not be cured within the prescribed time period. At each reporting period, the inputs used to determine the fair value of the liability will be evaluated to determine whether adjustments are appropriate. Changes in the value of this liability are recorded in the consolidated statement of operations.</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\W960U8F4W.5]C96(W7S1A961?.6,T-%]A-&(U
M9F1D.3(T.&4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3D%455)%7T]&7T]015)!5$E/3E-?04Y$
M7T)!4TE3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4U5-34%265]/1E]324=.249)0T%.5%]!0T-/54Y4/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-14%355)%345.
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y04D50
M04E$7T584$5.4T537T%.1%]/5$A%4E]#55(\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y!0T-2545$7TQ)04))3$E424537T%.1%]/
M5$A%4E\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M5$]#2U]"05-%1%]#3TU014Y3051)3TX\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].5$E.1T5.0TE%
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+
M2$],1$524U]%455)5%D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\
M>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^
M#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R
M;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@
M/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@
M/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE
M9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O
M<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q
M-2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!2
M96=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D-Y8VQA8V5L(%!H87)M86-E=71I8V%L<RP@26YC+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R
M86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP
M,#`Q,3,P,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N
M="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.2PP,#,L,S`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S=E9#5B93<Y7V-E8C=?-&%E9%\Y
M8S0T7V$T8C5F9&0Y,C0X90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\W960U8F4W.5]C96(W7S1A961?.6,T-%]A-&(U9F1D.3(T.&4O5V]R:W-H
M965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4%E!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@4TA%
M1513("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,RPV-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(T+#0T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T
M:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#$W,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#@S,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R
M='DL('!L86YT(&%N9"!E<75I<&UE;G0@*&YE="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,S,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L.3DX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA
M8FEL:71I97,@86YD(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV-C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5C;VYO;6EC
M(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#@P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L-#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L.#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPT.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH
M;VQD97)S)R!E<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)#`N,#`Q('!A<B!V86QU
M93L@-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%T($1E8V5M8F5R(#,Q
M+"`R,#$Q(&%N9"!-87)C:"`S,2P@,C`Q,CL@,2PR,3,L,30R('-H87)E<R!I
M<W-U960@86YD(&]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$Q(&%N
M9"!-87)C:"`S,2P@,C`Q,BX@06=G<F5G871E('!R969E<F5N8V4@:6X@;&EQ
M=6ED871I;VX@;V8@)#$S+#<P."PU,#4@86YD("0Q,RPX.3`L-#<V(&%T($1E
M8V5M8F5R(#,Q+"`R,#$Q(&%N9"!-87)C:"`S,2P@,C`Q,BP@<F5S<&5C=&EV
M96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E.R`Q,#`L,#`P+#`P,"!S:&%R97,@
M875T:&]R:7IE9"!A="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@36%R8V@@,S$L
M(#(P,3([(#4T+#(R,"PT-3@@86YD(#4X+#DY,RPT,30@<VAA<F5S(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$@86YD($UA
M<F-H(#,Q+"`R,#$R+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S@L-#,P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<V+#0U
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969I8VET(&%C8W5M
M=6QA=&5D(&1U<FEN9R!T:&4@9&5V96QO<&UE;G0@<W1A9V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(V,"PP,3DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4W+#`V-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!S=&]C:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@L-3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3DL-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD
M('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(U+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4L.3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P155!044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H
M4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].1$5.4T5$
M($-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A
M<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL
M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C$S+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!L:7%U:61A=&EO
M;B!P<F5F97)E;F-E('9A;'5E("AI;B!D;VQL87)S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,RPX.3`L-#<V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,RPW,#@L-3`U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU."PY.3,L-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L,C(P+#0U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4X+#DY,RPT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-"PR,C`L-#4X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14DV04<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13
M($]&($]015)!5$E/3E,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P
M="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3@X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A;F0@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,RPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0@<F5V96YU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(')E=F5N
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C0X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL.3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!G
M;V]D<R!S;VQD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L.#0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#<L,30V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396QL:6YG
M+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@P-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ+#0X,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P@86YD
M(&EN=&%N9VEB;&4@:6UP86ER;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPY,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<W1R=6-T=7)I;F<@8V]S=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C,T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0S
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L.3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDQ+#`T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#(W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#@P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.#$L,3$S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/=&AE<B!I;F-O;64@*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T<R!A<W-O8VEA=&5D('=I=&@@
M86)O<G1E9"`R,#`T($E03SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPU-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y087EM96YT('5N9&5R(&=U87)A;G1E93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV-3(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=6%T
M:6]N(&]F($5C;VYO;6EC(%)I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&]F(&]T:&5R
M(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R96EG;B!E>&-H
M86YG92`H;&]S<V5S*2]G86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-"PR-3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#<S,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PV-S<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!O=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.3DW/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!B969O<F4@
M=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,3(S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M-S<Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(W-2PQ,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8Q,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#DU-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#4X."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-38L
M-3`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&EV:61E;F1S(&]N('!R969E<G)E9"!O<F1I;F%R>2!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X+#$R,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E96UE
M9"!D:79I9&5N9"!O;B!C;VYV97)T:6)L92!E>&-H86YG96%B;&4@<')E9F5R
M<F5D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPU
M,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$:79I9&5N9"!O;B!C;VYV97)T:6)L92!E>&-H86YG96%B;&4@<')E
M9F5R<F5D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#@S.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!A<'!L:6-A8FQE('1O(&-O;6UO
M;B!S:&%R96AO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,RPQ,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@T+#<W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#,P,2PY.#$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!P97(@<VAA
M<F4@+2!"87-I8R!A;F0@9&EL=71E9"`H:6X@9&]L;&%R<R!P97(@<VAA<F4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T
M+#<V,2PV,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-BPU-S(L,3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\W960U8F4W.5]C96(W7S1A961?.6,T-%]A-&(U9F1D
M.3(T.&4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V5D-6)E-SE?
M8V5B-U\T865D7SEC-#1?831B-69D9#DR-#AE+U=O<FMS:&5E=',O4VAE970P
M-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14E(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/
M3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#3TU04D5(14Y3
M259%($Q/4U,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ.#@@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPY-#<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T+#8Q,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(U-BPT,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S=E9#5B93<Y7V-E8C=?-&%E9%\Y8S0T7V$T8C5F9&0Y,C0X90T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W960U8F4W.5]C96(W7S1A961?
M.6,T-%]A-&(U9F1D.3(T.&4O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%2DI"23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY$14Y3140@
M0T].4T],241!5$5$(%-4051%345.5"!/1B!#05-(($9,3U=3("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3@X($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6YG(&%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(L.34U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-"PU.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@R-38L-3`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT
M<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O
M<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<F5T:6]N(&]F(&EN=&5R97-T(&]N(&YO
M=&5S('!A>6%B;&4L(&YE="!O9B!A;6]R=&EZ871I;VX@;V8@9&5B="!P<F5M
M:75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IA=&EO;B!O9B!I;G9E<W1M96YT('!R96UI=6US+"!N970\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,CDW*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN('9A;'5A
M=&EO;B!O9B!%8V]N;VUI8R!2:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!V86QU871I;VX@;V8@;W1H97(@
M;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPT,3,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(')E
M+7!R:6-I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R+#4W,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&EN
M=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9I>&5D(&%S<V5T(&EM<&%I<FUE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!F;W)E:6=N(&5X8VAA
M;F=E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-S0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Y."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;7!E;G-A=&EO;B!F;W(@=V%R<F%N=',@:7-S=65D('1O
M(&YO;BUE;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R97,@:7-S=65D(&9O<B!)4"!R:6=H=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A:6XI(&QO<W,@;VX@9&ES
M<&]S86P@;V8@<')O<&5R='DL('!L86YT(&%N9"!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;"!A;F0@
M:6YT86YG:6)L97,@:6UP86ER;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPY,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,3(U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V
M:7-I;VX@9F]R(')E<W1R=6-T=7)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-S<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@:7-S=6%N8V4@8V]S
M=',@;V8@4')E9F5R<F5D($]R9&EN87)Y(")#(B!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3$W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N<V%C=&EO;B!C;W-T
M<R!O;B!S86QE(&]F(&5C;VYO;6EC(')I9VAT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A
M=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S+"!I
M;G9E;G1O<GD@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA
M8FQE+"!A8V-R=65D(&QI86)I;&ET:65S(&%N9"!O=&AE<B!C=7)R96YT(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,#<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-BPQ,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW-S$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPX
M.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,C$V+#@Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T:6YG(&%C=&EV:71I97,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E(&]F($%,24=./"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#<V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!U<F-H87-E(&]F('!R;W!E<G1Y+"!P;&%N="!A;F0@97%U:7!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L.#0V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!S86QE(&]F('!R;W!E<G1Y+"!P;&%N="!A;F0@97%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V4@;V8@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,34V+#8U-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9&5M<'1I;VYS(&]F
M('-H;W)T+71E<FT@:6YV97-T;65N=',L(&YE="!O9B!M871U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C(L-S(Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@<')O=FED960@8GD@*'5S960@:6XI(&EN=F5S=&EN9R!A8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,S4P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O9B!C87!I=&%L(&QE
M87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#<Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@;W)D:6YA<GD@
M86YD('!R969E<G)E9"!O<F1I;F%R>2!S:&%R97,L(&YE="!O9B!I<W-U86YC
M92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#8W
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL('=A
M<G)A;G1S(&%N9"!E8V]N;VUI8R!R:6=H=',L(&YE="!O9B!I<W-U86YC92!C
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M-"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!P<F]C965D<R!F<F]M('-T;V-K(&]P=&EO;G,@86YD('=A
M<G)A;G1S(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y087EM96YT(&]F('!R969E<G)E9"!S=&]C:R!D:79I9&5N
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#DX*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5P87EM96YT(&]F(&=O=F5R;FUE;G0@;&]A;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V]V97)N;65N="!L;V%N(')E8V5I=F5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO86X@<F5C
M96EV960@9G)O;2!#>6-L86-E;"!'<F]U<"!0;&,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL,3`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!O9B!C;VUM:71T86)L
M92!L;V%N(&YO=&5S(&ES<W5E9"!F<F]M('-H87)E:&]L9&5R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX.#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO86YS(')E8V5I=F5D
M(&9R;VT@<VAA<F5H;VQD97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#8T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A<W-U;65D
M(&]N('-T;V-K('!U<F-H87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-RPY,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W1S(&%S<V]C:6%T960@=VET:"!S=&]C:R!P=7)C
M:&%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PY-3$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&-A<V@@*'5S960@:6XI('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DT-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-#8L-#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@<F%T92!C:&%N9V5S(&]N
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8W)E87-E("AD96-R96%S92D@
M:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0L,30U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#8T,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PT-#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PT.34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-C0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,S4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-C0P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-A<V@@<F5C96EV960@9'5R:6YG('1H92!P97)I;V0@9F]R.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A
M>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR,#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!P86ED(&1U<FEN9R!T:&4@<&5R:6]D(&9O<CH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.3$T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY38VAE9'5L92!O9B!N;VXM8V%S:"!T<F%N<V%C=&EO;G,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N
M<R!O9B!E<75I<&UE;G0@<'5R8VAA<V5D('1H<F]U9V@@8V%P:71A;"!L96%S
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!C;VUM;VX@<VAA<F5S(&EN(&-O;FYE8W1I;VX@=VET:"!L:6-E
M;G-E(&%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@;W)D:6YA<GD@<VAA<F5S(&]N(&-O;G9E<G-I
M;VX@;V8@8G)I9&=I;F<@;&]A;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('!R969E<G)E9"!O<F1I;F%R>2`B
M0R(@<VAA<F5S(&]N(&-O;G9E<G-I;VX@;V8@<V5C=7)E9"!C;VYV97)T:6)L
M92!L;V%N(&YO=&5S(&%N9"!A8V-R=65D(&EN=&5R97-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#@Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@;W)D:6YA
M<GD@<VAA<F5S(&EN(&QI974@;V8@8V%S:"!B;VYU<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!O=&AE<B!L;VYG
M('1E<FT@<&%Y86)L92!O;B!!3$E'3B!A8W%U:7-I=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V5D-6)E-SE?8V5B-U\T865D7SEC
M-#1?831B-69D9#DR-#AE#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S=E9#5B93<Y7V-E8C=?-&%E9%\Y8S0T7V$T8C5F9&0Y,C0X92]7;W)K<VAE
M971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.05154D4@3T8@3U!%4D%424].4R!!3D0@0D%325,@3T8@4%)%
M4T5.5$%424]./&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3D%455)%($]&($]015)!5$E/3E,@04Y$($)!4TE3($]&
M(%!215-%3E1!5$E/3CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.05154D4@3T8@3U!%4D%424].4R!!3D0@0D%325,@3T8@
M4%)%4T5.5$%424]./"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R!.05154D4@3T8@3U!%4D%424].4R!!3D0@0D%3
M25,@3T8@4%)%4T5.5$%424]./"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DYA='5R92!O
M9B!/<&5R871I;VYS/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY#>6-L86-E;"!0:&%R;6%C975T:6-A;',L)B,Q-C`[26YC
M+B`H)B,X,C$V.R8C.#(Q-CM#>6-L86-E;"8C.#(Q-SLF(S@R,3<[(&]R('1H
M92`F(S@R,38[)B,X,C$V.T-O;7!A;GDF(S@R,3<[)B,X,C$W.RD@:7,@82!D
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P
M+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^0WEC
M;&%C96PF(S@R,3<[<R!C;&EN:6-A;"!D979E;&]P;65N="!P<FEO<FET:65S
M(&%R92!F;V-U<V5D(&]N('-A<&%C:71A8FEN92P@86X@;W)A;&QY(&%V86EL
M86)L92P@8V5L;"!C>6-L92!M;V1U;&%T:6YG(&YU8VQE;W-I9&4@86YA;&]G
M=64N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE
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M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS
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M86P@8V%N8V5R("@F(S@R,C`[3E!#)B,X,C(Q.RDN($EN(&%D9&ET:6]N+"!W
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M870@36%R8V@F(S$V,#LS,2P@,C`Q,B!A<F4@<W5F9FEC:65N="!T;R!M965T
M(&]U<B!A;G1I8VEP871E9"!S:&]R="UT97)M('=O<FMI;F<@8V%P:71A;"!N
M965D<R!A;F0@=&\@9G5N9"!O=7(@;VXM9V]I;F<@<V%P86-I=&%B:6YE(&-L
M:6YI8V%L('1R:6%L<R!F;W(@870@;&5A<W0@=&AE(&YE>'0@='=E;'9E(&UO
M;G1H<RX@2&]W979E<BP@=V4@8V%N;F]T(&)E(&-E<G1A:6X@=&AA="!W92!W
M:6QL(&)E(&%B;&4@=&\@<F%I<V4@<W5F9FEC:65N="!F=6YD<R!T;R!C;VUP
M;&5T92!T:&4@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F4@86YY(&]F
M(&]U<B!P<F]D=6-T(&-A;F1I9&%T97,@8W5R<F5N=&QY(&EN(&-L:6YI8V%L
M(&1E=F5L;W!M96YT+"!S:&]U;&0@=&AE>2!S=6-C965D+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)A<VES(&]F(%!R97-E;G1A=&EO
M;CPO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E="!A<R!O
M9B!-87)C:"8C,38P.S,Q+"`R,#$R+"!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,L(&-O;7!R96AE;G-I=F4@
M;&]S<RP@86YD(&-A<V@@9FQO=W,@9F]R('1H92!T:')E92!M;VYT:',@96YD
M960@36%R8V@F(S$V,#LS,2P@,C`Q,B!A;F0@,C`Q,2!A;F0@=&AE('!E<FEO
M9"!F<F]M($%U9W5S="8C,38P.S$S+"`Q.3DV("AI;F-E<'1I;VXI('1O($UA
M<F-H)B,Q-C`[,S$L(#(P,3(L(&%N9"!A;&P@<F5L871E9"!D:7-C;&]S=7)E
M<R!C;VYT86EN960@:6X@=&AE(&%C8V]M<&%N>6EN9R!N;W1E<R!A<F4@=6YA
M=61I=&5D+B!4:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H
M965T(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@:7,@9&5R:79E9"!F
M<F]M('1H92!A=61I=&5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!I;F-L=61E9"!I;B!T:&4@,C`Q,2!!;FYU86P@4F5P;W)T(&]N($9O
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M(%-T871E<R`H)B,X,C(P.T=!05`F(S@R,C$[*2!F;W(@:6YT97)I;2!F:6YA
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M(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%S(&]F($UA<F-H)B,Q-C`[
M,S$L(#(P,3(L(&%N9"!T:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS+"!C;VUP
M<F5H96YS:79E(&QO<W,@86YD(&-A<V@@9FQO=W,@9F]R('1H92!T:')E92!M
M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,B!A;F0@,C`Q,2P@:&%V
M92!B965N(&UA9&4N(%1H92!I;G1E<FEM(')E<W5L=',@9F]R('1H92!T:')E
M92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,B!A<F4@;F]T(&YE
M8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(')E<W5L=',@=&\@8F4@97AP
M96-T960@9F]R('1H92!Y96%R(&5N9&EN9R!$96-E;6)E<B8C,38P.S,Q+"`R
M,#$R(&]R(&9O<B!A;GD@;W1H97(@>65A<BX@5&AE(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E(')E860@
M:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D:71E9"!C;VYS;VQI9&%T960@
M9FEN86YC:6%L('-T871E;65N=',@86YD('1H92!A8V-O;7!A;GEI;F<@;F]T
M97,@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L
M(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R
M="!O;B!&;W)M)B,Q-C`[,3`M2R!F:6QE9"!W:71H('1H92!314,N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^4F5C96YT($1E=F5L;W!M96YT<SPO9F]N
M=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/'4^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY386QE(&]F($-O;6UO;B!3=&]C:R!A;F0@16-O
M;F]M:6,@4FEG:'1S/"]F;VYT/CPO=3X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D]N($UA<F-H)B,Q-C`[,C(L(#(P,3(L('1H92!#;VUP86YY(&5N
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M<F%L(&-O<G!O<F%T92!P=7)P;W-E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z
M(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;F1E<B!T:&4@
M=&5R;7,@;V8@=&AE('!U<F-H87-E(&%G<F5E;65N="P@=&AE(&EN=F5S=&]R
M<R!P=7)C:&%S960@-"PV.#@L,#<Y('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A('!R:6-E(&]F("0P+C8T-S8L('=H
M:6-H(&ES(&5Q=6%L('1O('1H92`Q,"UD87D@879E<F%G92!C;&]S:6YG('!R
M:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&9O<B!T
M:&4@<&5R:6]D(&5N9&EN9R!O;B!7961N97-D87DL($UA<F-H)B,Q-C`[,C$L
M(#(P,3(N(%1H92!S:&%R97,@:7-S=65D(&%T(&-L;W-I;F<@87)E('-U8FIE
M8W0@=&\@82!L;V-K+75P('!E<FEO9"!O9B!O;F4@>65A<B!F<F]M('1H92!D
M871E(&]F(&ES<W5A;F-E+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4V5E("8C.#(R,#L\:3Y.;W1E
M(#,L($9A:7(@5F%L=64@365A<W5R96UE;G1S)B,X,C(Q.SPO:3X@9F]R(&9U
M<G1H97(@9&5T86EL<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/'4^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY0<F5F97)R960@4W1O8VL@1&EV:61E;F0\+V9O;G0^/"]U/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3VX@36%R8V@F(S$V,#LV+"`R
M,#$R+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I<F5C=&]R<R!D
M96-I9&5D(&YO="!T;R!D96-L87)E(&$@<75A<G1E<FQY(&-A<V@@9&EV:61E
M;F0@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R`V)2!#;VYV97)T:6)L92!%>&-H
M86YG96%B;&4@4')E9F5R<F5D(%-T;V-K("@F(S@R,C`[4')E9F5R<F5D(%-T
M;V-K)B,X,C(Q.RD@=VET:"!R97-P96-T('1O('1H92!F:7)S="!Q=6%R=&5R
M(&]F(#(P,3(@=&AA="!W;W5L9"!H879E(&]T:&5R=VES92!B965N('!A>6%B
M;&4@;VX@36%Y)B,Q-C`[,2P@,C`Q,BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4W5B<V5Q=65N
M="!$979E;&]P;65N=',\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQU/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3D%31$%1($%P
M<&5A;#PO9F]N=#X\+W4^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M<G1H(&EN($QI<W1I;F<@4G5L928C,38P.S4T-3`H82DH,2DF(S$V,#LH=&AE
M("8C.#(R,#M2=6QE)B,X,C(Q.RD@9'5R:6YG('1H92`Q.#`@8V%L96YD87(@
M9&%Y<R!A;&QO=V5D('1O(')E9V%I;B!C;VUP;&EA;F-E(&%N9"!T:&%T('1H
M92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K('=A<R!S=6)J96-T('1O
M(&1E;&ES=&EN9R!F<F]M('1H92!.05-$05$@1VQO8F%L($UA<FME="X\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY/;B!!<')I;"8C,38P.S(V+"`R,#$R+"!T:&4@0V]M<&%N>2!P
M<F5S96YT960@:71S('!L86X@=&\@<F5G86EN(&-O;7!L:6%N8V4@=VET:"!T
M:&4@4G5L92P@=VAI8V@@<&QA;B!I;F-L=61E9"!T:&4@<&]S<VEB:6QI='D@
M;V8@969F96-T=6%T:6YG(&$@<F5V97)S92!S=&]C:R!S<&QI="PF(S$V,#MB
M969O<F4@82!.05-$05$@3&ES=&EN9R!1=6%L:69I8V%T:6]N<R!086YE;"`H
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M97(F(S$V,#LQ,2P@,C`Q,BP@<')O=FED960@=&AA="!T:&4@0V]M<&%N>2!H
M87,@979I9&5N8V5D(&$@8VQO<VEN9R!B:60@<')I8V4@;V8@)#$N,#`@;W(@
M;6]R92!F;W(@82!M:6YI;75M(&]F('1E;B!C;VYS96-U=&EV92!T<F%D:6YG
M(&1A>7,@<')I;W(@=&\@<W5C:"!D871E+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
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M970@9F]R=&@@:6X@3D%31$%1($UA<FME='!L86-E(%)U;&4F(S$V,#LU-3`U
M+"!E>&-E<'0@9F]R('1H92!B:60@<')I8V4@<F5Q=6ER96UE;G0N($EN('1H
M870@8V%S92P@:70@;6%Y(&AA=F4@=6YT:6P@4V5P=&5M8F5R)B,Q-C`[,3$L
M(#(P,3(@=&\@8V]M<&QY('=I=&@@=&AE(&UI;FEM=6T@8FED('!R:6-E(')E
M<75I<F5M96YT+B!4:&4@0V]M<&%N>2!C=7)R96YT;'D@;65E=',@=&AE<V4@
M:6YI=&EA;"!L:7-T:6YG(&-R:71E<FEA+"!E>&-E<'0@9F]R('1H92!B:60@
M<')I8V4@<F5Q=6ER96UE;G0N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V5D-6)E-SE?8V5B
M-U\T865D7SEC-#1?831B-69D9#DR-#AE#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S=E9#5B93<Y7V-E8C=?-&%E9%\Y8S0T7V$T8C5F9&0Y,C0X
M92]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]5
M3E1)3D<@4$],24-)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]5
M3E1)3D<@4$],24-)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'
M(%!/3$E#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B
M;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+B!354U-05)9($]&
M(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+V9O;G0^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U19
M3$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^0V]N<V]L:61A=&EO;CPO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5<V4@;V8@17-T:6UA
M=&5S/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
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M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H(&%N9"!#87-H
M($5Q=6EV86QE;G1S/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M<FME="!R871E(&]F(')E='5R;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&D^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY4<F%D92!!8V-O=6YT<R!296-E:79A8FQE(&%N9"!!;&QO
M=V%N8V4@9F]R($1O=6)T9G5L($%C8V]U;G1S/"]F;VYT/CPO:3X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M960L(&%T(&$@;6EN:6UU;2P@;VX@82!Q=6%R=&5R;'D@8F%S:7,N)B,Q-C`[
M($-H86YG97,@:6X@=&AE(&%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N
M=',@87)E(')E8V]R9&5D(&%S(&%N(&%D:G5S=&UE;G0@=&\@8F%D(&1E8G0@
M97AP96YS92!W:71H:6X@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP
M96YS97,N)B,Q-C`[($UA=&5R:6%L(')E=FES:6]N<R!T;R!R97-E<G9E(&5S
M=&EM871E<R!M87D@<F5S=6QT(&9R;VT@861V97)S92!C:&%N9V5S(&EN(&-O
M;&QE8W1I;VX@97AP97)I96YC92X@5&AE($-O;7!A;GD@=W)I=&5S(&]F9B!A
M8V-O=6YT<R!A9V%I;G-T('1H92!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C
M8V]U;G1S('=H96X@<F5A<V]N86)L92!C;VQL96-T:6]N(&5F9F]R=',@:&%V
M92!B965N('5N<W5C8V5S<V9U;"!A;F0@:70@:7,@;&EK96QY('1H92!R96-E
M:79A8FQE('=I;&P@;F]T(&)E(')E8V]V97)E9"X\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N
M,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4<F%D
M92!A8V-O=6YT<R!R96-E:79A8FQE(&%R92!I;F-L=61E9"!I;B!P<F5P86ED
M(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R!O;B!T:&4@8V]N
M<V]L:61A=&5D(&)A;&%N8V4@<VAE970@86YD('=E<F4@)#`N,2!M:6QL:6]N
M(&%N9"`D,"XR(&UI;&QI;VX@870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2!A
M;F0@36%R8V@F(S$V,#LS,2P@,C`Q,BP@<F5S<&5C=&EV96QY+B!!;&P@=')A
M9&4@86-C;W5N=',@<F5C96EV86)L92!W97)E(&1E96UE9"!C;VQL96-T:6)L
M92!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"!-87)C:"8C,38P
M.S,Q+"`R,#$R+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,C!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$R+"!A<'!R;WAI;6%T96QY
M(#DP)2!A;F0@.#8E+"!R97-P96-T:79E;'DL(&]F(&]U<B!P<F]D=6-T('-A
M;&5S(&EN('1H92!5;FET960@4W1A=&5S('=E<F4@=&\@=&AR964@=VAO;&5S
M86QE<G,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M24Y$14Y4.B`R,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DEN=F5N
M=&]R>3PO9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^0WEC;&%C96P@=F%L=65S(&EN=F5N=&]R:65S(&%T('1H92!L;W=E<B!O
M9B!C;W-T(&]R(&UA<FME="X@5&AE($-O;7!A;GD@9&5T97)M:6YE<R!C;W-T
M('5S:6YG('1H92!F:7)S="UI;BP@9FER<W0M;W5T(&UE=&AO9"X@07,@;V8@
M36%R8V@F(S$V,#LS,2P@,C`Q,B!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q
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M-SMS(&UA;F%G96UE;G0N)B,Q-C`[($$@8W)I=&EC86P@:6YP=70@:6X@=&AI
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M;B!F=71U<F4@<&5R:6]D<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&5R92!W97)E(&YO(&EN
M=F5N=&]R>2!W<FET92UD;W=N<R!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$Q(&%N9"`R,#$R+B!);B!T:&4@9G5T
M=7)E+"!R961U8V5D(&1E;6%N9"P@<75A;&ET>2!I<W-U97,@;W(@97AC97-S
M('-U<'!L>2!M87D@<F5S=6QT(&EN('=R:71E+61O=VYS+"!W:&EC:"!W;W5L
M9"!B92!R96-O<F1E9"!A<R!A9&IU<W1M96YT<R!T;R!C;W-T(&]F('-A;&5S
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D9A:7(@5F%L
M=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]F;VYT/CPO:3X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&:6YA;F-I86P@:6YS=')U;65N
M=',@8V]N<VES="!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!A8V-O
M=6YT<R!R96-E:79A8FQE+"!A8V-O=6YT<R!P87EA8FQE+"!A;F0@86-C<G5E
M9"!L:6%B:6QI=&EE<RP@16-O;F]M:6,@4FEG:'1S+"!A;F0@;W1H97(@;&EA
M8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92X@5&AE(&-A<G)Y:6YG
M(&%M;W5N=',@;V8@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<RP@86-C;W5N
M=',@<F5C96EV86)L92P@86-C;W5N=',@<&%Y86)L92P@86YD(&%C8W)U960@
M;&EA8FEL:71I97,@87!P<F]X:6UA=&4@=&AE:7(@<F5S<&5C=&EV92!F86ER
M('9A;'5E<R!D=64@=&\@=&AE(&YA='5R92!O9B!T:&4@86-C;W5N=',L(&YO
M=&%B;'D@=&AE:7(@<VAO<G0@;6%T=7)I=&EE<RX@16-O;F]M:6,@4FEG:'1S
M(&%N9"!O=&AE<B!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E
M(&5M<&QO>2!A<'!L:6-A8FQE(&EN<'5T<R!A<R!D97-C<FEB960@:6X@)B,X
M,C(P.SQI/DYO=&4@,RP@1F%I<B!686QU92!-96%S=7)E;65N=',F(S@R,C$[
M/"]I/BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\:3X\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/E)E=F5N=64@4F5C;V=N:71I;VX\+V9O;G0^/"]I/CPO8CX\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\:3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4')O9'5C="!S86QE<SPO
M9F]N=#X\+VD^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%
M3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
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M87-S=7)E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!O9F9E<G,@82!G96YE
M<F%L(')I9VAT(&]F(')E='5R;B!O;B!P<F]D=6-T('-A;&5S+"!A;F0@:&%S
M(&-O;G-I9&5R960@=&AE(&=U:61A;F-E(&EN($%30R!3=6)T;W!I8R`V,#4M
M,34L("8C.#(R,#L\:3Y2979E;G5E(%)E8V]G;FET:6]N("U0<F]D=6-T<SPO
M:3XF(S@R,C$[("@F(S@R,C`[05-#(#8P-2TQ-28C.#(R,3LI(&%N9"!!4T,@
M4W5B=&]P:6,@-C`U("8C.#(Q,CL@,3`@)B,X,C(P.SQI/E)E=F5N=64@4F5C
M;V=N:71I;VX@+2!/=F5R86QL/"]I/B8C.#(R,3L@*"8C.#(R,#M!4T,@-C`U
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M=7)R96YT('=H;VQE<V%L92!A8W%U:7-I=&EO;B!P<FEC92`H:6X@86-C;W)D
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M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/D1E9F5R<F5D(')E=F5N=64@=V%S("0P+C$@;6EL;&EO
M;B!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"!-87)C:"`S,2P@,C`Q
M,BX@1&5F97)R960@8V]S="!O9B!G;V]D<R!S;VQD('=A<R!A<'!R;WAI;6%T
M96QY("0R,"PP,#`@86YD("0R,BPP,#`@870@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,2!A;F0@36%R8V@@,S$L(#(P,3(L(')E<W!E8W1I=F5L>2X\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5-4
M64Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D-O;&QA8F]R871I;VXL(')E<V5A<F-H(&%N9"!D979E;&]P;65N
M="P@86YD(&=R86YT(')E=F5N=64\+V9O;G0^/"]I/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE
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M9F9E8W1E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
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M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M9B!A<'!R;WAI;6%T96QY("0W-2PP,#`@870@36%R8V@F(S$V,#LS,2P@,C`Q
M,BXF(S$V,#L@5&AE($-O;7!A;GD@:&%D(&YO('-U8V@@9&5F97)R960@<F5V
M96YU92!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\
M:3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D-L:6YI8V%L(%1R:6%L($%C8V]U;G1I
M;F<\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
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M:6]N<R`H)B,X,C(P.T-23W,F(S@R,C$[*2!O<B!C;&EN:6-A;"!R97-E87)C
M:"!A<W-O8VEA=&5S("@F(S@R,C`[0U)!<R8C.#(R,3LI(&EN(&%C8V]R9&%N
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M;V0N($-O<W1S(&]F('-E='1I;F<@=7`@8VQI;FEC86P@=')I86P@<VET97,@
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M;G-E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\:3X\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;F1I='5R
M97,\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
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M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z
M(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^1F]R96EG;B!C=7)R96YC>2!A;F0@8W5R<F5N8WD@=')A;G-L871I;VX\
M+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
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M;G0@;V8@;W!E<F%T:6]N<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M86-T:6]N<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
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M('-I>F4],T0R/F]F(&$@;&]N9RUT97)M+6EN=F5S=&UE;G0@;F%T=7)E+"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$
M,CYA<F4@<F5C;W)D960@:6X@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64N
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1F%I<B!686QU
M92!-96%S=7)E;65N=',\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS
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M9G)O;2!,979E;"`Q+"!W:&EC:"!I<R!T:&4@;6]S="!R96QI86)L92P@=&\@
M3&5V96P@,RP@=VAI8V@@:7,@=&AE(&QE87-T(')E;&EA8FQE("AS964@/&D^
M3F]T92`S+"!&86ER(%9A;'5E($UE87-U<F5M96YT<SPO:3XI+B!-86YA9V5M
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M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26YC;VUE(%1A>&5S/"]F
M;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
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M;V8@=&AO<V4@87-S971S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&%P<&QI
M97,@=&AE(&=U:61A;F-E(&-O9&EF:65D(&EN($%30R!4;W!I8R`W-#`L(#QI
M/B8C.#(R,#M);F-O;64@=&%X97,F(S@R,C$[(#PO:3XH)B,X,C(P.T%30R`W
M-#`F(S@R,C$[*2!R96QA=&5D('1O(&%C8V]U;G1I;F<@9F]R('5N8V5R=&%I
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M=',N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M92!A8V-O=6YT:6YG('!E<FEO9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&D^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY3=&]C:RUB87-E9"!#;VUP96YS871I;VX\+V9O;G0^/"]I
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
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M17%U:71Y($EN8V5N=&EV92!0;&%N("@F(S@R,C`[,C`P-B!0;&%N)B,X,C(Q
M.RDL('=H:6-H('=A<R!A<'!R;W9E9"!O;B!-87)C:"8C,38P.S$V+"`R,#`V
M+"!A<R!A;65N9&5D(&]N($UA>28C,38P.S(Q+"`R,#`W+"!A;F0@<W5B<V5Q
M=65N=&QY(&%M96YD960@86YD(')E<W1A=&5D(&]N($%P<FEL)B,Q-C`[,30L
M(#(P,#@N)B,Q-C`[(%1H92!#;VUP86YY(&AA<R!G<F%N=&5D('9A<FEO=7,@
M='EP97,@;V8@87=A<F1S('5N9&5R('1H92`R,#`V(%!L86XL('=H:6-H(&ES
M(&1E<V-R:6)E9"!M;W)E(&9U;&QY(&EN(#QI/DYO=&4@-BP@4W1O8VLM0F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT<SPO:3XN(%1H92!#;VUP86YY
M(&%C8V]U;G1S(&9O<B!T:&5S92!A=V%R9',@=6YD97(@05-#(#<Q."P@)B,X
M,C(P.SQI/D-O;7!E;G-A=&EO;B`F(S@R,3([(%-T;V-K($-O;7!E;G-A=&EO
M;CPO:3XF(S@R,C$[("@F(S@R,C`[05-#(#<Q."8C.#(R,3LI+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.
M1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D%30R`W,3@@<F5Q=6ER97,@;65A<W5R96UE;G0@;V8@8V]M<&5N<V%T
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M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY396=M96YT<SPO9F]N=#X\
M+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A
M;GD@:&%S(&1E=&5R;6EN960@:71S(')E<&]R=&%B;&4@<V5G;65N=',@:6X@
M86-C;W)D86YC92!W:71H($%30R`R.#`L("8C.#(R,#L\:3Y396=M96YT(%)E
M<&]R=&EN9SPO:3XF(S@R,C$[("@F(S@R,C`[05-#(#(X,"8C.#(R,3LI(&%N
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
M96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@3&]S<R!P97(@0V]M;6]N(%-H87)E
M/"]F;VYT/CPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4
M:&4@0V]M<&%N>2!C86QC=6QA=&5S(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA
M<F4@:6X@86-C;W)D86YC92!W:71H($%30R`R-C`L("8C.#(R,#L\:3Y%87)N
M:6YG<R!097(@4VAA<F4\+VD^)B,X,C(Q.R`H)B,X,C(P.T%30R`R-C`F(S@R
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'
M24XM3$5&5#H@-G!T.R!724142#H@.3@N.#@E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3@E(&)O<F1E<CTS1#`^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#<S+C<E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
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M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XQ,B4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^36%R8V@F(S$V,#LS,2P\8G(@+SX-"C(P,3$\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3`N,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DUA<F-H)B,Q-C`[,S$L
M/&)R("\^#0HR,#$R/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP,B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-
M"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@-S,N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<S)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)
M3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E-T;V-K
M(&]P=&EO;G,@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4R)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%=)1%1(.B`Q,"XQ,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,L,S0W+#`S,SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXU,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N,3(E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@-S,N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#$P+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU,BPP-S`\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#(N-3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$P+C$R)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXS-#0L-S@T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`R)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#<S
M+C<E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VYV97)T:6)L92!P<F5F97)R960@<W1O
M8VL@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4R)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q,"XQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^-3$V+#(R.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU,B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N,3(E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@-S,N-R4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-O;G1I;F=E;G1L>2!I<W-U86)L
M92!C;VUM;VX@<W1O8VL@86YD(&-O;6UO;B!S=&]C:R!W87)R86YT<R!A<W-O
M8VEA=&5D('=I=&@@96-O;F]M:6,@<FEG:'1S(#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU,B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N,3(E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
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M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#$P+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXR+#DS,RPP-3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,#(E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@-S,N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]P=&EO;G,@=&\@<'5R
M8VAA<V4@8V]M;6]N('-T;V-K(&%N9"!C;VUM;VX@<W1O8VL@=V%R<F%N=',@
M:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@3V-T;V)E<B8C,38P.S(P
M,3`@9FEN86YC:6YG(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU
M,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N,3(E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/C8L,C0R+#,Y.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXU,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-S,N-R4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%
M3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-O;6UO;B!S
M=&]C:R!W87)R86YT<R`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-3(E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$P+C$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,3`L,#`U+#$Y,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU,B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3`N,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXQ,RPX,30L,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`R)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#<S+C<E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!S:&%R97,@97AC;'5D
M960@9G)O;2!C86QC=6QA=&EO;B`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C$R)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#$P+C$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(Q
M+#`T-BPW-3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,#(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B
M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUP<F5H96YS:79E($EN8V]M
M92`H3&]S<RD\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/DEN(&%C8V]R9&%N8V4@=VET:"!!4T,@,C(P+"`F(S@R,C`[/&D^
M0V]M<')E:&5N<VEV92!);F-O;64\+VD^)B,X,C(Q.R`H)B,X,C(P.T%30R`R
M,C`F(S@R,C$[*2!A;&P@8V]M<&]N96YT<R!O9B!C;VUP<F5H96YS:79E(&EN
M8V]M92`H;&]S<RDL(&EN8VQU9&EN9R!N970@:6YC;VUE("AL;W-S*2P@87)E
M(')E<&]R=&5D(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!I;B!T:&4@
M<&5R:6]D(&EN('=H:6-H('1H97D@87)E(')E8V]G;FEZ960N($%30R`R,C`@
M9&5F:6YE<R!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@87,@=&AE(&-H
M86YG92!I;B!E<75I='D@9'5R:6YG(&$@<&5R:6]D(&9R;VT@=')A;G-A8W1I
M;VYS(&%N9"!O=&AE<B!E=F5N=',@86YD(&-I<F-U;7-T86YC97,@9G)O;2!N
M;VXM;W=N97(@<V]U<F-E<RX@3F5T(&EN8V]M92`H;&]S<RD@86YD(&]T:&5R
M(&-O;7!R96AE;G-I=F4@:6YC;VUE("AL;W-S*2P@:6YC;'5D:6YG(&9O<F5I
M9VX@8W5R<F5N8WD@=')A;G-L871I;VX@861J=7-T;65N=',L(&%R92!R97!O
M<G1E9"P@;F5T(&]F(&%N>2!R96QA=&5D('1A>"!E9F9E8W0L('1O(&%R<FEV
M92!A="!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDN($YO('1A>&5S('=E
M<F4@<F5C;V=N:7IE9"!I;B!R96QA=&EO;B!T;R!I=&5M<R!O9B!O=&AE<B!C
M;VUP<F5H96YS:79E(&EN8V]M92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&D^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO
M9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@
M2G5N928C,38P.S(P,3$L('1H92!&05-"(&ES<W5E9"!!8V-O=6YT:6YG(%-T
M86YD87)D<R!!4U4@,C`Q,2TP-2!T;R!A;65N9"!T:&4@9W5I9&%N8V4@;VX@
M=&AE('!R97-E;G1A=&EO;B!O9B!C;VUP<F5H96YS:79E(&EN8V]M92!I;B!!
M4T,@,C(P+B!!4U4@,C`Q,2TP-2!R97%U:7)E<R!C;VUP86YI97,@=&\@<')E
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M8V]M92!W:71H:6X@=&AE('-T871E;65N="!O9B!E<75I='DN($%352`R,#$Q
M+3`U(&1O97,@;F]T(&-H86YG92!T:&4@:71E;7,@=&AA="!M=7-T(&)E(')E
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M97(F(S$V,#LQ-2P@,C`Q,2XF(S$V,#L@26X@1&5C96UB97(F(S$V,#LR,#$Q
M+"!T:&4@1D%30B!I<W-U960@05-5(#(P,3$M,3(L('=H:6-H(&1E9F5R<F5D
M('1H92!C:&%N9V5S(&EN($%352`R,#$Q+3`U('1H870@<F5L871E('1O('1H
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U
M:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$
M14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^26X@36%Y
M)B,Q-C`[,C`Q,2P@=&AE($9!4T(@:7-S=65D($%352`R,#$Q+3`T+"!W:&EC
M:"!A;65N9',@=&AE(&=U:61A;F-E(&]N(&9A:7(@=F%L=64@;65A<W5R96UE
M;G0@:6X@05-#(#@R,"!T;R!C;VYV97)G92!T:&4@9F%I<B!V86QU92!M96%S
M=7)E;65N="!A;F0@9&ES8VQO<W5R92!R97%U:7)E;65N=',@=6YD97(@1T%!
M4"!A;F0@26YT97)N871I;VYA;"!&:6YA;F-I86P@4F5P;W)T:6YG(%-T86YD
M87)D<R`H)B,X,C(P.TE&4E,F(S@R,C$[*2!F86ER('9A;'5E(&UE87-U<F5M
M96YT(&%N9"!D:7-C;&]S=7)E(')E<75I<F5M96YT<RX@5&AE(&%M96YD;65N
M=',@8VAA;F=E('1H92!W;W)D:6YG('5S960@=&\@9&5S8W)I8F4@=&AE(')E
M<75I<F5M96YT<R!F;W(@;65A<W5R:6YG(&9A:7(@=F%L=64L(&-H86YG97,@
M8V5R=&%I;B!F86ER('9A;'5E(&UE87-U<F5M96YT('!R:6YC:7!L97,@86YD
M(&5N:&%N8V5S(&1I<V-L;W-U<F4@<F5Q=6ER96UE;G1S+B!4:&ES(&=U:61A
M;F-E(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG
M(&%F=&5R($1E8V5M8F5R)B,Q-C`[,34L(#(P,3$L(&%P<&QI960@<')O<W!E
M8W1I=F5L>2X@5&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N8V4@9&ED(&YO
M="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S=E9#5B93<Y7V-E8C=?-&%E9%\Y8S0T7V$T8C5F9&0Y,C0X90T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W960U8F4W.5]C96(W7S1A
M961?.6,T-%]A-&(U9F1D.3(T.&4O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1D%)4B!604Q5
M12!-14%355)%345.5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y44SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&04E2(%9!
M3%5%($U%05-54D5-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6X[(%1%
M6%0M24Y$14Y4.B`M,"XR-6EN)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+CPO9F]N=#X\+V(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@."XU<'0G
M('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]B
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)
M6D4Z(#$P<'0G('-I>F4],T0R/D9!25(@5D%,544@345!4U5214U%3E13/"]F
M;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%S(&1E9FEN
M960@:6X@05-#(#@R,"P@/&D^1F%I<B!686QU92!-96%S=7)E;65N=',@86YD
M($1I<V-L;W-U<F5S/"]I/B`H)B,X,C(P.T%30R`X,C`F(S@R,C$[*2P@9F%I
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M+"!W:&EC:"!A<F4@9&5S8W)I8F5D(&)E;&]W.CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R!4
M15A4+4E.1$5.5#H@+3`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<@<VEZ93TS1#(^)B,Q.#,[/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@."XU<'0G('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T)R!S:7IE/3-$,CY,979E;"`Q.B!1=6]T960@<')I8V5S("AU;F%D
M:G5S=&5D*2!I;B!A8W1I=F4@;6%R:V5T<R!T:&%T(&%R92!A8V-E<W-I8FQE
M(&%T('1H92!M96%S=7)E;65N="!D871E(&9O<B!A<W-E=',@;W(@;&EA8FEL
M:71I97,N(%1H92!F86ER('9A;'5E(&AI97)A<F-H>2!G:79E<R!T:&4@:&EG
M:&5S="!P<FEO<FET>2!T;R!,979E;"`Q(&EN<'5T<RX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CL@5$585"U)
M3D1%3E0Z("TP+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X+C5P="<@<VEZ93TS1#$^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/DQE=F5L(#(Z($EN<'5T<R!O
M=&AE<B!T:&%N('%U;W1E9"!P<FEC97,@=VET:&EN($QE=F5L(#$@=&AA="!A
M<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2P@96ET
M:&5R(&1I<F5C=&QY(&]R(&EN9&ER96-T;'DN/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4
M.B`M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N
M-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<@<VEZ93TS1#(^)B,Q.#,[/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@."XU<'0G('-I>F4],T0Q/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY,979E;"`S.B!5;F]B<V5R=F%B;&4@
M:6YP=71S('1H870@87)E('5S960@=VAE;B!L:71T;&4@;W(@;F\@;6%R:V5T
M(&1A=&$@:7,@879A:6QA8FQE+B!4:&4@9F%I<B!V86QU92!H:65R87)C:'D@
M9VEV97,@=&AE(&QO=V5S="!P<FEO<FET>2!T;R!,979E;"`S(&EN<'5T<RX\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P
M+C5I;CL@5$585"U)3D1%3E0Z("TP+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T
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M86QU92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S('1H
M870@87)E(&UE87-U<F5D(&]N(&$@<F5C=7)R:6YG(&)A<VES('=E<F4@9&5T
M97)M:6YE9"!U<VEN9R!T:&4@9F]L;&]W:6YG(&EN<'5T<R!A<R!O9B!$96-E
M;6)E<B8C,38P.S,Q+"`R,#$Q.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,C!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`P+C)I;CL@5TE$5$@Z(#DT+C8V)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#DT)2!B;W)D97(],T0P/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y,979E;"8C,38P.S$\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7
M24142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DQE=F5L)B,Q-C`[
M,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-C0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
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M(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^3&5V96PF(S$V
M,#LS/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^
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M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#8E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N
M-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT
M97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N
M=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B0P,#`\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N
M-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT
M97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T
M9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)2!B9V-O;&]R/3-$(T-#
M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@
M5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/D-A<V@@97%U:79A;&5N=',@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[
M($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$Y
M+#@Y-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7
M24142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[
M(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z
M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,3DL.#DT/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#0V+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P
M+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
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M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C0E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-#8N,3(E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0T-B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY787)R86YT<R!L:6%B:6QI='D@/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
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M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXU,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C4Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#0V+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^4V-O='1I<V@@16YT97)P<FES92!!9W)E96UE;G0@/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C.#(Q,CL\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-C0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP-B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#0V)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z
M("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R(&QI86)I
M;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#(N-C0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7
M24142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW,3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXW,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP
M-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1O=&%L(#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3DL.#DT/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW,3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3DL.38U/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T
M86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U
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M=',@87,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q,CH\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU,1494.B`P+C)I;CL@5TE$5$@Z(#DT+C8V)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#DT)2!B;W)D97(],T0P/@T*/'1R/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V
M)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y,979E;"8C,38P.S$\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N
M-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DQE=F5L)B,Q-C`[,CPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-C0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q
M,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^3&5V96PF(S$V,#LS/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
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M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
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M3U143TTZ(#!I;CL@5TE$5$@Z(#0V+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B0P,#`\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B0P,#`\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X\+W1R/@T*
M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#0V)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%
M3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-A<V@@97%U
M:79A;&5N=',@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$W+#0Y.#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N
M-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<L-#DX
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#0V+C$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^16-O;F]M:6,@<FEG:'1S(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M-#8N,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0T-B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<B!L:6%B:6QI=&EE<R!M96%S=7)E
M9"!A="!F86ER('9A;'5E.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E
M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP-B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/E=A<G)A;G1S(&QI86)I;&ET>2`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-C0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$P+C4V)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N-38E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
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M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$P+C4V
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXY/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0V+C$R
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^4V-O='1I<V@@16YT97)P<FES92!!9W)E96UE;G0@
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(
M.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$
M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR
M,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T-BXQ,B4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0V)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z
M("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R(&QI86)I
M;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#$P+C4V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXR.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXR.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`T-BXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#0V)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E1O=&%L(#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3`N-38E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,3<L-#DX/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[
M($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%=)1%1(.B`Q,"XU-B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#$X,CPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,3`N-38E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3@L-C@P/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#EP="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG('1A8FQE(')E8V]N8VEL97,@
M=&AE(&)E9VEN;FEN9R!A;F0@96YD:6YG(&)A;&%N8V5S(&]F($QE=F5L(#,@
M:6YP=71S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)B,Q-C`[
M,S$L(#(P,3(Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS
M1"=724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R
M9&5R/3-$,#X-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@.#0N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DQE
M=F5L)B,Q-C`[,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
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M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3XD,#`P/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO
M=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@.#0N-24[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@T)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D)A;&%N8V4@87,@;V8@1&5C96UB97(F(S$V,#LS,2P@,C`Q,2`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<Q/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\
M='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#@T+C4E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%
M6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3
M86QE(&]F($5C;VYO;6EC(%)I9VAT<R`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$L,#DW/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^
M#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#@T+C4E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X-"4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#:&%N
M9V4@:6X@=F%L=6%T:6]N(&]F($5C;VYO;6EC(%)I9VAT<R`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C4V/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#@T+C4E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#:&%N9V4@
M:6X@=F%L=6%T:6]N(&]F('=A<G)A;G1S(&QI86)I;&ET>2`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#(\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#`N,S<U<'0[(%=)1%1(.B`Q)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@.#0N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@T)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D)A;&%N8V4@87,@;V8@
M36%R8V@F(S$V,#LS,2P@,C`Q,B`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I
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M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY%8V]N;VUI8R!2:6=H=',\+V9O;G0^/"]I
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($UA<F-H)B,Q
M-C`[,C(L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&9I;F%N
M8VEN9R!A9W)E96UE;G0@=VET:"!C97)T86EN(&5X:7-T:6YG(&EN<W1I='5T
M:6]N86P@<W1O8VMH;VQD97)S+B8C,38P.R!5;F1E<B!T:&4@=&5R;7,@;V8@
M=&AE(&%G<F5E;65N="P@:6YV97-T;W)S(')E8V5I=F5D(&-O;G1R86-T=6%L
M(')I9VAT<R!T;R!R96-E:79E(&-A<V@@97%U86P@=&\@,3`E(&]F(&%N>2!F
M=71U<F4@;&ET:6=A=&EO;B!S971T;&5M96YT(')E;&%T960@=&\@=&AE('-P
M96-I9FEE9"!I;G1E;&QE8W1U86P@<')O<&5R='DL('-U8FIE8W0@=&\@82!C
M87`N)B,Q-C`[($EN(&-E<G1A:6X@9&5F:6YE9"!S:71U871I;VYS+"!T:&4@
M0V]M<&%N>2!M87D@:&%V92!T;R!I<W-U92!E:71H97(@861D:71I;VYA;"!C
M;VUM;VX@<VAA<F5S(&]R('=A<G)A;G1S+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!%8V]N
M;VUI8V%L(%)I9VAT<R!A<F4@86-C;W5N=&5D(&9O<B!A<R!A(&1E<FEV871I
M=F4@9FEN86YC:6%L(&EN<W1R=6UE;G0@=6YD97(@05-#(#@Q-2P@/&D^1&5R
M:79A=&EV92!F:6YA;F-I86P@:6YS=')U;65N=',@/"]I/B@F(S@R,C`[05-#
M(#@Q-28C.#(R,3LI+"!A;F0@87)E(&UE87-U<F5D(&%T(&9A:7(@=F%L=64N
M($-H86YG97,@:6X@9F%I<B!V86QU92!A<F4@<F5C;V=N:7IE9"!I;B!E87)N
M:6YG<RX@)B,Q-C`[5&AE(&9A:7(@=F%L=64@;V8@=&AE($5C;VYO;6EC86P@
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M9F%I<B!V86QU92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!H87,@8V]N8VQU
M9&5D('1H92!F86ER('9A;'5E(&]F('1H:7,@;&EA8FEL:71Y('=A<R!A<'!R
M;WAI;6%T96QY("0Q+C$@;6EL;&EO;B!A;F0@)#$N,B!M:6QL:6]N(&%T($UA
M<F-H)B,Q-C`[,C(L(#(P,3(L(&%N9"!-87)C:"8C,38P.S,Q+"`R,#$R+"!R
M97-P96-T:79E;'DN)B,Q-C`[(%1H92!F86ER('9A;'5E(&]F('1H92!D97)I
M=F%T:79E(&EN8W)E87-E9"!A<'!R;WAI;6%T96QY("0U-BPP,#`@9G)O;2!-
M87)C:"8C,38P.S(R+"`R,#$R('1O($UA<F-H)B,Q-C`[,S$L(#(P,3(N(%1H
M92!I;F-R96%S92!I;B!F86ER('9A;'5E('=A<R!R96-O9VYI>F5D(&%S(&$@
M;&]S<R!I;B!T:&4@8V]N<V]L:61A=&5D('-T871E;65N="!O9B!O<&5R871I
M;VYS(&9O<B!T:&4@=&AR964@;6]N=&@@<&5R:6]D(&5N9&5D($UA<F-H)B,Q
M-C`[,S$L(#(P,3(N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&UO<W0@<VEG;FEF:6-A;G0@
M:6YP=71S(&EN(&5S=&EM871I;F<@=&AE(&9A:7(@=F%L=64@;V8@=&AI<R!L
M:6%B:6QI='D@87)E.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP
M+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH:2D\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X+C5P="<@<VEZ93TS1#$^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G('-I>F4],T0R/E1H92!#;VUP86YY)B,X,C$W.W,@8W)E9&ET
M(&%D:G5S=&5D(')I<VLM9G)E92!R871E+"!W:&EC:"!H87,@8F5E;B!D97)I
M=F5D(&9R;VT@=&AE(&]B<V5R=F%B;&4@<F5T=7)N<R!O;B!D96)T(&9O<B!M
M;W)E(&1E=F5L;W!E9"!P:&%R;6%C975T:6-A;',@8V]M<&%N:65S+"!A9&IU
M<W1E9"!F;W(@=&AE($-O;7!A;GDF(S@R,3<[<R!R:7-K('!R;V9I;&4N/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW
M-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#`N-S5I;CL@5$585"U)3D1%3E0Z("TP+C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH:6DI/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@."XU<'0G('-I>F4],T0Q/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)R!S:7IE
M/3-$,CY4:&4@86UO=6YT(&]F('1H92!R971U<FX@=&\@=&AE(&EN=F5S=&]R
M<RP@=VAI8V@@=VEL;"!V87)Y(&1E<&5N9&EN9R!O;CH\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C<U:6X[(%1%6%0M
M24Y$14Y4.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M=#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="`Q:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#%I;CL@5$585"U)3D1%3E0Z("TP+C(U:6XG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^8BX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X+C5P="<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q:6X[(%1%6%0M
M24Y$14Y4.B`M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T(#%I;CL@5$585"U)3D1%3E0Z("TP+C(U:6XG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^8RX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X+C5P="<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R
M/E1H92!F;W)M(&]F('1H92!S971T;&5M96YT(&]R(&%W87)D+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BAI:6DI/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@."XU<'0G('-I>F4],T0Q/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R!415A4+4E.1$5.5#H@+3`N
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CL@
M5$585"U)3D1%3E0Z("TP+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXH:78I/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@."XU<'0G
M('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY4:&4@;G5M8F5R(&]F(&-O;G1I;F=E
M;G0@=V%R<F%N=',@=&AA="!C;W5L9"!B92!I<W-U960L('=H:6-H(&ES(&)A
M<V5D(&]N(&$@9F]R;75L82X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="`P+C<U:6X[(%1%6%0M24Y$14Y4.B`M,"XU:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
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M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
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M=F%T:79E(&QI86)I;&ET>2!W:6QL(&EN8W)E87-E+"`H:2DF(S$V,#MT:&4@
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M;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M9B!T:&4@97AP96-T960@8V%S:"!F;&]W<RX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%
M3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M
M<&%N>2!U<V5D('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@=&\@8V%L8W5L
M871E('1H92!V86QU92!O9B!T:&4@16-O;F]M:6,@4FEG:'1S.CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#`N,C5I;CL@5TE$5$@Z(#DS+C,T)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#DS)2!B;W)D97(],T0P/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T-BXT,B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0V)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#(S+C4X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/DUA<F-H)B,Q-C`[,C(L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(S+C4X
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DUA<F-H)B,Q-C`[,S$L
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-#8N-#(E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`R
M,RXU."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
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M,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`R,RXU."4[
M(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT
M97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,#@E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO
M<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0V+C0R)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^4')O8F%B:6QI='D@;V8@=6YS=6-C97-S9G5L+W-U8V-E<W-F=6P@
M;W5T8V]M97,@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%=)1%1(.B`R,RXU."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C4E("T@-S4E/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`R,RXU."4[
M(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,C4E("T@-S4E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0V+C0R)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^06UO=6YT(&]F(&%W87)D(&]R('-E
M='1L96UE;G0@*#$I(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,C,N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#$P+C`@;6EL;&EO;B`M("0R
M,"XP(&UI;&QI;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(S+C4X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,C,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0Q,"XP(&UI;&QI;VX@+2`D,C`N
M,"!M:6QL:6]N/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0V+C0R
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#8E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^1&ES8V]U;G0@<F%T92`\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(S
M+C4X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$V)3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,C,N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,38E/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^
M#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0V
M+C0R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-#8E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M5&EM:6YG(&]F(&-A<V@@9FQO=W,@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R,RXU."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX]
M,T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C<U("8C.#(Q
M,3L@,BXR-R!Y96%R<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,C,N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XW-2`F(S@R,3$[(#(N,C<@
M>65A<G,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#$N,#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-#8N-#(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0T-B4@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY2;WEA;'1Y(')A=&4@/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,RXU."4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(S
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV)3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,C,N
M-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-#8N-#(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0T-B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,:71I9V%T
M:6]N(&5X<&5N<V5S(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,C,N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#$N,"!M:6QL:6]N("8C.#(Q
M,3L@)#,N,"!M:6QL:6]N/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`R,RXU."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD,2XP(&UI;&QI;VX@)B,X
M,C$Q.R`D,RXP(&UI;&QI;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,#@E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX\9F]N="!S
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M96YT+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T(#,Q+C5P=#L@5$585"U)3D1%3E0Z("TQ,RXU<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z
M(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^3W1H97(@3&EA8FEL:71I97,@365A<W5R960@870@1F%I<B!686QU93PO
M9F]N=#X\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQU/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5V%R<F%N=',@3&EA8FEL:71Y/"]F
M;VYT/CPO=3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1H92!#;VUP
M86YY(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K('5N9&5R('1H92!R96=I<W1E<F5D(&1I<F5C="!F:6YA;F-I
M;F<@8V]M<&QE=&5D(&EN($9E8G)U87)Y)B,Q-C`[,C`P-RXF(S$V,#L@5&AE
M<V4@=V%R<F%N=',@87)E(&)E:6YG(&%C8V]U;G1E9"!F;W(@87,@82!L:6%B
M:6QI='D@:6X@86-C;W)D86YC92!W:71H($%30R`X,34N)B,Q-C`[($%T('1H
M92!D871E(&]F('1H92!T<F%N<V%C=&EO;BP@=&AE(&9A:7(@=F%L=64@;V8@
M=&AE('=A<G)A;G1S(&]F("0V+C@F(S$V,#MM:6QL:6]N('=A<R!D971E<FUI
M;F5D('5T:6QI>FEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN
M9R!M;V1E;"!U=&EL:7II;F<@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<SH@
M<FES:R!F<F5E(&EN=&5R97-T(')A=&4@)B,X,C$R.R`T+C8X)2P@97AP96-T
M960@=F]L871I;&ET>2`F(S@R,3([(#@U)2P@97AP96-T960@9&EV:61E;F0@
M>6EE;&0@)B,X,C$R.R`P)2P@86YD(&$@<F5M86EN:6YG(&-O;G1R86-T=6%L
M(&QI9F4@;V8@-R8C,38P.WEE87)S+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@
M=V%R<F%N="!I<R!B96EN9R!R96UE87-U<F5D(&5A8V@@<F5P;W)T:6YG('!E
M<FEO9"P@=VET:"!A(&=A:6X@;W(@;&]S<R!R96-O9VYI>F5D(&EN('1H92!C
M;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N(%-U8V@@9V%I
M;G,@;W(@;&]S<V5S('=I;&P@8V]N=&EN=64@=&\@8F4@<F5P;W)T960@=6YT
M:6P@=&AE('=A<G)A;G1S(&%R92!E>&5R8VES960@;W(@97AP:7)E9"X@5&AE
M($-O;7!A;GD@=7-E9"!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN
M9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@=&\@=F%L
M=64@=&AE('=A<G)A;G1S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#`N,C5I;CL@5TE$5$@Z(#DS+C,T)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#DS)2!B;W)D97(],T0P/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`V-RXX."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8W)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX]
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M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
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M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXX-B4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^36%R8V@F(S$V,#LS,2P\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO8CX\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`V-RXX."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8W)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3XR,#$Q/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU43U`Z
M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3XR,#$R/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-
M"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@-C<N.#@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V-R4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>&5R
M8VES92!P<FEC92`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD."XT-#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N.#8E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B0X+C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#8W+C@X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-C<E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^17AP96-T960@=&5R;2`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C(N,3,@67)S+CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XX."!9<G,N/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO
M='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#8W+C@X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C<E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M4FES:R!F<F5E(&EN=&5R97-T(')A=&4@/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,BXX-B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C(U)3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,3(N.#8E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$
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M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-
M"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-C<N
M.#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V-R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY%>'!E8W1E9"!V;VQA=&EL:71Y(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3(Q)3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(N.#8E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^-S<E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#8W
M+C@X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C<E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^17AP96-T960@9&EV:61E;F0@>6EE;&0@
M;W9E<B!E>'!E8W1E9"!T97)M(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(N.#8E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(N
M.#8E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,2XP-B4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/E1H92!#;VUP86YY(')E8V]G;FEZ960@=&AE(&-H86YG92!I;B!T
M:&4@=F%L=64@;V8@=V%R<F%N=',@87,@82!G86EN(&]N('1H92!C;VYS;VQI
M9&%T960@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,@;V8@)#`N,2!M:6QL:6]N
M(&%N9"!A<'!R;WAI;6%T96QY("0T,BPP,#`@9F]R('1H92!T:')E92!M;VYT
M:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,2!A;F0@,C`Q,BP@<F5S<&5C
M=&EV96QY+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\=3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E-C;W1T:7-H($5N=&5R<')I<V4@06=R965M96YT/"]F;VYT/CPO=3X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($IU;F4F(S$V,#LR,BP@,C`P
M.2P@=&AE($-O;7!A;GD@86UE;F1E9"!T:&4@06=R965M96YT('=I=&@@4V-O
M='1I<V@@16YT97)P<FES92`H)B,X,C(P.U-%)B,X,C(Q.RD@*'1H92`F(S@R
M,C`[06UE;F1M96YT)B,X,C(Q.RDL(&EN(&]R9&5R('1O(&%L;&]W('1H92!#
M;VUP86YY('1O(&EM<&QE;65N="!A(')E9'5C=&EO;B!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(')E<V5A<F-H(&]P97)A=&EO;G,@;&]C871E9"!I;B!38V]T
M;&%N9"!I;B!E>&-H86YG92!F;W(@=&AE('!A<G1I97,F(S@R,3<[(&%G<F5E
M;65N="!T;R!M;V1I9GD@=&AE('!A>6UE;G0@=&5R;7,@;V8@=&AE($%G<F5E
M;65N="!I;B!T:&4@<')I;F-I<&%L(&%M;W5N="!O9B`F(S$V,SLU)B,Q-C`[
M;6EL;&EO;B`H87!P<F]X:6UA=&5L>2`D."XP(&UI;&QI;VX@870@1&5C96UB
M97(F(S$V,#LS,2P@,C`P.2DL('=H:6-H(%-%(&AA9"!P<F5V:6]U<VQY(&5N
M=&5R960@:6YT;R!W:71H('1H92!#;VUP86YY+B!4:&4@06=R965M96YT('!R
M;W9I9&5D(&9O<B!R97!A>6UE;G0@;V8@=7`@=&\@)B,Q-C,[-2!M:6QL:6]N
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M('!A<G1I97,@86=R965D('1O(&$@;6]D:69I960@<&%Y;65N="!O9B`F(S$V
M,SLQ)B,Q-C`[;6EL;&EO;B`H87!P<F]X:6UA=&5L>2`D,2XW(&UI;&QI;VX@
M870@2G5N928C,38P.S(R+"`R,#`Y*2!P87EA8FQE(&EN('1W;R!E<75A;"!T
M<F%N8VAE<RX@3VX@2G5L>28C,38P.S$L(#(P,#DL('1H92!F:7)S="!I;G-T
M86QL;65N="!O9B`F(S$V,SLP+C4@;6EL;&EO;B`H87!P<F]X:6UA=&5L>2`D
M,"XX(&UI;&QI;VXI('=A<R!P86ED(&%N9"!T:&4@<F5M86EN:6YG(&%M;W5N
M="!O9B`F(S$V,SLP+C4@;6EL;&EO;B`H87!P<F]X:6UA=&5L>2`D,"XX(&UI
M;&QI;VXI('=A<R!P86ED(&]N($IA;G5A<GDF(S$V,#LV+"`R,#$P+B8C,38P
M.R!);B!A9&1I=&EO;BP@<VAO=6QD(&$@9G5R=&AE<B!R961U8W1I;VX@8F5L
M;W<@8W5R<F5N="!M:6YI;75M('-T869F(&QE=F5L<R!B92!E9F9E8W1U871E
M9"!B969O<F4@2G5L>28C,38P.S(P,30@=VET:&]U="!3128C.#(Q-SMS('!R
M:6]R(&-O;G-E;G0L('1H92!#;VUP86YY(&UA>2!B92!O8FQI9V%T960@=&\@
M<&%Y('5P('1O("8C,38S.S0F(S$V,#MM:6QL:6]N('1O(%-%+"!W:&EC:"!W
M:6QL(&)E(&-A;&-U;&%T960@87,@82!M87AI;75M(&]F("8C,38S.S0F(S$V
M,#MM:6QL:6]N("AA<'!R;WAI;6%T96QY("0V+C(@;6EL;&EO;B!A;F0@)#8N
M-"!M:6QL:6]N(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@86YD($UA<F-H
M)B,Q-C`[,S$L(#(P,3(L(')E<W!E8W1I=F5L>2D@;&5S<R!T:&4@;6%R:V5T
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M)#8N,2!M:6QL:6]N*2!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"!-
M87)C:"8C,38P.S,Q+"`R,#$R+"!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M5&AI<R!A<G)A;F=E;65N="!I<R!A8V-O=6YT960@9F]R(&%S(&$@;&EA8FEL
M:71Y('5N9&5R($%30R`T.#`L(#QI/D1I<W1I;F=U:7-H:6YG($QI86)I;&ET
M:65S(&9R;VT@17%U:71Y/"]I/B`H)B,X,C(P.T%30R`T.#`F(S@R,C$[*2P@
M86YD(&ES(&UE87-U<F5D(&%T(&9A:7(@=F%L=64N($-H86YG97,@:6X@9F%I
M<B!V86QU92!A<F4@<F5C;V=N:7IE9"!I;B!E87)N:6YG<RX@)B,Q-C`[1'5E
M('1O('1H92!N871U<F4@;V8@=&AE(&%S<V]C:6%T960@8V]N=&EN9V5N8WD@
M86YD('1H92!L:6ME;&EH;V]D(&]F(&]C8W5R<F5N8V4L('1H92!#;VUP86YY
M(&AA<R!C;VYC;'5D960@=&AE(&9A:7(@=F%L=64@;V8@=&AI<R!L:6%B:6QI
M='D@=V%S(&%P<')O>&EM871E;'D@)#(P+#`P,"!A="!$96-E;6)E<B8C,38P
M.S,Q+"`R,#$Q(&%N9"!-87)C:"8C,38P.S,Q+"`R,#$R+"!R97-P96-T:79E
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M96-E;6)E<B8C,38P.S,Q+"`R,#$Q(&%N9"!-87)C:"8C,38P.S,Q+"`R,#$R
M+"!T:&4@0V]M<&%N>2!U<V5D(&$@<V-E;F%R:6\@86YA;'ES:7,@;6]D96P@
M=&\@87)R:79E(&%T('1H92!F86ER('9A;'5E(&]F('1H92!38V]T=&ES:"!%
M;G1E<G!R:7-E($%G<F5E;65N="!A;F0@87-S=6UE9"!A(#,P)2!P<F]B86)I
M;&ET>2!O9B!F86QL:6YG(&)E;&]W(&$@;6EN:6UU;2!S=&%F9FEN9R!L979E
M;"!A;F0@82`Q)2!P<F]B86)I;&ET>2!T:&%T('1H92!O8V-U<G)E;F-E(&]F
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!215!!240@15A014Y315,@04Y$($]42$52($-5
M4E)%3E0@05-31513/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4%)%4$%)1"!%6%!%3E-%4R!!3D0@3U1(15(@0U52
M4D5.5"!!4U-%5%,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4%)%4$%)1"!%6%!%3E-%4R!!3D0@3U1(15(@0U524D5.5"!!
M4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S
M='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-"CQT9#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XR-6EN.R!415A4+4E.1$5.5#H@
M+3`N,C5I;B<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^-"X\+V9O;G0^/"]B/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#@N-7!T)R!S:7IE/3-$,3XF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]F;VYT/CPO8CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T)R!S
M:7IE/3-$,CY04D5004E$($584$5.4T53($%.1"!/5$A%4B!#55)214Y4($%3
M4T544SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0
M<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R!C;VYS
M:7-T(&]F('1H92!F;VQL;W=I;F<Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@
M,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-
M"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-S`E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y$96-E;6)E<B8C,38P
M.S,Q+#QB<B`O/@T*,C`Q,3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,3Y-87)C:"8C,38P.S,Q+#QB<B`O/@T*,C`Q,CPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
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M;CL@5TE$5$@Z(#<P)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-S`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R-BXU)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C8E(&-O;'-P
M86X],T0S/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B@D,#`P<RD\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO8CX\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`W
M,"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!T
M87@@8W)E9&ET(')E8V5I=F%B;&4@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXU-#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/C<S-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`W,"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/E!R97!A>6UE;G1S(#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S(Q
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXR-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-S`E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY!8V-O=6YT<R!R96-E:79A8FQE(#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3$V/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-3(\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-S`E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!O<VET<R`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C$S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXQ-3,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@-S`E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE<B!C=7)R96YT(&%S<V5T<R`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@-S`E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY4;W1A;"!P<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT
M(&%S<V5T<R`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,2PR,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
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M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D%#0U)5140@3$E!0DE,251)15,@04Y$($]42$52($-54E)%3E0@
M3$E!0DE,251)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!0T-2545$($Q)04))3$E42453($%.1"!/5$A%4B!#
M55)214Y4($Q)04))3$E42453/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%#0U)5140@3$E!0DE,251)15,@04Y$($]42$52
M($-54E)%3E0@3$E!0DE,251)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-
M"CQT9#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XR-6EN
M.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^/&(^/&9O;G0@<W1Y;&4],T0G1D].
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M5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY!0T-2545$($Q)04))3$E42453($%.
M1"!/5$A%4B!#55)214Y4($Q)04))3$E42453/"]F;VYT/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D%C8W)U960@86YD(&]T:&5R(&-U<G)E
M;G0@;&EA8FEL:71I97,@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=-05)'24XM3$5&5#H@,"XR:6X[(%=)1%1(.B`Y-"XV
M-B4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y-"4@8F]R9&5R/3-$,#X-"CQT
M<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-C@N,R4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8X
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y$96-E;6)E<B8C
M,38P.S,Q+#QB<B`O/@T*,C`Q,3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C0E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
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M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXV."4[(%!!1$1)3D<M5$]0
M.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^36%R8V@F(S$V,#LS,2P\8G(@+SX-"C(P,3(\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`V."XS)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C@E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R."4@8V]L<W!A;CTS1#,^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
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M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4
M.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8V-R=65D(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(N-C@E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C,L-#<Q/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-C@N,R4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8X)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)
M3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]T:&5R
M(&-U<G)E;G0@;&EA8FEL:71I97,@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,BXV."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/C$L,3DS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8T)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)
M1%1(.B`Q,BXV."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C$L,3<P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#8X+C,E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V."4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C@E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R
M:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C0L-3`T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`V)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V5D-6)E-SE?8V5B-U\T865D7SEC
M-#1?831B-69D9#DR-#AE#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S=E9#5B93<Y7V-E8C=?-&%E9%\Y8S0T7V$T8C5F9&0Y,C0X92]7;W)K<VAE
M971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY35$]#2R!"05-%1"!#3TU014Y3051)3TX\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$]#2R!"05-%
M1"!#3TU014Y3051)3TX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4U1/0TL@0D%3140@0T]-4$5.4T%424]./"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S
M+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T(#`N,C5I;CL@5$585"U)3D1%3E0Z("TP+C(U:6XG/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C8N
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(%-43T-+($)!4T5$($-/35!%3E-!
M5$E/3CPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3
M=&]C:R!B87-E9"!C;VUP96YS871I;VX@:&%S(&)E96X@<F5P;W)T960@=VET
M:&EN(&5X<&5N<V4@;&EN92!I=&5M<R!O;B!T:&4@8V]N<V]L:61A=&5D('-T
M871E;65N="!O9B!O<&5R871I;VYS(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H)B,Q-C`[,S$L(#(P,3$@86YD(#(P,3(@87,@<VAO=VX@:6X@
M=&AE(&9O;&QO=VEN9R!T86)L93H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`P+C<U:6X[(%=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0X,"4@8F]R9&5R/3-$,#X-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`S,RXQ,B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,R4@8V]L<W!A;CTS1#,^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C
M96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^1F]R)B,Q-C`[=&AE)B,Q-C`[=&AR
M964F(S$V,#MM;VYT:',\8G(@+SX-"F5N9&5D)B,Q-C`[36%R8V@F(S$V,#LS
M,2P\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`Q+C(V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,RXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$U)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XR,#$Q/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$U+C`R)3L@
M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,3XR,#$R/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XR-B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P
M/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@-C(N-#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S,RXQ,B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,S)2!C
M;VQS<&%N/3-$,SX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XH)#`P,',I
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XR-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@-C(N-#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0V,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S+C$R)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!B9V-O;&]R/3-$(T-#145&
M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^-3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,N,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)2!B
M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$U+C`R)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXQ-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XR-B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`V,BXT."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,RXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,34E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#,N,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$U+C`R)3L@4$%$1$E.1RU43U`Z
M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
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M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-
M"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@-C(N-#@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@8V]S=',@8F5F;W)E(&EN8V]M92!T87AE
M<R`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$U)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q-24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C(U,3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,34N,#(E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P
M="!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,3`R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q+C(V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^070@=&AE($-O;7!A;GDF(S@R,3<[<R!A;FYU86P@<VAA
M<F5H;VQD97(@;65E=&EN9R!O;B!-87DF(S$V,#LQ-"P@,C`P."P@=&AE('-T
M;V-K:&]L9&5R<R!A<'!R;W9E9"!A;F0@86UE;F1E9"!T:&4@;G5M8F5R(&]F
M('-H87)E<R!R97-E<G9E9"!U;F1E<B!T:&4@,C`P-B!0;&%N('1O(#4L,C`P
M+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VLL('5P(&9R;VT@,RPP,#`L,#`P('-H87)E<RX@5&AE(&%W87)D<R!G<F%N
M=&5D('5N9&5R('1H92`R,#`V(%!L86X@:&%V92!A(&UA>&EM=6T@;6%T=7)I
M='D@;V8@,3`F(S$V,#MY96%R<R!A;F0@9V5N97)A;&QY('9E<W0@;W9E<B!A
M(&9O=7(M>65A<B!P97)I;V0@9G)O;2!T:&4@9&%T92!O9B!G<F%N="X\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D$@<W5M;6%R>2!O9B!A8W1I=FET>2!F
M;W(@=&AE(&]P=&EO;G,@=6YD97(@=&AE($-O;7!A;GDF(S@R,3<[<R`R,#`V
M(%!L86X@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS
M,2P@,C`Q,B!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z
M(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^
M#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0Q
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
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M(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
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M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y796EG:'1E
M9#QB<B`O/@T*079E<F%G93QB<B`O/@T*17AE<F-I<V4F(S$V,#M0<FEC93PO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y796EG:'1E9#QB<B`O/@T*
M079E<F%G93QB<B`O/@T*4F5M86EN:6YG/&)R("\^#0I#;VYT<F%C='5A;#QB
M<B`O/@T*)B,Q-C`[5&5R;28C,38P.RAY96%R<RD\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
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M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,B4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#$^06=G<F5G871E/&)R("\^#0I);G1R:6YS:6,\8G(@
M+SX-"E9A;'5E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-#$E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E
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M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0
M.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,3XH:6XF(S$V,#LD,#`P<RD\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO8CX\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Q
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/D]P=&EO;G,@;W5T<W1A;F1I;F<@870@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,RPU,34L-S0Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`Q,"XW)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS
M+C<S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV
M+C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ
M-#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@-#$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY'<F%N=&5D(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*
M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`T,24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%
M3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D5X97)C:7-E
M9"`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<W
M+#`V,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N
M-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XT-#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#0Q)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.
M5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^17AP:7)E9"`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@-#$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#86YC96QL960@+R!F;W)F96ET960@
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B
M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#
M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T
M,24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@
M5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/D]P=&EO;G,@;W5T<W1A;F1I;F<@870@36%R8V@F(S$V,#LS,2P@,C`Q,B`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,RPT,S@L-C<Y
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,"XW)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+C@P
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXV+C$X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXR,S,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@-#$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;G9E<W1E9"!A="!-87)C:"8C
M,38P.S,Q+"`R,#$R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
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M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
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M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@-#$E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY697-T960@86YD(&5X97)C:7-A
M8FQE(&%T($UA<F-H)B,Q-C`[,S$L(#(P,3(@/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$R)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C(L.#@R+#4P,CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"XR,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2XW,3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,C,R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF
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M;G1H+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL
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M;F0@>6EE;&1S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/D%30R`W,3@@<F5Q=6ER97,@9F]R9F5I
M='5R97,@=&\@8F4@97-T:6UA=&5D(&%T('1H92!T:6UE(&]F(&=R86YT(&%N
M9"!R979I<V5D+"!I9B!N96-E<W-A<GDL(&EN('-U8G-E<75E;G0@<&5R:6]D
M<R!I9B!A8W1U86P@9F]R9F5I='5R97,@9&EF9F5R(&9R;VT@=&AO<V4@97-T
M:6UA=&5S+B!4:&ES(&%N86QY<VES(&ES(&5V86QU871E9"!Q=6%R=&5R;'D@
M86YD('1H92!F;W)F96ET=7)E(')A=&4@861J=7-T960@87,@;F5C97-S87)Y
M+B8C,38P.R!5;'1I;6%T96QY+"!T:&4@86-T=6%L(&5X<&5N<V4@<F5C;V=N
M:7IE9"!O=F5R('1H92!R97%U:7-I=&4@<V5R=FEC92!P97)I;V0@:7,@8F%S
M960@;VX@;VYL>2!T:&]S92!S:&%R97,@=&AA="!V97-T+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
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M;6)E<B8C,38P.S(P,3`L(&)E8V%U<V4@=&AE($-O;7!A;GD@:&%D(&)E96X@
M<'5B;&EC;'D@=')A9&5D(&9O<B!A(&QI;6ET960@<&5R:6]D+"!T:&4@97AP
M96-T960@=F]L871I;&ET>2!A<W-U;7!T:6]N('=A<R!B87-E9"!O;B!T:&4@
M:&ES=&]R:6-A;"!V;VQA=&EL:71Y(&]F('!E97(@8V]M<&%N:65S(&]V97(@
M=&AE(&5X<&5C=&5D('1E<FT@;V8@=&AE(&]P=&EO;B!A=V%R9',N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^17-T:6UA=&5S(&]F('!R92UV97-T:6YG(&]P=&EO;B!F;W)F96ET
M=7)E<R!A<F4@8F%S960@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!E>'!E<FEE
M;F-E+B!&;W(@;W5T<W1A;F1I;F<@;W!T:6]N<RP@=&AE($-O;7!A;GD@=7-E
M<R!A(&9O<F9E:71U<F4@<F%T92!O9B`P("8C.#(Q,CL@-3`E(&1E<&5N9&EN
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M;B!F=71U<F4@<&5R:6]D<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M;&]Y964@;W!T:6]N+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$
M14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE<F4@
M=V5R92!N;R!O<'1I;VYS(&=R86YT960@9'5R:6YG(&5I=&AE<B!O9B!T:&4@
M=&AR964@;6]N=&@@<&5R:6]D<R!E;F1I;F<@36%R8V@F(S$V,#LS,2P@,C`Q
M,2!A;F0@,C`Q,BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE('1H<F5E(&UO;G1H
M<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$Q+"`U+#$S,2!S=&]C:R!O<'1I
M;VYS('=E<F4@97AE<F-I<V5D(')E<W5L=&EN9R!I;B!A<'!R;WAI;6%T96QY
M("0R+#`P,"!O9B!C87-H('!R;V-E961S('1O('1H92!#;VUP86YY+B8C,38P
M.R!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q
M+"`R,#$R+"!T:&5R92!W97)E(#<W+#`V,B!S=&]C:R!O<'1I;VYS(&5X97)C
M:7-E9"!T;W1A;&EN9R!A<'!R;WAI;6%T96QY("0S-"PP,#`@:6X@<')O8V5E
M9',N($%S('1H92!#;VUP86YY('!R97-E;G1L>2!H87,@=&%X(&QO<W,@8V%R
M<GD@9F]R=V%R9',@9G)O;2!P<FEO<B!P97)I;V1S(&%N9"!E>'!E8W1S('1O
M(&EN8W5R('1A>"!L;W-S97,@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M
M8F5R)B,Q-C`[,S$L(#(P,3(L('1H92!#;VUP86YY(&ES(&YO="!A8FQE('1O
M(&)E;F5F:70@9G)O;2!T:&4@9&5D=6-T:6]N(&9O<B!E>&5R8VES960@<W1O
M8VL@;W!T:6]N<R!I;B!T:&4@8W5R<F5N="!R97!O<G1I;F<@<&5R:6]D+CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!3=&]C:SPO9F]N=#X\+VD^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!.;W9E;6)E<B8C,38P.S(P,#@L
M('1H92!#;VUP86YY(&ES<W5E9"`U,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T
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M,C`Q,B!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#`N-6EN.R!724142#H@.#8N-C8E.R!"3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$.#8E(&)O<F1E<CTS1#`^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#4V+C$V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-38E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0[($9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C
M96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.#0E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/E)E<W1R:6-T960F(S$V,#M3=&]C:SPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
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M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`R,RXP
M."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^5V5I9VAT960F
M(S$V,#M!=F5R86=E)B,Q-C`[1W)A;G0\8G(@+SX-"D1A=&4F(S$V,#M686QU
M928C,38P.U!E<B8C,38P.U-H87)E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO
M=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-38N,38E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0U-B4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CY.;VXM=F5S=&5D(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&
M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+C@T
M)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#
M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,3$L-#4P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`Q+C4E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#(Q+C4X)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,"XT-#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`U
M-BXQ-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#4V)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@
M5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E9E<W1E9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.#0E
M.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH
M,RPQ,C8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#`N,S<U<'0[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/BD\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#$N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,2XU."4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,"XT-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`U-BXQ-B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#4V)2!B
M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/DYO;BUV97-T960@870@36%R8V@F(S$V,#LS,2P@,C`Q
M,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#$N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,2XU."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,"XT-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,2XQ-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^4F5S=')I8W1E9"!3=&]C:R!5;FET<SPO9F]N=#X\
M+VD^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N
M,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!.;W9E;6)E<B8C
M,38P.S(P,#@@86YD($1E8V5M8F5R)B,Q-C`[,C`Q,2P@<F5S<&5C=&EV96QY
M+"!T:&4@0V]M<&%N>2!I<W-U960@.3$L-S`P(&%N9"`R,S@L,#`P(')E<W1R
M:6-T960@<W1O8VL@=6YI=',@=&\@<V5N:6]R(&5X96-U=&EV97,N)B,Q-C`[
M($5A8V@@=6YI="!E;G1I=&QE<R!T:&4@:&]L9&5R('1O(')E8V5I=F4@82!S
M:&%R92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY$=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,BP@=&AE
M($-O;7!A;GD@:7-S=65D(&%P<')O>&EM871E;'D@.#8L,#`P(')E<W1R:6-T
M960@<W1O8VL@=6YI=',@=&\@96UP;&]Y965S(&%S('!A<G0@;V8@:71S(&%N
M;G5A;"!G<F%N="X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@,C`P."!G<F%N=',@=F5S="!O
M=F5R(&9O=7(@>65A<G,@86YD('1H92`R,#$Q(&%N9"`R,#$R(&=R86YT<R!V
M97-T(&]V97(@=&AR964@>65A<G,N)B,Q-C`[($$@<F5S=')I8W1E9"!S=&]C
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M;6]N=&AS(&5N9&5D($UA<F-H)B,Q-C`[,S$L(#(P,3(@:7,@87,@9F]L;&]W
M<SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU,1494.B`P+C5I;CL@5TE$5$@Z
M(#@V+C8V)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@V)2!B;W)D97(],T0P
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`U
M,2XU-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$X+C0V)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y297-T
M<FEC=&5D)B,Q-C`[4W1O8VLF(S$V,#M5;FET<SPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
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M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`R,RXP."4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^5V5I9VAT960F(S$V,#M!
M=F5R86=E)B,Q-C`[1W)A;G0\8G(@+SX-"D1A=&4F(S$V,#M686QU928C,38P
M.U!E<B8C,38P.U-H87)E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T
M<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@-3$N-30E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1T;W`@=VED=&@],T0U,24@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.;VXM
M=F5S=&5D(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$X+C0V)3L@4$%$
M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,C4U+#$W-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,2XU)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`R,2XU."4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`N.#`\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT
M<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-3$N-30E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0U,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY'<F%N
M=&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q."XT-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^.#4L.3<T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C4E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,C$N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C`N-34\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@-3$N-30E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`@=VED=&@],T0U,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$X+C0V)3L@
M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^*#0L-C@Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P+C,W-7!T
M.R!724142#H@,BXX."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C4E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O
M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,C$N-3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R
M:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C`N-#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O
M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@-3$N-30E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`@=VED=&@],T0U,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY.;VXM=F5S=&5D(&%T($UA<F-H)B,Q-C`[,S$L(#(P,3$\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$X+C0V)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C,S-BPT
M-C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#$N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,2XU."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M,"XW-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XQ-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S=E9#5B93<Y7V-E8C=?-&%E
M9%\Y8S0T7V$T8C5F9&0Y,C0X90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\W960U8F4W.5]C96(W7S1A961?.6,T-%]A-&(U9F1D.3(T.&4O5V]R
M:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44R!!3D0@0T].
M5$E.1T5.0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A
M8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6X[(%1%6%0M24Y$
M14Y4.B`M,"XR-6EN)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXW+CPO9F]N=#X\+V(^/&(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@."XU<'0G('-I>F4]
M,T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]B/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0G('-I>F4],T0R/D-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453/"]F
M;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\:3X\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DQI8V5N<VEN9R!!9W)E96UE;G1S/"]F;VYT/CPO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z
M(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
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M96YT(&%P<&QI8V%T:6]N<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M;W)S('1O(&1E=F5L;W`@82!P<F]D=6-T(&%N9"!O8G1A:6X@<F5G=6QA=&]R
M>2!A<'!R;W9A;"!T;R!S96QL(&$@<')O9'5C="!A;F0@:&%S(&%G<F5E9"!T
M;R!P87D@1&%I:6-H:2!386YK>6\@86X@=7`M9G)O;G0@9F5E+"!R96EM8G5R
M<V5M96YT(&9O<B!$86EI8VAI(%-A;FMY;R8C.#(Q-SMS(&5N=6UE<F%T960@
M97AP96YS97,L(&UI;&5S=&]N92!P87EM96YT<R!A;F0@<F]Y86QT:65S(&]N
M(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES+B!4:&4@=7`M9G)O;G0@9F5E
M(&%N9"!C97)T86EN('!A<W0@<F5I;6)U<G-E;65N=',@:&%V92!B965N('!A
M:60@86YD+"!A<R!A(')E<W5L="!O9B!T:&4@4T5!34Q%4U,@=')I86P@96YT
M97)I;F<@4&AA<V4@,R!D=7)I;F<@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q
M,2P@82!M:6QE<W1O;F4@<&%Y;65N="!O9B`D,2XV(&UI;&QI;VX@=V%S('!A
M:60@:6X@07!R:6PF(S$V,#LR,#$Q+B!!(&9U<G1H97(@)#$P+C`@;6EL;&EO
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M($IU;'DF(S$V,#LQ,2P@,C`Q,2P@=&AE(&QI8V5N<V4@86=R965M96YT('=A
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M<&%C:71A8FEN92!B92!I;F-R96%S960@8F5T=V5E;B`Q+C(U)2!A;F0@,2XU
M,"4@9&5P96YD:6YG(&]N('1H92!L979E;"!O9B!N970@<V%L97,@;V8@<V%P
M86-I=&%B:6YE(')E86QI>F5D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
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M.R!&;W(@=&AE('EE87(@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q,B!T
M:&ES(&5Q=6%T97,@=&\@)#`N,B!M:6QL:6]N+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\:3X\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/DQE9V%L('!R;V-E961I;F=S/"]F;VYT/CPO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z
M(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!!<')I;"8C
M,38P.S(W+"`R,#$P+"!T:&4@0V]M<&%N>2!W87,@<V5R=F5D('=I=&@@82!C
M;VUP;&%I;G0@9FEL960@8GD@0V5L9V5N92!#;W)P;W)A=&EO;B!I;B!T:&4@
M56YI=&5D(%-T871E<R!$:7-T<FEC="!#;W5R="!F;W(@=&AE($1I<W1R:6-T
M(&]F($1E;&%W87)E('-E96MI;F<@82!D96-L87)A=&]R>2!J=61G;65N="!T
M:&%T(&9O=7(@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!O=VX@<&%T96YT<R`H
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M;VXI('!R;V1U8W0N($]N($IU;F4F(S$V,#LQ-RP@,C`Q,"P@=&AE($-O;7!A
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M=&EO;B!O9B!#96QG96YE)B,X,C$W.W,@25-43T1!6"8C,3<T.R`H<F]M:61E
M<'-I;B!F;W(@:6YJ96-T:6]N*2!P<F]D=6-T+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.
M1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D$@4V-H
M961U;&EN9R!/<F1E<B!W87,@96YT97)E9"!&96)R=6%R>28C,38P.S(L(#(P
M,3(L(&%T('=H:6-H('1I;64@=&AE(&-O=7)T('-E="!T:&4@9F]L;&]W:6YG
M('-I9VYI9FEC86YT(&1A=&5S.B!-87)C:"8C,38P.S(R+"`R,#$R("AA;65N
M9&UE;G0@;V8@<&QE861I;F=S+VIO:6YD97(@;V8@<&%R=&EE<RD[(%-E<'1E
M;6)E<B8C,38P.S(T+"`R,#$R("AT96QE8V]N9F5R96YC92!W:71H('1H92!C
M;W5R="!E>'!L;W)I;F<@<&]S<VEB:6QI='D@;V8@06QT97)N871I=F4@1&ES
M<'5T92!297-O;'5T:6]N*3L@36%R8V@F(S$V,#LQ-"P@,C`Q,R`H8VQA:6T@
M8V]N<W1R=6-T:6]N(&AE87)I;F<I.R!!=6=U<W0F(S$V,#LQ-"P@,C`Q,R`H
M<W5M;6%R>2!J=61G;65N="!B<FEE9FEN9RD[(&%N9"!*=6YE)B,Q-C`[,BP@
M,C`Q-"`H-R!D87D@:G5R>2!T<FEA;"!S=&%R="!D871E*2X@1&ES8V]V97)Y
M(&ES(&-U<G)E;G1L>2!O;F=O:6YG+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M5$]#2TA/3$1%4E,G($5154E463PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y35$]#2TA/3$1%4E,G($5154E463PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE
M<RQS97)I9CLG/@T*/'1R/@T*/'1D/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^."XF(S$V,#LF(S$V,#LF(S$V,#M35$]#2TA/3$1%
M4E,F(S@R,3<[($5154E463PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&(^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0<F5F97)R960@
M<W1O8VL\+V9O;G0^/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/D%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,3(L('1H97)E('=E<F4@,2PR
M,3,L,30R('-H87)E<R!O9B!0<F5F97)R960@4W1O8VL@:7-S=65D(&%N9"!O
M=71S=&%N9&EN9R!A="!A;B!I<W-U92!P<FEC92!O9B`D,3`N,#`@<&5R('-H
M87)E+B!$:79I9&5N9',@;VX@=&AE(%!R969E<G)E9"!3=&]C:R!A<F4@8W5M
M=6QA=&EV92!F<F]M('1H92!D871E(&]F(&]R:6=I;F%L(&ES<W5A;F-E(&%T
M('1H92!A;FYU86P@<F%T92!O9B`V)2!O9B!T:&4@;&EQ=6ED871I;VX@<')E
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M<&QU<R!A8V-R=65D(&%N9"!U;G!A:60@9&EV:61E;F1S+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
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M,38P.S,Q+"`R,#$R+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1U<FEN9R`R,#$P+"`X,S,L-C<Q
M('-H87)E<R!O9B!0<F5F97)R960@4W1O8VL@=V5R92!C;VYV97)T960@:6YT
M;R`Q+#8U-2PU.3D@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M
M;6]N('-T;V-K+B!3:6YC92!I;F-E<'1I;VX@=&AR;W5G:"!-87)C:"8C,38P
M.S,Q+"`R,#$R+"!H;VQD97)S(&AA=F4@=F]L=6YT87)I;'D@8V]N=F5R=&5D
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M;VYE(&]R(&UO<F4@<V5R:65S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
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M+C(U+"!W:&EC:"!I<R`Q-3`E(&]F('1H92!C;VYV97)S:6]N('!R:6-E(&]F
M('1H92!0<F5F97)R960@4W1O8VLL(&9O<B!A="!L96%S="`R,"!T<F%D:6YG
M(&1A>7,@9'5R:6YG(&%N>2`S,"UD87D@=')A9&EN9R!P97)I;V0L(&5N9&EN
M9R!W:71H:6X@9FEV92!T<F%D:6YG(&1A>7,@<')I;W(@=&\@;F]T:6-E(&]F
M(&%U=&]M871I8R!C;VYV97)S:6]N+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
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M<F5D(%-T;V-K(&%S(&]F($%U9W5S="8C,38P.S(L(#(P,3`@86YD('1W;R!D
M:7)E8W1O<G,@=V5R92!N;VUI;F%T960@86YD(&5L96-T960@870@=&AE(&%N
M;G5A;"!M965T:6YG(&AE;&0@;VX@36%Y)B,Q-C`[,C0L(#(P,3$N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^5&AE(%!R969E<G)E9"!3=&]C:R!H87,@;F\@;6%T=7)I='D@9&%T
M92!A;F0@;F\@=F]T:6YG(')I9VAT<R!P<FEO<B!T;R!C;VYV97)S:6]N(&EN
M=&\@8V]M;6]N('-T;V-K+"!E>&-E<'0@=6YD97(@;&EM:71E9"!C:7)C=6US
M=&%N8V5S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D9R;VT@3F]V96UB97(F(S$V,#LV+"`R,#`W
M+"!T:&4@0V]M<&%N>2!M87DL(&%T(&ET<R!O<'1I;VXL(')E9&5E;2!T:&4@
M4')E9F5R<F5D(%-T;V-K(&EN('=H;VQE(&]R(&EN('!A<G0L(&]U="!O9B!F
M=6YD<R!L96=A;&QY(&%V86EL86)L92!A="!T:&4@<F5D96UP=&EO;B!P<FEC
M97,@<&5R('-H87)E('-T871E9"!B96QO=RP@<&QU<R!A;B!A;6]U;G0@97%U
M86P@=&\@86-C<G5E9"!A;F0@=6YP86ED(&1I=FED96YD<R!U<"!T;R!T:&4@
M9&%T92!O9B!R961E;7!T:6]N.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,C!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`P+C%I;CL@5TE$5$@Z(#DP+C8X)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#DP)2!B;W)D97(],T0P/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`X,BXY,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z
M("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/EEE87(@9G)O;2!.
M;W9E;6)E<B8C,38P.S$L(#(P,3$@=&\@3V-T;V)E<B8C,38P.S,Q+"`R,#$R
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C<T)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`Q+C0T)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
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M;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$P+C$X/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`Q+C$E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@.#(N.3(E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY996%R(&9R
M;VT@3F]V96UB97(F(S$V,#LQ+"`R,#$R('1O($]C=&]B97(F(S$V,#LS,2P@
M,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXW-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,2XT-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,2XX)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXQ,"XQ,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,2XQ)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#@R+CDR)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#(E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^665A<B!F<F]M($YO=F5M8F5R)B,Q-C`[,2P@,C`Q
M,R!T;R!/8W1O8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-S0E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
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M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,3$N."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!B9V-O;&]R/3-$(T-#145&
M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,3`N,#8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`X,BXY,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/DYO=F5M8F5R)B,Q-C`[,2P@,C`Q-"!A;F0@
M=&AE<F5A9G1E<CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXW-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,2XT-"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,2XX
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXQ,"XP,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,2XQ)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P
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M.S$L(#(P,#4@*'1H92`F(S@R,C`[17AC:&%N9V4@1&%T928C.#(R,3LI(&9O
M<B!T:&4@0V]M<&%N>28C.#(Q-SMS(#8E($-O;G9E<G1I8FQE(%-U8F]R9&EN
M871E9"!$96)E;G1U<F5S("@F(S@R,C`[1&5B96YT=7)E<R8C.#(R,3LI(&%T
M('1H92!R871E(&]F("0Q,"!P<FEN8VEP86P@86UO=6YT(&]F($1E8F5N='5R
M97,@9F]R(&5A8V@@<VAA<F4@;V8@4')E9F5R<F5D(%-T;V-K+B!4:&4@1&5B
M96YT=7)E<RP@:68@:7-S=65D+"!W:6QL(&UA='5R92`R-2!Y96%R<R!A9G1E
M<B!T:&4@17AC:&%N9V4@1&%T92!A;F0@:&%V92!T97)M<R!S=6)S=&%N=&EA
M;&QY('-I;6EL87(@=&\@=&AO<V4@;V8@=&AE(%!R969E<G)E9"!3=&]C:RX\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M(')E<W!E8W0@=&\@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,B!T:&%T('=O
M=6QD(&AA=F4@;W1H97)W:7-E(&)E96X@<&%Y86)L92!O;B!-87DF(S$V,#LQ
M+"`R,#$R+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQI/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^0V]M;6]N(%-T;V-K/"]F;VYT/CPO:3X\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/DUA<F-H)B,Q-C`[,C`Q,B!386QE
M(&]F($-O;6UO;B!3=&]C:R!A;F0@16-O;F]M:6,@4FEG:'1S/"]F;VYT/CPO
M:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XR
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D]N($UA<F-H)B,Q-C`[
M,C(L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('!U<F-H87-E
M(&%G<F5E;65N="!W:71H(&-E<G1A:6X@97AI<W1I;F<@:6YS=&ET=71I;VYA
M;"!S=&]C:VAO;&1E<G,L(')A:7-I;F<@87!P<F]X:6UA=&5L>2`D,BXY(&UI
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P
M+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^56YD
M97(@=&AE('1E<FUS(&]F('1H92!P=7)C:&%S92!A9W)E96UE;G0L('1H92!I
M;G9E<W1O<G,@<'5R8VAA<V5D(#0L-C@X+#`W.2!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@870@82!P<FEC92!O9B`D,"XV
M-#<V+"!W:&EC:"!I<R!E<75A;"!T;R!T:&4@,3`M9&%Y(&%V97)A9V4@8VQO
M<VEN9R!P<FEC92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C
M:R!F;W(@=&AE('!E<FEO9"!E;F1I;F<@;VX@5V5D;F5S9&%Y+"!-87)C:"8C
M,38P.S(Q+"`R,#$R+B!);B!A9&1I=&EO;B!T;R!T:&4@8V]M;6]N('-T;V-K
M+"!I;G9E<W1O<G,@<F5C96EV960@8V]N=')A8W1U86P@<FEG:'1S('1O(')E
M8V5I=F4@8V%S:"!E<75A;"!T;R`Q,"4@;V8@86YY(&9U='5R92!L:71I9V%T
M:6]N('-E='1L96UE;G0@<F5L871E9"!T;R!T:&4@<W!E8VEF:65D(&EN=&5L
M;&5C='5A;"!P<F]P97)T>2P@<W5B:F5C="!T;R!A(&-A<"XF(S$V,#L@26X@
M8V5R=&%I;B!D969I;F5D('-I='5A=&EO;G,L('1H92!#;VUP86YY(&UA>2!H
M879E('1O(&ES<W5E(&5I=&AE<B!A9&1I=&EO;F%L('-H87)E<R!O<B!W87)R
M86YT<RXF(S$V,#L@5&AE('-H87)E<R!I<W-U960@870@8VQO<VEN9R!A<F4@
M<W5B:F5C="!T;R!A(&QO8VLM=7`@<&5R:6]D(&]F(&]N92!Y96%R(&9R;VT@
M=&AE(&1A=&4@;V8@:7-S=6%N8V4N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P
M+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4V5E(#QI/DYO=&4@
M,RP@1F%I<B!686QU92!-96%S=7)E;65N=',\+VD^(&9O<B!F=7)T:&5R(&1E
M=&%I;',N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUM;VX@4W1O8VL@5V%R<F%N=',\+V9O
M;G0^/"]I/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&9O;&QO
M=VEN9R!T86)L92!S=6UM87)I>F5S(&EN9F]R;6%T:6]N(&%B;W5T('=A<G)A
M;G1S(&]U='-T86YD:6YG(&%T($UA<F-H)B,Q-C`[,S$L(#(P,3(Z/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L
M92!S='EL93TS1"=724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4@8F]R9&5R/3-$,#X-"CQT<CX-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@-30N-24[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/DES<W5E
M9"8C,38P.VEN)B,Q-C`[0V]N;F5C=&EO;B8C,38P.U=I=&@F(S$V,#L\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$S)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^
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M5#H@8F]L9#L@1D].5"U325I%.B`X<'0G('-I>F4],T0Q/DES<W5A8FQE/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/E=E:6=H
M=&5D/"]F;VYT/CPO8CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`X<'0G('-I>F4],T0Q/CQB<B`O/CPO9F]N=#X\
M+V(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M
M4TE:13H@.'!T)R!S:7IE/3-$,3Y!=F5R86=E/"]F;VYT/CPO8CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0G
M('-I>F4],T0Q/CQB<B`O/CPO9F]N=#X\+V(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T)R!S:7IE/3-$,3Y%
M>&5R8VES93PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0Q/E!R:6-E/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M-30N-24[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-"4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY!<')I;"8C,38P.S(P,#8@<W1O8VL@:7-S=6%N8V4\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
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M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3,E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#4W,2PT,CD\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,"XW)3L@4$%$
M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^-RXP,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-30E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^1F5B<G5A<GDF(S$V,#LR,#`W('-T;V-K(&ES<W5A;F-E
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$R
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/C(P,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,3,E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C$L,#8R+#0Q,CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^."XT-#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-30E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.
M5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1&5C96UB97(F
M(S$V,#LR,#`W($-%1D8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,R4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^,3`P+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XT
M,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\
M+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-30E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^2G5L>28C,38P.S(P,#D@4V5R:65S)B,Q-C`[24D@<W1O8VL@:7-S
M=6%N8V4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,C`Q-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q,R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-CDR+#(U-CPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,2XP,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*
M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-30E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.
M1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^2F%N=6%R
M>28C,38P.S(P,3`@<W1O8VL@:7-S=6%N8V4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C`Q-3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,R4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S$R+#4P,#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!B9V-O;&]R/3-$(T-#
M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,RXR-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-30E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^2F%N=6%R>28C,38P.S(P,3`@<W1O8VL@:7-S
M=6%N8V4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,C`Q-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q,R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-S`U+#`P,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,BXX-3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,24[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*
M/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`U-"XU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-30E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.
M1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3V-T;V)E
M<B8C,38P.S(P,3`@<W1O8VL@:7-S=6%N8V4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,3(E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,C`Q-3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,R4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-"PQ-C$L-3DU/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,"XW)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXQ+CDR/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#4T+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U-"4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY*=6QY)B,Q-C`[,C`Q,2!S=&]C:R!I<W-U
M86YC93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q,B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXR,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$S)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^,RPX,#@L.#(S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,3`N-R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@-30N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4T)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,3(E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,R4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$P+C<E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#4T+C4E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q,B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q
M,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXQ,RPX,30L,#$U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C4E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M,"XW)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXS+C(X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY4:&5R92!W97)E(&YO(&5X97)C:7-E<R!O9B!W87)R86YT
M<R!D=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q
M+"`R,#$Q(&%N9"`R,#$R+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$T+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\W
G960U8F4W.5]C96(W7S1A961?.6,T-%]A-&(U9F1D.3(T.&4M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Consolidation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries for the indicated periods. All significant intercompany transactions and balances have been eliminated.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Use of Estimates</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include estimated levels of product returns, and inputs used to determine stock-based compensation expense and the fair value of financial instruments, such as Economic Rights and other liabilities measured at fair value. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Cash and Cash Equivalents</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cash equivalents are stated at cost, which is substantially the same as fair value. The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Trade Accounts Receivable and Allowance for Doubtful Accounts</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">An allowance for doubtful accounts is provided, as necessary, on trade receivables based on their respective aging categories and historical collection experience, taking into consideration the type of payer, historical and projected collection outcomes, and current economic and business conditions that could affect the collectability of the Company&#8217;s receivables.&#160; The allowance for doubtful accounts is reviewed, at a minimum, on a quarterly basis.&#160; Changes in the allowance for doubtful accounts are recorded as an adjustment to bad debt expense within general and administrative expenses.&#160; Material revisions to reserve estimates may result from adverse changes in collection experience. The Company writes off accounts against the allowance for doubtful accounts when reasonable collection efforts have been unsuccessful and it is likely the receivable will not be recovered.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Trade accounts receivable are included in prepaid expenses and other current assets on the consolidated balance sheet and were $0.1 million and $0.2 million at December&#160;31, 2011 and March&#160;31, 2012, respectively. All trade accounts receivable were deemed collectible as of December&#160;31, 2011 and March&#160;31, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">For the three months ended March&#160;31, 2011 and 2012, approximately 90% and 86%, respectively, of our product sales in the United States were to three wholesalers.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Inventory</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cyclacel values inventories at the lower of cost or market. The Company determines cost using the first-in, first-out method. As of March&#160;31, 2012 and December&#160;31, 2011, all inventories were classified as finished goods. The Company analyzes its inventory levels at least quarterly to identify any items that may expire prior to sale, inventory that has a cost basis in excess of net realizable value, or inventory in excess of expected sales requirements.&#160; The determination of whether or not inventory costs will be realizable requires estimates by the Company&#8217;s management.&#160; A critical input in this determination is future expected sales forecasts. The Company writes off inventory that is expected to expire before being sold.&#160; If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required in future periods.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">There were no inventory write-downs during the three months ended March&#160;31, 2011 and 2012. In the future, reduced demand, quality issues or excess supply may result in write-downs, which would be recorded as adjustments to cost of sales.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Fair Value of Financial Instruments</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, Economic Rights, and other liabilities measured at fair value. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. Economic Rights and other liabilities measured at fair value employ applicable inputs as described in &#8220;<i>Note 3, Fair Value Measurements&#8221;</i>.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Revenue Recognition</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Product sales</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company recognizes revenue from product sales when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the selling price is fixed or determinable; and collectability is reasonably assured.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company offers a general right of return on product sales, and has considered the guidance in ASC Subtopic 605-15, &#8220;<i>Revenue Recognition -Products</i>&#8221; (&#8220;ASC 605-15&#8221;) and ASC Subtopic 605 &#8212; 10 &#8220;<i>Revenue Recognition - Overall</i>&#8221; (&#8220;ASC 605-10&#8221;). Under these guidelines, the Company accounts for all product sales using the &#8220;sell-through&#8221; method. Under the sell-through method, revenue is not recognized upon shipment of product to distributors. Instead, the Company records deferred revenue at gross invoice sales price less 5% of the current wholesale acquisition price (in accordance with our returns policy) and deferred cost of sales at the cost at which those goods were held in inventory. The Company recognizes revenue and cost of sales when such inventory is sold through to pharmacies. To estimate product sold through to pharmacies, the Company relies on third-party information, including information obtained from significant distributors with respect to their inventory levels and sell-through to pharmacies. At the time of revenue recognition, the Company also estimates a provision for returned products based on historical data and future expectations; this provision is charged against revenues.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Deferred revenue was $0.1 million at December&#160;31, 2011 and March 31, 2012. Deferred cost of goods sold was approximately $20,000 and $22,000 at December&#160;31, 2011 and March 31, 2012, respectively.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Collaboration, research and development, and grant revenue</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Certain of the Company&#8217;s revenues are earned from collaborative agreements. The Company recognizes revenue when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether these criteria have been met is based on management&#8217;s judgments regarding the nature of the research performed, the substance of the milestones met relative to those the Company must still perform, and the collectability of any related fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Research and development revenues, which are earned under agreements with third parties for contract research and development activities, are recorded as the related services are performed. Milestone payments are non-refundable and recognized as revenue when earned, as evidenced by achievement of the specified milestones and the absence of ongoing performance obligations. Any amounts received in advance of performance are recorded as deferred revenue. None of the revenues previously recognized are refundable if the relevant research effort is not successful.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. All grants earned and received are not refundable. The Company had deferred grant revenue of approximately $75,000 at March&#160;31, 2012.&#160; The Company had no such deferred revenue at December&#160;31, 2011.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Clinical Trial Accounting</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Data management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations (&#8220;CROs&#8221;) or clinical research associates (&#8220;CRAs&#8221;) in accordance with the Company&#8217;s standard operating procedures. Typically, CROs and some CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into the trial and any initial payment made to the clinical trial site is recognized upon execution of the clinical trial agreements and expensed as research and development expenses.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Research and Development Expenditures</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Research and development expenses consist primarily of costs associated with developing the Company&#8217;s product candidates, including upfront fees and milestones paid to parties from whom the Company licenses certain intellectual property, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs, amortization of purchased technology and depreciation. Expenditures relating to research and development are expensed as incurred.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Foreign currency and currency translation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date.&#160; Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from remeasurement of foreign-currency denominated intercompany loans that are </font><font style="FONT-SIZE: 10pt" size="2">of a long-term-investment nature, </font><font style="FONT-SIZE: 10pt" size="2">are recorded in other comprehensive income.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Fair Value Measurements</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Inputs used to determine fair value of financial and non-financial assets and liabilities are categorized using a fair value hierarchy that prioritizes observable and unobservable inputs into three broad levels, from Level 1, which is the most reliable, to Level 3, which is the least reliable (see <i>Note 3, Fair Value Measurements</i>). Management reviews the categorization of fair value inputs on a periodic basis and may determine that it is necessary to transfer an input from one level of the fair value hierarchy to another based on changes in events or circumstances, such as a change in the observability of an input. Any such transfer will be recognized at the end of the reporting period.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Income Taxes</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company&#8217;s management has established a full valuation allowance against its deferred tax assets based on the determination that it is not more likely than not that the Company will recognize the benefits of those assets.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company applies the guidance codified in ASC Topic 740, <i>&#8220;Income taxes&#8221; </i>(&#8220;ASC 740&#8221;) related to accounting for uncertainty in income taxes. ASC 740 specifies the accounting for uncertainty in income taxes recognized in a company&#8217;s financial statements by prescribing a minimum probability threshold a tax position is required to meet before being recognized in the financial statements.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company records income tax benefits related to research and development tax credits, which will be claimed from H. M. Revenue&#160;&amp; Customs, the United Kingdom&#8217;s taxation and customs authority, with respect to qualifying research and development costs incurred in the same accounting period.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Stock-based Compensation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company grants stock options, restricted stock units and restricted stock to officers, employees and directors under the Amended and Restated Equity Incentive Plan (&#8220;2006 Plan&#8221;), which was approved on March&#160;16, 2006, as amended on May&#160;21, 2007, and subsequently amended and restated on April&#160;14, 2008.&#160; The Company has granted various types of awards under the 2006 Plan, which is described more fully in <i>Note 6, Stock-Based Compensation Arrangements</i>. The Company accounts for these awards under ASC 718, &#8220;<i>Compensation &#8212; Stock Compensation</i>&#8221; (&#8220;ASC 718&#8221;).</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. The fair value of restricted stock and restricted stock units is determined based on the number of awards granted and the quoted price of the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, the anticipated exercise behavior of its employees, interest rates, and dividend yields. These variables are projected based on the Company&#8217;s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&#160; The Company considers many factors when estimating expected forfeitures, including type of awards granted employee class, and historical experience.&#160; Actual results and future estimates may differ substantially from current estimates.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Segments</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has determined its reportable segments in accordance with ASC 280, &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;) and related disclosures about products, services, geographic areas and major customers.&#160; After considering its business activities and geographic reach, the Company has concluded that it operates in just one operating segment being the discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Net Loss per Common Share</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company calculates net loss per common share in accordance with ASC 260, &#8220;<i>Earnings Per Share</i>&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock, restricted stock units, convertible preferred stock, and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 6pt; WIDTH: 98.88%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="98%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,<br />
2011</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,<br />
2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Stock options </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,347,033</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,438,679</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Restricted stock and restricted stock units</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">52,070</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">344,784</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Convertible preferred stock </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">516,228</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">516,228</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Contingently issuable common stock and common stock warrants associated with economic rights </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,933,052</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Options to purchase common stock and common stock warrants issued in connection with the October&#160;2010 financing </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6,242,398</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.12%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Common stock warrants </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10,005,192</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">13,814,015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 73.7%; PADDING-TOP: 0in" valign="bottom" width="73%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total shares excluded from calculation </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">20,162,921</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.52%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">21,046,758</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.02%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Comprehensive Income (Loss)</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In accordance with ASC 220, &#8220;<i>Comprehensive Income</i>&#8221; (&#8220;ASC 220&#8221;) all components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. ASC 220 defines comprehensive income (loss) as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recognized in relation to items of other comprehensive income.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Recent Accounting Pronouncements</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In June&#160;2011, the FASB issued Accounting Standards ASU 2011-05 to amend the guidance on the presentation of comprehensive income in ASC 220. ASU 2011-05 requires companies to present a single statement of comprehensive income or two separate but consecutive statements, a statement of operations and a statement of comprehensive income. ASU 2011-05 eliminates the alternative to present comprehensive income within the statement of equity. ASU 2011-05 does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.&#160; The ASU should be applied retrospectively and is effective for annual periods beginning after December&#160;15, 2011.&#160; In December&#160;2011, the FASB issued ASU 2011-12, which deferred the changes in ASU 2011-05 that relate to the presentation of reclassifications out of accumulated other comprehensive income.&#160; The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In May&#160;2011, the FASB issued ASU 2011-04, which amends the guidance on fair value measurement in ASC 820 to converge the fair value measurement and disclosure requirements under GAAP and International Financial Reporting Standards (&#8220;IFRS&#8221;) fair value measurement and disclosure requirements. The amendments change the wording used to describe the requirements for measuring fair value, changes certain fair value measurement principles and enhances disclosure requirements. This guidance is effective for annual periods beginning after December&#160;15, 2011, applied prospectively. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 23,640<span></span></td>
        <td class="nump">$ 24,449<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory</a></td>
        <td class="nump">109<span></span></td>
        <td class="nump">182<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">1,423<span></span></td>
        <td class="nump">1,200<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">25,172<span></span></td>
        <td class="nump">25,831<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment (net)</a></td>
        <td class="nump">166<span></span></td>
        <td class="nump">167<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">25,338<span></span></td>
        <td class="nump">25,998<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,116<span></span></td>
        <td class="nump">1,763<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other current liabilities</a></td>
        <td class="nump">4,504<span></span></td>
        <td class="nump">4,664<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Economic rights</a></td>
        <td class="nump">1,153<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities measured at fair value</a></td>
        <td class="nump">29<span></span></td>
        <td class="nump">71<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">6,802<span></span></td>
        <td class="nump">6,498<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">6,802<span></span></td>
        <td class="nump">6,498<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2011 and March 31, 2012; 1,213,142 shares issued and outstanding at December 31, 2011 and March 31, 2012. Aggregate preference in liquidation of $13,708,505 and $13,890,476 at December 31, 2011 and March 31, 2012, respectively</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2011 and March 31, 2012; 54,220,458 and 58,993,414 shares issued and outstanding at December 31, 2011 and March 31, 2012, respectively</a></td>
        <td class="nump">59<span></span></td>
        <td class="nump">54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">278,430<span></span></td>
        <td class="nump">276,452<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="nump">65<span></span></td>
        <td class="nump">57<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(260,019)<span></span></td>
        <td class="num">(257,064)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">18,536<span></span></td>
        <td class="nump">19,500<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 25,338<span></span></td>
        <td class="nump">$ 25,998<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of warrants and rights outstanding. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 00-27<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 98-5<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJJBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">188 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,955)<span></span></td>
        <td class="num">$ (4,588)<span></span></td>
        <td class="num">$ (256,504)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of interest on notes payable, net of amortization of debt premium</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of investment premiums, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,297)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ChangeInValuationOfEconomicRights', window );">Change in valuation of Economic Rights</a></td>
        <td class="nump">56<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">56<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in valuation of other liabilities measured at fair value</a></td>
        <td class="num">(42)<span></span></td>
        <td class="num">(78)<span></span></td>
        <td class="num">(6,413)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnPriceRiskDerivativesNet', window );">Warrant re-pricing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">15<span></span></td>
        <td class="nump">86<span></span></td>
        <td class="nump">12,570<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">886<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Fixed asset impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">221<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,747<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(98)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockOptionPlanExpenses', window );">Compensation for warrants issued to non-employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,215<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims', window );">Shares issued for IP rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">446<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property, plant and equipment</a></td>
        <td class="num">(47)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangibles impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,934<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">102<span></span></td>
        <td class="nump">251<span></span></td>
        <td class="nump">19,125<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Provision for restructuring</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,779<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance costs of Preferred Ordinary "C" shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,517<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_TransactionCostsOnSaleOfEconomicRights', window );">Transaction costs on sale of economic rights</a></td>
        <td class="nump">33<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, inventory and other current assets</a></td>
        <td class="num">(126)<span></span></td>
        <td class="nump">40<span></span></td>
        <td class="num">(184)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
        <td class="num">(807)<span></span></td>
        <td class="nump">397<span></span></td>
        <td class="num">(6,120)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(3,771)<span></span></td>
        <td class="num">(3,892)<span></span></td>
        <td class="num">(216,890)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase of ALIGN</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,763)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,846)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">187<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(156,657)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Redemptions of short-term investments, net of maturities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">162,729<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(6,350)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,719)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,678<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, warrants and economic rights, net of issuance costs</a></td>
        <td class="nump">2,911<span></span></td>
        <td class="num">(80)<span></span></td>
        <td class="nump">94,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options and warrants exercised</a></td>
        <td class="nump">34<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred stock dividend</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(182)<span></span></td>
        <td class="num">(1,898)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of government loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(455)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Government loan received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">414<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Loan received from Cyclacel Group Plc</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,103<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders', window );">Proceeds of committable loan notes issued from shareholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,883<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections', window );">Loans received from shareholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,645<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents assumed on stock purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,915<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Costs associated with stock purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,951)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in) provided by financing activities</a></td>
        <td class="nump">2,945<span></span></td>
        <td class="num">(260)<span></span></td>
        <td class="nump">246,404<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
        <td class="nump">2<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="nump">476<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(809)<span></span></td>
        <td class="num">(4,145)<span></span></td>
        <td class="nump">23,640<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">24,449<span></span></td>
        <td class="nump">29,495<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">23,640<span></span></td>
        <td class="nump">25,350<span></span></td>
        <td class="nump">23,640<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CashReceivedDuringPeriodForAbstract', window );"><strong>Cash received during the period for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="nump">11,751<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForOperatingActivitiesAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,914)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ScheduleOfNonCashTransactionsAbstract', window );"><strong>Schedule of non-cash transactions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases', window );">Acquisitions of equipment purchased through capital leases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,470<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements', window );">Issuance of common shares in connection with license agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">592<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan', window );">Issuance of ordinary shares on conversion of bridging loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,638<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest', window );">Issuance of preferred ordinary "C" shares on conversion of secured convertible loan notes and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,893<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus', window );">Issuance of ordinary shares in lieu of cash bonus</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">164<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Issuance of other long term payable on ALIGN acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,122<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Assets acquired under capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_AcquisitionsOfEquipmentPurchasedThroughCapitalLeases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CashReceivedDuringPeriodForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_CashReceivedDuringPeriodForAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ChangeInValuationOfEconomicRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the change in the valuation of economic rights during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ChangeInValuationOfEconomicRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares through issuance of license agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesInConnectionWithLicenseAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares in lieu of cash bonuses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesInLieuOfCashBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of ordinary shares through conversion of bridge loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfOrdinarySharesOnConversionOfBridgingLoan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Preferred shares on conversion of secured convertible loan notes and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfPreferredOrdinaryClassCSharesOnConversionOfSecuredConvertibleLoanNotesAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based issued intellectual property rights. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_IssuanceOfStocksAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from a loan issued by shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ProceedsOfCommittableLoanNotesIssuedFromShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ScheduleOfNonCashTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ScheduleOfNonCashTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockOptionPlanExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based issued to non-employees for services rendered. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_StockOptionPlanExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_TransactionCostsOnSaleOfEconomicRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the transaction cost on sale of economic rights incurred during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_TransactionCostsOnSaleOfEconomicRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 143<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 410<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnPriceRiskDerivativesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net gain (loss) on price risk derivatives included in earnings in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5624171-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnPriceRiskDerivativesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 26<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743430&amp;loc=d3e92212-112881<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7, 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations incurred but not paid and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph e<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaidNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the amount of amortization of purchase premium related to an investment in debt securities. The purchase premium is amortized to expense over the life (holding period) of the security to arrive at an amount of periodic interest income which results in a constant effective yield on the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 91<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeAmortizationOfPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the amount of collections received from related parties to reduce the carrying amounts of loans and leases receivable due from them.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.7(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Subsection I<br><br> -Paragraph 8<br><br> -Subparagraph j<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 9<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Subparagraph e<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansAndLeasesReceivableRelatedPartiesCollections</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's financing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in financing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's investing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in investing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) the entity's continuing operations. This element specifically EXCLUDES the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in operating activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of liabilities that an entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition that are not presented as a separate disclosure or otherwise listed in the existing taxonomy. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common and preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the reporting period for charges associated with the consolidation and relocation of operations, disposition or abandonment of operations or productive assets (that is, for reorganizing and restructuring charges and other related expenses). These charges may be incurred in connection with a business combination, change in strategic plan, a managerial response to declines in demand, increasing costs or other environmental factors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRestructuring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the return on capital for preferred shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash received during the period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIncomeTaxRefunds</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest received on loans and other debt instruments during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromInterestReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from principal payments made on loans related to operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLoans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br> -Subsection 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-12-037471-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-12-037471-xbrl.zip
M4$L#!!0````(`&2`KT"9;N#?6H(``,MN!@`1`!P`8WEC8RTR,#$R,#,S,2YX
M;6Q55`D``WRVLD]\MK)/=7@+``$$)0X```0Y`0``[%U9<^,XDGZ?B/D/7.]&
MSTR$98N7#M<QX?)1[1B7Y;5<6SW[LD&3D(0IBM02I%WJ7[^9X`WQA*6NKMEY
MZ"Z9!_++!)`7$N#;OWY;N\HS"1CUO7='ZLGP2"&>[3O46[X[BMC`8C:E1W]]
M_\<_O/VWP4"Y"(@5$D=YVBJ?2!!0UU4N_&#C!U8(#2B#0?K@1^*1('WT.OH'
M#5FDW'@A4`JM)5%^^6)YCO)AJ(Y&__-IJ"9O?GL*7'J&_U<`E\?X3_KN:!6&
MF[/3TY>7EQ.\<N('RU-M.-1/J0?->38Y2IZWM[:=/0Y_N)9-W!/;7\/CJC;4
M=35]TJ7>UX:&\?:3Q;*&011+R]ID;RPL]L2?3FY@^^I@J`YR"MB@DX,OMC\Z
MC6]FC[(RDR]Z^J1Z^LNGV[F](FMK(#)+F6]HZKA)//$3Z0L.$>`P8I\L_>=3
MN%'%P(Z,$ESJ=#H]Y7>/H-<4Y2W^/&,<Y0-9*/S66;C=D'='C*XW+D+FUU8!
M6;P[PEX:I!UR\HTY1\IIW%`\`&P?!LJW4*'.NZ,;Q!63R>X3+Z3A-KF67:4.
M7E]0$B@<"BE!3UF]N/G;T?LA"%;5<?"]/15?3DF=5M!**&U(0'UGAS[OGO`]
M%Z2J@2"SQI,[Y98+K:27$L:;9*']YP\G#6TPU`\@C4ML^N;Q\H<0![`<A)>@
M$-_#Y!D-AI.!JJ>MY/>$EXCG\,N[,DSO[$.&Z@\RHG(QI:IJJ/81H7HX$?XH
MD[(D0JV_"`\T"F]^H%%8TO('T6LHC>&/)HOA02W>?/:CR0-FBCE0S7W((_)H
M+(S/<]'6K8G%HH"\3_R\,W@B;2B]56P<6ZIL>;ZR`L)J&D_4`W]$JG5`=4\"
M3D,@X=!G$+LH1GSQ+EIC_.`'V<V^3!<%7=UB@=PE\?PU]9H)M@E"I+C;:'JW
MP/>N])*(XNS"8JMSS\%_KOXWHL^6"R.1G8<75A!L(3[[+\N-"!?PH[4$I]TA
M-EU;+GMW--"/E&0@/:"_'?O0"I+@?_.!I!F&,85I\/:T%\%78-3:,*(9%5'J
M(V/X6I0WWC,\XP?;:^I1MB+.1]]WV!T)9XL'PDCP3%B*4>\M1W6BE?!U(":-
MSI"0H#J<O@[??4`V%G6NOFV(QPB(?A:N2'#.&`G9110$T%J*S^PO/11>$5X'
M:M+P1C+B,S3]=0`KH8S[SU=SHJLE)'UI3F3FGZF.M:Y4[P,?3%JXO7?!UH%D
M<'YNUO`8C*X4Q+3_$!F-A0ZHI](?#[A:$H-B-)*$%$LO(RZAMLWI=%+1(8UD
MI#2OJ>L="-FV'X'^O;>VUI-+A!&G2JC3\:@\WZHI]$(AI395=22#(XB(<TNM
M)^K2D!)Q"JK]-:0QXA:P!*2:2%\L,NK0,(=2:+Z`=;;03GO.`UVN0C:+0G2)
M,=&<`9)14*IJEL=+$Z4RI@;1]-=2(T.8EFT2J:>NR:BDT62HR=+/"/=71TUL
MM].3T4M-C.YX!@L"G#OST+>_EEU1"<4D>@%BV]V)R[EQO<A?^.NU[U70[J^`
MS/*$%UON2%=&V9C3'I3/'8?B(I3EWH-[=N-=6!L:6FX&0,+C&H\,4W!^JHGT
M0R+EAXTGACZ4P&+;T3IR<26.^ZD@PTU`5N"ZTF=RX]G^FMSZ+';_'ZUO&<;^
M"M`<BW:A#^&]H-:E%*>Y/]P/)+2H1YPK*_#`W+!"8Y=D06V:Z7B]OZH=:"!B
MP1=H)R@-4$8W#S3PF=3IJR#R^;WR78<$#/WH<)M!DE#:4U.(+W>;[TQ>2FU/
M3'W4"T#!G($+TP"GOR;?C1W:B$E"DU'VN_%&/W!EDWAO!;-@'N(HX[8B34!F
M$$OFX.;NNE5\>0IS>#+$99-^A%\%=M(*=D>@!X0;9XO/HW#E!_17XF0PI[UD
MFB:=XQE:Z]R(U&20&<.>`CP8MAO&H@(N54IBJJ;JJJ$UHXHIM2.J",0,[7"P
M:J.Q#M+2)7OQX/(R#@EL1V)8/B,\>4M!(SJ\""N^03R;E!QPHV0NAEULISX>
M3LRA^?:T%\'78!RU8*PRL/ID.C3&(RF4%9%%FRXV]F<X.E"5A[E/D_$:H+4J
M6<Y8J,.AJ)(;B/5&9<H:BKWB*JL]4\Y(F(:F#0UST@"H2N7M/%2A[TPY^]`!
M4:UU:).1K&DP)].I;JC&(:0D:Q4Z8&K(:=K)LM2<!,_P!WL@S\3+=:S9&#9D
M-76"EM5587#7TA&B*<O-[J3KC!F2QB@AK4S;">C*"9DJ`CT@-":%+FLLSDC=
M)X3&;%!]?TSZRB&Y>1WXZX\\09XA:,SUU"(8&>5H;:?]>AD4V!\UIFPD!D&C
M\(N$&Q,P$EW?F7!C8J5.W*`1AMU)7_@LG"WX.)A#Q)R1;DR@U`E[.!+,6JGM
M;H0;4R<UPIZ*>6<)NE+*3IT8/5C&H@DKL+$FY1*ZP_7YPF]2'I`!D=%U^G`R
M%*98`RD95%+J3S?&AT4EI1'5R5@5NJT'L#EQ7;"E\:X5%UXX=]98'A/BQI9G
M(B)LU9A5\V@B3*1N-%^#<]RJ7*OZ=SK]S7&VZ^(JE:@:$_W52'']FF"`*&*2
M4M.BFR2V7J;-%QA@E(9!9(=1`-!1TV2&>=RJKJL@:".]K#AKJ.PJ4,RR)CAS
M#*V:NV*H&U/!0(NM=Z3=KKTKE*:AC_=!NU5A5\I^J@X-O0?YV09K4J%+\I6E
M#$&K<JZ0_(`[9:7>WZ70'4*[)JZ`H&OCT?X@2#FG`VVB8GEW+Q3WUA;M`YLM
MKJEG>;8X'2?MVK0*BFZ:0@JYADXQ<18_\MES2/`QLM"=)IEFFDAI2W64+&77
M$RB+XZ-%/132S+LD`7WF&O3&0RW"T8//>0^J+5]\G4@IS)$A=%-7LF6PUWY`
MZ-*+"UWL[2,PQ"P;%6_:W@>R@&<*B\43&9=L,"H'/3WHOAZPE+>F&M\/L)0C
M-S`TH>Y#&C.6.K,0QTT\Y_G^8[B2`93RX\HA8!V-?DBF,I[:Z!!`Y)2+/M;E
MQ!)?%7ROJ90J,4;CL8"AU'J%[W7G>W[9+&00VGVO"K]GO.MX[9+HAZ,]<JX2
MA020W?MBK[2Z8Q6S12L/BUHB?;&TNV<5,U>H%-T;F';%7-%'YG0ZEH&3NR^8
M:KL`2M2+X)7$O_&]1!O&SX%.).P3]?R`AMMT0H`[6FXEKJ?X1,*5[^0S-_-\
MIJV*O-(5'8_%G2>_&?+O+[)VO[7*=5:%S2;_GT0&FD+.UQ^;8JW^=Q8;-)A,
MW0_$(PM:V&S2:EZK9I(Z%8UK)96>4-J-;!44P0'>#Q2I1,=`G8Q4<>]=!S00
M0NS&F1"W2^DX<U*61ZGQ3G1EDAP#;6J:KZ0KE>`8:.9(W`%209K'F)=\DZOG
M0"B7567,`@=BWF`;KV+F8*0LJ#Y)U65'>@5P#\0A9(T;><H5(RQK)0<GMT)G
MJF:.K9U<E>"$9W-$<OEGK4)6`HD^*)IWSM7Y8'M'(16PZ!-]VA5'Y3@_?[:H
MB_WYZ!<6YY/RU`\6HW:.L%71UGA/P_IIUDY^3]AEPB!P8X0<[/?!+A4Z#?2A
M.IVH^X.?UKVGE5+\$5R2HFX4YA4L:GEKH-9AE.3U6H/AB5K`VT)2$M^H!5]#
M/1G@&XXD\7TAN(N/..?/X+LMR5VT?B+!;+%3!R-T?LFB#-NDF9;>&"-SK*F3
MXG;"/N3W@GS2@KRF:,@8C]21MA_D%9M>Q+TV:O,>R5JU-A+R9PVD^F-JWCE9
M[TP9XI+1/C%)&2CPLPQ]9_M;-U1B[NU\[0<A_94'/K,%V+@UC=8Y/JEDVT#3
MIF*VK0/5NB6&^X#:Y(&RKWG2OU@DI3;OWJM/)9<]U59Z97B7!.1M4\X!_';Y
M0BZN*A<XRQ'*Y$@FY;"U"\'70)3)2:CF;PFQ>0=?;?I9,P5GJ3_,\G"]\4`Y
M+BE8>>$DA>9]>W4`)T)'-Q,39O-Z8]$`Y]5L<>M[RUL8JT[\X,_$=:[]X'.>
MBE2;M^W5:ALA3=N)9M_UH<]>0"RW6&VM-N_HJYW6X[&@L/L0%RN2;'_IT;@C
M+A/O7RB959MW_M76IXCUD?64"@$/]R9G&[YEP;4\L2Y!;=[V5S]#BM%H#8T"
M"JQYQJ-FP5W@D1!,G?1<!9!U6O(["RY<BZX+X*22"D92MR5!N<Z>8'4D&IW"
ML2S9F2PY6ID%56'D=2/Y.IARRZAFW;IZ#Z"^[[Q0U^6YT)*.RA5$#E.J4F,\
M%:J5NM`4:LV2$((XZ"'!2"Z;%$.FPE@SA4+?2AK]<$@5'`MG7>P#AUQAVQ2,
M;&\H::D+S-Q2`5H.1C+S*RXMU1%JLO'EZAL>?K+XB)\<GI3BQS.S&LQ]/=V=
MK#G8+$8N2?SOC9<</98:C\HCR'+L,LNU`^&P/3D,^^5#:JE7VUD0^NY\2(4P
MZL3X#1@1SK9*7\Y*YBK.[E$-F8!'WPD:7P'E(%Q)K=M.AK]SMDRYI=5X?>TP
MC$&XC6=X@A^"R7?GPQ9""C#YV8OGX+\_Q\=75:S?YIQ)K:CJ$Z%"^75H#L.9
MU`*M/A[O)*]_=YS)67U-'4VF.XLB>V,N]2$>_7,;_&%P;B)&/0(*-#[MAQ\\
M&]_)(UA3RD/0Q4,.^]!N05U[%F6.66;)N=K?:J?Z>K12,>5$W,,EC3CP;4(<
M7@)2$3E50Y8T]3OGG':EW"+D^0K\ST<2K*NJ;N0VH$*WC(03OSJ1;1-N(]3V
MS:+5E>_:6)NVB+8=:XVJB9_OKOOD]IWN%'N\`LIAV));11CI9B>%+L7:`SC&
MZ58+S&)B]R:'Y-VB\S)[<NE2Y$/*-.GCG4//.I.NGQ%Y*JQ<EP`S/S_-A%_)
MX4N9(Q4LZWA2.T.ZX^C"2V'1/(<M%:L*NV-;R4FCDXE`M:DJ'MEY*'A2UF9J
MF,(1`J\`6$@HLZMO)+`I*_A([1MZJS)P]0J[BI@T-IEX3TA9'@Q<A_V[5>FG
M88,?T0%>IKAJRJ(:U$_[1MZ&PK17`-@C!W+9T8FPV/-J'HH&Y,X/21I?YT"E
M#)4AE(W6D:D?L=5@Y':IJ/7SJ!N86]\JV.X.^X4KMY$/Q0\\"`1*)YK%]V*]
M2,,0\>%#'&]\4A"?9Y@<3VK"<GR2D<RD4.0J`T`X(0A9@N''_1#V0&Q"G[&1
M!\+/9+VW@MB[<EUBEWVC]AW)U<GZD5$>=+T1"$4WA5@86>6_&2TM<G38N5PU
MC<=3P=-NH-6PTK&)`GN%7MZB?"ZJ*K>;69T*JU&-Q#JY]]D:1$?WOGWO<Y6#
MQI/P[<Y]1S"'84PF'-.F1J>`[+LR)E<(8HR,W?+^O?%VM5C`E(:1^@V&K+<D
M#S#?9U[U%YV:N9,YR:CL%KT6RZ$XDSDJ2?LA.),RSX9PF,1^F:L9W,U\2!T<
M`,Y.)YUQ(,PRI2X08$^_(V0I$[[[O3AIT*5X.-D5&#LKA1!-Z@B!>G]3I".!
M2.HH`?.@B.3.%`!_OB&#T@-6LB<0FHZ*^[KD3AG`:+4^OA:)51]W@-_K*%8W
M=SALH-*QGJIB<4"I_4+<4O!;6>PH\G6#^\1W=!Y7@1\M5\4494%0<FM<1E*3
M*PV@LAZQO*./SV,O#A.^T'"5'DNZ#`@IKQVTGUY0O4F_L%U-&D0'1F;8QC,$
M:[Q$Z$-`G24NGD.DE',@%3ZJH^2K"I+D*['O[*^\<"W&+JK:FA,["K!&#"^%
MM!BM8CUV_/4P\1025>Y(A<EDJE?Q>BBX.^=$V&!H9@$&L,D?A6'/RR**G[0`
M>&OBJ#G/<C&KJ@F5#'(P*F+LSM^>;3[LX*8FP6N*:S\'__YL\P$#\7>W=T.]
M:45*H!_*6;"TO*3^#T86\]WD4/HX"\B@@7)MH.7R(]:Y\L#J0-?'CPP_`M(/
M;B%;J>%Q`E76_?U/;OB&IX84%FY=\NYH`4\-&/V5G*G#3?A&X7\OK#5UMV=_
M>J1K4/=WY$5Y\->6]Z?C$"\<,Q+0Q9NCGY;AFS_^@;<8%'X[^>]-2N73^</'
MF[LS94B]^+]-R%_'AY[2'T@Z?>%Z=O<X^')U\_'GQS/ER7>=-PJ_-+_Y[ZLS
M)8;*+UR??[JY_?N9(D`]4I`GW(Z(K:LG/UGKS9M_5T?#-\V_E+OSQ\\/5\KL
M6IG=7SV</][,[N;*^=VE\N%\?C/'Z_</5_.KNT=^"V&?(NZ4A].,F]--3SGL
ML"_':X&K'7!](67,T%?UT?SQ[[=P!0TXM?OP<F>%,+P5?Z'DOO@N5_2?2OAO
ME,>K7QX'-W>7,,C@SHEF4F_?."^VMFO9Q%7NP=2MX5<44AN4WW'.`'BL)\J?
MX[\GFCIZ4_B9OIY=&K\I_%3\0`%CHM2\ZZ\WEK>M?O4O"F6*!;HX.Y5WP$)K
M290GZF]*4$&]\7;@60?^Q@W)H<_)%EY6+,_!!]>XH(6[?.**=QA/G@\/'2MK
M@LD"RM:#T`J6!%MQ@FC)>%L!L4)E%8'P%!O]A8#Q]GPTE`KJ0#]BBD,9]TE/
ME`JA,(4?,4N66^0+VGR*J.L@@Y0[%@L*!'=9>TIJO$`9VQ%?]_.4%5E;H>_Z
MT!0'`?$$_^,)G63X$QK=^$&X`!/B(X,YU\HF\)W(#F/T)>$J&[HA+M#*1,+9
M1W8=M$3`UN]['/]H\ZTT-FR0/._O4H_`L`KB&EW\:DLZ`J"#F;6Q;-"A3]!?
MQ]"7,,TLUX7AD)X[<*P`!9@80(LH:^ASEY<Z*EX$%WQ&'0)O63!J(O*O;MT+
MSGFA2W"&/Q&4-P'7+^(:":"@1II?G7^ZO9K/4=LRHNB@6G!>QD^#FX:S$YZ.
M\-!5F*#S#>'S]C[P0Q^FN8*U^HS%"BV-'947""AYZY_GRK7O.WQV7^+L+1YN
M#>,FT^':\,WUY7GVEPK:=I&HZD6`;A_7!%SM<0J@$RP["F$L;6%X4D=Q2?25
MK*F5\D5P%=&-%1)<BKG30*Z1@^,7&^>O.ENV@<`*E)O"MIX3^.A$@K[Q!@P\
M;C<>MF[D+1,]6X)\-[^XO2B!YDI]!8BA/7>[WJQ\>XMMI_#^-;CW@O,+45;6
M,Y@&;^GS@9JJ*[`GR\#"W9U>V=B^6)0KG$44<!L)%L0Z46;0I?PG#'A,@K%<
M8\4CARD!>:;DA3C'R@M1<),?M`N1])J/1QR>8&(I#TRW."HW4<"B$J&RR3^%
M@;>!(-<C?$\9/`+CTN(;7HX!M.U&_',\K#1[/329\#.>-'QV,;"--@6^GXX5
M/T*;CY,U%T1F)@MN$V<I?Q';Y2.87_<LQFW]UEN2^/V=T7Y?&NLGR@U8]N1[
MOEPZ:ROX2D)P(`)BAS#WDJGX&8)34"$\.F3*+V!M:)"`&AMOE`N8U&L^(0/+
MB7>_@]#`YPBAY=@QN(O6/H7I67@K_DI:[5W_5P)\Q//\&PE\%OHX^Y2?_1?H
MC^`X%7RV#J@L^0'\H%$L)9[YUAKWB&"?!O&&9U:(U$#O">Y*[`L2S+*`G61@
M\5CTA,>5A#0VA=`D60`><':@311,XFZB\X4]%0_I)T+XT/43MQ&""WAIC8,B
M2+X-P;DNT#Y.%75I*G!%#H,J>1#O<2>+5P;P_8R`E9<K1/'$X67:Q]`+E/&&
MDB]`XTO0H4$43R#\$]0WQ<-P$!S#-*)[HL"4M.-/MG.M"TJ/;I"I<`6>*HY0
MS.G$^A%_D#P-P97Y!@!\H]#I!%[_#TT_&2D0Y[LX&.#]3\AV+GU=/58P:\#=
M$!8M\(N\V`<@KC4A,;D<`HQY+)0>X*Q57OS@:Y$[#[/@,5.^@NEO_C*H_UBQ
ME.:A(%H^N`"<"QH@Y!WJD6_PXX6XS^CD>.&*%48<3!"85)X?0A>#60GP"\.Q
M=%+%`M>YY@$DV`DEUN)E`+B#L85+0M(:3Z`&XRH)&4K\[(+W7.@MU"\5_MXQ
MRBV"F``H;0&+C2L&__P&['>38<`SCOCD**;;_I5BV`/.1Y@ZJ#)QQ0,G39K=
MQ(C7<M'RP=!'16)Q^==H'VY$ZMIA62Z43\$L173,)W!V))+B^HP=YVIQX?HO
M+'-]PQ5XU(DF`=/B0+NUFA!:P)QUK,K@W0TF`1STGM?*>;2,6)B_I>K'"GXR
M1_DS>!R$5];^!75++:/<<("&"N)J-\PL)/E=QG.Y_&/IJ;VW["3_P0,\7(7@
M>CKR+/!MX.T3I:?\+XE-\!RP'60J.F@.GH9$$DXY_9A,N=U%FJ0N]DSL;^7(
M>9/GGH<&\8%@S@*#VVLPOP79#0=_@]9<>"L+<_@"3!(8@Z32,@^%ESLR)D8Z
M\RO!D6J01R5N%.<F5@IQ_(T@GE)U8<6[6[E]!D,/1M`%8-S2X(NQH\-=$AL[
M/V>_[*@5$7\\/[_?"<[0?PCHN@"1>NBJQ"Y<$G@AF,#A79J)*X@`4"[1V,%8
M\I0`%E/\7WOOVMRXC>P/OS]5YSNPYI_4SE31BBZ6+,\D6^78GJSWS&W'SN;9
MEQ`)6<Q0I$*0]F@__=/=`$A0HFS)UH624;6;D242!('N1E]_K;0C6*6&<T:W
MPZN$4U>>0WZ,-*6WCJ@2KYY]]#".4TE["5?ECX/I@J59=D7HO"\.8,%).ZS:
M(=*-<0#4NY1;#Z00:(CR8"7]TO\S4T5;H!R,`M#K]$O%$<PEPO=!EL.#FC2O
MX@;0-#PPNT%;)Q51DH(S!,4:;GQ`*JTDW;0D@=&S<!DYMD8QYAK*\)CY7/*(
MIC@]HZ<\`#@`Z4<O8$#Z#[EI\344[>D'H%L4E/KO$TY>$/V\*:CA^!S<E87"
MJ8V^9B(95,/(%L3[5N=VI84-<%K,E]9@]&<6>84UN)K8TQM;(:AGWQ"&6"Q]
MW3D!.N]`%T^2I\#ZS]4@SCY<_08_>&21O0*."VZC7UZI/^NG]VPSY(CY1S"V
MT5^P(G)U",ID/J5L[<[5D&2%+#1S9#D.'?W`??$X\)ROB&-:L:S9`2SK5G3T
MS]&L#&^W3;U;.T^(H4D"@;!FCJXLF/5&:X.;?P^H)A>NAW_3#&4H2<<"#SGW
M@,PZ)1JGN4\"/7TJA<Z%LX04`?V((5=Z(%<8=5+DZ^L+176HT]%S\Y_B*;DC
M0CDW,>=%UMT>:?V;YPA[T5T<WI&G`CWS%+3+`ZB5#AZE'25:ZX'S(@')C*X:
M6+M)+&Q@;4WSI$9U4C_AR3C7:^<IU%4:+):+QT!_^@K?.79[_;[;/#D%)8":
M#Y0]A^60G91%0LJB%'D!`6/QEA^:C=[Q22]7,P6ZW]"/):/2<`3[#(-UA+GL
MH&6G-&2/+_U$K3DHNU-I1_#S']R/N(`'N',,K10ER1_J#0,J!\,7T/.03K[!
MGT#(#O$XIA,=91/]*-1+(Z6RY+Q%#E7X)5`)=9:FUS)/P^6OJ<>D`M>@XD2G
M5*.#(&%2"B5T+)*'4_Z<>X,E.;::/Y()"X)]F%&"32']T.!*0RG3M2!4<RB$
MWP*G=HE^/#8Q7?GP3EIT^WQ(G@P!)X.V<\S#9@QL0H8)C$.$ZO"`-'N]*'B4
M*$Y-G'N%`4KT+7"E9'7@':]:$R1SG?-)\Q2.88'/*A:%,6XI>STJ'>?F>N=^
M7TRC=3JN\QZ,:T>F9G[D#%U?4G$N-J+PQI(P+`*`0%KA"SA4-Z9MYZG02M'6
MY>E6NUZC=MVK4*Y+I_VO,4OHL+V@^"Z*>,Q+1NL?'2H8Q.2@>"88005QGJ24
M?T'BW5<;IEV55</W?G2,!/;<ATH!L5D",%V3,[^5O)2D^8,PGBC1+Y7N1*1Z
M@O@ZY*J1<3CRL\C$`F3=>XS!D0MJHK`#8ERVJ>&\4`I,O3=[S]P3U]E`@$)@
M713/FMNGL^N+LW\Y9Y,)9Z&5E,\Y?.XPFU8%(')5,%=O69X0)+74$+14KBP1
MN0F83Y8&PZE*^"GR/E#H!"E('"E"$WXK`VD48@C*01/,FQMGX]PJ&@2^LM!4
M@$,YBWF*VD>*P03G@_)U?,U"7JQW][C;?,W>O&Z]*;Y[;29%@U0M[E"BU,]T
MOI+3ZC=!K(<@SQGF44T%AC/B>ZFURG<PWT!ZFUFZG!EY#VJOH:S[/%3OD%MV
MBK!_"^,!*,\?*>?H\`7PMK2",Z"IT##1J]0"(_88`,E-0A95;WU.O$A.VOM`
ME^>!`W(9Q,),H>-4+9_)!&%&V5<))L,0?0@8.S5RV@;4$Q4N4V2A2?Y?8%F!
M1>BIF.(7%O'0F:5R^K8<BB7%:.JTNN9[R[O)'7BGYEQ%R`L7PE496RIOT)=Y
M/%3+S1>.I@F?,@J9S&YBZ,!4$7NMT)296\8HQ^P["0M8S7ENG?.1&%QUG;+A
ML#0-$EUJ'5U9/D%5K\XU1DK+@:%6'CN<J,KU.<X'82<<3NJ@1\)S7IZAPZK5
M:#;Q8>.8$LWIG90`Q`ESBH$)[F5D3:>8.0ACT.M1ECHNCLB`VO`=K718C^^G
MG+48"$SI4/EJ:K_SG55E'@L$P:Q+!0@=P_C8`0=T>1(JFOH5D2OR5*762NH[
MP1"/3TSY$\J%&F"V97ZSEP08,&;E4U&-)<>8H*M\]H#L-H']):/E?LW*\U;%
M^=%9R3#E$V>C74289Q`^Q"5Y-M]T_I1?\+0;8^&*_+U\`<3B)5CR?9ZOQVZ+
M*>B3+.B4'Y/B(U*EG'91`KON>M:9_B7!;41B,DK/\AR3+S&F6G-140.[H!7E
M"ZV!;3><Z]\_PB3^@T6LUU>_?;IZ?W5^]NG&.3L___S[IYNK3[\Y7SY_N#J_
MNKP^<#MPUUFG)=Z8?QV;;?JD;--2JLTJR3\Z)4SGZV31?/T`I=K!U_>C.`RG
M1_$]A3"R@0C\@"6ZW$D>D+H@5<;.1,,Y@Y-7%-)+YECI`M:T:$HG0]HJ@4P8
MZ5E@H9'MNX;<\+W/V=D1SV(S1:")2SCR,5G!UJ&OBVTGV*<HR2NS%W#H7)+K
M[XWKAH,YLUJW$D;V)U6IL&^@*^OMDNG5B&DB08Y5KBZ9P2H=$7/GT%P:YP)`
MUXR%1N<<F4D[GZ)-RCBI)%0H(GL\X<6EF],YH_#![,&J2>E*J5+ZB^D[DC>I
MTB$00`WG'!.GL?*D6`XM\_0W6-UYQT.ALFZHD"7A:99$*G4^B"893$!GSQ0%
M>N0S.))UZ)[96$[-+7\93)UU[BBZ5]IGS!)*,I6D2P8EF*\SL5BC\MY<S[&,
M$E(J0S%\48NO*@L%B>[BY2E_.<_]H:1NJ?<;Y)+PHK9^%&"X7:[@=UQ4KIUN
M\.,=DT@`<G9S)&8>(@.0X[#*.N<5.R7%TKS+\CP6+TB\;(Q%;1YF-9VI^+5*
MED7+QP^&0UZD80ACVH=OA=?F/#C7I7;TP4#\L0?#.@`39NL7*4$I)4&%GH!8
MI$:F5;D*E))5V!A+?DM"H638`W\&E(B(90(CD#%P8RCK70.CPPP=-82U$-P&
MF'DR1D@:Y40MI<2#]A<B9H=B>;02*3=*^0KRC#3)^K/UF7)V,?GDL>?X@REA
M>*]QUDW0!)[2"J%'C@WY;89A9"1.\B(GH$92;:,KS\6`BHG4Z^*[5)1W5B-6
MZ+J#<CQ$57:RE(9END8Y4:></$:L:-J::+I)&)SLN@&?4P"ITTZ=82")]"BT
M6"[B;)`.LS"_W(JO-<SS+)+QNGR9?;W,N7T9B-R![Z*DRJN-7,K@H"U,\IT3
MA3("8@%DFLJX0,\\NY7%UBF_C1.MHAHJBY<#YAO:"X@"]DU5J,>Y.)2*&\FO
MZ828=\*F6%AM#"?%2ORG+-<Q!H^SU)/0'E2C)%VG#M>*')FV&MD(S?/`T)(\
M2@LQU'$U+BM"5HO$H;%(9L8A>00>WX,">H+2>95OV)6(2D6*C=01C>'/*7-&
MY/68CSQ))AZB!8,'&&Z146I&9P+#X-4@S;5F/'E@<)U!3N:+`>QRQXO4=V-:
M'QEYHJ7B*^3ZQHX^!`KU%O5(J5-*/9+Y,@#H%:]523;E4_0>'=]X5@V--\6X
MG*K5?VQ5[D<\,K5@\Y$*QJ'P@601E<<+04.0.P8W,`R^<77H%Y0@D_T5#@"N
M^QW6+QS^$;0=HYUD4[Z)QJHCE9OE:A/9@KBP4@LK3HL'92@KJ?-0(27<>@^[
MB(GVK0*W`KZ%+]HFD,4#I<QX^<):S$*DAE/ILTL7OBG-Q,?2@D($T@H\5DS]
MP`Q>''FV-Z`AO%^U7+6EZV&Q&K=4C'3:_)%^Z_=^+!.'.XOX(5A8'`7E>F8B
M%`JPXGS0>\SQZF1]IOHF5O&0M&%L$0DZ3C*UFNTZ#'/M62.CFHKC:'4-[R;F
MJ272'PIZ`":8R/RQDNJ0^P^%O"P3VGU)R<-'0>2J3Z!6@DF:CM"1>?90-;U$
MP'N@DAI-?7.^Q)L>0G[+NA;T%Z""-8+/MS%%;FY*(2`63O_+I3-1CS/5?M,<
MI*A0&K&`Q8>K@N&4JFU`+HR5OHOZ%YR*`8%,Z%P:AGD;Q<!T(:;R,+E$$GPB
MD.E)@E8"JR)!?T)D4SQ]:$\H@:@8I71]7F4O)99IQ<_JSN6$2[@7E#4ZN6%T
M"0ZAGX"3$WEYI3&=W#%?Z)V#Z4(]OO!HE##`*+N"#`_R0$LI2Y`DYOS@"U7+
M-/.*F+GFP;:(A9KKS()CX9X>`C9%;9)*@9.0C:"B^*7B)E1_R4VK/!^&=8,J
M$?F%ANPN3F0JSPA3V$:QX(8=-9B6P2N*6J=B?C3I(S^^CZ0"/\B7F+0MM0`Z
MZEAO.;(O\@Z()E'J7A0OV`LC]O($M2/',9'[AZH&*!487>(P&S!,L6Z/FL5A
M,1PY&A5#BVR"B4V&+0<+8TQ,>TCO"VP+PP(UD$[(`R"HP)JXYO!IIS;:B5'R
M!JN?IT4!3>1!,:NWK,,NJ`HW2K^7)/R%T(ENE0%H?*GJEA2`EVP$8@8IW=E8
MIKMB,).P;%03"3,0O+$9FW;0O+NQF!I*/JZS1Z,<J]],HZ&R#'C85(U#*)$Z
MB!)@@/,Y@5Z'CR=A/,7Y`MO)SK,R3,U001"@.@SDV;BNJE.;?K,C.?E59CU@
M,".^C8*7D#CWZO$E7]_Z?C%=&0^M[/ZNY]8RFHSR-:35_Y*E)<F7G.UEMQ$Y
MP1'D-V.$\F:F]V.8`/$-5*27@'7$.ZK8NN.)+/2(/?*E^J@8HIL_**<.)JB%
MPL_O9%R<AV&!.X)64_!=WIK;4R!%WRF@VU((AH(ERE4_I3P7ZU+?!-7$F-V#
M1K\._1!V11%(1U]YB8+D.8ZDH,-XJG[J-@MDPAR\R=GUN7.=#=)X`D=MK]D]
MPNJKJE.Q0M`Z1THZ"$,6%*=CJ50<GR.'G\/LGYU"T2"F_0Y6;/G9.)_O"$MR
MA=DTRQ5H.6R0D*M$35!F<$AR=8E*H\)PAFT+AY7Q/&2O(U6\9<Y)^Z\*N"+S
M2O6SFTN)0*A:524_?">;8/7F2#9'-'/T,!4/0X+!($.X@`89#ISY<X6T8/BA
M3J3J^/630)VZ31!6$D&N4"3(EY/B@?P6W1^U3J=#-KD36^*<JP[K\I;7%9F:
MZ"E7J80J5^6-JM53DRG9GMJ+2%\B8`"9L-)=0DXY:8R/>$B*76Z1E_T[%:)7
MBC3S221Y*>'0<)<)<N_D%7A8=R6[\Y"V>A/GSJR"'A9>/[L)8<!5J"M(_"-L
M43`U057-Y@0FUFH\4."_='J8B>3FUE<A,01)A:-2-B@HJ&_F%<_*"4QZ^9*"
M`V?X)!2QF3@ITQH(D)<:#M#.<[]H0U255DG](0@US?3BR<+2=]+A5PP+?W@C
M[-?DY]'FHGU`K>7\OIQ'%[-R`DO&RX'7Y>*L3A[<="YFV5UR,W$/#C^+!-AT
MF\VF#/"VV_+SBL^<">G6>\GWS6`X!^V0#>)$2:[%?3/PBUO$Z-+$9*V+IT??
M%(;:@^E0NCP`Q2A+\G/#*S;LS@!&%(\>G%LU4(9\+68)"(H%X2NI].55RP8$
M-J?@3WXZ%>&8TOK^F?FWTGF($`2$FU[A_\K90;66X4HA4YG*!>8CR%/$\HO(
MQZ4P]X([Y55#G:=4QYV)5!5RJW$+!/'YA#FE<\BZ-XY'^[5$N2XE>>61*H]E
M@L_4T)3:,)G+IB&^Q[+HN\!EE<>W6=/FSJH0_U4HWW)^Y5H5E0B(75ID1AKN
M*64%6EMS3?/\ND!2YY)#AXT,`:):TQ7=TU4Q/:BQU&E+US]JR,6%QX'1#<J=
M2XJ4C",)-A<43(8T)1,UG(^:7]"+771JB`BX%Y/<\SQG@]K8C#"3;T5IMP5,
M!K4N&&%]CK:QRJB7!J?FX.X#H06A+B924Y4L/@@5K":JU:@JCTVOO/1,`YUK
M>6#>.[LVLY9;P_D41X:X44)_DB,IE=Y?PE[JU0GT36`1R'-9;99,NM3F9Y%N
M:3EO+?/\S=2"%$;,+::F1JJW(Q"3SM\&<_H.C<Q\;X8Q;E^15%`F;Y-U_I*P
M/$0K"[A0IFRH=$TZG%TGF^A0#A8;YPP@TU,D+@\8:DA$1AQ*YDF2>B>TL%#,
MIY"[U$%1D%]9WQ@QPQ%04A,K6I:==+4=L#"%LIS$8CXETF@U%3Z0Q6;%X9-^
M;4(\Y[H_V@UEL!<8'X<>Z-F.28\>%D.[0RX=QU&`'A@$$7^@WFRF)5_I1#9Z
MHP@,I;,<F&A6$X@-<)ARYZ/SKY]%R5N,FH1^:"'#A(B]8*YMTOG7L_+-%1[(
M16^&T_4)<57VW*'`2`S*`%9T@YR:3G`*F/"+4Y2>LW@,8\$SG0&JX93I`Z)I
M:-HVALZ?1[/5]=*Z(&^NJ4](O0/4&TQ?CK.4)F:(V3G/=(('2!;AF-R?V:$B
MW3ZW98S29[G/Y`LD3^C<I$&,2[M%EH[324$7IK1`<$S,/$X$NJL-J8+4$)+<
M=*J2J*`:-3'0>\;PH$!*=5+.%IQ317>'\_(SY0%F()3C,^F.*`%#2%)XPO/L
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M,,KK)9$(%WL.S`.$B=QRL1KZ]I)5XX3#2:$BP=[4*/3U%)!5:#'-UEAG60"#
MY:U%?8[IDH0%1JHN53B4-X6\`WG&9*[B#%4[0U2?\FO34FB?ZZZJ$KLAFD,K
M,AR[TJ4U^_0C<WZ@'?,4&V@N@D.278<4$CWYK,Q$S\I9H7L293H%?@EU(Q:"
MBQE_B)Y6?NMK>=F;G^1]2C?-(9?*C3</7Z1L#Y2O>N<?,#<)'$_&;5"]UA![
M"N!$R1@=U,)2K"JZ)J(O5V+Z&/]**+^D3%#D-&4!Y<4I?BB7'DM\8Z,F237Q
M2K1%E8]G5(*H>`9U95:86?GD'Z(]\KZ'W$R.F'].]:C4JN^O#`]G,P!CJ7E]
MXCA4BIE1/`.ZIU!MV#P3UU,GQTNX+DZ(C@.>WF.LD94HR`!]5!2G!!W#9"=L
M8XRVOBRLD[&SLFR;%85Z1L0AN4C5I*9N/\IYI7RB&,B48<S,DV=N>QY8V/+2
MH2<71HMNCS"<>%0`+*FHJ?N,L4N!$@R-2WB!4N-D4!7C\0N`**^/HKB@I,*J
MA<^?Y]4B(,9%^(HH7C`^:GRS6!W3,$+DQY*M(<V!1P$(+K#.5+$L!8?@9DP7
MB0?H2\S#KUED?*&J<I0JBB62@R1F&G/2E9+J`_DD6P:N&R5(Q)3>A_,D6/M8
M7=>9N4X67^L+G=>"2XFU5*E/3HIO&L['PD>NT2-)1=8+4R"5%LNBWH]`@^3!
M'WBJ7IN\!6Q:2J60+6F"F1;S.38_]>[`6F=:%@SSYN[:&1Q-8SNP<864?;G7
MU\CSP%!72F=$"5^RP-MDZFJM&>O-,[))Y*2DVD^WY1,N:K\+'5PJ4M203(>;
M9V!)Z\UFAR2.K^C\<V[8=^N=7'N]1JE.0&H:3HHK;8"Z:BD[G:L$"$2>_9\'
MIN'NAT2TT>/&!(4S%,U<SUP`,"P36.`I>+^!=#SW.'D"\(A).`2X(U'HP:J#
M4(YZ3IV!L?Q<I>OSDM[+$EY"5=!`;^R[.AY(/R/)K!1LC1RF[A581"J1.2B#
MIR0X9<%\Y?HIUX=.O#'GD&-58-SM9H$Q:@1,J:F.,0\X%[-0XJ#,S#G/2D?K
MM&I6Y6TK92J:AP/FU\74GE=!G($,QB_G<(5)_N;"5UJP/.+#0./88R*A?/;A
M2]WM"P#E:2^57'F@`JAFR53X=$-53R?'3;?02HPH]I4A-\S"H4)`SY8UP5"E
ML+<1"V5YY@2Q9Q:IF`-5FY1$5,-10^5Y;L(LWUYB!//,)W>D5\%%E1CG`]GC
M#&NTI9JI^_),DGB@Q24JBV*$)0*,&&@2JW*C($>O\7/,VA)(2WE>"P3ABXND
M[J0&%BO/"IHI1)-!L@NC/GB#!YL<I`6<B=(VO9`%8^T(_`<H[@U'E0L:"X6?
M\/_.>2;2>*PR*91G\/^`4/QX7*)5/)/RX)LG;W)8!C(489_=N2HKF6TWE23W
M8+J=#ECESF?"J"XXS:K%6U:+KXW.!>=&W-6JR&L6`BH_5':7C"=Y60`6+TJL
M+OHEBX(\_CSS$S!:C!CE/($;)>J'#L7[>:OL0M\^&TOL)?S]*U>X\9?2-0Y'
M+6*RW7'G"_:2-,_5=K/9HV_-DS47.[I&[4[J;C,IJ"WJXMGLD=>6J>?/]K)N
M4U9I\T0FAI5"7\R8<J*G',\U"VT=TPC]Q9FN0BXWW*T[4R"6L]3R[QG*XF*=
M\A<VG"D%;HIL#)DAICY"J)2<*?">DGU^G6,?YZRH"#)<*S-@>J;5)(M+2K,C
MO:35KZY1+SW-K"*7K<OG>/G1&G%X4JE`O-ZLM2\B0*UL@0,X$XDHY;I05:@N
MM3=[RBBR*`/_S(2F9>*X4?6A?72E1V"JO7)%R;IUKM,?=;2.GB^?9YJ*&*Z0
MY%OVL<Z)J4K9)<6:`5DX:[A'&>:>&PRJ&5C7F?R5Q=1/3+=N79BI:W9YKEJB
M1C6T(_UV1%<:+T@YK8;(UK,+A-$UJ(!!^#5DL&?7'J$#@.SP,0U)216)"2U(
M(DDX>^UW)">A7NJ[&.-KCP&^BQ&3L)F>:G.*G3\HZQ235[_SQ`L$6@$C=H>E
M"]B$`TU_?6BX,LC%11%FHU.$"H%\9QKP4"%_"FY,6#XSAVLT]Z]JDC.U[6X)
M>K_(ZQHR3\(V&'CR$@1$"<5B`K(RK@#ZTXE<LTA^>D411'ZFXHY63K&5+I]J
M.->X%<J//9M'H0=ZE'5<PB+%&'5.&O#$(9<97JY!)XA?CX@F1XBY@4U#",``
MZ4O[QI!&U3"*0!5W2?HC]P<9`;`2NC;DCO93"QI=I.GJWB1R45)5@69V5$+S
M=B(!QXLL:;/%4IZ%HG_53O/Q`FA_N&.<J3).`^1?:?U*TI0[31%:/_<7'>I%
MMYHQ_JF(1M6RJ85"/YWFH]+*%UF,NJ?#C)31G"&A<-W9]A$&^+^9`U%>11.Z
MH=1D0*UDN4-/];H>_JE;'\N'W]J`["8LG1$K'?/2RX%Q+]EO6"U[58T**DOM
M?K-:X57[!;:,BJ$MI];">',H3%6]"]D`0;8U0(N;%X6XSBV/04Q,1MB_!<OL
M53CS3PPDDF^$D.P-L3!,>9++*P*R05>?;OM25/]*6(AB]`2K3LIE+@K12K63
MT(YQF2DE3TJ4K10?+>IWU!(K)Z",0PCJ_S%UR^G$!"4P'J.Z0(C5^JR)X&+0
M7,8<`Z*!&!^E"#5#2Y9DM_*(A=E2JKA'T5I]F&-/:+2WX(EX&B0Z5=%\;)'H
M10?"?3RWQ'"2@BVH6IJ44]BT/EAV7[TT'V9MI.@GT'@^('@6["E2+>K>UZAB
M6;&Z9K$*>HB'*A47I&:&>M&UP3.2I<S50K6W0*A>LB0"#A+.%QBIV+?'I6IO
M!DWN5R94?RL_"#/DS,63O"\?$(.IM#Q06.4W&7"VA,Q=&'48":%:0BD=[CDJ
MTJAVJGS"PI(T'RI*)85S.:J+HY^3&#5FJ;/1JZ%**X><,>U*3RB;H8O<?8L<
M@%B7$L'[R(8ZDT3'3]5-6F[G#[@G`!J\C[!<(FKZQ*-2(R()D#*>9&DNYBNW
M2NY1#O@GD?2+^GHRO7(T=51GC_2R/%T([XB_E49B3NOHP^5[8.<>/N^/JXN;
M?[QU3ON-?O_'=\ZOG[]>7'X].O_\X</9EVN8%:$)301_!<=&&(H)\V#G?WG5
ME']/L'^!^OL^\-/1+Z].^S^^`C&,YR)^;4PDT;/XAQ+6S<EW\W=?__[E[.+B
MZM-O1U_594'TSM'?R:F7OOKU\\W-YX_J2_4^)YW&R8_%)3>?O]#OK]#^I5-O
M$*>@U>2S/NG\^.JII](*A]&R.]QZ=(=GCA?ZE/H;6LUVH]M>937;RR[F*HK)
MOJRW8B&UW%C_G(TQ+Y,7"VANA;J<UK3RXL?V2`T@+RN-H':OU6RTJK8OOU4/
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MVNFXS6Y%5H5U'-3T*+>.`QSJLTI^P!X+JKG`LN<]Z@<R`]S#O@B$AURT!/KL
MI7&IZ5>[V6IJF*#HUGHE]D."6\.NM.)@UAVWW<YIC4P[2[Z6?.ND&EO?A/5-
M;,8W4:6$6`MO_Y+,-IQ/MI44_RT(ZU;3;3:[;NMT-U:E)7)+Y%L@\H[;;QV[
MS5;7ND[V1M.PKA,<ZB9.$>Y8@@#P[ZH@7L(O*4@%@E"LC:+],BW%`\N6-P1_
MN]'N`KW[<38(#R1UOMUT6[VV>]JN*`>V;&/9QK)--=NTW.9QSSWIUL@O^>+<
M.O(C9DRL:=8O&/WKO-1B4#7P>(UX8&_F7\[B?SVASUTUG%=[`9Q7U7X8:_\0
MH%=[!B8Q#`DM"J1X)#OH5+63E"V%WY@`JX@E-?.C1'=%U,:'&Y',P,,&1B>E
M:0XQ*W%Y&WH=L+<0XBH^-#T-7E5T=U,=8A4,&,NAK]$H,-O&FMWG9?<XBK.:
M[>/D3=A;,+Z/$#XKSA(/N\I\FET(8[`EUW*NK75:W7^UO,0Y#+'L/:+ZB[#O
MJET5]0]D24+0O.E#4X%WB%6'FWM>6GY<0]FP'N&?8Y`<?$Q$8CN/UD`J?^4(
MH.&<%6U5OB1Q%&,'(XMXNT;1_,\LXJ7$B98$;WU_=OVK3KLP-N$:L0$)=?KL
M^G<'+S]J=HD9L>U%N7660E7'YE"P8\R$\I]CUB#2PK!1&CE'`I?MJ*BO5:R'
M!*&':.3A3`_NR@=@=XK[V!%\PA!VUAED*<';<D^A(>82W,5AJWMZD_1CCS^M
M_`X\#&1;9M63*U1]T>^X^2Z5L\;3,JAH<2]E?_DQ?LQEKSEU1.!-4J81Y.X8
M,78'Y4/L`4$.ZT6PY-@N%`9Y6"X:@Q/VN.R8!B]7'*2SD.@X<S'*(1BI]1K6
M_Z9)3"V98'!LI@+KC6T*2.CC\PC2,8H0LERC.@[X;1!%=`82:/$%2(YQ*1VH
MU75IE<PY`.G/7[B`_/4BM]H:+;-H!I@?R4+2L,$4N.KRZ-+(];.L4"R7IP@,
M\9OQU/,4]CQ_Z+2=75/FJP8/U'4`UBUG13_PB30(69,5+0<"8"HO?:C_0=$*
M'1V.F^B\5OLS<5NBN-QAZ&%2;!YK4B3!*^8DK]'_P^S6HN1L'Y1.@J3%4CXE
M*Q;<(>%P-<:X%LA2UY4M?GX[._M"EUU%2K+%$9#(^YQ8<K1SX_@P=?>K]U^O
M2XK[ZE.1V+>T%G)JAA"\!]L#'UYTVI:-D8H^&/I]4+K(!Y+FFL_"S7E<]4]<
M-,,)W.@%DU!A?/-H)/7K!V9MLNGZ1)V;B]2)*5`;^R@GMBX2EO.Y_/Q3)HYN
M&9N\O0;[AF1XE!:JTA=8#0_TE1O^/?TUC+UO?__?_W&<G_4]V,&<&IA?%/C]
M^:5.X/_RZH;=MIN=5[BRZ$O\RH>_O+I`.+U_M5[]G?QJ)O(OOL41ON5;N1ST
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M=Z`N#[#%"<E!?&@6&5\$T21#'47HSL+TT-*J1Z27)QS,P21FOA-B@X\<$E_V
M:-=-%`<\C._?UIN(U\!L,+/'I?GRT[V>CD&<5<ZRWYF?Y8*!GR&*'Q+*#[Q&
M><8?D"Z<UEOG7T8#/]!ALT@Z,+G_1G:M(,5-,I,RNY&(P)KC8.41E58SE53V
M9%-Y^*19-^!BKEUAP0VW\#"I^(^"VQ'V35.L,45Z5W-6;/!T[6O-!&'I=V?T
MVWX+HIMDHG0I`'U&I9:40ON;-.WD%&R(5=7GM3AZ\G/&=7A``\M.OG#4P*]!
MI/^R)&A)L//6^;WBC,[IC`YK\CL"0:4AN2&C6*LGV(`3525VQX(0[U]*.,*Q
M72T;.R]--F[+D:7[(LTZ4<RF<!GVA_TOM9(-,Q6#X]XH"O[*N/98L^_!&*ZA
M^S)!+2_G:8<:V<&S9J^LT@7+#40GL3Z4,3:("K4P.G22'<\35(FG#BBY?I`Z
M22"^X4$?2`@*.-2U0[YX3>L/75O7L'*3YD6>I\+9I!0HI`A#@RJDB]*ZR,IB
M:$]E"3GZP/0*5'C8:.E5=+H=QB$($6J"J&B.XL3SWK=.2WK?UF8FM'=GD2_N
M*P4;;N1>G1XW>KWU=)8ZKD-GJ>/>BE69QSW;6NJAC-;>L>UUL_M$V"?GO'9[
MM:D1VG6O&U(;C5B+92W+6I:U-L%:NVX995G+LM:!LE9%2QW+6I:U+&L]@;6H
M+'?'_-1J-*LVQ'8W+#[N"@G'NA+LR6%/CE5/CF5[M-5B;U<\,'YH-BOZ"UDN
MLEQDN<ARD>4BRT66BRP762ZR7&0]`/OB`5@9K>9QMT`:3TH^@=KCTYTS,:*B
M9'@#OE&LW"=`:JU\QNPA-M#>0FIMR)N\-W!:K5.W?[JY)K"672R['!*[U+*K
M@.49RS.69RS/6)XY&)ZIFUKV!!M_#]EE\\;Z>NWRFEGAGZGZTBQ]R2M>6&I4
MTRPJ3]E39^_+D.][[*-]BKRN77LW2]J6M"UI6]*VI%V+/;.D;4G;DO;60\('
M;1S6.9+;WI(-^8?N=EK`Q]7'"_(RG88;\RDM$,6'X<&S7F]+P):`+0%;`MX5
M`7=KU5C1TJVEV_VC6QOWV^.XW[9LMFL/B"`0(^>2$`N30'#G[#;A$E_8^M:L
M;VT7X`P'HB);*K=4;JG<4KFE\@WW%:\HH[/$;8G;$K<-`]HPH#8IZY9*:H.#
MARO;;47!OFGQEF<LSUB>L3QC>>;E\LQ)C:)7EE4LJUA6L8'>0P_T;LLJ)[QQ
M&]#=0\&]/1G=;K2[0))^G`W">E1.U*OTWA*Y)?+=$[F-Z5I*?QF4OD$EVQ*X
M)?#=$SCH*Z>]KHWOKM]$E!^Q#_&:9FU[9>^J5_9'EGBCN4;9[:<WRM[17MNN
MV$N*&MO*:B?:R2%`MA^DFG.X31!M5VS+6I:UML%:MBNV92W+6AMA+=L5V[*6
M9:WUL);MBEUS?C)<;-:58%T)!TSIAW-RV!Z*EHLL%UDNLEQDN<ARD>4BRT66
MBRP760]`73T`%D3!=L7>>2Z9K<S;T\J\UHE[?-JW[&+9Q;)+3:I)+,]8GK$\
M8WG&\LS+Y9FZJ646-*$.X?J:@R9<>G$4CP-/,L@&C?"=^'1?AABOF\2NJ7RV
M5>66RBV56RJW5+[_5-YR6]V*K'1+WY:^+7W7,S)\T#:B#>@NCXJ_"-;`>A3W
M7[SOPJ.X;*K0[AR)^]_3U#**913+*)91+*-81K&,8AG%,HH-X^Z9B;Z3,.ZV
MFIS_P9*$81*U-K^G-I*[8T9_D*<7"-A]=%7:@),E.4MREN0.F^1.+:%90CM<
M0K-1OT.+^FW+\KCV@#(",7(NL;9WD@2".V>W">=C#N/7QXRV_J8#\#<=;O&`
M+;BQ/&-YQO*,Y1G+,YODF78%\HQE%<LJEE5JS2HV"+C'0<"Z)>#:T.`>RO:Z
MB?&:"FT;&K)4;JG<4KFE\OVG\K8-NEKBML1M`[T[-QOK'.C=EG5)C:ML0/=P
M!?>.O8?M1KL+Y.S'V2"L:S7!GB/"69:Q+%-SEK$Q7<LWEF^>!!C3K^B`;3G&
M<HSEF&J.Z;N]O@WQ[LY6EQ\9$-13*.3AUD)KU48>>+.E9ZU-\],-&.8C[@SC
M,(R!7V\=6E`GX5X<>4$(=Z7P\X#?!E&$/[/(=WCDX\<!"UGDP17QT*&&[T['
M":))E@H8+J'[TE'"N3.&>8X$WL9]YR-+O)'1&K[E.NUFJ[T(U&GE!6J"I`&J
MW\U&RL53C\O%9?/'7#2>?_[PX>S+-<P`&"]D$P'"T.-A*";,@S7]Y553_CUA
MOJ__SH4C2<<X\7F"WV_07?60F.D?-[JKB)G^L>TO_9">L])BVF:$M8HY5'EH
MGQEPJ,L.K]B2D.2_(=5WS%:MC80H#H&I-A_KL(>'/3SJM]Q[>G@L!9!4EXW=
MPS:V]IS8GYCX4PZ/VD?%?Y5&M,/(C+[@'A\/>#)G'[=J%3A?]=C90S_3UKQV
M#V=Y5(CZO7&0GK1JM,PORC-Z4)K]UD3Q-0LY"N&\I=G7G;8TVXQNOW\B=;W2
MLZ:RLN4V3T]VLX0VF]-JKD\AV?,1BVZY`T_%HD"6!G&T5>EI]5:KMVY$%G=[
M-5IFJ[=:O?5I@OB^-I#.!Z_)[JES>2N1R2T([-?'F\M<G%O_1N>DB]/;K?J\
MX@J]J8,8MFKSO,-W03:4U9H/5J"O,Q%W52F_9!;N/BGK-<M;?UGZNORX?`9N
M#=-KYP.QP<))+H[(%O.^OOG/!_@F2&'+O57>9<9O,O]"^;QFH[9[N>Y;R=K]
M',T>L.VV/&!=2D\^C\<3%DT="LES'TRH-':8,PPB.*(IVSD'HKX/TI'C\21E
M,'_^/1`I_AY$\&^:H<G%0IAP['T;`7'P1#2*9SJ_1_"-S(?FR9C.??PC']R%
M<>XXW)T(3+SFP1W,!<@A39B79C!P(EUI,#GUL^,Q,7+X7_@C?-MJ_HB#XJL,
MLS1+N(/X7;?2%!0\34/Y$@D/60ICPRTX`3'A7C`,Y(OS,.3R:9,DGL"+3EU'
M9(,_X4N'5L5C$_.EKJ)\.7P.*P:C"%@*>J8H+^^839T1@UG#.($0&7=X0%!C
MF.2LULZ+QV.<[(@EF%&>Y.9KH]XDMB^L@$G^6L3`<BOG+"RVPSPOSB(D"\S:
M![64P88FP1WL)&R9X@6X!6D]R8B.,B+HL^MSI]_JNDXN-2\>OD\Y@^G2U[I0
ML]U\IP;*OVF]>^-2H0%.KQJ"KN%(KX=`MX>!3(=W8.W";03OCG3M<)9@X8)H
M.,564<5#<9/BQ_GE&<%J##B'08#-Q\0ZF2"Y`$OD!0)(]RC%"@<&)#P5`0+F
MI:/8-_GD9@1?P_]8!+,!*N='`R9@('DE/!C>"W]()G$"3Y#U%OP[L"8^;L`C
M8*X4&,J+!6X8K`KPYZ"`Z(/)HZB`6>'.Q%F*SQ!JB^Y8,L7Y"H]'+`GBDEBZ
M9-XH_X4$'"P7/KW\;C!W/Q":1I3HF`"7XO/D`LI%P>\]R?)Y%>[).^%XL'M!
M"LS^9R9PB"00WXZ&.#2^L-QHX27!`#?9N>>X]MQ\S2D^U><H/$'.T',,2J@W
MW^V3?-#R&LD>RW_"#`MVT@IF"4ROXCW*C`ELUW?BD7#J_-!JM)QQ$(9X_N#^
MPA?MXHMT\:F,%R^PB5U@;#RQ4+R$TS*+5;&S(<2`OQ).7#<SSV[/;3:;SC")
MQXOFA+2W8$8->K(>?$82X:H8DHCD:A@+$EB24R)RN)%4$2G\0Z(5)H^GKSQ&
MJ^JH'/@UB/V'JZDL4ZR-*<8@=^%+V,8A'`U1JDO<@OQ4T++O02:!@^DP2MP>
M=*(U&R==M(;+;K1F8P/3?1W,.S47#-UO=,$&6I04NX5/\^Z\!Q9AH5Q>X5!U
MG?M1`*=[KL"0,$05#R4=$FL\$#RY4[6>8#*`L(GQLD%*0F<<)RA!0=*"-(*S
M&-3R,?,X6#J@'@EUS(/ZX18ST+*J:K8X.SS0AT'XC`-[F^2U=]Q0>W9X)A.P
M,6J@^G"7-*NUT=Q\UG1_#ZH&*;]`PQ-5KAQ'3Q?`^T9YK:JY;N+08//<O'ZJ
M>R;E*)M(DT[A&D&_"RJY2!VHC@6^4KPH?#[BY*,HWT*^C`'2'RAO=]+"9,Z?
M&5!:FJ"U"T)0.EQ\?*ZTSK(DW8>]W"O"&^P!X95%EN&'0S_+/4M\+:[2&>.K
M<#>`G>W'8_2EI&"O2,\!TJ=Q>L=3%H*"*9T'8,J3+9Z?\^93P;0@DO9@&'(<
M5+K]#&I_A_;8'A##7E&NMP>4"[K<^`&Z?;9YN6<8+%O6Y&JJRCV3ID"^_"F=
MFB#<2"&3]$6AC&$8WXN%ZAP<H:$O];D!3^_1H!%@FR0@M12V#-RIOYERE@A#
M[\LF(#`7G.9@HJO3&A_%M6<&#FPZZ-$1ZG,]2[*JY#`HJ-EDPM&]+>!2N(@\
M75-UL_:@DC\K-1@*+UDK0^V;9KI53KH[2$:*,BP1G7'\Y]F>%%"0##/@,MR6
MZQE`J[D*P8@FL[!"@Z_C9NZ3RW!1;"CV>>AD0D91/!9Z&89C*WV')?=UPO_*
M@D2%ALRP"`J4$([,2%Z71WEP_`$O0B84/&,@>!(5,<KETR0.*,:Z*"J$4A"I
M#,.\Y!,"\@+U,^(S0Z!!E(4J)NX,00:BF*P,.\$*)1QHC[MS[Z/U7B52!Q@Z
MCMBME)7P"ASG-O-@"F'..VCU65*D1-/R6\?X6N9Y%H:*3BGN00YQW(@L,BP3
M^7WABKSC,@@*1*D3$?APB/D%<?0H$Y12#U*49%&<`@D($>"S8+>YW&K)3P$8
M4XL&)BH:PL]P^L*:>?%X$$1$(^9#_A'?HT+A.B!>4:\`\^M11C5B8NB`TI$A
MUT%G=3XTWC0*;K4Z4AHL#_Q66HODY2N-`VJ3&D;':&50E8\G83Q%Q@<%1*J4
MI?N(E\/@&T;!`EI..C=8U7/ERX`\0:9<*>XVLQ[`N2I2)J\L]$#CJ1AN!NJ8
MXJFU:$7T0$!<.$DX!+U@0@1EZ'8R8*[WH%%Y$-\\0BH+WV<FDV9&*#^J;<(-
M`;K+8T/A'('>2LN1%&JF^=)R+X)"-A:WSFJ9,V:;6GQ4B/5K2D>`9`)@W4%\
M)P/Q($"1KV"S"Q]$@#./0\4AM99+^R(_']42\L#-A">XJY@*,C4.,TK=`K-9
MH(#-=3HEB8$:[P)?WF(D9=`&RXT70#8>%PWG3!VJ"9_$"1W?,KSL*D.,QE-D
M*F>FA8$6MWXY.:-D(5%H2&;^T#&-P7>@?`I0$<UB0ML0'5".5Z3S*-&P2#(6
M]J(EQK6G?DCMM`0(R\"$&$]D/L*<WEJ90*72IYX>;MG13I306^6T=#(X+7R>
MY7W::72.UP+J>MJI`Z;K<:]QO%(][_+-:^?SJU=(J]Y;7+Y>WP+S;7&].XWN
M:@O>J<F*KXB8-Y^BMNN5MY1N*7T+E-YI[9K26XWF2@MOP2*M]K*G,L;*].77
MNW;(#XM.B.>!/^SK,8*Y\):=+#M9=CH4=K)ZV'Z!=C^NG.U=(^LOY6!/%HD,
M5D*(81;^5'PL2C$7^!R?SR=/Z:JXZEFTAP`5^PGFLO1)LTQ+B'9G71`N6TG1
M;'=_=(Z<D^Z/EE4LJUA6V3-6>8)*MH>L4G<?UZP:53.EZ2ROA9%Y+'F=%&6H
MO&Z]V14XZ8:L\QH)]<.).ZR)%G]H-1O-'([BR/FA;?QMR="2X4LEPXTY5P[Z
MW+8^D?3=12G[N#ZZZ<LTXS:VFD^1OWMD7+5Z-3*K+.E:TMU3TK4>`>L1>#SM
M/*_^,2K`K?5EK:_M"$RL779RD++6.P3'/Y'@`98(+1&^3"*T#@#K`'@:)7\U
M8*BL_;\?<M8:43-K7B<;RE*NI=S]I%QK_5OK_]&E_E#`8F!E?R0VF2AI[2YK
M=\V$7HW(JVE__="QF0"6'"TYOA"'@/RX?`/#^B+%U'!*#@%!;@=4^75KW5"?
MSP#I/#,1<]@W+OL*EA'F):;L1.-Q*:AP`F$ST<#O"<A3-\^;L*G1*E!!)?$[
M!>[-HJK<RF?`>W9:C6Z%-MBA!:P?O<V79^VHE>=G0L#Z$!1-VCX:3>S>(\+<
MOQ$W:?Y-#ZO'9SZE;,US^T.#W>HUGL[/,3N`!=PZ_)>$"S;`A$'F9(DW0M!&
MW9ISF/?JQ':GJM&@[,ER&PC92-4/$@1U*QJI(@1=R!6:X'L^2#*63`TDFV;S
M9`994O!B&@@>-^`$1C;?K+(`982A\??$IP;KU+%5M98TQSZ3$A8;KVG@LA0>
M(Y@G>X)4HT#F<X&_?^@U^L6`6F_#AF\&XFZ6PJ3^JWN#_1HR[]O1M3>*0UQ#
M.AP0!)(61P$#EVZHQ%][*QLI49LGPE&%DT!YW+72V'[G'*,)X1:`>7>$W4@K
M9%[6[YH7^0%"!D:^,PTXG#CFA<T?53=.V.$Q"R+5+B7O3AL&0UJFDV)-*(+5
M6``0JI:2T*AI4V%8+1\7@!'27C+G%F&(8=^ICUZYS>>R+?4:SG4&C\"1A!X*
M=H10#26<=L85?+*<!FXE?!V6J0`IDG_GB1<0]&*""PDT[\MWGD/3J]K^H_+V
MTRL^B+PG%]&<AD78VQ>$O=Y)H[^2(=4[L1@U._"2'`(*0.U!-5KM1K^W=E"-
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MBL+!S?KIK>ED3:<-RF6CS+4^BVY)V)+PGI/PB_,!R(_+`PEM!=EA'Q$HC*I^
M*ND?L>B6ZP+_'$:@J,,7.2S`\A@`A.'0;+1RR"U"-YA,DOA[,(8[PJGSPW';
M;3:;A#)!"!$C#':,X7U'P@%5"`:?KRMSL$:`!L/L9A?>1:"2%-S!B$^'X=D7
M4LFGM&ZTEVL/A$4@1LXERL])@LFR9[>P'[BS\].UP"_+PA1%SC^SB!LH+&TD
MX>:I6X*@8F-)[_A=ONP2KJ)J9U[K`ZG=?'=]F?_1>O?&>8U#&#^?X<BTB<95
MKD,8'P0J$\/1&<;WI>G`EP%BR=`L$)+$SPBX1:.+J.OR8_'D'4*%"([<:LJ`
M,/:8PJ/!UPB1;0,$(U4B1W/^A"4(X62,Y[!\%6`RX]@/AE-UZ51^"R:1T/,I
MEDP),5BFR`LF+-2@7W"AWH/.N^X\L,SK&='4-\`"6>I4UH_3/L):WH\">.WK
M2V?$?'@ROPOB3,`@I(K0V\,KY-`C:NTDB$DQ<7@Z&H`2<R?A^C5AWMD$E\"8
M?3ZQ$CB9N7\"SO]@&'@@OL.IW#Z<!\CRG)HJMJOA?,D2D3&YYB212XNL*8FH
MAPD1>X'$6:-W.Y]Z(?-X6"(*7,XD@&TH2"A`4",V'.*R5L]HR#SR5+LF;4B"
M\(E>)3T$\)>Q3,4"M1[?WE;CQ-S>:A9]@\,3F`HN]'WL\+\0B@>!C+P1A^4B
MY@X-B*66R=O#(!%(D/"V83@_RV:CV,C9Z34;??W;&\(\FK#`IT-/8D!IA*`J
MXEY]7+CPGRPJ@T7UZ*!MFIA.5[!4OA](`"<Q(M`\Y@RSA)#8B@T><!0G7I8D
M^,YCF.DX&ZL]#X%60X0D<D"]Y0AMA.)AP('H^<Q:PN./B;+B+'4*(4=D!>P-
M7()J")&C2?IC-L7AXT&(T,>28!#2;Y:+CN>)!'Z_OM3L3&!%`\0/#+TLI)%(
M#QJS[_0^I36O&&QVZ7N-=DD5@B^.EY$P2MFI5H1F])\WL+Y"T'*,6?*-IV5,
M*`4N-D+_TF"*`DL!(:9P@LD-0J)2>V3*["&CQ=#'!,@XX27!`-9$;Z^\J>%<
ME0X(YQX$(*XK@2MJ.33[I,J!Y6^N"=PXB5/8;I`FL)Z:,VG/3`3'`>?1C)Y9
M[%.GH/^Y#>HV3@O>F%=6EQND5RB\;]:UJX>OU6[)``H04BQ!Q4.J"N)AI#L)
MNH?@=L?]IDON5X*.O`@$XJ9E<&8A$9L0E,,D'CN7?V4:+)&N+VEK:KBR,D9J
M$1R6!H!E@>C6<,Y)62*.-(#>$!VM#,\&IR>>"L"%Q9Y<2*0UY**(I3"Z%@;Z
M_(9;)23;+8^\:7[&A,$W'@:C./;)K/.D./=X6=B.8,G@;B_,M/(ZBT0'KU6L
M*)XX,PS3;I()N"Y6(:5J',.Y:ZA`L#:3+*7UX[!U\.@<`/"AV>("2Z$4#XHM
M)O3860GVN'R4ZSH#/`N/RR(28T!]681'#LTL1@40E2E'((X>!U4\GG)"T(,Y
M1K//(/$M4?P:B+PXB$$=>^IRFO,C:#WF"(]'#$:'&UDX%4BIA*:'JEB2P,+K
M<V0>AO!!LU)*6<3?H\=TFC\::SW%(7!=<47DTK*R,I&OOP).;)5OSU>[(%X<
MDE:414IIE@='%*=TU!/S+;?&"S`4\2Y%;1*7,"[@*A<LD<$>2N7@^+O678K;
M[T><-"WF_YF)%!=00B021\'2PATE65%RYE30-@J/Q%\1V?%9#KN??\K$T2UC
MD[>(STOPO-C3.HQ1[(D;_CW]%2S&;W__W_]QG)^]J>>]_8*64.!?JNX59Y%/
MN+_G4KD\$X*GQ7U.X/_RZH;=MIO'KTBHP0]?^?"75Q=(VO]JO?H[.69->$1\
MDR,\)=[*XX3^'C(XPJ=O_S9SG/S-12(0KH"]'KXS8Y]FG-1?[LC+L1@?!.Y^
M2N'ZBL?B<<66#I[Q_"61OY=#`W_63.8QP[]\O?QR=G7A7/Y_7RX_75]>.V>?
M+IS/-_^X_.J<__[U*VP!'/?7ES?7#TS$.KP>GJ?BV*+A#`KGF`27-@D9L:W$
M:A>IEH,Y).M^`Z[JX$RSN19D51RG!M"J)\U5(DUP]:J!I:?P]]X"=G4MP-"2
MRUU#@"&++O08INH@<7Z2+U0+/"_+;9;;]I_;JA%62ZRV<ZPO"_15RT(6J[S9
MXV1?E[NWXGIC&W<PLL"R@A\[]5C\%27]ZQ^:S::8;[5FA7D]R'SSPGSE5-#5
M)7SM"R.^ZFP0]!_YZ.:/)S+QAWUWO`24Q10]V#RX(^_+XW[I[666KWI"[&%6
M[O82RW>359X$MZ,T%TSRKS43>/>XPC2V1&N)MLY$>]*I$]SABZI^."##<6M*
MQ)<\D5;L"O9@,^;B_DG1]0K,FHK'3GMS9[HE,TMF&D?SI+^;!;0P!]:47YU<
MSV26K;#V^KY)4VOZ&&!&K5Y]UMD2K27:I8BV6Q$4MO;Z'BL4!VVO7_!)+`)K
MK.]:A+X(*ZK5L51FJ6SS)_!NR,S:ZM96?PI>256E1GU4R!=I]^Q+'[B-Y.KN
MC:G5;IY:/K%\8OGD,86H62,_FG5)6)?$([`A<<I"1`)8LJK5VI1[)]RW),?;
MC787"->/LT'X<`?<NDINM]UL6OJV]'VP]'W<MLZ:7:,VKWM7US3MGW]:'9!&
M`MEHS!N=!O%%0M?!GTG&?0,^3`]F?%7`XZ@G5(#=="W8S=(Y]R\([.;L_/SK
M[Y<7SH>KLU^O/ES=7%7BW1B_/C"AF@.P[!ST1O%RA540&NB`"O"&^P<&>2.G
MI<^Z1MLXV$Z/&[W>6H!P3H_K@(/3ZS<Z*_4@ZMMBZH?4^MZQK:;>7P.ANH?.
MR\3GV!<T',MQEN,.@^/V`1%G4ZTA#X'==AN8L)J</5?V>+U7:U[8MZ@X5J`?
M@$!?O6GP$Z1\[7/TM+<I60"1\[B?>WMI2"L?"WN88;&].J45F];N55Y0QST^
MJ14BCB5=2[K+DFZG5K@X+ZTQ\$&9CSM*]3<#51LCY9V8D#42K]:CN&M1W7);
MI[NJ^[/T;>E["_1]LIL<S8VY1@Y:QSA0C\;^6RPOT_[;EQ*JU:7Z\MG)>V-V
M'KN]7HW,3LLQEF-JSS'=9HTXYL4Y:N3'`Z@%V$Q.?[E>H+CN\Q`[,O-(4!/>
MKSS$%KWGL4C%]8@E_%<FN/]%X1Q7%`CT;('`L@32:RR=OW]]\_G\_X#GKR\O
MG///'[&C[-G-U>=/\Y1ET^B7G.=UBG0[0'(&BBTHGOK,#SB/5,?MHDNWJL=U
M0FR0':1\+)QX^6[60.`)79R.$HY]XZ-T)!P>85/LZ@;ILGDZ,I`#4Q*C^#[2
M[;/S9'Z'>.J@4OI/NL:IU5]/9]M^+1K;]MJ-XY4"4[W5_7)US=?8P')V&JL!
M=W5>4GY,[;VEG07;]SQO::>S_]EG[V,CL1^DO?D''!W%G_(,H4GEB<ATH!27
M5.<M[S2IK6V3VG;G`K;'DSV>ZKC>M3N>6E4@(,^,Y'5KLL,KGD<U*"6SO+3?
MO-1H;@"(;G_9:?>E8E8)LTI8[5;>'AS[O]XK+_@!&.QU*1>S0GV'0GWUY*JG
M2/K:UXLM;*6^(![P?)Y8>>&?<";L821\:WD%*Z%EHM*^-QD<W<TEMUJBW3'1
M5ENDAT&WK9,:K?3J6LD>TNW!VHQ;TQM^XQ%/6$AJ`_/'012(%#,G[C;8OG4G
MAF.-I&L-'86U\1)NI8G+;AJX6])^\3[P+5!WO[L3XMZ8%^2@M0OKO"AR0H\J
M<D(]S']V!GP8)]P)(OB-.RG[OLGR=6LA[EK0K[,D9E7%9LEZF'VR2MO=&B'N
M6&:I,[.LKBH=(+^TFA5I`M:-8ZO':E5&<Y9200K6C+%H*F?=;[=.WF';NBAC
MH2.P;&P4ASY/@-UYBE4KH%)]9-/B'5O'6/'2[+LTF$`U3-X!HTPF27RG^EVP
ML2R8P:NB#"'0L<B&GB`(HC#!*[,(GX77P)@]YTO((B>-G2ZV%'.;S::^077&
MJ)H[:'ACF"3-Q'6RB3-,XK'3P;N-$1K.#=S/[EGB"^<V85&ZX.DC=@?7.6/V
M/1B#N!NS-$N"=(HS:#6+99ARELAV?[?2'19.G3LN4@<6(('[AW&6'.%%SH0G
M0>S+6>&CL/0(1Z-)5#2>68UDE@KUOC1"=T0V'K.$-HUY:7"'&ZB+NN*)+/(J
M-K^*J@J"6+D8K.T$`LO`9.67V.^*+WVH--=3W87CU*"\ZWBESFK'JWL>ZII<
ML1$`J\TT83R$7);Z^SHWTW6Z%CN\8FK89WDN6&ZRW%0S;BJ2+MOUV.T5.>L/
MCD8W]^EI>?GC&2C*[):7O[S\SA,O$$;EY)<D\+AE2LN4-6/*6NSPYACQ*Q^S
M(`+MO?SU.4PM`9,J8V'YAX)X;G@R+OYZ38;RKA.N+0-;!CX$!CZ[O4WX+4MG
MF/4*F#*(1."5O_XW"[-='YV;:6%^"'QG>+"M!\1Z0`Z4R@_D=#'NK/^A8OGH
M\)?[P/FH=BX/RU.'O]P'SE,O=V,M'UD^.C`^6A7W((B*O:T'!H)U#.S,,;!R
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MIP?0AM4LN=FPFB6\0Y=S>[6,EM@LL=FP6GW-"1M62]^=LP@!E\'N^`GQJH<\
MV&AJGW7Y++.8>]+"8T.8I?OBUM^&$67Y9=]=I-8DLV1\`&1L2=>2KB7=0U]M
M&Z2R0:JG8)\L:F=DW6Y[9R!NR19<LI=C?4-H'?>XTW=[)Z>6QNOK$UTY-7--
MJU2;1,QUYUS6E1D;_<V5T%L^/-P0S\KX(JV^I3-+9QMOH][9'/B2#2+:(.*:
MR?7W"!L88_OFA:9@?9P<+](_=Z`1Q>6MR+V)*G:[/;=U<F+Y91^4$5LLN)-%
M/.1BP5;CQ!Z6!\K\>Q3,6I%J^XWNYARAEFHMU6Y&UM9HE>NB%NRS+7[0H==_
M*Q,[\ATNL7`8&#TV^GI0QG3M[.::2NZVV^^WW6YS<ZKR"Z=Q&WVUT==E%_"X
MT;;1UQKSX:%$Q;J-D\UI[);.+)WET=?=J!6'''V5']%B66G3M475!(45%F/-
M&_WHN]1DGF?7Y\Y)J^\D_*\L2.`Z+QY/>"08)N."-8B?P1(4(O8"AD;B?9".
M'#%B"3\:,,1,9?<L\863QLZ`PS!>?!O!^+X3W_'$24=<#BV"E#N")W>!QYT)
M3X+8=YW[4>"-L#:4KCN')[-HZ@2"_I07P:#I/><1?76+[2$<'^9!MBI^17_@
M!YJ&@\%BX<"``Y@(OK9ASS:<C[%(G7A87"_DD##;P;0TA]<XODB#,#3SD=^X
M]``G84AN4_F*PSA+G"EGB7#EXK1^.BX]A.[!;&:PJ^A"9YC$XV+V<*U\,7PF
MW-ROOILS6*LQ[/H(?TPX&Z8\:11TYOPCON<P(=?Q>)(RH"'UBF/F<]P>6`HO
M2X,[?.(0MB$1\FW41B6<KAKB!>IU?`[;[\NITXS@B6.AIA<D#A]/PG@ZYC!W
M>G-C!1O.%4S`]P.D(Q?I`J^:F1&\];>C(#H:!B%7@W$N*M:XF-W\8G=Z^,,R
MZ]:H-RONB\BX,?@$UW@,1"Q,WAPRH`TX6S).O"W2V/OFQ)3>KRD@$Y3>'ZFO
MCR9)X.$WX]CGH18,0>2%F8\$P9(`.5@X(H/OF100*)P\Y-V[.`1Q%0;I%"D`
M*83DDX.#<E>21)3"`R8DP91(X"`C1NPN@!FJNW(*=.'10.J*#/%O9$T_N`M\
MX`=G&O#0%Y::-G,`*:B`##_+0T43&24!D1B"`<MB,^%W".`-&S=T(I`U0K!D
MBML(%#,0,#1*'WFB"+R&>6G&PM*S_&`XY+ELCD7Q7-%P;D9P*K&(A5,!'^!_
M'.F;YO17QA(@%A!5^DPJ1B7R`3'X9R8=K**8G"FY?P_E@\*IHE8Y.WWZKG*H
MXMSDN0S,%D?A5+T+<03R#2PA2D9+O1N4A27IA&<F$NMB,3AA(&B`P-(X(0D&
MQQOLV[R8DOYY');)4BDV`.7$&69$:OJRAG.=`D7BP/FA/-]`NMUL-6'`".F,
MV(B8S3C`<PB"DW?"E(RFEI3P,""!"G):@-Z`QW7D!#"6?)O`@]$-Z<R0AX`I
M)S!K]32U'B7YKP5\U4Q@!]@M)Y5C@$^_TT2=(H<2N]VCUD:ZZ`1('JYD2NG1
M*V6>%YJ?YK:KF)PP6?5+@CL!DZ]>4A<53Y8)7EJG$4,]%I38238(`P^9,@$5
MR*?CD3EA,"9H%*T6+SK<0`O/QG*][IG!YGA]]8+#>TPXO*%'$PE@K99Y846=
M5D2L!WPS%PNX&V`VY>:`7&SS#$*MI;2ME<SX'0F%1QY8-.]1>S$*)A7%EMD4
MR!&&GCN68#I-QT`:<;K-'\LJ__T(:)9.M1@^*YM%/8+FJJPG/!^+Q\GC3I`<
MT#*1N,]XT<?/L=(R\.\I<CQ-`S7#A<>WB[8?SJP@[SC_B8YVTB"-D_U\Q*);
MN!\HHM`S9O?$.('!%(FS6YB"XV7C+)2R1;XR2:4@,JU7>&V/'D#+.&9@W<(B
M>5*-8>,XB\@@K32ZYRQJ&%I),*7)6`Y=VR%^S]'=ASH:4":<,$X2B&]'0S0[
M2[9`<:J(F1_(C0%FN<C@%/>`0U)43H&>L@2,8'@Z"7\Q*IP-[[D/SPJ=KQQI
MGSN_QB!VP7`>YK8VT@:[8T%(\?B%HP-5P1=)-I;3`BTS3AU@+!A;';-STA[.
M87VH*XYVG?.I%S(/SE\2&&G5JJAS(KV/YV8ON*??U`M!Y13IPH?3E^6G/YN4
ME0\7W0P\R9VXZL^72]@);B+\)XISP:U=7CYL%_I'`G0GY3M+GA;I9M+VDCH0
MJG-!6B39,"G$2J.US/-";LO,9M`NP*8MV`37Z;JM3JMD9`BY\SSO;@6R*@M)
M]4#GX&22Q-^5V>G\T':;S28=14S`SB>QQ[D_:Q.8BO!3IMEVI>M23DRV+IJ9
M<C';-$Z!B=%+5)YIYYBF&D3Y+!O.6<E@<)2$#E'SAE_8=P<$$H@EEH#P!#DM
MC2]2!R:DSVM*+RPL>O4@`I&6WX]*1O'2Y,B5+SMO"I3>UW1LHV"6LAP/]X@/
M@]3P!G,_\[1.:*Q$>864@@$S2U#?@/,HEM:>?(G#Y\)\2L'R<[N^^<\'^"9`
MDO)6F2^<;BF852@OKW$;YF<=/'G^]5G2K6S]5>1\`KU_UFAN]F>Y1&2PVMTF
ML;GR6X%@2HJ=`'49I(WB"^`D4YD1V>!/[I'NH>,@AN$#(N,.S`TTZIUKX/-@
MB"8S^MTP.*-<>?-Q!/'$V`T'P\-+I6=$CO-H%(<\C<:[RI>4#T&KGWD>6@W:
M>9":WG;E'IV?&2NL"AH]-RD,@:;-4E328'&R\9@ERNR`)XU9+IBDV58Y0?WS
M\B<"SH>ATS<,XWOQ]OE"8;M,16'G\K1T2+[1->+O_5ZCU_LQSYL\__SAP]F7
M:YB7!R_.)H*_<A`K5X!M"'OPRZNF_'N"$33UMPK.]WN8H1TGH'SCU\94MIGR
MW.TU6KU5<@JZO963"@8+M_0/]8*#./2U@%\MX:#UZ"8/RMN]Z2R@?G\C:4"K
M&$?[LM[URY'N-/K'ZP<L[M1DD_NK;7*A,17;O4!ULCQF>6Q)'FMW&LVJ[7L>
MC[4[SV]LLVM^^T/YZ(J-/Y/.NN*+WU`YH]DDSD_R'2]`1RPN^#>JC\6?7TP-
M_1HU\!WS;FM%;6/I#,9#X%WYL59`-(^KAVD\*>F&M0>B^11'1P44S4*73XWJ
M/I]PX.UAZ>>>PM$LJS(:-S^H*>Y/873+/>YNKJ;'<LDA<4EE<<S3>&2OX6Z>
ML5U5^O"F]ZT-&[>4LK[,SK6?L75;EV[-QO%Q?63;$]3F/91MF]=_UZOJUDRQ
ME>`/&R/:G;AD7L9)>PC>RBW(Y-<=M]7N;8_`&YV3+LYPYT2^XCJ]V8D,J-;Q
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MJ[TE]E<@%`4B50'UE`.KE,H-Y^^050=TB\G19]5;K4H6@B>45"AX(H$UM@%<
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M*BB7\E=L2?F%4<-[<0,GUJ]A['W[^__^C^/\K`>#`<8!=8(49Q'<&V&9#H^\
M@(OB.?F]3N#_\NJ&W;:;)YC.&N$Q^)4/?WEU@14W_VJ]^CM1IUFZ@N][A.OQ
M5BX<_3UDXR"<OOW;S,+]S<5.V<(5/`F&[TH5*";M+ZE)R@*P65URIBSL*;F6
M*Q+`247IW>`9S^\W0.M8F,_YX"=GO3,AO;STKN>?/WZ\NOD(2WWMG'VZ<,[A
M8A`JEY_.KRZO'WAXS8NQ5JLJ6ESHO0Q-/;GV^T/@@2C`*KNSVX13S^D'*[\/
M8?&WWC0=&_11MC;5+J:Q$^:KSO)5EXW,F<=\/@X\*I'$#G]H8SIQ<LNBX+^R
M(WK#^3WR58DDED8*57<IN#%:N408)Z!*NGWU<"[['G)O%,5A?#NE!TX8M2!F
MDPE<I)]V4^[N1\V,$]ET>,*F3A)/64@=4>.\=:]@H6X%'6.[/U5MG/=2+)X:
M)\Z0A=0",:.W\D(6R%>JFDR]]WQ?:/-+EHB,%?6\%RP(O%'@7+/HVU13)U<;
M(NN`36K*"4CWGE,[11JNK+H5#$M'X4P/(NY267G(F>_X27;K>-C&&VN-YQI'
MR@>RR(D'H$3*^EZ8(G::QZ[`<40Z`A;PLKLX(0+V^1T/XXG#<E)#.HX'-*^$
MWV+SZCB9RNKX.]DK6/`PG+D!&828)R?KF36!2663HV&"&S#D'-$:@O$`UI'8
MC=ZY?$>YFWF4C7E"7;=5S3,P*&@S7*38<V^BU"W)]"8_,8>JMI/IT6!ZI#YB
MU_!`\:4Y)[J[V!)LV6S.4<!+WG%GP#G^&F`!MN]BL3-3/5-U^?;UY=G'#Y?7
MUTZ:!+!@)+B0/[_`(G&G8[;3JT(G:,&@\^^&/_[0:O3PEQ#W]9Y@!P)J^'TV
M28*P#(?1<,Y`F"34M?>'5K/1S&^$Z]DM;-4M5JM7K"&L4NAC4W'X1NJ41;-$
M!OL#!*,G!(*'7D.H)HFDG2:J[WH^=%&:7U78[L.M0A&J1YIPQJ4HER(9J`R?
M#OOU-=]8K)77LX/7H7:)>G/SFG751EKQ%@R3<MDW-5"]4=4-*$'Q'MA6"20@
MB]?+6X3E]]AI%=X+93,.K+C8UWP@9@9V)>=SK,8'WD0S(5GT$C"KB*=2[#=`
MZJB/=(W/AR`$?*0T'/TVP2ZUJBM\$-W%,(V\6;B6!?`^!$4Q'`9A@"WL\1LU
M860=&!M6'DP-'`7^]N`\"NC08]_Q=S$*)A,Z7F'G!BAX^"!5_6TEX^0G)3`D
M+)WNE!ND$JH`C!GY*V$B*#$I\1$B)1&C."=0^3;R=>-[>!TIR((T[W.N7^P>
M>Z.3X`*!%`=XO,'O0>(3!,?4E&CPQL6N@?!&E`5#JAX-F+%YN'?_A%\CEV@/
M_M*"(`S`5).GISLKU,89D,8`^V:G0/Z<1()S"TH""AZ2YD@HDH(2/LR$E)^Y
MS(W\G^9FJ2<"KQXY8!1B^W0IZ/6Q,@;I.I`$'D0D$V=V7Y(SJ`C8MA0V$^S*
M""?HN=AK%+[T@#@%&_(46YJ:$U#'!(E.$7Q7D`\&O]*K>IQNRR;(M?<\O.,+
M+W2H=2FL1LBR"!6QX8/;4.YQ6KPR"T5<_=ZJ,;G<?7QQQ&\AN0M\PT`J-YQ+
MW5_5^6<63HLGM/*VV.;J%H1-C53'$NX"^SPG";^+/>!7($,FP7WT7%"LR/V>
MH9`)L8S(29H5S67S)K#Y`],12PWUT-A1>/P21[*YKB3F4]0:$/@D*L0=K-DU
MGZ25"$I29\9[>+E7-O$V2GNE7>*%(%@&(%U@V7%3X:)O`:*2)($HE%&1>:/B
MC97DP"65A[YB?[K`IT<J)!5YAH-NC!+#AP,A;ZAKK,C,4A?:<RY*<6:E11G@
MNGA(Y$@]'(@76+4%.N*/LC=OH]O\$0AGHIK9QU*@A\BO.-;B@6%(Y-X7T%A[
M6P!@H`M$ZL#6V@`<@0)V@'G`(2)(%0^1LQBWZK.7QB6B[B)_-T_*:C+=C?P%
MQQ\H:(.L8-X"\(9_]\),((^K'W*M-S)NU,`XLPH`XB$0%AR>O`T)%C;+['A,
MWO%<$9P9")3<`#M:XV&01;S$I_!64JC.&Q:HA<.Q6LRY-%6E3=$3RE8I:>^@
ML$7!.!L[DPQ,9E15#2MB'L-((A\9)JJ^S=?+,`%Y&<29(+7*E.SOU2I3JVPI
M7Q=6W+;Q>"<,)5)CX.$_`,EI9?;PV:T^CBXP&$+<;`^,/"!;Z^5:QSP_SQMO
M)T3WS;+40EU$\`3=3]+-A4K;!`YC/$;!T")=Z)R'J##"3<DD3IAI[)1$DG,1
M2$P7N!*.X%SJY5\#5U_P$+O3@VW'^3>R!-!2"UDB=8\_,_^VT%D(A>T!\++X
M7OLXA/.:5`@M]]`U`3?"Z0X*P`0T!YCPGX6==G.$L%E..!U/1K!XX@V9"&#U
M`/5*;1O43(0S0T%:6H32\[74<QT0A2`4$W@":'%H/:'RJB="J&H^BD%8!Z;/
MEZH!KZYO/E^<_7]JUTZ.WSFOC5?`]<Q?XTVNVSJ?9Z5YJW*OY7Y**$%Q3PX=
M7ZIOH*1+_4L;5%4[DA/&O(R7(Y>'`IF=W.)V:.HA^M)+JBU]KLZP@`[)+,FW
M$^>F2<1G8W;+Y2E:M6JE06$Z]W2BXO=_@G%`&CIHGP$?RIF7GK.K3:NW^-@7
M,7?F7'LC[F?DI_Z<D%O4\.F_YX,D8XEAF[5=!=3)-)`B!BFU>P5D%BJ"Y)[)
MG34BN(W0R&7*ZR#>SB:8M=6HSNO"!D$%!EVK>*+]]&<<D-E";J,$O31OWE5:
M2\=ZH!2L)=!4A_`:D5?XK=0D08T+8]+QT`X,"G/I+(071[OQCJ3N!!6TKUS$
M(6FC\-"9F;?D`SM*>J)R#-2>23DY`C4*G@%WG66WF4BK;A,$_FA(B4$2H%\)
M[T(.FM$RZ;9CY_4)K"3>!'=*9Z9($>D4E_=-`V=.2BSYGKT,[.,(.32.;F$=
M;Y_..K5/!E@M?B]C_SX/WEXB6/#T*[\E616EGX`.JR/ZYU/8:#C[T&F<C.$3
M$(;'0CC!KB*O\?-/BT:;?=8Y1X=L>`5D_?W_^+3Z8<TF6/^=9JO7,P>>N;48
M^2+V,GSWF^EDP>Q;S:-_R:',:^='^`(&4.Q?1C[B554/A?\>-3M'G59YP-*M
MQ<AGFK'?A^RV>L0A+".7@Y6N+@8YEZ3\'K:2A?\![GIPAD=',$,]O46WSNV+
MO.XK!T4-B0<5LTQ4/^`_7)3VI?+6V0>\AZ,^.8<GWZ)R4#GN]9B%<)&3CZ1U
M!?-II7'F=[!XT??PS8(7P'_+NS=SVZ)QY28_,/*_6E7C&K?-K3O!Z!)^(67K
MB,]9"C)-NGLP%`%K(GYY=?7I?3G5YDH^\?KS*X(%IN_D`*_^WCUM-CO`/J5-
M>N`Y<D[>U//>7@F,(WK\\Q`.Q2`""2VOOHH^!#S[/#QG8O1K'&7"F-M1IR(+
MZ.KFPIC9[]<7P(2]8V#LGW]:[4'E1"5Z`8EJ+B[_RN#%/L4IK\I1JGE>TC93
MC_J&KZ/J$ZBAY__WC\\?+BZ_7IL>\\M__7YU\Q^;K[-1-\:7A(.REFBD:^O$
M6(=V3_[P!8C@9-N"T7Z/_VFY[5;';1VW)>`YW5?LB&R>H>'X,0W!$,X,$PWD
MCP5P.D6VF\X$0PTX(.JD&$K`>*1RWL\.CPX$."PPB(+:=QY8T.#MH*^#.0RJ
M;J!$ID9W5[C^B;JN]Z/V>(0!2$9?FIX3>AK9`NK7F>>[><Q71?U)838BS:AP
MPZW:)')A7>$_LYH]KHYND>'JB"LNT[PI1?O0[#:<LV@*9K1>'AV[E#Z$N2!B
MR7+^-6:)3UXALL)CA;9/0\"SU2H.,QR7'$*XR"$Z#.'MV!T+0GIC-+'U!/)\
M`VGKS^Z2]$@O7EG8^&+784W#C!#Z$TTY642Y$?GK6CM^;4EY\_R*AS^8@6F`
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M^X!3%Y)8)<925IFTB9&_LW04R]8EZ,`'.T?J",5,)F6USC63UA*>,YXZXZK.
M,_$0TPTIA0*S2V(*B20!MT?*^O.\,<,']CK&UC0>*0^*ZBHUN3E"=0+)6VB<
MDM-5"^]E&$XFF7_'Z"8\X8=.%][6+9KXM#`S1`UE2.[2(^94/=4I2";AM)M.
MFC#I:&!3H=-`\;T[S2-4^_3/$_)?N([*0E$):4-45TLCP,-CZC:F<JTDI\C5
M,R9I"75]A(I:#L88I-YQP3'H(),#G5MTA4<ZL#E+K.4<IZ"<U3@$#5GHQ&G?
MM&`PWC8[%.6'!]\-`T(2C"B.@`H9AKJ.:E;G2YJ1670DE3&*`4QV'ZLXFTH.
M7]X>P#,":QLH!TXKXFJ$AR9%W\X:-S+\(!OUE>=$)ZR>N5],7>()&%;:F'/R
M:(YX2)H<&%%SX9N698R-&04J$PE$$4BY="JM:QFO!]6$MD9E*>5"S)"J<Y+=
M)<D\255:(>7D8B0[2,"41WW8L^?QFN;Y'DWY^>Z;O:I<NC&Z)E"<P3Y*@P_K
M.GS.QPL.;#A/XY`4*2JQ2%(7#1I*DB;GP;S/0">$PJCC29H?N:*P_DE/I'3.
M,+[7KH!(9\ACXE@H2Q<6>P=`'RWGJ`^-!SZ]B=W,?K5WYR)\J*]=RZA*/VTV
M>OVU]+4[;6ZKK]W*2$7]=N.TO4KM??\9$&5;@];!8)KTP\TSKTIT1QJ?2Y+5
M]N/CH?'M82Z>K-2+\#`P%S>'RW6\TFI:)+G*56PU5H(\:>T3D%P+#H%^C=:Z
MT:H+P1XJD-R3CL"]._#:#QUXG8T1_)K/MMJ3\D;0D58^M`[MB%KW:53CLV=S
MNN=ZCYG:<^+F#Q5K;"UY]G0>.GMJ!-MKC2UK;%EC:[L'7K-7H[6VQI8UMI8!
M[JX^YHXUMD_"J2C=&E76J*KQ4?1RC*KF;@#&#]NHDA^71S6V@>7'<X?Y=V_$
MHEN.J^H6(6+,\Y.U_2I.7)E7G..=191'-9M<+J.Y`WX;1)'"\UEPD#6[SFL<
M4*>YM)OO+M7$'*S?R[]OO7N3XR54I<;T?H2OBVSHZPQCH"I=Y8(/8%(9)AF^
M-AY4?%UZBHY\JX`T9;PG0>0%$Q;JZ#;E(.6#/IK9+#,YBSM<3$22N92(>Q:&
M,F&#.^VNPL*32#,XC])R*,S'.PV@*K(!9F&D`47O13`.0I;(D'HL%N7'V82-
M=4&(S*0$]XS*FV7K.;"^$!,?D><(HHZJ0AQF9)EY3(P*%E-%*TOPP*7!X7,2
MP&2$F=]*W$"5]4"R$Y74NP@]LRT3[.X)Q)(H-$;M]#X0.71G#KE82@I;5^:\
M.N4]PC;(CWGU9_U(M#:%>;)B5NW\W-L<5E7>J\?7>GT+.PN"@3QRK3!,S44G
MF7[IQ9A>Z3E?*3OOH8W8W^7?D5ANMROD<AG7G!7@:P8.)8H^#4?*OP>"TB>#
M"/Y-"2^$<#F*0FT7=`8)PEBNB_JAW3C-48`E<!MFN\/UB&N(!4OJ&4.N,'LU
MUK+4&_3U1<WD$!0;679(RL.`$'DH[Q?3^300B!,&J<*1.TIDNXQ\9!3#^K&P
M`CS$;-Y,`HU-.&)ZXCQ0L5%0J(ZGP*TX+M4D%C;Q<TWSK`;%KR!(2;]!=$?U
M.L(`_L-NI'VW>;)JL9,L["MJ[9J-WO%)SZB^R+,X<;26K):`LSUAMT^M]M`Z
MO$R==PK`SS^X'W'A,ZJ\+?.O5A$0F1<S'C6^NJP),;.5B\7)NP:8T-@%0*/Z
M6>I6^5NV9*T)E09(2-."A1#Y*`VE9-#<I`NF)`RW%";SK%0JBF+PR(D)RGA5
M,*)&G!8@7S3R\4S:KU+^8U60K5!X]:*@0%($@$!/":+3B%EL7W6%+O=.\XVD
MG%YSI@@P<91-]%ZI:JQI'H,S\W9UJ9<5"FN9YS7G3JZH(/:'TW&=]RQ(G'\3
M_N='SA`'I&A[0A<2=VET7Y^G6-YR^!NR5:VNI+G]H5C,JFO/\DX9P/^J\0&"
MIL%%!%T8)V,I@-D`:Q:T6%NR(OOI501U*!G0WMUF<RW%`3C.<ZL#:M?,M'M<
MV37R>=WHN\<K>\@'"^EE<7.S92E(-CZ[HB.[H*,@*CZ?Y[#=Q7=_@';P$-7-
MF/2;#A:NU-MSZ5CA*NZ?)VS1T@&.N=YTSUCNVO%8JRJ._CP.:]5EAU=DPDN$
MB*<#Z8$=?MHT9D@)QTF<G_+1-_<HBK18\6#%PU/%0V?]XJ%3DQU>43Q(^\``
M'21K^W!$!0%:8B#>B@LK+NJE3:`]!$90I`VNG>_VBJ+C#X[N25#P#T98G$E7
M\>&\T.5W[-<F'I=^^T9[7]")OV.9OID,MD.0Z/+CD_*H-RC\E\]Y7YL/Q[CW
M0==-[0N9YCK'-GLJ0*8#*0N<A,]GP2>4*JVJ:^UAJ<)^\LURFM0R7--ZQK;M
M(`-KHX7DED,.B$.6<DTLQ2&=/:IV:[O=DY9[W#ZU3&*9Y'$F::R/2_:ZLO89
MVU7EKMCXOC4;)VO;N.8>B;>33=99K5[+:RMY-UO)N\`\7$/T?FL&7T6KQ6;S
M9%LVWRY<Z34ZA=?AG%JIDGPSP>WUV4Z;`T*QE/9L2JO2Q=8>)]U&-;3;[+7=
MXQW!3%EB6ZYN?#5J>V'0!-7Z]8,Z=$V9L=\XWHW0/V1<@KJ`O3U%/ZY]B.2"
M>[/MOU%C/H>IUL?T>Y%.K8W9T2OKV#9B8>EV]XNYNL:^-XZV5K/I-NOD:[.$
MNT["75G[WV/?_L86\0E&PO[P?^.X1LQO'>W6T?[88O\S"\M.]E/GFOJ&%E]>
M75F_>YW.+>MWMY16`TH[%+][[[3MMKN;P[JVI&:][M;KOJ3ZO"L\8.MUMU[W
M)ZG/+)I-4VDU;6G"'AY`UOT^HWQWZ[/4EFZM^WVI/-=6V^U:]_NA$JYUOUOW
M^X/KW&FTZ]2SJB[4NL]FQJ&[WW=I/UC/E'6W;T?CMY1FW>U:1V]V-YHB8TG-
MNMNMNWTYD=_H[T;D6W>[=;<_K5O-;*=RZV[?->E;=WO=E6]+M];=OA']X=AM
M]5IN]]22[H&2KG6X6X?[(PD[IYLK5[<.=^MPWWB^>ZMEO>UU.J2LM]U2VC,I
MK7X`_O7I][&-(+S;;_;=?GMSY=N6OFM&W\OA8:Y&X'L45:C?ABP)=+G:CM0W
MD`$$N)OZ'1O(L(&,S70W?=F^LP-8S8..5]1QP5\F^>X)8OK+;"M@V:0NJ[DG
M;'*0C05>P+Z]U,8"=11PM8D";7`M;1CHF8M]$Z<LM`Y*&^IY@JVT5POY`LBM
M?N[75=WA[4:["\+/C[-!^+#I4U,]H-5Q^ZUCUP8UZRP*;%W'NO.T:LJ-G4:[
M;\,A:]:SY4<&`KJFYL'2A*@5ZV:C"]NS;L5ZQ!/NW.-_HMCAJ@&\<.*A<\^2
MA$6I</PL":);)QUQ^'_"N3.&9X^$PR.?^\Y'EGBCXFT[+=>A-"T6^?BAW7CR
M^]?$8INEI)]_RL31+6.3M]>8B3:*0Y\GXO*O+$BGG^*47P3""V.1)?P&E(5?
M0[CF[__[/X[SL[[M,ZQD\B%@@R`,TH"+\RQ)0)5U?.X%8Q:*7UX==5XY'DP/
M[O_*A[^\NL*%_%?KE9-%@?SF]^N+5W]OGS:;S6(Z"\9=Q\/G'GW26OW1O[$@
M^A`+\3FZX$EPQ]+@CE]%(DVR,5PK/O'T2\)3]OV!N5S@7.87XJ1?FLVR#]K(
M]"KVZ;C]C.EY4\][>P.<*)B7!G%T'HL4;KUF(?\\O(2GQ^/`^XKGDEA]9IT.
MS6R%9ZQ]4E<W%^N:E5[@+TGL<>Z+]TD\EE?#-Q.>I-,O(4BTL\A';IV,'Z;[
M!4O6/BYMY@K/,I;N?,2B6]CT?[,P8_ANS]_*;J]8M$>'7^=4*C9PU;G\_-/W
M01(&;_&_\.?_#U!+`P04````"`!D@*]`0!7Q<0T/``"9SP``%0`<`&-Y8V,M
M,C`Q,C`S,S%?8V%L+GAM;%54"0`#?+:R3WRVLD]U>`L``00E#@``!#D!``#M
M75]SV[@1?^],OX/J>U9D)=>TR22]L>4X]8P3>>2D=V\W,`E):"A"!U*R=9^^
M`$E0(@F`"XHR$38OE[.XN]@_/X#`8@&^^^5I%0RVF$6$AN_/QB_.SP8X]*A/
MPL7[LTTT1)%'R-DO__KK7][];3@<3!A&,?8'#[O!)\P8"8+!A+(U92CF`@;#
MH23\B$/,).GUYK\DCC:#FS#F+<5H@0>__8I"?W!Y/G[]^O=/Y^.,,R#AM[?B
M/P\HPH.GB+R-O"5>H5OJ)0V\/UO&\?KM:/3X^/CBZ8$%+RA;C%Z>G[\:Y5Q:
M"O'74)(-Q4_#\<OAJ_&+I\@_&W`_A%'2-J`12<XU+%`_OI*TX]%OGV[O$^6'
M).0VA]Z>J])*QC=^\^;-*'F:D_+FB4&A7#3WWF"0^H_1`,_P?"#^_3J[R;F]
MG1<@#P<O/+H:B8>C2Q0(YOLEQC%O,>&.=VO\_BPBJW6`Y6]+AN?OSSB_Q]TV
M?GG^*G7:3T7^42,=[F..DA4.X^G\A@-OA9LHHA#23)L)BI;7`7V,FFAQP'RT
M+^YCZGU;TL#G'>;#'QL2[X[TBTK@";2<H,![V;JJF=1#?3W^TR9(1H5;_G>A
M1?P4X]#'OFQ3J`WM!DD3LI&`>@7!@1B'*"O:DLE-.N8<10])[^1#YP*A->^E
MX_$(!W$D?Q%6CX?GXVS@^2G[^?>+*,)Q#KL`/>#@_5GQQYC$P@[YXZA;52<;
MQGBXE!J7GA44SY\5]3^(YP4KFH*8)R7Q_RT$LSHB9A2C:+-:)=*&A.-*\L\9
M757<2LUJ'VCV=I`2#F(Z*+%L(DY*UX(*!6<#RCAZLQ?J(R:+9<S_Z#!F8FRZ
M"'WQC^A26Q1PK:.+>((8V_&7_7]0L,&E6%KQ9,X"\G0=^W*D:3-K%=#()`N$
M`"4ZCIR;<,O5IFQW34(2+;'_D5(_^HSY0#W#$69;7!ZU+#@R/X(X',2,O:5F
MQ(#DJ?'RTA6\W#&\1L3_\+3&880Y_J?Q$C/3.\."(_,BB,-!O-A;:L8+2%X&
MD%?N`(2N,8MW=WS6%7.=Q=BX%C._S[B*C'K2'!(FTJZQ4`0!V"C-U,,LP?'Q
MX9:@!Q*0F."(JZY?YV00@))G'JLG=\%PO8UZ<[H$,3@(U&1,`<UU(@7."Z(<
MGR8=Z*I^R^D)JK%VX!VF"B,%6*$+<BF>W\NZZ<+SZ(;/VN_0#CT$6+/H-1+)
MU:^&R(D0*^8J(*-TT3Z8H^CDN!]XML%^;;>NI=N'7T?G,`)`IL%`H!/E^'3E
M5[Y81V+9'OHSH4TTW<0BYRYV2$I0@)!F+C.3N@H("P,!F#!+4\/"F45,LM"J
M'1QJJ#)?::E<Q0',+``$M(*R</]<"+?XH[.`URY4:I<F]8L15Z?TM:99S^Q5
M$AU_$=QQ69C#,[5(E2\W4.SS5E6*[C!@CGJ].86PJP.M%.+XU&]"5RL::L.L
M>RQW0"J/70UPC2&`Z%8E.-Z)+WR?I+K=(>+?A!.T)K%0M#BG-U/)&;V.RM5X
MP\P"A%TKR/%)&U^%;%;"-IPFRCE\UPPO<1B1+4X+1VYIE.ZW?$%/U95>$^[]
M^L^.VUD4'>4&"+IL&U"C[F=74#?#,2(A]C\@%O*E371@WQ6>$X^45PUPALRI
M$`97X61M+`!!$)EJT/Q="9IWH[+3;OG?IRE&JI:R=85;WL'VO>UBBT@@\G=?
MZ,%+/_/\)8J(5P)Q0^XLR-;<G?7N@J8F'Y@L[+)[-@T4-=M7Z*:6;8@^7)+M
M^))AK^HU=^J$AC$)-WSHF:YQ6AH=7>(Y9=GKB[^U</2)A)3Q`2LIBL:1V,<M
M2DG'LT\X7E)?%(9$L1@6JL4VS]YR7K3SC"T[TC^*Q3]=>5[?M](BHF?4R_%^
MF=D<+K1CM(%"IF=5%-WAL0O848B?"JA\1BV31+)*.\>Q>8\"',WP%H<;7"U]
MTCR5N>3RT^[P:`(&K;.C@!F%I"177);@>%QOB9=5X]UCMN5_2.4K!2$U='E=
MB):NPT6=)JP4;E=Q(5>4EU:+:.4XCH!#8V0%KZ%[ETD4?7Q/XF3(`=;415LM
MPO%T<J:O>#E]3/:R*YD<S?,\<5-Y[F1\Z^RH"ZZ"W_%4\81&265"5EI=#JSN
M<;X'5'[L[/NYQA+("[HJ`M!MAUU'=SI/AIE[&OB*X"J>'L2V\+2[T&IC1^N,
M*(2U+$;&M,#N^"M7'(_A+A/GK:[X8!/0I!X^LZ@R*@-H\Q':2.MF[&T,K$5"
MC3#'W]#W..`R%^EU!`&WX<)?B;-5L1C(ME@-$#LF.5T#,KD)F48FUV('*M7Q
MR8`8!A])$"09B1B%"_(0X.0XSLUJC0A;52O_;%@R;\)8W(1/`W-KP0.3Z=IN
M;[)ES<?,F&V\>,,X^A/;REE',]5A8:B*RDT0P(RJC;M6C'&/MHNM/QK2XHQ8
M_3JII9-;@GJZ_[MT,]1G72:=#3HZ/BNZ0[O$BNG\FH0H]#2C5!V9K&K5DG6X
M:U>+'PJVK[C=IA.<5+MJ!9YL^52]24?\(B/\->3M?-P@D73!E7IE$TTQMF6:
M[R.P1LNLHUJ6YGJ2XR,BH1C%IN$59F2;S+AO0O%:33#Z&<=W#,>5,D=;-CE[
M!;,YCIV&]L/A!&_`\<+&:_XJ)8LP/;3C[;[PCA$A3V@K34Q?M]52V@:<F9NM
M.!U'6G,OP,%FU89-361'-Q&ETZ_43#EGJU1$F<D.[AQ2DSD.&Z!]<(SH!:H!
M\=H=0*2*JI==FJ=Y^$M/G8^ZR1J;8)?DJ&/\#V>F,4DZH&J2*J&BISI,J*BH
M'`\^S#HX"+3RU&#XY\F6*9,E"A=\P!&GQQ+%I_,/'M=K1;ST3'AY:PY*+S?K
MZND=#[VMQ7`0`"2K$O&=#@9YYB:SXQ*'>%XY0%-#5:A?5E`Y6VM<9Q&D+E@A
MXW0+64VOOR);XN/0YTN@_'SPE/DD1&QWOT2L4FX!9\@\`6%P),QV1RZL/7'L
M.0Q(@\\.H!GV,5X)W8OGRZ-<V\J6/Y0AW_>O9_@N`63MB6,!!&D0L/][HA&H
MI)-NW-&0E4>;"MEW"1&@U:V-+)5F`'FO82>',_<W_'=XW%`H<<>H<)Y_N?L:
M87$"7['75=Z%M.?<'U6$<W9Y$%.E95ZS>.'%''#)+4.-G64IS.P_L+!.!Q%K
MS-"6O5<>9J`*98=(CU+$M2K'/APV;@,9EF>/CVA2<139-5"(NQ6Q4%:=!M4]
M/KB7LOBX#^BH,;IE@%1;<ZW@HYSBOUA1%I,_L[0/GX"MR&95`HX5CV931</3
M!X@U<4_+N`.JX%PY;;X!?L>(AV<D^K;?"5><E0/35TH1M/1]`*"M6UH&'Z!Y
MU7YAI^GC*[QFV".)$?S_@V30%F7I!QVGG`*P8)'I`!!+'R#8P#DMHQ"F@6I3
ML],I6V&@+E6W5SX"!R*6T[D:XCZ@SLHA;4_U:MIN;\>TI8E??E1B.K^EX>*6
M#\Y^JNR_<>!?4_:U6CAAPR,G?C">/L"OB7O:GOC!5,C`^,85,-87HWT-&48!
M^1.7S^0V8067#!ZR]@&A1SBK9:#::2(S*^?.3!AGV*.+D*2C_56V3:&^S@5"
MFF\NFDC[@$`+9[2,.'/+$F'CTVTM)IM8TV3S2GR?37.!1`W5X2<#5%1]P`C,
M!2W#0]NH1$8+*3L-,&ZB:".^,YU]X%H<>Y2?0.'#I+SC:,HF`2*KRC6/C9CE
MY,R2N0_H.LIA;4_7+'616'0P8R<N]Q&IQ8,/4.9?G]2F[2!,E=R=F:D/$&WD
MH)-E\<PZ2$AJBC!^7,KP_:/QR"L<6L"BS84/8V>.)255D)>(6RN^5,"G$ZHT
MLIE(3O<T1'V`%\@!;4_V-&U*"#ESD$F>&^>S@<+%%R40U9&5SN-7R?H`)*`3
M6H:2OE4))G=.3!5SU,6;",0M7B1*O\AJW&>H9U/N.)C8^H"^ADXZZ2Z$20N)
M3G<V)$*/83XD7^'TWQMQK("_W7V9J\F6Y-R,Y)2:<DOL."'[\S^-A/0!QJTX
ML/5JEF8ZR5HK=[+&54M*'\&6)N3>47QM70OU!K*TB+>2U4_@-W?GR?%OI9KL
M!J>[4^A@]R9YT\B<@?'$KAU3YEDH4Q\0V<A!+4,/JH/F%JL6-IA_G`\_)<:.
M.T1^-+S@)\T=^N#WC^NSGB/S?<0=6RWFONNT4-V$-.P6GAKSTY+PEHZ[60HS
M'W<#"W,.X`V/NS7SW@F.NX$5<>W4BDRZ?:$7WA\;PO#E)B(AYNN^].N_PMCL
M2;E>K`EK*7T*8W4.K;:PHT<Y"P)7H$:':5:8)JJ3>)TN_"OJ%[93Q3W7FKUR
M>T8=6`V,O80JU%&G!JI!#^=NAN6Z>AC[R?W6BFU_$T[M.250;3A[@=3&KFH;
MJC:*N'96L-+/[I>4Q5\P6^D_B6S%HQM'U3R]`&8#]YQZ]%2K8+[XQ8F!$P)'
M*R;M<-EC0#9QT,D'22,DG2D^TEB>;PFWD0:P%&9.`X"%.8?LAFF`9MX[01H`
MK(AK<X`97N??U1"GW42GG*`UB5%P*S;*I@\!62@!W8`S/Z)CP>D<5&TQ1X]Q
M%02J0(72`SP6BKB7`3AXC^S+_HLWW/$9=_H#Y@^37PPS!GLABAF$C9`^@+D5
M![:,ZZ8Z.9>45=IQ<,\C",P*>B-N"_3]A:C>+<^"QD+SKDT#"E/T_3&^Z,,3
M9AZ)JEL`4'K5DDM-WS?@0=QR0N!IFG?M.T?[K[IIKJRM?Z$WEU#YQIZ%A%[`
M]6C7M0W@)@JI"P@<65-]IC&6-8:&!92*3+%:*I+U`8)`)YQP'51LU;EKU0['
M=`.8ZL@4[^'^@0GHA!.^=95@<N9\R*&FMQ154CK:YPKT9,_[!AN5V2?$2]9<
M>Y=)Z3Y9F[69+D-('`N`BL83P(I%"O:36:,XU9E]3$`#CB8B2OBQ$]$GB!WA
MO!.AT$XCY2U270YI20?BL\(D?1G-L(?)5E@RP]Q5V+]#+'5"$&!/E<5NS)]%
MI0%_'_!\K-M:!G,#==J\K:H=*!_6WXF>E_Q_E-RV50(M@%*>P3!1]@&(<%>T
M##ECPRU>>'6"2Q#6&^8MQ6[/7!0GQ3M-0L5(J[H.H4K;!X39N.-$Z1!-T\JK
MK#H=PC[,YWR`Y1H^><FQI!D??:=ATE5"7_PC5-^B0!@%J)EH2UP6G>/%.8?G
M.O"V[,%C*B>.5\68N]9^JBQ[(/[SP+L/_^5_4$L#!!0````(`&2`KT`\IM@X
M.1P``!.]`0`5`!P`8WEC8RTR,#$R,#,S,5]D968N>&UL550)``-\MK)/?+:R
M3W5X"P`!!"4.```$.0$``.U=67/<.))^WXC]#UK-LRS+O=VS[6CO1%FR/8J0
M7162O)ZW#HI$56&:1=2`I([^]0OPJ.*!(P&21;!&+SZ*R$0>'Q*)^[>_/6_"
MDT=$8TRB#Z<7;]Z>GJ#()P&.5A].T_C,BWV,3__VO__Y'[_]U]G9R25%7H*"
MDX>7DZ^(4AR&)Y>$;@GU$L;@Y.RL+/@%18B613^G_\1)G)Y<1PFK*?%6Z.0?
M/[PH./GX]N*77W[_^O:BH`QQ],=[_L>#%Z.3YQB_C_TUVG@WQ,\J^'"Z3I+M
M^_/SIZ>G-\\/-'Q#Z.K\W=NW/YWOJ*0E^/_.RF)G_*>SBW=G/UV\>8Z#TQ-F
MARC.Z@944A9G$M9*/_U4EKTX_\?7F[M,^#,<,9TC?T_5JJ6@N_CUUU_/LZ^[
MHJQZK!"HQ9I]#9(=0;7PS^?YQU-FZ).3W-24A.@6+4_XW]]OKW=T_HL?>CX*
MW_AD<\X_GG_T0E[/W1JAA%6642<O6_3A-,:;;8C*W]84+3^<,GJ?6?CBW=N?
M<OO^I4Y_;B7#7<(`M4%1,E]>,XQND(T@`B:=I;DDFRU%:Q3%^!'U(IJ0HYV<
MEUZ\_AR2I]A&I`IQ9RO=)<3_8TW"@,6`3_]*<?+2T4@BAE4I/>J7@A;_K,JZ
M:QLX2LX#O#DORIQ[8:@73-(BRT;&P\O/F;P9MQZD8O_F:"#164`V'HYZ%+'-
MN@]Y,U9G&[1Y0+1/8>M\>Y!TS82B?OJ`SG:&Z%%>(?=^\8"67AH"HK(-($K>
M58G9CSC"O#^^8?^M58N>$Q0%*"@KYJ)">Y6LAK*.D/@UQB'/``@5*I0IL_3B
MATPCEK2L/&_+-+NX.$=A$I>_\#AR<?;VHNCR_U+\_/LNHC!MT#7[YRY2AMX#
M"C^<R@LD..'ZB0J<CZ[.O?>P1T!3E=K'IAK%Q[H*>Z_/:%T9!LF24X%.HR"[
MI&2C-#+1R+V7[/U)F\U)0DZ:Y&G,R,B6DWA,#D)9%\*RW[<\_<T;PWL_)#$*
M/IPF-$7['PG+8)^33V'&C+4RM.+_<,';=SZ*/(K)[!E+\2LJT_1]O<R0$%#$
MW08DZDXG,(V$J,@XU1!1YZ`"QG@^+D3\'L5;Y.,E1L%5+0<H_:PK5_I:7FY(
M?\LRF(:SA2XE<.V$?J\RS=PO9W:<$/C]G7,@J*<M75'04G`8'+P;%P>S.$9)
M/'N($^KY2</YXH^%.9H?!W6R*/>'=/-*#?3=?)/<81=>II0R\96>E)2I.;15
M9B2_2CQ'8+I475OGM'=KBX.3@9I/F,RB@/_%IR0>O9#)',^22X_2%QRM_L\+
MTV92;D136`Q(,RH:9#XG=BJW0=*H@&,%R-A)[%Q'CTQ80E\^,SWC-0J^$!+$
MWU`R7]ZB&-%'U,SL#2@*(X(H7$6-N;H@S(#8.MF7+"C:>CCX]+QE215BN)\G
M:T1KBC808T!1F!!$X2IBS-4%(0;$MH#(3PZE&ZHT0Y5>N.O@SJYL,!`W\_\>
MNYF3+:+)RR+TF/!1P'NV+<]^OZ%V^]87W35L55'G\D@#S=3II)J1DW$^5T+8
M>H7-UD'W":6%Y/TREXP<5V^P]X!#)CN*&8;:2Y&2D9TI66$H.)F3XWI+K?4C
M?CACUT&DGA#0%VP#Q96I`6/G$P-]JQ"!5M0`SC0F%F:^3U(VE%UX+WP-0Y+0
M*0N5782DT/CP4.5Y$,TD8!!E?1)VKKJ>IBAH:]3VOKK<'@"R<JYC`*2?$0QD
M')W,`W]XE'I\/BL*;O%JG<3S-.$;`/EVS088($4+>ZF+.@T)`RWAJ%`SG4@B
MH4T@M(F#XZ[O,0S`V__/X[HYFV;2^EI3JC"/M)337H?I!G>]E)\;,S\5R>0-
M6MZ277"F3<[??Y+O:(<.GC<`CYD=G!NP`8/5'($)-B8W5[!@O!`+3KE>HG5D
M18G]6DZ[Q&@S1A`<Z'6J3Q*I7"[DY>2([Y)L-B22.EKVN=P;T/KLM(LUVL#]
MVV;D9,R?!0'.)5IX.+B.+KTM3KRPX6--J7(H+ROEM,=ANL$=+^7G9""?^7ZZ
M24-^.#++/@5GO6Y(G.\_N/>>VY,\-M3[J1\S:K=QU,D6!O@RK<?)5>1;E#!S
MH^"31R,<K>**5E?,%#YNYIQP@L*B$`*G`66L,1Q#$-9.SCG(CVU*AR;:(8GC
M,-!J!'>[B)78S;\X,],@'#L9KF,;KE]/:FQJJ'L/LQ>2:ISL9G@6CI,-RB?0
M+TF4L'"'(K\]A04H61G12$M."#EPC6U!HZQ!C)?_>?NV@IC?SAMFO&'_'>3P
M;_LFAM$/4=Z\G@!^/0'\>@+X]02P8_.!KR>`7T\`>R&*;]$CBE+T#<GV"6I*
ME>Z7E7)R\RA,)T`7(./CY"SQ#?:+LR5WB#ZR_Y2BMP9BFG*[$9BTW%A>U_B5
MP)6K.5_,-A]12=DYW^;+,VF*!M\L(FCM^R+N.AV@$M#?8DY.-O="RL_,2%^R
MS6>MN5C)]]W4:^N[NQ[6*0-TKX"-DPL^#1747;:ZJW;9JVI%+)JLHK6./L<5
M9_,KQ0%0V84<NF*[V2U9,2?S,:!6^H1,SLC)9LS%G2^S?N2.A('`UX*O%1?7
MOH[D6:WOB$Z3JEMEW$KGUK@XF6'Q\_W,;/S*B"L6=$*2'00M]&EUP8"RN^Y8
M6=9A[YMH"<6"AJ>3"=D="AG/57Z/=<@DGP4;?CU$PJ^Z?D1BB)@1E5T\D,AA
MT%CI#44/E+F3G08/@$\XY&)?1XD7K?!#B+*#S=>;K8?IIKU]WX2D,"6,Q&$`
M6>@,A0^,M1MY9;:[B$7+A*9^DE*&^DRS!D`TI:KG.T2E'(8!3#.HYZ7<W-A8
MTQ1=,WC0#!J<]JM&%Y.<LL[&R:TT\RU_^H+!;;\UL-F"Y27*UBLJX>1P4*^+
M?B0HY.'DR/\;B4A=V/(2*/$4`+A\82M`>2=18*JG'A,`CD[NEUQX+]GVF_GR
M,XZ\R)=TXKIBY8D=:;&18`!W-`$K606#EG]VDD?*M^=9AO;[(_R7TL??(\;]
M2^KQR6?4.HVE*E/W;K/,A%RK5,_6KTVF3DX0?&%FY!W5/+I"%#]F8]'KB">;
M&32_H61!4=(ZOV%*5H[PP&13`(^E$8SQ!*^GYV1#$C<NUVS\R23@Q].R!\WF
MR_*RB6;VKR]9#@14):<`!KBJQOY7LH;LAATAKGPF%.%5E%]$X+_<,VECI@Z3
MLD3S1[1D9=I'PRPH"\,:44X!4_:F,,:8455.9JS\_N,XVS.>*YD]T\A^:<!+
M5ZQRP[2XV!2``U32&"5RODY.893BB9<Y)%]W`&A\G8;?52I9N+O!3NSEOSHP
MW=S61S3=+"]5G6X6E9J"]V$J&J-`RE:6>K@YM06=TH).94T#$U`UC5&A8"S&
MQ:_#CT(^^4RH#?;S^^[T8Q%Q>?F(I%E^"@`P5;N/T4FS`C<6L?>S\GRO97ZH
M,&6:%=/V)"I2W+P<2W11_!5'A.+DI>P(L]77*I?\Z.)7E*Q)L$^.V@^<'+SF
M719SP)J=G-(?S_;ZQ8&#RN9HAEYH5@26CRAB5FN/V92E:E@7E'(8ESJ=H!@2
M\'$R5_^&$NERLO!;F875OSGI497\@(7".G7/N;4DA[K"CSA`41#/H]VU<G,:
MX,BC+W=KC[:V<\`)"L4A!$YZTUA3O8LA+`^3.]^B`*$-/T-<OTTPWHG8\#N<
M8+=U6$_@I-^--=7['<)2MN([5(-O2")KYI)BS<;=*N:D:X%:&33D%B.)&T<^
M'U#K6V:/'@XY&.])Y:K)XBJ6CUZ,?56_#*<6]=P0:B>AT\T&AKT_A+\$:"/O
M)BBOA5L@FG5HF;#\O`0.TP0U#QL!2Q=&U)9V$CAF.NJ!HN57(F'DR98?B,_]
MH&#VR(:R*_0MY8:;+_,TI_(2A2C@6-&6KX"8T3J)F2[ZZQ%DR%T2:*I[2D:Y
M;$MP>^GKS5NO-V^]WKSU>O.6`!*O-V^]WKSU[WWSEJ"_E-S-#BBYO]!47M+)
MU`JN&^3B!P4O_6;OPV5-EUZ\_AR2I_@U07I-D`Z5(+UF1*\94<[!C?[O-04Z
M9`KDAL]9=\S[O@4E?+X^^/CRG86?ZVAW3G?F)_@QNY%<M/="=A:V5Z;[6?)>
MF#J9=`UB,="<>B_5NG%0;]H[)WJ&@,%NBWYJ%NS0<"/$S8)_IL46KWMRBU@R
MY>,0U42])T`#2`+>D%7L'H`;HHJCP?H!/#!,DQE&<#<"\LSW*>(:B\\7R#[O
MG[!K?!X)K8-BBVCM4,7=$*(4#]\U1'`C=C=/T\TVA";XSV(3_8*B#4XW#5@9
MT4C.,DIHCA2`-A8[!"J!<KD1[/97$"PH]M$MCO_8WT4@N-`=7+YU,82T_)'"
MT]12AX`F0"8WSGQ?H2U%/L[:#/MWF$5Y?K=FI2TUD&E"4FYS!)$<*3XM['4(
MB,+$<N.02SVR-Z[O;([E887++%)3^$@Q:62C@V28&H'<.'RSOREVOKPAT>J&
M1?,@%_'O*`P^$_J]?4F""4V9;\)HCA2<-A8[2+X)D\N-4_SZZVB^1Q1Y(?ZS
MM:O8AA1\@5"5]$CQV\%^AX"QF7A=ST_U]3Z#3U:Y8>;+J^+(B/@A-$C1W1$K
M5=$C1:>!?0Z!1K4X0YWBRLZ#S+/-18O0*Z>UVEL4E*6JS]J+2ATI@&!6.01V
MI))T/C4F@<UU'*=>Y*/Y,C^NQH9+Y3V"+*J6CPG.Z67HX=8.+3OB,B,T)#Y2
M['6RX4%R1$,!'3EVMI^OX@^O\<E3?FU-\L*;5<(OQ-CF.\HD4Y00HM8\I9KH
M2`%L9;/#SEBJ!7/D=-SK>SK#0[7;6SR#`=7D'9^+D9^)*$^8HH#O=6?9B6A"
M75VHS#(EA8X4?"";'"3'E`A2`LR15R98<E%[X:@!,5VQQBL3[6)'"C.@70X!
M-+DH)=2<6H2I/[B1G9^/?9*VK^XS)1,NS*C(CA2:EG8[_&*-2K02NF.OVT0^
M12R&7Z'\[XJ&E]X6)UXHV;EI3KB_2@],>*0`MK;=8?8.P84K03SR''A;Y`5%
M+.,-REG3\FK9*,@NG!8NCG=C(@4WC,E(0+<`HA"^%I:J0ADNAAB@L.I=V9C9
ME'[FYWT"2W/X:;=2[)T);K#W@,.LG6HA:\%+BEPC7A,'L+W=^L2QD11=-V]*
M)O(KBYY9UE+.>BGO/S<C*BP')3K2),#*9H=(`*""2:ZBZ/L>V7_?N_B'1F"7
MZ_N'`M]D;OQ_?=QPI-4AZ_<0AU\?THGFR`/-G8[@-?#<#[->3JH?T:',7JTZ
MV(GE3B*Z$<4E6N3GIWJ^Q<&2J;IM&#.=TBT.W2QF?8N#<;5N8+E<)KDG,_]?
M*:;H8QHS;>,X.U8U7W)5BR_-?<TVI(V%,1BI6Q':%E^DD\4`\=A0L.HB&4P@
M-^;"6C+7MM;,HD"VO\J<4(96!>'Q8A5JK0,A52&.&R>4F8`^0D'V!I9@#Y@*
MJ.:4)5)-*(\'JM;V&@BK)O(XF@;<K0E-[A'=R!\1-**1A5(QS?%`T\)&!PJ@
M8DG<F&UHMR`('HV(I!'SV!%I8Z5#Q4DE)D?>&MA-[UY'^[V.\H\(V[U:=1C,
M=Q71C0LD)%KLMJ[U.0-FR53=-HR93FD&K)O%K&?`C*MU(]>X1=LB-<JO(>#=
M3['QXH;OL)@_A'@E#.(6E+N3T@:4;H5G6W"1+O8"Q&)#N?*ST@;R.#+Y54F9
M]F<CZZ\^LO%E_@-B'[-?%(FR.1-!XFS"Y&C0W(L5AP&VK6CN39SMI:\\/`F"
MLZ"\$KFU\D<.4KEM#HG'FA2.3(-51Z3[VQ#B3\^(^CAN+X%!RXMF&\3ECQ)Z
M$-L,#SV)%&ZDH8M=*B)YS%G?K=MS:,S.&G$X'L!VMM]`$+:1RXTYLVJ&_8TD
MJ-RDKAA(B8H)1DWU8D>#0:`EAA\/U2MW8]:I&LL5:-(5$_3%1XHFH"6&[WF%
M:!KY$&M5OAOBM69WI-\%^"F^'R5P1+H/CYBBUJZ7?TJ.AY0UY8,0G"0<F+S*
M#*A\B(*"+&/DMU6L2<B$D,'#AD4#068LC@YD'2PX+`[-!'/C9L^LW;"$,)O`
MC&^1C_`C%_\6A5Z"@H5'<PN$(?)%<]K6](5'+.B/!M!=;3<,FBVDZGQ-:$\O
M1%=VG_+VEOT[S@S40"V@9'EP3U7R:)`(M\<PF%/6W_DVT0&N>MJFU%_S)9\E
MWYJ7O$BF5I1E19<^M<L>#<9,;#+LQ(A$`D?N`NVF;Z][)'K=&W%$4.[5JL-@
MO:N(CMPS^FFY9%D&:Z//?G9F^Y:E(/,HZRZB@/_%&^^C%_)F#6@.?;$K7->=
MG9/;A'JVDGZ#4/<*W9B^EC0Z^SAM'Y0G!#=[W:VWGKF\5U(,^QG3@](7)C&_
MM*(YA6U$4QW9Z&F<A(R-OGJP`+F*KZ09>7;Z+MUNPTPE+^0*?`[)TW6T)'23
MH5NRA=:0JKP+&4KE)';L=-:C!\Q7C)_>;S1B(N23-RBXRFZR72"*"7\F2P(&
M`XI*"-%2C`4"0S<3&P/44`&KL`PTVHH<W$`:)8BB."E%5^VKDQ05;:EK%1T)
M,2;N;VZ54ZM;A0F@EM86N!9W%['!KS>Z]YYOT3*-`M7BJ*RH$!O-HE/$AE+=
MSMAH<G=D4^Y^K@UP^59[VA1R8U=K_E1)-)U^R,H,EET1M"XW4%5&PH6'@_:;
M[9*ON[MG&U]'`H2A=XE.KZKC8;SS>V$;/+MV*;*7_OPU"E)^5O<;R69T*A=_
MRL*`$4TY)H'13,;G-C:P0P*PIH%N`JZL],7Y4DQVS\6B6)T)[M>4I*MU]9A5
MZX6+#BS*URZL6(S5HQA!@_1BH%KO`JD_>Z?"JMZ!`M'^',F<!CCRZ$NV'2?.
M)@.C?"O##YRL;["?W>N^H@B);HWHS*?UHJ0QGZG@KB]368&O0^4#A3J91',N
MT2.B,>87$7^D.%BQ8,VWX0"AIV>@P9R*P=3!!C9.KRA3U=KUZ)H67KO3'J5,
MEZ$7QY<BR>Z0GU+^MAK_*<'5?8NS*)CY/DWY>DF>*TKA.'2%+?@.5^'TX'X@
MXW=L'L-)V?4XGG&^<(-1FE]U^9%$*3P_D-!I\X$6W?0P:F:*GOO[5F6.;!8@
MD<]DFE.^H[;X3R5CSAYEJ;S%,F/Z;5!PT=PXT(U+N8G`ELM4H-B/F:R`:5VU
M8#O";^<-.]^P_^9?!!]J'D#/"8J"_=)$S0<LXH6>C\(W/MF<9\;?K7$6+ZD7
MQQ:*O9*CK7)+5W;+J2/YTF\Q3R0H,-ZB?2G,O>!8HOAC4XW[X8\@>F%HM+ZN
MDANPC-X@KTT'<!F#Y+T?DA@%'TX3FNWR*'XD+"5X3C[E$]\?3F.T$MU;.X9[
M\U;#'S`F4;:EY!E+@:LJVW2^N.R06%@S2NJG#^B,_<K&S94#`@ULU+U/S#04
MPB3C6(.(F),;BZ,-V:ZRSJSA=&69<H^IN,R@'6_IVK.@)E'#PTH_$IAV0D>+
M&&?;1,4,)^[OW]\YY7&T]-(PZ=/E+07[<+IX$]78B]ZU:S:^UA+7W48(>9'=
M!@A1D9$R;74C)B"%JOX6\LLW-8CXN-&V*S=/"9TJ_5[NDVM_=]6=.E5`OA0P
M<:.!SH(`YR&#KWM?1\72D]"IH++E^J&ZK*O.-E$1Y'@-0S<N;9OY?KI)L\/,
MV>";ZT'1FG>`_$T]OI]*#`A3NMWB,IC.6:!8J@X##9RY&U>OE4^`<T&9E-F>
MJFRR\2-?U2YW7@@Q9$-:V-*,U%4D=3``"$QF_-V8";Y%"9,>!9\\&N%H)4:.
MNM#NQC-Q(5?1`%(*Y'<9)T?.=`&[&&A<G6`7TFN7H>\B1CZ.Q62B?#_3%<K_
MOH[:L^BW)`P_$_KDT>9)"DOJW4970VHGCVEULX%^GMF8_U`;(*L/1DORY_)\
M]`^/4B]*%A3S(_RM\4I71KO!C#VCD:!D"Q;2H]FJD#.4)Q\ZV<LAG@P;>=(D
MTSB__*QZEB4[1/L-/65?VJL@!C2[U1`0S?20:6.,CB`$5NGDY*M$]GP7B"'@
M)$1JQ+6(1NM737`C!YK:"/4>%E"C`E^MFGH.:+*S*0JQKZCW=$6>HMV=CBC(
M6TQ^@P[Z[/E\PT;SXJ\^60+B&YSE<84_2U,.&!WA$HFQW?=N8&5+ZQ?<=CPA
ML=1Y>/>*45TD[@'T?<BKC>-=F\(APWR124L?;+&B!01N`>UQ16B=<08,Q8*J
MQ4#K>\NXLE58(DU##(FB[F#-#C"ZN&@"-2,)M)$.C+1#AK0%Q8]>@A9\0V_U
M"7M`1).1`@):F_2XXIG&-`.&LW;-8HQ9+V+91#,[D*EI(;',&9A98447R0Q`
M9E*_-HY!(>;PC.)^C;>Z\FL0^]0,`!%0QN"XXB#(3`-&0UG]8L".O.RK;'1=
M$`OA``FGCF&V`_!TH=48M^:R:,.L&78=#K;5T[J58[K9P=WL$)M!W`7S`H1@
M`*_CBL:FQALP,`-$<?/B7%6+[0GHALP@D=M=J/>#5UT\[X+\3A)JH[QU0Q@Y
MX(,V(-0W9-44O$(/S6%@GRQ--J=H64ZO%QC`E(?8L**5Z#"788,;K`#$5K2F
M(7Q46/:*+9/`K0%E'W(9A6L5)`\YA7N+N$A(_GZ='3$@@Q813R]8=C+/@#FR
MJ&XQVJQ?!;4)@+9PTU%#@J!#@+-$C2[@&0'.3`9M<(,#KN_P!HG=V4NCQ2O?
M/SS!BP+=F!ADC"(FTPM[O9CK`%FA2`89*H>(@[,H*%=N)4U-%/_@5-6X!Z&:
M'M+L#-)'SPJI5(*E03(XI3QY$#8&4YT,C*:2;,SNTP`3(!@)3='J,/6UPO!3
MUC;9^9E"M5PSB\Y42&_0CS;HIQ?8NAKI`+UGHWH)5OL^IJ9*3/.?F1IWB#YB
MWVCY1TH+&*P*:*>'N"[&&7"H*JA:@K2#[ERWA)J&&#)0=0=L=HC1#5--L&8D
M@7:0"H?:"&-4_E(LO\DU]4+IDQ"=^1CTL!(^TXM[?1GM`#VN1`P)2`^ZJQP"
M3WL&P%4,AP#9'56`]0LC3%I+!%FY,("ED[LL\MU4_-L\$]CJ'(Z2'K)Q4TP_
MO9#:U4A#;ML45R_!ZLCW,:DW\=FC%<``M&G3*;S:@TZ[9=,0LL:2Z#=L&J'6
M_>FA3*N'Y@;46Y2O#J$B_\XM<(M\LLI-*YH2/U1U!JEQM^JF%^X/[((#)-K=
MI)4TRY'/`%SA1QR@*(CK%QPWFI.F5'D%I*S4],`+4[@CYJ252*`R\E9DV>VG
MWR.F<(C_1,'?F;*LC_K"'')#XG@>[7>5SBAK(]&JVHE]0\E\>>\]-[`V=#6%
M[X:K9GIH/Y#).S:7X:24M+>^MWG.-H0F^,^LU^"[^2IM7G?0RH:TS$V,2*<'
MW@ZFZ9HS&-4L`9GU5KK!KGXMVX7D^7,#"OEUL&V*Z0'/W!`=\0:J4';Y7<^Q
M3!^,F>`(KZ)/S_[:BU9H'F5O8K(R6R]ZR?98E<(O>#-BGDX2BA_2A.^[NB<+
MEFNW#NX?N%9PJM!3K2.U`1,@@[*%(9Q0;3L`@6$)0T^".CGC(M.^T/DR99U5
MY+]4WH6<14'VOS#KL?8CXO[:Z:!U:UKK0'5/N\T>PB$]MMR!Q'7RPEB9#?C(
MIK\6:<A-T\;`W*;=:NR,UF,[``O@QHLTU8TTS;4HP:=RE:GV:7KC`X5J79<R
M:YPET<N%^ZYK2N2S+DUU16N3!F35%4D0V01Q9&>2/I;+0;5*\#?R,VK*E5,X
M%.TX@.Z*<PN@QBC3WA9G"E*H!/K[XHR`6AVFR1ZP+W[G?_#U/_;+_P-02P,$
M%`````@`9("O0-T%$GKH8P``J+H%`!4`'`!C>6-C+3(P,3(P,S,Q7VQA8BYX
M;6Q55`D``WRVLD]\MK)/=7@+``$$)0X```0Y`0``[7UK<^.XF>[W4W7^`\[L
MUDE/E7JF+Y,].\E&I]2RW*.*V]+:[F134Z>F:!*RN:$(A:3<[?SZ`X!W$@`!
M`B`IN3\DTR;?"T0\[P6W%__Q?[_N`_`$H]A'X9^^>_O#F^\`#%WD^>'#G[X[
MQJ^=V/7][_[O_'_^C__X7Z]?@V4$G01ZX/X9?()1Y`<!6*+H@"(GP0+`Z]<Y
MX4<8PB@GO3S^MY_$1[`.$ZPI<1X@^*^_.J$'/KQY^V__]MNG-V\SSL`/__X'
M\G_W3@S!U]C_0^P^PKUSA5RJX$_?/2;)X0\__OCERY<?OMY'P0\H>OCQW9LW
M[W\LN+@4Y*_7.=EK\NCUVW>OW[_]X6OL?0?P=PACJEM"24Z.6UBC_O(^IWW[
MXW]]NKJEC7_MA_@WAV[)U=*2\;W]^>>??Z1O"U*LWA<TJ!"-OQX`Z?>+4`!O
MX`Z0_WZ^67.Y?_Z14/P8P@?23U?./0RP6BHB>3[`/WT7^_M#`/-GCQ'<L64%
M45031;[MS^3;OOTW\FW_I:[AQTI3`_+H"O^KIA=^36#H02_73&0+O@%533\:
ME5S(1FY-:D`PA*+ZSW&?71<W]^V[-^]3(/P+>?+;!7*/>Q@FB]!;A8F?/*_#
M'8KV%(.+^SB)'#?)!='?\*?O5%CP:_*+Y%A^K/\JHJWVNR(8HV/DPD9[Z'^4
M?HC49ZZA)/T92IKV`6X@\2TP?/WY]CO@>TH"YCD5(.XCI0,5PO_XL?P&[>^V
MB.J0<"(W_RWXGQV_/Z/XT478W@[)Z]JGV$5HKX@!U*>/JI_\#T"&$R0(J.CY
MT9@1;?%+'".@=YL@]^]7_C^.OD>5I2]PF(%_<8)C$[BJ;-DGD6?3,BC5UND9
ME8(VOF%)"YD7E("2SD"%&)34@)*/:VK**$%]>[!N<K+<I=E-#)B__:0"39P9
MWJ,87DT#H;CM%8S&*4:#"D8/)4:?7@)&R\X\-Y2^4T&IET4V*FD",'WWW?SN
M$?*0Z<<@P6\]?Y<_N8?)%PA#^KA*&-9$D(R'4C@10!&&/QU>49S'`.WHN_C1
MB>`/9P_[=^<*^_<JL">#Z<FXYO>*KAF\PO#V4!`X4?S]V0/V_>B`U4GDG6?B
M73_C,7GT\>A$3IC`5M8NHLE3=#:-GF6)]&HFWQS1`F-A<LRSQX`^!\6+D4$O
M[#`D]7T;8&:15I`[5.^K.5&)W,$,#HB')%F!Z\2/`!V378"^`#(`!PZ(X"'#
M"([C3@B.80S=(_&D`<)_[AS7#\A,A_,004CIOOC)(XWXMRY*$A^+7)')U4/D
MDRE0Y\D/'P#^>T\S@U*\AWV)GZ8*2[0_..$SB/V'T-_Y+FYD\(Q)O:.+]?I)
M7(K&?0`QI'"S#S"=Z8W'SC$TT,MUQE/!KUSN*YJ^M0'?=Z4C.U)']G#ZCHR;
M2)J`@D;$73[BGH'KD(1R:F^;W5^=B.B)&SB2H,Q^FI!2"\42;="+Q&(%?""+
M^.;I2S+(*EX37YD3C`MJF6Y%"M^_#F\!0PGR4?!B.G9;0`Z)XR5VGJK8^7)6
MV.'%R0FCQVSDM`&>=R\%/)S(:AP\.JN\_I/OP="+-V$QK-Y$GA\ZT?,MF4AK
M!EMYAGR%5X)!;WU7ND6:J[LR>@1KN]WL\X(&%(M-9`"4DX&4;N0%7GD`(/4N
M:BSN=O)5EG;'QYGIR&T=<22.US!W*#"'<LS1Z?2QQ[IV0,>+[J<&.[,AWS[J
MWLFB[BQ!Q\D*+(-.(T>X@1Z$>^<^@/69][AH1@.X\@S9)Y!AT#(B^1;IY0A2
M>OBV(\$^+VDJ&4)*56)H7,-1Z'^DWD-UL^GF*\UF`C`SG2)8!UP^9>_LT3&=
MF_>*#TMX,?@\Z`8.0:&?+=_#R$<>^>RE8Z?^_!$%'HQBX,1TOC\^!DF^:-^@
MC,$])-/W&&1/,$JH;"S/1?L]CA=T:77DC,0.QGD9R:FAW&Q&8A_D)"/)P)P]
M(WE)ACZ?^%KXU:4C<NIXFV@]2RAR\A3+4#0QE]%0QIO!X)`UYRU:9&;2>8YV
M0W,4;>D2&7N3J9*E-U.-B63FO"YLY^/BSF[FX`UJ1N8]#"JLS2B8P(<X-5#,
M">`3#,FR?(@2<'!\;RH3#KT1UCFY,!F,69H^,`*QRE3!"45D`^CIFB701X_.
MVKP3/]Y`%_I/T+LX1CA3WU+[OD01YVB8`D>^5B_#H;>*)M\FS;5[*46"Q30)
M_CDA`CD52,E`2D>V6(%?<]+_-_+JF@(24(^N:JRU=3-6UMRF`#FU;?\=^Y\'
M0!Y=SG7H#KD,>UZ*O4K8Q_C[PWFBCKO&:QMW&MZ;',GVC@'<[*Y12'3?14X8
M8R5D4R/'?ROQ9)]"DD?+H)3:I>?%957QK4E.PCPG(QDU)J18`E72R?AR-52@
M7IU6MRLIUM*R)@-!HUY]("02SU[%8HC"UW3G=E(A'MFOVT0@S[</@D$-_[YP
M_W'T8Y_*W^Q6^(\#F1788@0_.C'T[AXC='QX7#H'/W&"*XB?->?(=$1D'ZN?
M""U+U&FU7FSHJ9EOH+T$SJM<Q&(+/E`P@HP39*P@Y1W7BK7@ADQT?]W"^T@J
M#?Y$D&]Z;G$2-D#F)!=Q#),8.(2=S`BE1S7<#.\!I1MY>G$\P/.F)5\&Y$UF
M8=/`^[NVUX>%US\47C_)O'[="EZL$7`RNPD8@4S>EWUT^L%CZ/[P@)Y^]*"/
M/_S;M^0?)"=\^_K-VZRPV[_@1[\M<%,\TIP+&+N1?ZBZ\3SI$Y#D21V31,^.
M!5HUDS*V9($!LACFQ5-0>3RRY8AZ"LE\V0;N&9057,MTNL9X91W'1U+`;[.K
M[V%<ATL4AI`.E/[J)X]7O@O#&"[R`\#-08NVG.RC:,C1L@3M]NN9BXYZODWU
MESK/64E,:QR!(,O*)7]Z$CR3`$H1XQJI/AR1,634S;VWN-(GG)R-F![M3,Q:
MR+BG:B^-C?1%_N=7:(+,8(J*"F./BJ9@,;SQT8NT&9/#I:D9S+NZP>1;BXOP
MXC;"2]M:OAD+;QPU*6.Q/J*Z#)P'WE"J^JXYADK?F1D\5?48&C5E(B6&2Y2R
M,DXB?T]D@%3[_NV1$:-[FD,B0L(8"S$[S\(@:$/PGA6GW^P^1+[WX(</5\AI
MCM[["^@8]H@$6(E+W2VV,]`1ZE4/00)QPJ$-HD.;C)$0Y*R`\$XSZ$B`K#/:
M2`.U(\CPY71'EPEA?:@!RV"HEQVBN#7PWQ,)D-:`F^CHQ"[V5<<CYX+^(88>
MPT'_G1CZQ<[V&NJ)RP]>J,M7'5D,!'LC"5[KR/XR<.)XR6K,;5H"<UD>>R#-
MND8)C!>AMW#=Z`@]>J40C)M;-H=3V$H@[2DTY(9L?Q%3":K%=LKX-VOJ:]Z0
M4>B(Z@%+;DJ<:0,5=30[!E0A+1.?J02YSJEX4>O&R/"Z`SF`EH^VI9?ETU^L
MS[$W4#A3[],<B&P;9P?;Z5A>B;IZ_)!6I0X+=^-D[L;/E$QFL')._J9[,/3-
MXPS1#78&9^?J;AJ#/T:UL^^6WYGT/=]<CTW,ORC78V5;UY4/CYL=.0KS`85'
M^6U<'+[.;5LM/DO+Z9SVV=J6U5;79YV\*:5KVQ6A)Z_HJ43*,A5W(PL7B75O
M,=(Z5[D;[#*KVB-A=+AM45;0VK6F0*^/2_%*3R[>$Z;13W\,`5GU?4PG!-IA
M]B7906S'4@`3L2\`KLH[B2S`5:>F`JFQLZ%;X[<8(JNO![(KJ9G:=%#E=1-X
M5'K'U,6Z-6LC<(4+SJ!S>.;T!4C?`/(*Y.]&/FO>T7M(\E,W3I.SB2OGQX>$
M@^E\P"`PBG)S#P\1+4)6*3P7XE[#9CVC9]^2Y]?W]-`;V>P,:=$Y4KH`[@\!
M>H;XTY)R2#&,GGP7_Q%!<CP4>C^`15S*21[]&,`@O6C.)\-LX'@>N'<P,K\\
M0CQ(=P+W&.`?'CZ`$":ILWZ`(;D<#NN\?\XOBL/OR5G_)S_QL;9CG)?&\4//
MCZ";@#U,'M'8]>YTL<U+-R:&;J-5.`Q"F]100GOR1WH7#D%H?AD.#\8G#AA>
M<0U3@#$R<Y&6SEN$7G[WSB6*;C//L8F6@>/O^=,7*LRM.0PY9D/YMDI+3<UF
M2.J42;FE1-6R[JQH(ID\+:Y>(C:7<Y'+Q5.^J:3>2F!BY-\]P-A*P65DL/+P
MR6'9WJS'P*CNG1.1I8(@P.G'T0G`(2*Y2O(,(O_A,8E?=B8TK,EU3].<C]'9
MF;49VN)(4;1LJB8U)1(WUMO,=EX4=COG;`;%KD;"MXV0"Z$7;W8X"]_[2>)4
ME\G6M)\O\1>^K50L;UB$CHCL\_43H7?YMD:K]1+!GIH%-W;W$3C/N>B*5LE7
MW4RXSLP<\X(J\\A7?NO@#9GH_\9UX3TD56X3/PWHF\X;)V$$]#+G6@%G"G4G
MW662!;G[Y]IU#2/G:..!GY>OO0SXF\S@IH']=_40X%9"0&63E5\)`?&W$,#-
M_"9@!5I9("0WS^0SBCC]W.#A:;0\1A'VXFE524YY]#ZL1=:GPJII\^JMU,WR
ME#2*C%M!T'Q[L]HNUA=@]5_;U?7MZA8LKB_`YNZ7U0U8?KZY65W?@<7M[>KN
M=FP#[H$:I-.;37.5EU`U4PW`6C;/._@U^8"%_KV'?;9X%0RTPFO=0EOMM&^B
M595Z-EI*FF?DQ>(^G8VG'"!C`5DEWU\)%Z!L(U]XT`]'2B;+@Z&"S18BU(QV
M%!";'U*-`N=T(KXR4XZ9\4<B_W)B(`WUT<=5P\&;/Y(Z,X";'32-@^YW9Y53
M&8,P=Q@T`H1U+@SQ_OL8)[1ZVAU:>!XM8>T$6]R8=9B5JU[M=M!--KML1GX;
M^:X?MLJ>:0O*:Z1I"-(KJ*;]"S2KK^GH%Y1JZR]V7N$E6"VY`6&GE7BSHO*I
M!#*/DLD`F9"1B\'IHQ*9PT>CS%QO>96:=*=G+,;O'IF:V10;,PH)I+^<TG8.
MF>WD%S)4=OSAW/'U(>ODREV*.#J@B.ZB2&]5'/L*DTE8%?<ZDQ=J5T8O.)F<
M4>$T]*\M&_EF!M5^G[09Z!ZP2=<`JE>D_L4)CO`B<KY<H"]AL7``O17=\W;I
MAV1#R:7C^@'^LV%L)D56C^YHB]3?^F[H5QDX%*3?DH[=]+H*LN-&V2Z/VKW9
M,T!%S0`1!HBTRC813)P*!)E$D(N<P,9\4ZA&-E#%V/"O*;EQ.N#T#=#*,:RI
MFR+)F2D#+7N2E4,I*_-3,\U6XMM7C!\/F,8C=NIE=NH6=IIN@`:[S$YWF;XI
M'+F:I*$*#W-],]7&QS)^IFSR=IH=88<MZVP;X;=@J0VKD[-!\UE^NN'>;)K?
M3Z8XSU>5:<-Y]?M=5C)]Y:8H^RU%#<)</Y5U%LE^3VQW.3`MDQ'[+S71G0[L
M]`QQH(Q_:B9)<O[KX_X>1O6DGY?M-R?!SR?OGX3-*F;^WZQV@.1_<B9K,OT'
MK_S\TKWOOYFEH<'`M,S2TJ1_?C1T]15&KA]#3V%VG\LK,8W/X+4V!\%MI[V)
M>9;*?M,);4DR4^U%.8Z";9)NH0-&4E,!72B4&/&W1,@-[4?%\)!SVQ;17,Y6
M\W)5-]O:FV6J3@P<G+_&QX!ND2(4,!-&_L[+/4TS.[6"]S[SS">)^*&FB&W"
MO;+W(H?M"T)JC]E8:TBU-;_:,Z/J8):9,1W(.CM::G$.U(AA\D1)S6J>2%[5
M!2:Y<95>9L61(3E.&A?+@TXCVD1U?6(PWQF+:-W'&+RJ[)8]AGX2?U\$)4$*
M-LW4RA+D>TWEG2CH!YN%LXIX1H9U(M-CYL';9\++'G@M36%M(__)2>`V<%QZ
M:%1A!HO'*C&!U6:U-A+BM=+>]!5#8[\!4$N0S.15Q@0*KDG:K!A`4@.D#OA)
MC(Z:$N0&1R-B=\AI*VLHYFRQ[-A;B4)PR)!]R"5-,Y>R`.T^DU2G!^ZA9JCL
M(9N[*LE"[XQ6*L:4<#HWBPR#YAX369;0;&L:JU]6)>:5F<0:QGS%[;0XA67"
M<CF2I":P3B.WZH"1W'!(*[MBBY`<"HV)X4&GKNRAF;FC36(CV^DD658PWFNZ
MZA11/MA<E46(Z^5:)S*I91K@?::T;`%<)O?*/BS]J#%T?WA`3S]ZT,<?]^U;
M\@^2E[U]_>;MZRPSPX]^RVH57?JQZP1_@TZT"KT+W)*&W72195^(3Z9EKUW:
M]9(H@72^^7&9YGE]N/05(.\`?@G(VW&-I[,3D>P'KQL$C[K$OC0N+-?$(K6)
MXZWS3.H4_]4AI=,;>-,3HE`+BR7$>@D2?LOMU\!BZM:K.<(0*5_[:D9OC(A!
MQ@]2`=,O32)`GU)9DDX49\;=3Y9:,9*)&,,8-:X&,0MZZ7KH1M")R>5=HJI6
MWC%UV]0V#IEM?$G[5#`8.H'25O8,1Z>DU;F8SM!EK(:Q&SQLHO<*T7LDEL\N
M2<\#\#%"QP,>+KF98;QH[&O4L1H`^[I3UI4;S3BSYJS):GFNZC2U#)?^M(=\
MVPQ,34LIZYCCD)"134?7+H<5+/M/8`I#`2&H9_<Q)BVZF1O3%5.!I)69YF'`
M*5,CB0"W>7EX>U&?%!PE5[5.88[9(GZ%\\JGBV#CL\@#P9<[<UP#;8[-,X>F
M:$9X"&A:36?2F6CE?*;.)IW0Y&R6C:_>.MLI3:%-Q^XR(?))3<HP==-KX$3!
M]I@(DS:][.YG!=L;%)K#IS8&0<HN!A.E)SS./<W1!73_1&?JD!XVUS&)9[5L
M9V+KXG;1VCOW,8962X<ZTL>5"^OE]A^*>26.=3!XK6T?YK;3WL$.ELI^.X?;
MDF2.=F0OB:WF?!.P464<26T:[H)AU59E1<AM&AX5Q$.>\+`(Y_H44?5D!PXO
M@0^/-!J1>$/`'.?]@Z&61/[],4GGS6EYDC`AY?)`(8T\;$AT@Z-'MN=B1OR0
MW)>-=>S]5,J,+?[^&3S!T$-1>A'B#AW#"5PJ/Z1!]3E4<I(F-=2Y$IOV5,WB
M\OV\#4NZ1^'Q!<6#/J=(K,'7UCF2GHE<![/,29*!3+:CI1;/DABQ5IXHJ=,D
MIY+.=:%);B^R7D+'D2&Y%WE<,`]ZJ,0FK$7'2OKF=6UYG>E<32]7STDE>)9,
MK->!EA,ULL'.M%BU,-D\;V+S=,,ANL\)%GN(MKRY?TG\F>,F1R=8/$20GJ-I
MIH#:<A2V^'/D6-^=*6R__8W^//5ZFS/94CNV^[^N;O>O2`"EB.GOW13#46G[
MI@RR,Q?16YS:%LY)V<@8^_\'M!;U4P"UF4.2.ZZW(/(?'G$O.[G8&:F0##'6
M'VGFZ,$G&*`#/?I8T-`W`8X)(=9</FVM_9[`*0+;UJASEN#L[''H0P5#&B,C
M=^VVL/_M[`]_5+&Q;P:E<T!A,(.R-2,JDQ+W%R`S,VK#H?1O\0!32NH^I(>X
M[ANXSC]::^!6;CBMD"VKRY$<5$_#?-028YWIHB&LA^;!]D/OB4PZ6;.47M.I
M9V`K2DEKS^6X0<SDG=S"W!3G549"?)_I5ON(5RT=M'/B>_JUC_'K!\<YI/6#
M8)#$^9-F(:'L\6\+UXT@29M6:>&HYN0KYW4^I]IZK3?LY&@S,99LBQ8,$9O$
M\^()"4!^B)7!."&5N$*4P*+J0E&%R]F34@O_='(.#]XGX!#!O7_<CSR^XW4H
MZNJ$QEBL05498MG%A"EGK04(XFA+2&0/3ZUCN</L_EVK,2C>X%%*M$1[;"6/
M6+;_!->AB_;P<QA!)_#_2=>IH/^`=;N/N)?@)EP3.\0T!R=\IH4%KF&RV=TY
M7[?$^E"X2-+%<F*:=VCKD'I6#8P-K#7[T(-IU;*\@;^-GCD/UUB^EQBJ#7.J
M"-0T@535#)3*0*8-Y.I(O*(*7V<:TWI:,X"5@LT.8+4SD"D&5<W$`Z2ZQ_5Q
M0ULK&LD4ZOYX(.6EF__FGBJM-+W"^((<%9FU6::>QP_I+.2]$]";R>-'B%V.
M4TS&XY=.DMW;&J>EF^BD981<&-.94CQH"N/`H?7+XN-]['N^$SV#';T7V\?C
MV!A_\VPDEFZ'2WT?3*]$]\,GF&\ZP.D[`KMCZ&8KJ>G]9>YS?OBB+)26[N$K
MLOJ$^$>GX1=I.U,#RK?\K7>5'8"_BYFZ?')1;=[(_.FL_)DHK'R>.+_2MNO+
MT,]8ZF5]'/KKZS\S5X];GA3;$\&#@SOM58#B^'L2.(H/6@DF?@44:?VYD2>8
MSSU`\";HOH6(44.$R47OEQ0?\"BZDJ[*>9AO#F88*+]0!V-Q6?\)&SYNQF9W
M`>^5+LSA\4HNYC=XK2ZN,-MI=U6EJ;+_@DI=DNQ*2L9%4C'"-^U5%#:.I!=0
M1#"47#FIB9!?-!D-Q(,>;K('9W;9'_ZMA*RK<]P:V.\CWWL@!"0LI^OIY!]D
M002'[3B)Z(>8^(X3D_;0=_7\Y"QBL)-(%LV!L9=3`N&TLO0U0?BZ0/CI;!HQ
M"O:>"^=6P&ZIRM`-)&KAPOW'T8_]JD<79VT=S!)UAEC,U@I*\%MJK](04V>_
M6A(,43*UAC(V4.&;I/5V@4FJN$0G&,76RY$A5UR"I?L88YWHD$Z*#@KM(>L/
M605Y[UNFHPSX3BEKFDF:)>3W*0MT)M@?JE"07>#CU.V%.^\^I8&&@["M*;2^
MZ5@7M\PTVE`)65=;+4ZEF3%:KBRIZ;13L>M.2,D-JC33,IX0R6'52,&)IWS0
MB3:[8->XGOIDLC-K)M!K&NULC&"PN37+%L!.TDYDKLP&JOO,EPV(:EN755]D
M?CIM'?NF:B%-]KDX-%JV*=2KEVGQ1/,-C,TQSQ]GJ=)$KJ46]QB2^L!U.V"2
MEFB7ZWZ=:E65$SMDEGD'HPAZU,@^.#'TR%8$&,8.8]C1AS4_/Z7$JG>.ID<K
M-4_8J&D4G+Y1$31?-,Y>Y?2IJWU]3SA`E67D<SM]T(-T>K5QVD=!0N4DD))>
MDPF5BF;)(<7/*9)#^("=BL?/IT8!-!E+-"'MY9".*Y!V7R"DN:67SAG42D,$
MB9)GHZ":C@\.I%0#/3M-MLMG._7W!\?E'**MHAZT43_EV\Z',PG>J<[134)G
M7MA_"/V=[SIADA^@CR_\V`U0?(S@XCZFCYK3P4I,^2RP))/>I(!2RS3G?&5U
M"<;^<B+F%;JBQ,385274,(#Z]5!C2"_%6QG)]X.<-7.Z@U^3#UC<WY7LJ<4E
M95`5+HL6U6J;39.J*NMK4Z4,ME&!DA3\2H@!I?Y_4S:V-D`DK8V'+"ES*YAE
M[6U@1!I?]1@.FV1D<I>=<\0X]$I(DD6/"FS=`K:'8Q0?G?2<!Z9/SV/@GS++
M:G&1?(WLLRPKWI7U=2"MND+O/6"=TJPF?^F!QF0:J9]MJ^"NEYRV71A="!G0
M*-Z=8!YD`(2\Y8VA0#AHQ:SC_AB0J2+>(;4K%!>'SYJ3Q?VXRWI;:MRZI9?Z
MM-5,M2Y%S<+:34JRYA4&@&BE%;=6:84<B1^]UE,O$"'-GFW5B5(14BLC-5T4
M&ZPO-A:$L^ID!8CYY8+`*\+W?5H!"-$*0"\+V8(::.-@V]8Z_(HFR7^%0?#G
M$'T);Z$3HQ!Z=`-!U+`;*=KL>W70:EFN5#OTK+1+!=\FQ9SS]#4@[U__G1"`
MG"+=`AF-:V=R78R4>J)N04*6TE[4\&/7.OZ"@B,>6T?/EWZ`\Q.F57!H:M;0
MHC%@!1R])M#?%MV%^B9'CO;B.4A?3`'CO`Y#4M^7A>D&:1/+7;UO%\/+=.KC
M)I\=N4V<Y,B&LIBTAF@>J0%@BUMA`M]<#5TPYS#F:,]>@^(]2`FF@/J.OD4J
M?<"R`39'TQ0D86/7(J@9+G%"]H"B9Z8A,"EJ^&]0&(`]4Z<)M#<%=X&\3I]C
MFSX%^>,I()K=24CBJ[+P6R-LPE;<VW;1NCW>![Y[&2"GN9S-?5]#:NV]`9PR
M])E`:5UL%T:KU#E"TV>`/IP"/ED=@SJ_)0N;%;(F,D6]:Q>7-_"!K-<X87+M
M[)N`$9'4T-DD,0!0ME83&&U)[H)I@R%':OD8D.=3`"NGJY#,IV5!MD[91&U'
MKUM.B"%910C6H0>__AFR$P`.33T%;M*8R'W9>HTDO2W1G=EN@Z-(<]/G@+X`
M^,T4`,SKL69B*^S8>D9;)VVELAW=;QG$:+]'(=UVEQ[PV1R3.'%"#R?5;$1+
M,-3A+60P@76)%AD!OEA/IQ6(V`N3H$3I@8+\\#*H$$["0F00T#07>=34;4?`
MUS(D%:`-MZJ[=9[S6T')H;D(?CC&?@CC&*9S]4LG?LS>>`V4]V'-OJ(:JY85
M]FFED5,3BHKY!JHD:+[%7^*17)N-=F!QM?YX/:Y1]@()TNF\NJ&J2"A-=J+X
M-+5&.PHTR>IL3D^^=/8<E"S%<BQAR]][+P6_O"79$1!L^U#TI1^[3O`WZ$27
M^$ESEKZ#*JD?C&Y1&3D:S=%MYG!T6WCW\>@F3WE`.GT#R"M`WTWCB#2O]UJ'
MI,7=G!D!A[A]4+H+#L-`.SVNW0UN!AT3WC4Z@P!GZ#<)\;IX69!7N5HPS\H!
M3`[HK)[D0)W?Z4RP5\AY<!?!PS;@[[!8#L:KKQJP3E\907)5BQGP9A*[\4H)
M2XB2/Z>!R=J7;\&0T2\-Y!&*-MB8G3;@!F3/\],CEEO']];ATCGXB1,TP-%!
ME?U>+I7>EDNQ;A,;A+D:!+LH.3SS\@4XX#>O_1"XZ;N1-T-V="&2_-YU;'.(
M*UL8A\2$L>VVY@!!M\^6D"#OR/UURW.`!'>_JRE0#.@&:T?3+].[[L*')8J3
M>!%ZY-`(.E:NB<_]HB);[BBEV0P6@NANG0E7*J]2MO:#0$BKE@DIBTCOA'0)
M+7FRC?)"#YO(PY*B9_#=\KNL;-R4RCA(@(=3PD$:=KEY2G+S"C>,CE=C;GY(
ML-)`T(!K00TH.3VM6C"<.SCE:HM8A>=8\64=)AA,_GT`%W$,.Z(*CY@92]K$
M!BV2UQ+C<8.A2-8`6ZSM&%%0`(>23,G0N)W-,:\.<#!-JLG#,Z1!L63'IQL$
M$LM_ES1@<790DO//QL`TG"^^S>^O+F(%'H>@M+(MK_J3`DN2WP`@PZ)9#EJ^
M5;JU_J4TB2H^2PB8+S?7%ZOKV]4%P/^ZW5RM+Q9W^(\/BZO%]7(%;G]9K>YN
MQR[UK(`$U*>GZM8FPUFMX]P#=,-97G5]]!)_3O[M&Q*4V7<24FJ9ET0;#&0^
M8BU\BQ+QS>E:/QE-N.0?I!CBDQ/0/0(XY3GN(;T=(*U\>,BVMHQK5C+]C10Z
MIFY$`H;2=D8!DJFTQP**2,)3VS,"2%=-YS854Y#AY3G&03.PGPT]\I]5:?N+
M9.E$T3,>&=.[F%@>5Y:GZGN[>?2-1[9=IORQA+X.F^J4P/?1$S`K:1R@7MW$
M,+0NUH;)30%TO_VD`KNT?!Q.T*)D=/#AEHM2A`3<PP<_#,G$)![EIBT_7U26
M_7@FN%3**0[Y)1CCH_)=!RHA?OX2\"A*2$X1CTI523MRW`%@^+X"0_J/"NV,
MX#`G3V]_/F,@<HJ!#@+$X4_K7*+H!L9)='036OVU@?@NLL8IG#:9D1,-/.U&
M3]<PE'0?5V@QS;<1>L*#(3Q>VJ&(E.$M7T[C_`&W*UMG#3HZ/3,,'G7[!,%`
MZ#!]ML4(,&IG5@@R;LX)&5TG3@Q@8T#7&"$70B\F4QM7R`F;*]7<][DS;+_7
MPSE/GX&!/TNV`-PMZCGY#_9R+O2?\LFRY;,;."[^A1\C=#R`;>".#&]N?Z'.
M3]R`<Y.L@F/;G6[,J^GU./5CV<.TN^GCT^MAKLO2Z>/AG-2:UO*/$[*7]!HV
MEVXY;[-?VGJKA52.+@/.J2V9#]0F[3Q_,"XR>1V!.KY>'9,-HA*15GO2E,?1
MZ$;B;?)'=!LY/=A[6EW*<S2].W5()^-&T(GA!4S_NPZW$20'//)KS%9?R=UE
M$`]T::EFYL8^/2&%R^HG1-,>=%IN9'#:NPDB$^LE<IY1`9B^CF?`#Y]PZD[*
M_Y%9HZS0?U;2<PJ[##61A\S@H&GU?615G</)&(*Y^#$1&TBC4<H!7N6\WY.C
M3;EQ9'S4(-)+`Z:P1W)<0^`'P$F8PICA='.`D4/J^F:'P3@[,=49N6&3SVC8
M0W2UT,CX0$&IBC/@BIDO'[$,&!.31SE1%NNHS0>^<^\'?N+#^`]3L_E.S`CL
M7!)O7,OF\8NL>72HV@M@EG$J"%0%2WX:%_R:<XU\]^4P@)4/1E8A.^"V.+3?
M^PF=8R?KD2@DS8.ABSU4]X6U_9CSC7**S'J+\KU::F+KG*IBP4J]FJCY<O/I
MT_KNT^KZ[A8LKNGY@;OU]<?5]7*]&OG$0$_@(+WN;*S8*\FH+-U/%[?&=DZ/
M!5JZW:GD2+>;5'FF>2_SL'#F[H4:!]##QJI:9=O%,7E$D?_/5L58"<I*%.)2
M:IMN1QL,Q1>^%K%=\OCF6?GE."V_G-:%`$Y!,+ZQ=?4M4NB$MA%Q&.H6,SAH
M3#IWPXC)W7:K9/?BS#`C<KU&43.B4Z4W`W8ZU#H5SYGF5&9MHJ[;AA,M-"B8
M0\;#=IX^?3DQ(VCT(=\`F)W-@WY*+("]35!8<Y+]$<%SCK/TGM(3!X6T1^P+
MBQ$](?\.$(5['"S>^V'JQ@]5[RA[X8?XJ@^FGT13N>-#[78/]7L]Y&[T&`D\
MUKRH">3P_>ED+H@Q!QYI]ZH/GU$<+?/4->=UVZ$:.:[%T68,^1)'L)K$#7S3
MAY-+%WBGJ,2]U\9O\V14B_\88SYT2(NC&NYM-4_W!*-[)!DJU;N]XMBRH/BO
M;WYX\^8M.#@1>"(4?P1OW[R9O4G_UYZ7(>?P+J`+]_<P`N_?S@"Q/SJ'^@EW
M[6/^Z-T?P>]_FKU[]V;VT^__G;[^_;_/?O[Y_>RGMS_5QROIQJV*9Y%4,",'
MFP[03?PG&(Q\G9TZ8B5\KB9F!W6UAP@^PC#&7;$.7;2']%:6.^=KV^MV498.
MF$^I:YU=;=!VRP(%0E/E\LUK+T'Z%KRZ0G'\?7'1$":<@4621/[],7%(<3P,
MGJU#]D*.;AZ=W8X4^J=E,CR&FO7PI1IV_CQ%:G&@>\!D&F59;*C@+,#X.@_H
M"/RM5?`,Z85CW*2/"'GQ+0K:<ZO,MX6W;;S5-`&F+B.@;TH6`;U..R</B)M\
M((]`C)^-#6UVEZ".[]@$<(VH"MH&MUDO5Q-N;BS?NW]3YY7V,'T(;D^NA_E.
MRDP?#^>,KLH]J,OT-$8#1GR"[*>S"+0@R]<HY9A0X@1\Q\04SL<N@WQ^1S04
M9U<JFWC'Q;"@HU#WIZWCN$U70IDEPZ3':LLWY;2T^YZXKLK3&<B>GV+'\UR8
MV:X?TY%QSD=T$W(=FZ%-Y=TM,)"!"96H@+YRGJ'M\D8^MR#1EP(3$)]+X-.+
M#**4:=<GFCYV8!PN/%\YF2,$9K`C[T9-HF?L0KD2AP%4^80%<RULI59MG[7"
MN<I[J*6E\(OT3;$BG]S>Z)ZPRL=GLNQ=M?F8&HV.VV75&JV//APX:Z5,F_"<
MZ+[^`6"K5MET&.`.%VQ6NQUTD\UN]=6E1V=OG`1N0O8/24\F'/WP(3M'AUJU
MUTR)R[I"7YR61S#U:_3<A(%6\+V'MO!Y*H%,+>8R`!%"+O,05*PM98%2V+C.
MQAAVD6G\U!V3KM327^FWSV3\U6V-T27$21L=B>2EV<'<[")B=FY6`0&%:;GR
MZ5WF,#T[XZ4`IV-I`UY41_8G?7!BZ)&57QC&#N.F+#%1?AD=ATCO^CFA9@..
M@:M`<,\<FV5.]RN!>_("N)4W(U\F)^X[)/>E&Q?&,6DK5\1Q9)D,+VP=IL9R
MQF!!?#M]\SH%QO),@,'SL7:@,7RA_N8=SPT,=I$U"O6WR8R48N=I-U&IFJ^B
MNQI[BVF>W3T>Q\CU20E&\,5/<#)SCR+R!V[53V"]W4RC+CNW3UMUV3MZ/S,)
M'G6[*GM;GDF/R=-BNH"_$<C4"OBWK[$_=:1T5?`WCY7A7.A'QP_);MU->`$C
MG`4G="<AN6R`-OP:)ML()JT-TZILV8>39],R'M76&7#!"BKY]B4M)*NU1XJ6
MD;,1Q?WC:9W9RH(UV$.'S'[2XQ$[Q\_.4HQKD<K@07T[MFZOLMRE_<KK,^G[
M9;6:B@6#8I?$"D*;'1(@<R4E`ZAPT.,#,Y!RG3M@>2'F["`K=_6;;`GP89'[
M_IO?E>[>X6`\@=1I&_DNO/'COY=MC=L7CTC3MY(E+KTAF^UHCZGHPE<C8YP\
M[F8TH72`$%8"2SR!RS'D^Y]A=W*0:9D;AXUE9UP-=N($1YW:W:#22;D5Z)&`
M\%<GBIPP`1%\?<!4HU=?L`&R;J]^>C"32YW5\Q`[0'OW0H#6F07;!]H8^<.M
M$\#-;AN1LOG)\Q;#)"%KDH=]^WR2&E,KDQ`S&;(YF989-KL.E3*V)Q0Q?T4(
MOZ<'CTF2X?GQ`<5.0*\?SUAFX$"8Z*H_S#FG8J12:&%8J@+*6L8JXF59K%B7
MG?@@TFE^?L4R3!ES*X2<@#1G`)0#K%X"/KO#R9`('?`NG?W!\2/2ILWN"H4/
M5^3^V?2&GU]@X%VBZ'/<M`LEGOP&'3D>O1M)5-IE8,@@JT]P%8F4A/FE_Y7,
M#I'GP"]81KYF1`D$J%<?-:X6D6&MW"HBI\EDJ)!2:>PVG&'01^_`*0A)>""D
MKREM=BD;(-2O=RAZC3_F^:*2>^7-"+@<]+(UM(>W"<ZN]XR#@'E($%.5UZBQ
MJ70OHA+IUK0RKG#A!5-,GOER<WVQNKY=T2MF;C=7ZXO%'?[C]@[_)[U^9G,)
M-MO5S>)NC0E&OT=*V*5(\ONW[H=B$=<N@V)+FY9!W#E?NT]ZRI#63(-':L`^
MQ*TPD0V)U729"X=QCI^/73Y$JAN1RN=FV02;HVD8/+E&TQB!)H-W^9E'2W9?
M'RDK2&J?3?*HI#DP":[@LPRG`7?M1LB%T(LO\;<K6GP#=\?0:^W<E2#-=^\*
M2?7V8DJTPL0N7K$:P;9,$>,4G*U4-R*5S]W8B"G@J&S&%,HUNGE7H,G8!EX;
M:*$;>;/W@/0=J+C>C.9<H,3=U6L=3$/FM=CGP#C);OMNI;+,MT7VVGBKF7\P
M=1E9!FK+%J4:==IY_@#`],G8F02[2U#'=VQF"S6B:H+0X#:;8M:$F\LJ>_=N
MFCMF_;LZQ?[EYX-F>GBLK"]MY`UT(9DI$V9];%)FUM<D-1C$V:TPGO6UU,C&
M\09C`?LI16M.3W*BM;#?F;&ZSL&+U4VY]A*_NB8[B9\AP+`2O\QOYB3G@B2Y
MO,\&ED:I#MK`*>--N_ZGN?*-2HY2NI2Q$.95NJQX\12+%K=!R^^:#*$5`F95
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M!9T8QND,"+G:\08&9+%FZT2TSC\*`G(3:KM8<6_^/-"H\^M9<]_V&EGAZJ-=
M8.3*TN:4!43Y=!B=(:2WY68P'=G4>X,):?=OP_15Q51\@'H+C(8K5?7&XM:X
MV*:1C**;Q+"4#91\,Y!Q@HR5E,\NF%\>[+DQ;T+`'RX*7L.$%!#>1NC)]Z#W
MX?ES#+UUF-4.#A\6Y!;P],:;[OK]9H1EW:(K3,N7F/DE>FY%NPU\'Z,I>DX.
MK-.J_+D$</\,7A$A@)PQ+N2`4M`DB_8;`BPR"YNZ7]*363HIW;:9#-5Z;5$L
MU2^>_YZLE9&P3NR,EM\_IJ8%4&%93L'\S82Z:_&?AA&=2MCGS+B:%6HD#3`T
M6VOVEXV9%DC-H1E283!-F,R<G&&,&W)[XOEF,[)-.4$[<]5FVF3T$J"3,=3B
M:K]=@+YDF^=8B<;(=P=/V_3L9!YC&=^@F4AZ^H34IVDG%.UW95Y0?:?K/-IZ
MS(PM:G*%AERAI(&3%.H:W>`8GQ\)OUH+_"5)#<-53L-QH!3]VT\JG?D$HWO4
MX=#[="=NQ9S^_AV*0/((P3-THM/IV?(C3JMO#4W>]^W4;'2>G2[,RI4MDB3R
M[X\)F?PEGV3K1*.71%+J:WX0&[6O39;4[=OA[T_1+?,*WYKHT)%RA,63XP?$
MP.[0$NWW**QN-OC@Q+[;`%1/;E:>(<-M#O;R;36=JTAIEC0<"5F%80'G<`A\
M-W>?+J6?T#)]7RBQC5,9BRSC[1;",6\9[=8\>K=R*_%]6%QS<H2<C_1+R@FJ
MK#-`F5\6T*42CQ&A/F"L0V$Q]Y+^`G;I@TZZ/'[QZ?3,N4N_B9@DT"&P4BY7
M=AHEO>O&SZPRJYKP_<@&U]F=2/K+-TR(1UXQ%KY$HQ&`I\:8KS>+%^J_*R\+
M1[XZ&\AP_:Y%T$S`E_(6,&7INWRKJ65'V?:8&!9+Z.IA0^5BX(;I=<=>4Y#N
M\6Y;ZEB$ZV*3L"Q+2V==ZJR[9S,0ZW37TUE$MH`Z94]N`7?#>?9-O9V,M2,!
M1?:!F!1:EB30:2`;9DOG&PR+?E[NN1A_(E/414CBF]:!SB`LH<V48M*),A28
M<IL&^IVXQDW++]+YB-.$`,_;F0;!@!XM>G!"_Y]TF7Z)PA@%OD?_6(3>%D,/
MA@G]L[B(W0F*<N1Q=]%O6^)S7VI<O)XU6OJU!O)L"TT3N`+3RN;7B[O/-ZOZ
MC0#T>/>'Q>V:WA2PO5G=KJ[OZ*N1G8LMS"/;.&LX-<-:*A[1>/N-QE3#K3,6
MD$_9A&DJ4)%)-]R64ND9PJI<<K=.(1F4HJ=9Q_[T3)Z;R9R-T0^80Y$IIB7:
M'R+XB,>M],)UDNE]#B/H!/X_H?<+"CR<`%;NPX/N,4K+%D1^C%]=X#_#ARV,
M?.1=PV2SNRNOD\]S*<MJ\IS*FAH]KVSYUYO(L>PU4>"H;2F=+Q^Q1DB.?QT+
M6<4]KG[X!.-D_)OWK!L%&@J`#3]L25O%'UO[/4:3,4NM-):4G9/-TR2-KI?4
MA-=G;F:@5`,R/:!Y>6ZA#63J0*H/I`IG9(<%2?&PTF_^PQ227XH'&3BS:Z]/
ML!(S/E4UKV)1Z?M'OFX#SHTIO,,W,7@RQ\)8*9N``Q!T'I+\T@SC:Q,W;(<E
MS7CP;"LQ>MS0($;*\..?`3"$?MD"-`;VBC<X_8^.;D+]]Q+%26LE5$Q5]8HL
M*GW@\W4;\(I,X1V(9_!D>*^]`?35!,`OZ#PD^:49T&\3-Z#/DF;<*[:5F/>*
M9C!"O&(='^[IXT/H'"T@9,#KFIQG.F.YV5WXY*ATZ,5;+!Y&$4SKDZ;3G?@!
MQ%^7/FF@5$-"?KE3'PEZ]_?T;[.1.I_]]`NN_.DA;YXQD7'M(2=.[QP`7B9E
MY+N`-)"%#'1UX]X@=4&5ZX3ZM,+HC57J#3!VD=7X8*?77F5L!.\%XPP4K.GQ
MHGQE+^-.'[Y,,^!>H#4Q0Q@^6%XB'-,/V-8>G1AN=LRK<J1H&P&00VO$\(7M
M,!K4>)JZ+9K-.4]S*B>.D>O3$KU?_.0QBU0Y]31,5-S9+6.4P4;#Z)@L;?/B
M2+8149BJ3,<.PYBJQ0-2<*0D(>%A"K?AF(14ER>W":I1O#.CSA/G,),:4]M?
M"YE,V9=$RPQ,`D@KE#(ZD8BTCMK!\3W@I7,$I.#/@:ZJ$',<^;B3(B98-BB/
MI;8I"GB9-BG49<GC"W1:</UVX=@*!JR*FY,Y%647G!*18D!X#A@[R((PW=M'
M9^RV...,8.)'=#O?!QC"G2]S?D!73!Y?>HO1LV_-UIN(0?V;('`#?87.5_M#
M@)XA!!D5V&(5(\]E:V,,F>KOAHOH*:WB-'JWQVB4Z]D*8W%O2B9`8V/*2V?&
MTO6_.GMN'!/=[#Z^O7"#ZF0M9L#`6YO\NR4US.+%,7E$$=F0U0RO4L1Y$.T@
MUG,24BTQ$1"[%`EL7LPZ+V>^Z53:+*T@%P.GH!G9<.5Z&ZGU2<,$A3P50^N0
M;30`"749"S.V@$5#1GU19092(K`X2VAQ_?L@X!K75Z_C^"CEI^N$`A^=$QJW
MH7H++/GF0HF:^61L7)_LT_?3,YI&KPH-AHD`@:FD]&(SR67:]K^I'IN^5PLX
M(I^[/AOHJ/A9<^`9U[]NCDF<X)&7'SY(.%D&M<#3UJB-FPRC+99\;EV3FOU4
M>;G>%Y5$T[,C5I\+C8D/$H$]59C$1E63;MLM5Y39],V&`";RTIMSA9B*T[8!
MLK'<]]:)-A&M".#]Q0F.<`LCVG:A%^]B8CIS/I-!>^MJF7'7+E`H:X!<$6U'
M?W`B\$1HP"L_!!X*`B>*R8IT&@)&KO^E"!*.:4J"BVF?/%Z>F?)UV0L)/)UV
M(H-%?#+C!"8&*$I+RWB`TI/3R6G\.&=XR@60H0`Z9#A!+H1>?(F_,1FI./C[
M;W:5RORM2"))7P213GI-XY1LCY'0T:U+9)5=W/.<)+WVT<^(R%Y!-[M]);72
M+TX4.60?"5DL@]AFT-YW0>0_/";Q#(1I%8&"?0(GH^11@Y0[MFFO'6Q54^W4
M8#:,=*@S%T&LPC2-&U6@KBM`758N43D_S/&CQ'"H&SLVJ![<TQ(BC"*VC^]I
MM=Q:O-$[U=1/I"`RH0B/CYWHF<:B\H1?\3B=W#JAJ-3CU),)B`L]B<+)IYYM
ML1_I!CL(.!6K$0?*$S@1.*IYJ(7:L0UDG*!\C1(8;YUG<IV:(.RRR!B!M4YF
MS`.PM!L.C@T5<H9<8YI_1$\P"NE&PP`Y(8B@"_VG\5<T.WJ1:62"_F88496:
M;29U>;8B156+C5B@#9*V/Z=O0?;ZU)$BXW#-8F4<IWGK!-3ADTI2R3/9:I]@
M?T^.&1Z(^0O\J"0GP[5V<AJS(LDV&G;`W5KES*U+3L/^8DR>%A9)&6;@0%C2
M:;&<:3IV*8L?IJFJ@8]ANQT"V.;<J=56-.A0;"-`#`3B=ABYS6"\+6!,F684
MQZN7A6.9*#0&DL>,5;>/*$KN8+1?%_7%FW4%U9BX$8K-9-BH12VS$I<X"E6L
MF2EB?@,]N*>(H?5^8D+T&C=O7ZD$7TY][9TD*_,[-5,68D5@Q1(8XYHOBU=D
MN6Q==L,/2Z>]R&,)IOQX<UOBM4)_SN"4CRY#P'.DF$+FLS:IUUI]A9'KQXRC
M%9+TK$C"IC=GFJ+VF(X?'%V2-LGDGI,J_X?Z.(9.4:(LDI"LKUCAASG?A,Q2
M"`BV14I@B&6*+#:.%;(U6(L/+'560H-Y!#("`L5?1@=6YPLY*?]O&72#>GWV
M8`=[H+;#[R0M?;V`5-?".EMAQL.+U`A-B\\XWXIFH<`K/`H8?8.O1"<CE<YH
M61&7HV9``KF&'397DT%?;1Y+F8>N3@;5YX+H54'G`B:!4[8,IPFX8E[!0%GZ
M+J=LJDR@;'LL69-<(;9.;K%53=2@!-76%%'295B,"FO=&B9C8EDQN#NT<'$K
M(RB]Q*?,V"C0*<-HI"2B?`N-EEJ64MM='U%"S'Q;J8\[Y54]=<BT2B0JPRVW
M7FG^=J%$&9TV:GEVZS5=SW,PS-;J>N(/GM%/>S%O$/AV5?D<!\`C!B29=3P5
M'EX8LK&*I](N.\%'?7E$2D(MY+!7\"9FK)(+(CV0Q#/0CL40.4U6XXK5E;IA
MD,@+))-<I;.(2>FP,0`JAPL6-_!0W%ESA<('TM"E<_`3)[B"Y"*$^\#''I/,
M-#<LH@=G]F&5.+7LM4<;C001-;U\`U:14[WQS$UI0`!I@"FIQC7?/I!!&GU9
M-V0%`:4Y*VDU&6H4%)L*.".@-KU/,R<GT"4,:=3)6`#E`9N7!F)>/!H;QN/$
M)L&1HRXR1M0Q>.2H2[LYDY0^2,)E:IC:A(Z1=/8ATX*Z#QSQJ-F68>_`$4^+
MI.ONDW=HPZ7FFPE>'NIGU4X=,3(.UBQFAG2=E4N9%Z%W`P."G/*2FN[;7G1$
M%"ZWCPA-0^O?:@-;/'JJ%QEG#X'U*\K'ME,-&"$3W=JT;G5)5<OOTPZSD42]
M!>8&"!-`=QJ6*GQTA2/CK-YI-LG[6L8S!WZXFYI!#!DF$\</H;=RHA"W/UZX
M[G%_I+_@`NY\UV^NV<LS%"&PFT'3'\BVR$AXDU`F,O=.]GGV#^"4[ZK7:'KP
M"08H7:6+$^=A]'&+-!Z0>H\U#;6+KVJ6W3K,1J4N?>9BD&4(IO$EI0(Y&7A5
M(009Y<C;:NU@CQ\FAD3?D"'@"89'2+;5?Z1'7UH>G_.^</"M]YJ6Q-%GQ'VW
M98M,I4D]I_\%4?IB;/3S^@5U?LHFLAMD52"W))CUF@WQYIRD5D>G+I`^3`_J
MI(]/K\/YSLQ<EP_GJLB)SSAK7_LH#>=M]L-;;[6`R]$EY:(067/@(K<MF8_;
M)NW\CLC.W=/(<.5U!^KXAG6@-HA*F+:X3?JEAG!37DFC;RL>:0)G4%3[EN>&
M3/7N:"Z(<XJD@XKMD@R=&.G0;2"+XFN0AG-Y,"1[%O]A4HCF'_V0ZUHVOMO'
M/+C2+'JS7(DEKZ8#AZ:7`[_F;T:>M=2%AZ0#-`:0<1SB1X2\6)R8-4D8KK`D
M,8;ZIE;#3K`B7@[R!0,Y%^<=W8D,*84=Q80XISL9Z,XIV=`NY=AR?+D&&UZO
M=_\3?T>?@\+KT5<32_'4L"#CZ\R@84`O!Q_(C/L-/*`H\<.'[MT#"ARY#Y3A
MT+,'^3:9\)!2V@0&(\$__PC10^0<'GT7K,,=BO9T#]_(IJ/0]:A'WS3,JINQ
M8F4R6HRZX&Z%QCRR?;Q1?YV2@8)NFNOLMD#(]>X#PW!(WQ]@F0\?80@C)UB$
MWL+;^Z%/$O'$?X*KKP<8QDWTJS$5$4".2=,B55IF)`Y(*A29II2(>48W`P\I
M)=T9X]1HQ[9*)5B@?IW6M$P9WJIQRNDR&R9D=)J+%`,A,HT7&28_5C!9IP89
M^3ECDQ\WQD#G@-'#?PC]G>^2T_*NBXXAB7=;%/BN#V/NX$&)*8\>DDQZAJK4
M,A/10U:AP%;E1,QO/W_ZM+CY&]A<@MOUQ^OUY7JYN+X#B^5R\_GZ;GW]$6PW
M5^OE>G4[LJ&JH0/UZ[N&F4KQ5LQ44I?1("*ETU@0&0J8-(B4E*`D!3GME,8=
M5L')C2*CP'/`*$*NLB9#ILUNZ<2/EP'Z$O/6'B5(\X@A)-6S18E6:-J?6(/`
MZD2,\^7F^F)U?;NZ`/A?M]C?7RSN\!^W=_@_GU8X'.#HL%S<_@(NKS9_'3L0
MR'0U4NF2AE4)."JV))0[00M:AR[:0YPZ+M'^$,%'G##BS#%[VFE4*MQM.Y/C
M-F5Z*FTU9HV22J4,5$I6I\W>4J/=?-K>K'[!=.N_K,#5YG8ZQJL$*98]]\!D
MV\1EA#"M7D[[!!T!+2/^B`(/#T%(';/DN=O\NWG:1B_B,67JW>TR9N!"55)F
M+9`P%YCP[=UF^>=?-E<7JYO;WX'5?WY>W_T-O+I8X8':^F[DPPAJ$&$9L32R
MVJ;+9V4:K$C3=,Q4VC:E#=*:%9HPO:YYD+Y&Q[>TZKO?T0JOR?/8V_"43$?5
M7F2,I*]EF(*,L>D)TWBATQ`UQ*3OP2))(O_^F.0E(K9.1-9')[-USPBDN!,/
M5D$UIKLE=3VD72Z+F.MVZ\2&[8C5$M.6U-"A8DTUUCDKH9F:M3"[5F`Q`BAP
M;:;*([*;NNQIVX[$%C%5/J%%6=@NIMH^*VD.7Z>JW3$WD)V*"<KMW^F)**%A
MBG?RR&NTFS]QU-I+IZSBDIML$?J);C@;`+;R6=APP!TPSAP/AX`.X9T@GVFO
M;'KE)6MJ7'F,D>72,V.UMIF(+](:!58L*6->)01>:;2T0''\"'9DJ03X)>O8
MHV]%J*">_=@P7CGFBNG*:C,:<>24&HLWP^&4QIHJ4@DM(,35+?73&<];!BDW
MQHP$T^'BRR*.81(OCQ&9OVD8`?-=]H$:[[3,C*G'0%F%IER^U=0ILY(*;OHG
M<.C+<0V`W15(^`7K4*Z1E(!M<)KTGC71IGQDSSXE_BY],`/9H]/I4)YW,M&E
M(WD:3MXJI&%Y'D,YJ5"O@0R4)U\2O96%TII/&CEU%/<6&\OBM)!)RD&VG92/
MJ<**\^H/`X8SFTRFIH,)*3]G"!7#^;V_.A$MJ47JQ/H/CTF\.29QXH2>'SXT
M("A#FGT:,:F6"<BTPH!/[%##MPDAXWR%P8GVO@LB^FY<:Y#J4*3RX>N6(>(H
M#40LUZ3W%&DRY42MX(:XU/Q]6EJ;4H`*R;D@B>=E[6-I0)\+2=N@MWB"D?,`
MKX_[>QAM=K>/#H9OI<4?G-AWFTZX#V_NE=5X]6RM3SM-^&U%O0*#5)(TS\F!
MD](#%^WW*`0QI0>H`M=7?OYXY!V"_<"$M/JX8=8J(BIVKJ;9:!!146TLJHR#
M:AIW<EQG'"!E(2L&*5,U"LT`Y7LYJ.:&JPG@>KB`MJ2NCJY??H*DR0W+X;[/
M/AKCO9:-<O49"#`LV7QS:U//TT?I`O&XAL+O%M3Y)>MP;Y&5D&9(,.F.6^)-
MN5S-?B:NL]K3X-?T^<@3('VZG.?C3';Z<+YJ&Z$#C)+G;4!.VH8>V6E![R[I
MWAW7AS7[9&JL>A>B]VBE`;^HJ%9P0[J*H'E./0.4GHZ."XZ1;T;O`Q>DTXV-
M6](5)%0N2U?2:]*5JV@VY>5'02V)#4+<3G,[W7!XYD6<\1$]Z'6A$'?*(V[P
M17G!%KNTFQ1M>0&HB%;W(L3N=AB(-5UZA+<;"CCG^6MJCI5[S<:^9D6F>Y%2
M+[0N'.2SU&X6%$DV?*<F7Y7!RS-MX"B[#K-$4H5D&H753")*<(FE=4P-.6R`
M.QA%T.//<HA(BF$`BT0S:^)K-9+6,\6+$B$&P[QX.H5Y#V%'(9D/VTQ+VI35
M](,EQVSBW-9@+D$VT/]IPEM#P$3F0_I#@9^CF@;#T)O@&ABK/ZQM<S.RFTG)
M6<ELJ978LI1OHIW.YEG>)B31GJ/F)B,;>\W,;BZ3Z)IR^]B4NT6\&4RU8X:S
M\'7X!..$9%AI,:1UB.,_?M)`0!=9]J/Y9%K(Z])N(*T1J.`#E,LTS_\%?/IB
M7.1V=AZ2_=!U;/.H2[3SY9ET3#PMIER546P0=U:^`^G+&<A?GSI2>'[0'E;&
M\Y6+/;D:XI_TJ-1FAS.YO7_<=SA.(0_'BW)XC-J,L%T6_"M/G[Q!L27,JX_)
MGA2_M+5#2A//0#CVU55JL.!:G0R:.`;(9.5;(T>333?.5&G+IUO"(\?;-T&:
M49\O)F7#PA"H'"Y@E.M)FQTI/`K#F#;U!@9.`KTEBI.8;N7ZX,30VSK/Y)=Q
M;UPP)"WK`&UI6K9NZ+<8"$SZ+>&["%W9:>4?\&&1U@W^M%U=WR[NUIOK<1V%
M*2`BPVBHNQ9-H:73T6Z=R2"IV1A3X7/"5D-"[D6MD$E5",BD`"IFEFY9?GU/
M)(%<U(2V6$S-U'AQ_%2,;<!*2"X,G<A'G\/X`%U_YT/O`NT=/VR8=2==7NV(
M3Z=7-*9+OV:1&(%X05D8+M<\?S4#E9?@U_3UV'5?.OL227_V1F47'GFEE@M?
MXF1L(J_O?4<*\38-@?FR6:D^>VFF)'U-DV[QO89,B2+S*>F\^!O''?)D;!"S
M^Z%=#I[53SE<:S2,`N\9[^2`F1O1XJO?7/84TC1A6J<Q@U:67D.@;8B6P&Z-
MHX3PK/!4X%?R:BI89O99&]*"KFTBNTK*`'A=TE1PGJX^"JO9",O8&*U?8ZUP
MC4*IDK)4S>+V=G4W\GT[G!Y`XN_&6G#FE1VQ687&3OF9'IU9[AB86)T9V9X5
M;R;0[=L1PNJ5'\(U_B<WIK8(F@&U0F`FFK8TFJC<RA(N$4Q+\C*23B1PMCNF
M'35YG=<,F04=(UY69)@MPMV4;Z[:MF9?I_6SB]2?/`?TQ51R)J6NYY>]-MGY
MP[FN2\>/_N($QTJY;>["C!1M]EDZ:+7`+M4.`VZN2P_?"L2<\\O%^@;\97'U
M>04^K1:WGV_2>]7&M0>YWD5*G5"W$2%+:2X=DDVZ3:$J4Q[4$HR(7R4$@%)4
M9J:G-*]O$E0\USL$K(9SR/]Y="+LEX+G2S]T0M=W@DJA:IYG5F/*/I\LDY:%
MJ;7,@-.65L@W.TD1\UL80)>LL14,M2KMKXZA<_1\3#!RM2M%=*!^?5<W2CG>
MTCIE=9GT_G(Z386!P8!)`D.)R(*T?H/`9"*$77#R8L8X\!PNBES#A-QSL(W0
MD^]![\/SYQAZZS#=5^:'#PLW\9_\Q(?Q$H7XP1$_VQQ@1'\/;^+4K-"L0TP)
MU?($9G^9GI\PUA:^'S&D8H[EI#>4Y)+`_3-X180!/_P>%/)`*7`&2I&@E#F9
M"4S#&$=V$%9W9F9DE\[.5%M-QFHS;5*+Y1V9YLD8:KDYFQB=4_",?$_!M$V-
MESF<IK&-GGED>9/9S*.G4''FH2S4AE_K^<NL9![J;5%V:*HJNC*/0M[I9QY]
M,=[E#O5L1^P,%65W.D/EM@Z0>2BV:8C,8WJ&2N>H"UN<>N8Q$5-3S#PF;FRC
M9QZ2F931N0ZC<QRCCIRF,*=A<8AD<@YCDCY-%;"&1E$VQDZFQDQ3FIA03`O$
M5:`F:V4D#2!V1F_:/E3M[)C;F<^8G_AF4"R@G*))C9X$2"8U1J<=C$XWC#J(
MF<+T@L71BLGIA$GZ+%7`&AK0V!C&F!J^3&F.8(@D8'PKJR4!9>"OI@,[QE3!
M-X/JG01,S*2&+&#F1M")X05,_[M.;^1Y1($'HYA<@Y`\WZ`@N$31%R?R&B;=
MD[LH:J;(K5E+JE=;C10Z4]4L*C&E)FN>,X!7.0L908`JU^]`RC=VK:E^6$*:
M'=RL/J4DI%J'2E&[V3II2LK-54P;#=CI0KTTM,&OA!=DS",O7PV-='ZEM6E@
M?<C3A\UF;F'D(Z_Y@QI&ILI6G%249=,\T*;6.MU#;M+:1$??)(7,6<8\`RDU
M8#B`L0_**0(%]>W$YI$Z.>[J03M9?5.QW87WW\>TT&-\AQ:>YZ<MVCH^;O32
M.?AXK)?=[;Z.XR-LYJJ]^?-R!^K\>B?H^[;71-&$'KH%1_&5I<WI?TFAMB_I
M\Y@$=FQX(73IIOPO?O(((OC@QZ0BM`<\/\)O,,,.HSA\&/ED?V^D(>W.;U0'
M4!53*2"@W@*C]2-4U1LK,3$N]&FABI*)]$?)!@@?L82,<P8R7I`ROSS8<\MB
M3`CX0]X'Z:*'D#9XL[O(;A&Z@4\P/+:O@^PF+6Z#%)%JWN#7W0HA,'].S3F$
M#Z04)#^@=2@27>(G8)SG#W`HHD_&OK%/HD^1RK=OWM;'YZA>UB>2:_;^1[XF
M<]<_6@!.>OEC\9[D.062;LX+2?R;'VUC:=`Y=+2'5RB.+_'78\WW?X`[%,&4
M[L[Y"N-/?H@B/.C*;S19A%Y=2CHF^P231S(FRTO<-U?=1]!<SMT/IUEW;G3H
M;V1@;7+85@NG90=KQYP0@'LJ#R1$U.CSM(-;%QH1MJW9X:$:4)M9'NY7&UZ!
M&:KA!E=O7IJ+R5:-,"%X14B_!\32.:>=,D>4+2"ELBJWT\2SS$0`;=(,K+XF
MD8,BSP^=Z#FMVS8#U]B]8.FX*P(B?BIWNKT,QR98^'K1KFVXU'B)]GN4K@YN
MG6@3T?I^'JTMM841O;6AX4X5.+).E>+0<NX*;3(P^2ZGC>]/9?CG*1&("=4,
M')P(/-'::*_\$'C863E1##`P04S(1UY54X$$ZM%G=><@P5@:M906DWF&A$)3
M^<$`."3Q.$/B;8I$3`E0E-8(];)Z?9@ZO93G/&'(BU)#`W',;1B=&RXZMU88
MWT1A<##/%*ZR.R*_BSZN[8:`$]BU)^@IP=X&V5T,HOT*IJM"-^7_]I,*`@YT
M]P2VNBBQB`/<IOD'!Y.[(_O"?MU>?M))=[Q2_$P[?A4*%I_TN_U=T>TC3XGU
M['=N)?!)]?M[6SOD5+O[/7O?&U@D2>3?'Y/\!B4<Z2=P+4`O1+P?`A%#+P'A
M0?OJ*[F?$'Z`(=SYS=I,'52UI14&E8$)2JYN(ZOL?!U=LW]MGGR>+G&^@OOT
MV10FS?B=AR2_-&LJJD7<G#9B2#,_>]U28G:FV0@N*C.X^!W(7H)7V>N19RIT
M,2*>L#2/D@$OST`1]!_"Y3'"(<M]OHN<,';H7LZ/CA^2^<QT]A/_A`9">W#F
M%VNH<.I=CJ#>1@,3A6I:!7<G*,B99\0`?G4?L3AL>@$F@/'W/SY@XI'3TSY8
M01J=V+A=05Y`Y:X%%:U&+_205VSL>H_A`4O+JF60S>E!A0$0CFPQ<)8O^6&^
MEX%C[CTA(R-Y2G'I<QA!)_#_V3I0TH=5.C)562V;>;N51@8#BHIUK+TB:%[^
M&^R:H8I$JJD;-@,S"I;-19RT85>^GX)E5_4.&Z1*S<-%*0O`58M3)=]+@7/_
M2&4;T,/%JFV4[8"F,V%T;:]A-`**[+,Q*;1,5*!3Q@Z?8'2/1*,<MGR^U;'H
MY\7#?,?#O[[YX<V;M^7&AS^"W\_>O'E#_I?N>8B!<TP>442!XR3@`KIP?P\C
M\/[M#)`.`D[H@4_82![S1^_^"-[.WKU]/WO[T[M<B)^>+B*TZ)C$"?X'+=HC
M)_`'L'AXB&BD!0?Z$S!<(3D!%OC_./J>DQ\?^%>L]?^\^??9[]_\GHHA?__[
MSV]F/_V??Y/5-0.XO0=ROO()!B.O*HIPC"2`5_<1#,+2%3"EF`QA#`6F(I4!
MTR!QIS2.;!,&?3.;Q*'"ODC@Q0O36!AT*QUV`8\PC+&!IO-]US#9[/!PBG,5
MA`)'N96NFT-W_Y)LF\QLI9/0)MS"U,D_KQ'1,<;(-=M5^AWUZ)C6-J4NQMHV
MI6XMAO?+=2DTN%_.-MBR_7(5N-5VL\](>3N2#F"6&6>U>#*7>-A"J6`[W:`X
M'7([779I>KHJ3MJ.0K(/?/'5;YX8E*(M-MD):36W7TBT0W<?AEB%:$N&B'->
MO)[E&S-*"FQ>F&9DTY+K9*34%\U]&@*6ZI8-H>2I&!"GRL,G.F9JP%>*MB@9
M)*35+)`BT0XCI8#$>D2U3T2<\TI9DP-^_YH4^$DIQBYC(M/!2*D?FL5)!"S5
M0B1"R6:K[0A4F:NL8P5):<6<6HF<UV6)'/!K2C6R1S8)*G[-&_NP&K*63>+X
M(?163A3ZX4/,=,9BHJ)^#9M(L_:(2+,!O\M5("HYPF0A56I\UT^`X[K'_3&@
M)VN\(ZF3!CSX!`-T("$:Q(GS,'K=$6%_(KFOWZPTPJ*MUAAARS);J8:EPUR-
M&D-02>O2I&]`_FHB'E0/&OPR-#;`,6#F6IKT)GF$$6/<RLYB5?GRC%:>3R\A
M46V?B4Q70:<@5Y&6,J^0`D1H@5N;V_$I]8]T@]W(&UO5\8)Z=V4CJY%EKV0X
M\AJ-)M&R:HTEU,,"EB;:%<A2ZOJT6GTZ<B*18PCL<G/R$=$[7!1JS.Y<H#T.
MF@T;$=)D'XU#HV650KUZ]L<3S;<U-L>\.8L(?DW?C&PXXBY#4E^X;@Y,TA+Z
M'$E3@7E>@)`T$)LCW7Q!3]9_<&+H;9UG6GR%F6_U8<T^G1JKEJWT::6!Q$M1
M+=^\E`25Q5O="OFX%M<+)DBG^^KVJ2*A-%LUO293+A7-IK*N4=!*<J\"KU6&
M65H9Y?4]X0$YTT0RK^'@S,N_Q@?TP%55TCU;%W1V+[W1@VYCNH9?Z)OV<K`"
M3[7V2C>/_NE\V789"$&R^CJ.\7=**"^V<"L%N,A)A?2R1_R$?ZO%#(3I]@Z8
M'O*<0BT(:>R@7EW+J`[0Q=HH&-"MR7A5B2Z5IB+10*`EL8<29AM"04J:7<)4
M[!;%]"G!&<-26,AD8&!.(["48;$:+!6BC%B`1,CA";!FQ^(66PY&7.7]C)PC
MCA.F,(!=&)$5D2PTH2A.CS;L=CY^$X,C'KGC\`0CUX\I?\J8@CB>I7]FR:I#
M[@:,"VJ/'D!((M]-\F,:X!CZ2:JA^6JZ/J8#T%(.1\HH)'P/6XZ<(^*U8:AP
MR=8_1.P<Q,8DHVIU=%<?]V5;?2]1M(-^<HRF''?MV42?B#R\54PD5I-WF]05
MKW*OJQ*J1?PRD9K-;\^#B-IK.TYS=/=T(4QIG"@MCL$3=A)">,GY"`F$RC@(
MEAA)_\!NP6!!DZ5^D)AI'^^R$9.29,R@X'YYN.\5&@=&_C0"XQ*%3]C5^^26
ML?3?B7\?P%OH8LK$5YHUE98E$3`E9%GS)-*_PW(@E6E'/R?3+;E9-H#<0)RQ
M3#B.RB-0RK>H`EK"RW2*E/,X$BT;*NYV-F6(&#RBJ4C&YE(.R4LKDD`IZIMA
MM3%S>J8U>F"G`_58<=V3PR0.U2TF&UZ&TS)[P;>M4-EU-$687?RD5Q6E579&
MWARM"*8NYR`&H=@'-'@[C;VE:X"`V=!I.3*:QW%7K$O))[\@:@B>BD'*,D`G
M$G9T5D5E),@$I"'7167:;#M4F5NU$<J;_M+HB01&S34A!3.1\4@]UX3$K1@L
MF(ZR5CJDV<G&W)-?+K5N&[WB]0C6,95(WG_-5$*`5!P?;M54HL76H[BI=221
MN%X+IZ<25K56D^0Q*^4V>JTF"=LP7$@=825U.!.@\903*\$BBDBY?%H4Y/Z9
M=<`$+$B".LM766?%,FM,:A.GVE^BC?0+KD-;R41"JZ%55T5A,B%WI'57Q5]B
M.Q1;64Z2%2U:>CV12&QNN:@?Q&5\C_YRD73;!HO<8Z_%CF\]LJ/EDUV.'<G`
M>H7WR9C8D+?A/N$D$47/EW[HQX_0^XB0%],"RC<PAM%3*[8K<!2WY$IP:%Z*
M*MTF`Z%83IOHOM1N_GE!-/8UJ?*]C7IT1_/RU$[&ZD6J$EK,7KW;J=#<-;S6
M(99>SYN1S4!.""AE,0F;4Y\G"OF7^`Z+PXD,\])_KT,W@DX,+V#Z7Y6QG5B"
MS(".)\%>$BINL\6\DZNX9[+)D2>57Z9_@YP9O,K9ISQLZT";7"HI!5F9[)$M
M2#)EY+5B*GY#MEJI;,E(6]5(AZ@^VJ]XHZ"Z:+TPX_A7GRJ4750L$2I15'&@
M$J#62WX:1@GW/J%IU(\R`1F%ZX",@69(#QHG\2+T5MFF6.Y-<&*RPG_RR#2M
M0JS=B/?DJA"9!8=IOCG`R$E(2I/O-A[]2K>.#D2R'[MI!6SJJA'PY)EUG&PM
MYORF07RD7C/.MM_E;R=TL9HN5O@^TQ9:QO.8'9ZRPT,:AKV21T2)$\A[1"6D
M?S>_(](!:OG!:4&[&])R0.8#V*Z;L^7>E#J;[<Y.K:-E?5;_KA[.1UWY+FD1
M;MLMC)[P'_$-?()AZ[KW3KKL4PCHM.#<J=]`9B?2P<<XGPM#/<`T*$KW.F4;
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M3%?R=IAJ=^60UV0=(NCZ='R-_QU`\@\\&ECL493X_V250E!A*:[%DF'1O%U(
MOE4&9CHDU8DN%)(0,*]2T<&K4WD]]GU!"C!`?;JI>3M0-V?U5B`9/6:OM^K6
M:.Y:JP'0EUYC5=+-0$%)H;AX`5#D7U4U-!@'W>BU]Q-Z:Q9NXQ*%9$T)AF[[
MD)\$9;G9BT^INXNGJPUF-GP)M`@W\W#YYI67U*#<ZNNQEW2Z>Q8I=$%K.P^/
MH;:AAR_5\#XPGB*#.\%,PR?;#58#4(W@A_-`D&!+F%4,#>=O%]Y_'^.TD7?H
M!I)OZ@?P&B;I+C9R._<=6CKQXS9"9!+*^_#\.8;>.BPV/BW<Q'^BQ\HX6\IL
MJLBZQ8X*O3O>+?YJ`S'%4O,$E\?;4#BO2"6&%^5R:0E0LI.9/"7_IF5#CZ1<
M@A]6-JLXA<R1M^U9-1(T!"@;U]E;T%2Z5CN_PV1<M]%"4PG!6=@^24$:UE](
MIJ<'L_WIKXCT[\EKH@#D&DBYFE>?4W_P/2AW\9:*)K-+\W1=`R]].C_G,&#"
MYKKHB'_:UGEV[@.X/$81_J7-E$M(E"=-'"(]OR?4;")QX2D0N!\VRSQ_#@[I
MBY'-7-QG2.X+-PR-25LQ%8XLHY&0J<-8+#,%!QI/<D!DKV8@>WG*R.`Z82O8
M&-011D?H7?G.O1]09\WUA6*ZTAWRZ'3Q+]9OQBER=0@-@<,USUZ!H'R7UJA.
M'F$$W`PKE;>C6TA''R/I[FA9"9N\9B@\B8;]*%N-05=J$D290Z4PJKR=CD_5
M1HS`LUK#S'#^=4-,G7&PE>3/M+K(G?-U2Y:04+A(DLB_/R8D3MRAK</PPH:D
M91]:6YJ6)1KZ+7K6JM\(ODWKRIY3`?6#T_7Q>%'@!TN:@4P6J`HCMI**&]=1
MF`(N,HR>NLO1%%HZ)NW6F0QYFHU1"XP=IR0G;&_MV@QTYIO<EH4%@V?H1-]L
MB`V,T[2B\9.`2Q1!_R%,DQ;W^2YRPIBLI="=)?2O@&XL*>?BS*4,5G5W)!B6
M=%OQDE:_DX%!Z]#M5O>_=EHRKW`"IV"=IHNV:VR=#GT(6^]P_E::T!TJ+/WR
M(=(S*TTW-<OQ0KT.R1$E1F69;I`K!Q7M=`*PZKO*!IS^<.X<_9QJFON2/-U(
M.^P6GN>G+=HZOK<.E\[!Q\-.>CSGOGGQV0W\Q]&/_01FI^/3(IUD1?LAI%+H
M!=RBW786U;%VWEE19VX;CL6O87I'GIVF2N[0L:$\K0*<W0WE5O@GM+?&IK6P
M]]G8MT_6CAL+6CF[;ZS\/FO;]"RTULJ6O7-S#HRM?*460-203;N9(M'-K86Z
MO,Q.7E>\HO&;O[&%\)?J<89+);<1/.!?E96AP]DQ3:D7<0P3SN87!8ZL^Z0X
MM'RN0IOTG*:<(K[?D^&?9T1Y-40Z2$X'VBGA1/8[J``!]>BINO%+,);V*Z7%
M9-"74*BX="C.[`?`(0FA.1+S`JR,#5L.Y3E/)/("T=!8'/+RM/IU'>NPL6<S
M;W^QL;VRWZAA&49D%1>N:<G2O"3+P._0"SNZ31!=JZ4C><ZX78<DULU=SY40
M5IZ+N9K*5D\S0$5&\=*\O4M#9/5>+ZV6F;UY3J,I1D/I1&VK=GC@D!\><$YK
M$_64+(M_,][T;6NX!.`:)JQS;&FI@2-N==9\%#;#?0_.K".4.+6\3H\VZ@5N
M-85\5Z(B9TX63@4G4TLF4'*-ZR?Z8`=I=&K=`R@(*.U=2:O)R*F@V.ANU1&@
M3&(@`;-?9)E>-<ND!1AHH2'R#S+Q]N0$9,[N98"9%]#&AO.`E;UPBTD='/R?
M5=G[O&O(I(CS^EX=Q'H%FJ1:HEFAJ4N'H$B3F'6^S,V._F,U%;.3[%^DU@N-
M(DU"GDJ=I@[94S&@+#4EQ:3H\3$GX%F/!&4^VR^BU)MD[6Z#YNR^4(%@-E7`
M-U\LES>?5Q?@:KWXL+Y:WZU7MV!Q?0$V=[^L;L#R\\W-ZOJN^G;DN52)CD8*
M/=*8.>4S5&9,15*G8CJ;Z,$)LUJ7.$K&*/`])]MAMB67^H0)_7.SN_1#)W1]
M)[C%3^!>$**,RLR/'9B1J;>KU^3OTMRK:Z@I@CVX1C3,KQ=WGV]68',)-MO5
MS>)NO;E._<:'Q>WZECS?WJQNL>N@KT;>`6L4M\@*;!K[54V(KNQ#-=/2J?BV
MYLQ5ZV1Y/I=5>73AQVZ`XF.4E_6X@U^3#T'[8B,[PMD%B+2%FRQ38^B7FB]X
MI-\PZ<HXNJI.+9NR!'9>?1ZSQI1ONS*J@UL-2+OM%BM,:;;-4F6JT[%;=B4L
M9BF7<J6XNLQ2BBXV/X%?B7A`Y8]=3O&DK%RR>M>)VODD[A4HF\^;C.S#VWWW
M`(O75BUY?CNMU99GJNQ5;9XA:;[<?/JTOON$\X<TI5ANKN_6UQ]7U\O1TXA^
M<)$I1]^)MGSF4T6$5,%ZEN:IF'9ZBO#.^=IIR!*4Y18V/J7N7IJN-FAO/Q,H
M$&Z`X?+-\>,);$_I[#RD\)5;&TMX#+5M(WRI4S&'2\>/Z+F%LI&\*4P9TNPS
MB4FU+$*F%7HFT:&!;Q-"QOGE8GT#_K*X^KP"GU:+V\\W*QJ/QC43J3Y%*M^^
M;B@BCM)2Q'*G8BJWQ_L8_N.(`][JB1X?XLR"==+E%]KRZ?2NR^S2;V":2:1#
M<)<FEVM>O@+INY%OUNSL0R3]N1LW;O+(*]=O\B4:O5:5I\;8':MF04)O7VW"
M9$)3!28PP[VGU2)J!AU6%Z<I\9CA!B9^1!=*9`;5JISED%J>4W=`K=I&[>&T
M@D+A8%I:SGRU/P3H&4+P`89PYR=@BZ6.O3^H!SJ01K>UQL^R`FJC9WFM4['?
M_SPZ$4X,@N=BJ7,=[E"TI[^BTX9[<F<?6YE;RY9[ME7/GM65\FU:5=;\%@;0
M3:`'"DY0X0"OCJ%S]'Q,,/+U]7U1A#2[MF[SBD)*NU?6/A7;+]NVV=6K(@1.
M0@HEQ$E<UDW8.L^BW5!FA.4WMFL*T[M*V\@OT?,;VFT07+ZM)WI^>[=9_IGL
M:UJ12?=/V]7U[00V-1F"'S(+@L:UW5HR*Q=Z:[9M*O[G!N(6'=WD&)$KUTC&
M1-O/OZPN,U-EOJP;%/BT'(AR^_1\A8HZOEN0ES*OD8YK]NI00+U[J6[,TNRE
MW2IHG(J)?D3(^^('`6[M.DPP<GRR)X!4PUCO#XX?[6&KXI`*2_9)Y5BT;%*E
M57KF**F);XE2`N8Y%=V"4]*E18=`23FN?2J!`?7IK+I5RG"6!BFGQ^0$K8Q&
MH_42!D$CF<:MX=$O*&/@GST4>3.\9P'&]RI@?(+1/1H?CN^Y<'P):'P_'!K'
M/O.`\Z@M"GR7/U;H)JR?16`2FMB<+&B!D6W&;/F=6X99;//;SY\^+6[^1HXM
MW:X_7J\OU\O%]1U8+)>;SW27'=ANKM;C;[23Z-SFKMQN(&3FPJ=O[95ERIQ*
M!G\+'XBMWL`#J96/QQUL.^DBRS<X<,GTUJT[M&LN6O.E"]:L>4SSCQ`]1,[A
MT7>KT^DC+U1W=1^2_=2-16H.=66-FBMO,A;06$7G64`'&6>+CRD+Z-!N=MN&
MG`7PF*:^LT<`?KD^YNS08("?*V\JX+_&G\V)'S?1UHF2[(^%FU:])D=<&R<Y
M<(9WW$/O;0.CFE+RRF%]I>A58-)KNV9%L=[*!269>LJ<9[0`1>0FI@3D?U>8
M9XS37)F`D<LT:2(0&8)#HWA3/V&50DY]6V.T1EF_1AB=IYJ0H9#9K#7^MX/!
M2*XT2ZMU!BA\`/A'[//RGH!<<':%AT?`*66^;"/AUCB;J)D,%X973A3BY#C>
MPHBNS'YP8M]=A-Z%'QP3Z#7,4I(Z^\B=U%K.0;(M>F&R6PG?RKMXYSD!N0LF
MO3MF!B@1G1O,R,8U7-D.1XJ]4C?##J;2W#JEFXP^'<J,1AF+.,NK7]*;UP\8
M:3$A`J\K4/.R[_S*#X&'@L")*I0C[\$SC4!>*!@*@].ZWI&4%4R>R5X=%&)"
MLFTG?()10B;5+^!]:]+:H$B%:QJ[15J_:DWV5]F_3$VB)7H7IG4J4+D2+14&
M"FDD;ZW(`T3@]"\^D\:TTN5FBI:2S_\;D*QV15EW.X>^^+"K149C\TD893XV
MI`-#&K=C,@YT*55,=M7CY_>1[SV0@NT!<M)+LZ_(/ZY10J[;)GO`QE]_GJXY
MZMPG."V#'+"\:6,`S+X+L(,J+T'*H](K*LJ6:NI<*O^G"4I_<ILT;TV"3N02
MOZX>1-*?FW$A?)N\<77[4*`P&%0,XB)'1?4RGSUTR#9\#S@)V#E^!)Y(R8/3
MQHAEA,@X1??9=8FK>_?F?>;HR)/?[B(GC!TW+=L:)_$FO'4"N-FM\-=`>]^]
M\1\>D^9%-VI,V8^69=)"OUK+]/RCM"Z^64B*F%?H`"4D"1(A):E13@Q2ZG$M
M11$:J%_'U>U(CK<TJPDAT6BV/Q@@23BO0M+-(1EGD(0Y)*.SAR0O_)\R*)7V
M)WO(I6,ONF-K9%R^Q[A\]&,``UHD`$3PD-8>QQ_Z$8*D@5D!9,F-2R3:>L"C
M1XLH?Y1OR")3S#[R?CAK8'/V/`\$;(V<9OF(0037]*+YK.B\,)V1IL]KI733
MZU5(D6V/$$(_I^89P@=R((X?-62T"8JB='+/4Q(RM?J4$TTN;9&'`%+NI489
ME"ZV2O&3L7%F:B;!,L1(.E*"["\O"F2\]..D8&8XW[`-MXXLPRV@2/ZJ^;QF
MDC'=W,(*5CD9Q4EA]2>#`S;;0/WIY0;?LI_L8ZWZ]:[PO_##_!'^/U(P!#_Y
M_U!+`P04````"`!D@*]`3TAB&=PF```F>`(`%0`<`&-Y8V,M,C`Q,C`S,S%?
M<')E+GAM;%54"0`#?+:R3WRVLD]U>`L``00E#@``!#D!``#M75MWX[B1?M]S
M]C]X.\_=;L\DDW3.S.;(MXY//"W%]F2R3W-H$I*14(2&I-SV_/H%>)%XP:4`
M4"+`^*4O8E6AJO"A<"]\_Y>7=7SRC-(,D^2'=V<?/KX[04E((IRL?GBWS=X'
M68CQN[_\[W__U_?_\_[]R46*@AQ%)X^O)S^B-,5Q?')!T@U)@YP*.'G_OB;\
MC!*4UJ37VW_A/-N>W"0Y+2D/5NCDGS\'271R_O'LN^]^^?'C6<49X^3??V9_
M/`89.GG)\)^S\`FM@UL2%@7\\.XISS=_/CW]^O7KAY?'-/Y`TM7I-Q\_?GNZ
MXQ)2L/^]K\G>LY_>GWWS_MNS#R]9].Z$^B')BK(!A=3D5,,6]==O:]JSTW_^
M>'M?*/\>)]3F)-QS]4JI^,X^??IT6GS=D=+BL42AG6CJO9.3TG\IB=$=6IZP
MOW^ZNQ%R?SIE%*<)6K%ZN@T>44R++43DKQOTP[L,KS<QJG][2M&2+RM.TY8H
MYMM/S+=GWS'?_JY=PBE`U?`UC(,0Q1]"LBY%7Y)PNT9)/DNBJR3'^>M-LB3I
MND"%6FLJ+Z1:G7WS\=NROG\GEV>FXWD0L[JX?T(H-]&IS6^OPR)(J85/*,=A
M`*A:N4(=86;:W><4",SM\^4-C3)K9*(51XBU-A=DO4G1$THR_(P&48TKT4S/
MBR![NH[)U\Q$I0:S8<O#61B3;)NB+T%._YPOYQM4QON,MI[S(,/9?+E(44;M
M-F^/!J78VG._7:^#]'6^O,>K!"\IL&D\"$.RI0$A62U(C$.,C)RN7X:M+=<!
M3O\1Q%OT(PK8_QD(+547B+35E-;A)L#1U<N&M@W$*G=.PTIZL4U9@)EE&;)5
M'%:"K1VT%M,M[=5P\(ACG.->08TO=O;HE63=*G(2_INV-Q2Q$$8].$";%LFT
MU95*6^.\`"9UR04I&A4=OUJ[7"IX$`\_D3BB@^&K7[=T\#&`=SORK'O$8914
M"+3VY#ZHLCI*@]`V=O`E6N.4=L(,1_0O9OIS$-N'9Y%,^_A,:,^;OR[BH!P>
M4^$;5H6V05DHUE;C.Y3EZ3:DPP;:2.VT[(BRU>R*EDY>$3JGL^$ESIGMEK7.
MEVBKYT/P8ALQ*Q&VFGQ&9)4&FR<<VD[P5"*M8P^*44BGM7_?!FF.TMAZ1@J4
M;#_J?<S0KUO:\JZ>[:-07UI3OTUCO'Y+?V@5A5YRE$0HJ@MC>IJN`!1EUJ7&
M)&P5%+/5(Y*JC&*__"(K9?:8%1U"+2AF"QH_O--AH9^9D3"64WVK*N\52S,9
M"C^LR/-IA/`I-?2,_8-9?/;^XUFU[/4[^M,OI09W:(59P4G^)=A/?BL39225
M27R2M@E-.,S2MCE!&M82Z3];6.@O>U44IYMB4>)]^(3C'8R6*5EK5@H!6=C4
M_L\GD`).<G+"%TQ2.@SZX=W91[;@>M1ZOD!L5!/?T);W\C?TRJUH`4VKIGLT
MGE6UW$:;NNY)KBK[FV-6=JWR`Q4KB%?-3YVX5'[RID8E%IE59%M@57_?CE%_
M"Y1B0I6-+NE$2E"17)I.C79HO*M:F8UV==R17%7V[X]9V3.J1\1TN8Z#5:>2
MN=\JPSO?O*E4F4UFE=F16%7B'T:IQ$N4A2G>-.<!W;KDD'2KM$7B7\V*+;2L
MX);@JIZ_.V8]5VNNUW0*%,3_AX*4'YQ59)4WQ&3>U#G04K-Z%PNOZOZ/QQ]"
M_XSB^&\)^9K<HR`C"8INLFR+T@X`0+2M(;60UALHZ-AL,\06EE"!XD_'!\4_
M2+REUJ2OUSA&:<8%@X"F!8(>C6>5+[?1IM)[DJO*_C3")+J,2G=H0U*V,\2V
M.;;\.I>3MJ?4`E+/$`"RV&J"+2A@MZAR?$`4D+R@_=**I/PU%2Y%J_H[%)[5
MNLP^F\KNR*WK>(25L\7V,<;A=4R"[@JP\'NK?EO?/:M=L6TV==N26M?L49?)
MJH!"UFN2%!O4]T_4<]E\F[-SE5%C/[$=U`$,[=`N9?`,#!K66X5Y:3$U7$99
ME=M/1Z[I+]V.7T'569GK47F#!IB==JMS/=EUO1]U@:ZM3;EBJ*YY#AVW[EMT
MGM:^V-8AZK\EO49`<W7O^].>NV[I#P?:BFX=U+9#X#+('HM:VF;O5T&P*6&(
MXCRK?^GBL?KYE\;1JFN<4'TP]1/)L&2G6H>EJCT8BV4S',`)#\%CW%V"XW_L
M&E9]'*W=:54*45C5;FP0T:RQ=45N,RJ*%&NL[*S_D)O5`U3U?8B2@,:#V0ON
MQE\I3;?BVS3CUW^[/@G,&D&%%[):5=N6X68-5RK^E&0;%.(E1M$E60>XNXVB
MI*MK6DPW?FUSZY3`C1-4?%-L4?]B<6YBH#:$]M'HAOY3V,1[!-WVW2`8O[K%
MC5MD![AE-P3PJ[2<45-Y2Y2FU3T\B56%2>RB)FK=V!L!#.55#<%@AO^QWD;M
M?!P?`/UJ)@H;!`#8"2JV13L"9&W:6P#4%W=D.!#0M.#0HQD-%8)Z)S!KVL!H
MR]J#HB=C8MC@WW^8Y1=!FK[B9%5<7>MNRNOPU#OT,)Z1L21"##$SF@>Q3A'%
M[CQ,],20=Y.PH^Z$;40F.'M"T6="HNP+HM.L.^JV]!EU!RT:'%4%@#C<Q9R^
MP4#$@01/;!C4OL]:W_ULN:B#-PV.ROT@#G?QIF\P$&\@P:T#PAX"3`8EF0^]
M@<<`0.B(X(>8WYL@@.1!/#8"A+<SOZ!^;%&3[H**C-3!T;>&;:I!N%S4Q'JH
M=M:&5N3@A@PG*Y^K+VRN):I0HQ[!A7C0SC71O[HOF(OKLE5.AK,YNHYC:#=D
MA0<N>F(QI6&X?`%(3=B'F3M+0=K0(1H6MP$&+:H#NZDO)%7IF+)%\,K6U@7#
M8"E1W;D)B%P`EVQT#+%-""7>6%D@<'K`Z>1E$F)'3K>'CXC.?02!+-0$D4CF
MQ'JZGX.4909@0?D.KYYRR?%3"&GE:SFIXX#2L%,'4W*Q`X[A78"5,BXIFZN'
MD6C0$`2//7_P=:)7+&<JD:*@JEPKI'(<,S#K=(`CE&BS3NA83!$'$W$4<0,*
M)O.L0TRL!AW(N!!,P.M$X!42)]>"3*!DN":D@RS]M2%OAS:+6N7"9MY)#PG%
M?L>S3S'B^B($16JKNDN*,L!PI0TW1W]&Z2,9'RN-:V3<(T&"S_7IG]YGQR&B
ML$<''WU1P_57CH!C%D6XM&81X.@FN0@V.-\_EE`OX,BIZN4;$97CB(%9IP,<
MH<2)=4.S,-RNMS%[W*1,Q]Y_\^&69.7II(?@I;\L:,*]7RS4XW8=A5;>T$*G
M;DD#GO5P`;5W*`]P@J*K($UPLLH:_KA$2QSB[F@=SE#5!H3!<3AJVZR#0(CP
M`=>97`"=^#D!X910.15T'D1*FW1`PQ/&!\EWOJX?J&:[FJ=--$^9>+:BH&G]
M("M6@H(F=A@2\*I,8_*H>G]F/X]4/"CC">[@-IM#3EH&'VU_^OAQD+YQO$P2
M[1?V1K^`^Y^<5J*],D8K9IX6&D?%.L@"I45"(NF2HXJ)NPHI9AK_X",P/861
M%\S25D"+FMBQH[;996JLV39_(BG^;1]XN*`4$7/!V"?V%(0*JX<`7[^(B9U1
MXIE;)-V%`*Y-*`%;3>@UT+C6#@>R6OS$UE)YIHK/P0&I)5!SXS3<$'B#'HVS
M`1W@G-P(ZZ&"-[S:!MQB.KV("A^4'^@\`JFWC-5L7'#)V#Q%&=@30\!-5MC$
MED0;VZO`&88&1W_[>@)S"WW[S2`)*F?`M5?'T*B84@`H^^CS>#(!M]<:;=!I
MQ!\G@S+N'$)!)4*7=[,'F)T#H4H^;_C39!`EGC1HY"UW-%^[-<"&GBO("^!#
M[9.'Z_0-?Y0G1,9?GQ\XX_%;)M^W3+YOF7S?,OF^9?)]R^1[`#`$,<KNT#-*
MMN@+$F7R4%#5L!!1C8^-/@((U"H!2&Z;N6"$DB:VPWF+PRK;WCU*G^E_:J-[
M!\`4=+N37T*Z\3"C0`6!F]>!#E]P>9)+*'!B"&HZH<X0*@DV71).I-F3N`P9
M@%%@M/!E3:QCJNR[I@[^7*2&Z*!$^'UWU+WWW65\J,P!@X,C:&(;TAWCY4,5
M^1#%;4S(33$*%Y)(X?&IX*PXC5JE`A8]2Z$BVRTPBL@<'<4"[8(,8\6B)M:Y
M,$/GRZ+OO"=Q?Y>#^[4!D-;7T7"AK'FBLJ4-"I&\&AHM.1,;E[(<]=3C[-&$
M2QHJ8U*D!*X\T1MZ`&AWPQ`IK=/8T;$3CB2%U(E%FGL44YFKSRA!:1!3FV?1
MFCV00-V1XV?$!Y@>4SVT`3(Y#3DCR^'8@XJ?V(B9A>VO.&8&WU`_)2O\&*,B
M0?;->A/@E#7`#@1U6*IJ@+$X#3\#J^'@@PFW&(T[DKJCN+M/HWR>;L-\F]+V
M5GBE`S`%53-S'8_*:1C!;(,C1RC/_Y.6;:,54S;%5,UQ5"BLT1N+MP5-[+KY
M?(-8AYRL]DD_NM%#3%%'#AZ%HU-XM360V3M7RL2>O_A"$M(VLWX`BK_H`Z:O
M_`R@=Q1#NI9"$`60Z<R5DX$N.P6OQ>7VW>DZ_N!%15;?0!&2C08B.$P(V,PV
ME)0E%'=+A)*=65<2W6$J-?\IH7I]W@9LBP7U+BS):-K8Z-)X!0RI@>:HZ(H=
M8$GH4PF)!*W8A9&QH\SG`">L>YXGERC%S\7:PTW"AO=%H_B"\D6*\EY>.EVV
M>EX.9O,#?(9N,,`CO"1GND%!U+IX"I(5U9U=E2H\,%_63RYTYUQJRGKZ):/T
M`TIP8PW0(Q4^2*X<MZ+:-4D17B5E2OWP]8%:FE%74`OK=G2.EI2FGW#3@+.J
M%BU./S!I[@P#C&H5-K%KONS%ZJS(956ZYX:.-J@'NU-(%5GC77`^F1^P`YII
M@#&QY(G=U*T-XV_J";[NX-/YZ@MJ9$89@:4C<(![MFYUD\5B?M\7O.T1,55S
M>X1'Y0=Z8$8:H$@HV/=+M4+KH>N>T/5.7R`$-=0`1!+1`]Z?M5M5AT_WKD)J
MSAJ'Y?-ZZDD?GUX\]>O2^P$?7<.'F09VBS#9E7&K4]MO.;&#YV5>V"WU2K4G
M19)J'E'2T=D$RG[$"4EQ_EKW^,6QB*:4,OOLCRA_(M%^#-F%[@@E[X9L1RS9
MT5VG\;P/V;\ZJG83>W]RYY,JI)VC!"U[+U`HJ%HMA4/E-*I55L$1R)$TP-37
MK1[@"\J%IS6XW^H1:/N;HXB060#:26_S#Y@\ZB#CQTO\C".41-D\V64!G*<1
M3H+TM4PGTZEA.$/E-`B#HUC0MA4"$(C0`1)$#14S!+BY0Q%":Y8^H9T\,MN9
MU\$-G&%WGT+-X"ANM&V%X`8B=(#9ZH%QLU.V8X0HR@C(NK&E1^8H,H!V:<61
MGBC1P9J)##EFSP&.63MX((W<9]5#)N=!AD/9H`3.S1NV0+@=A9Z=%[2'/I`2
M!$`U.@+FPDRJ?DRNSE!;F,ENO^%XF_=2;`*IJPI04CL*.STK(3!32JQQY.U5
MPI\16RY$T>P9I<$*?=FN'U$Z7_;2._*"G1%OY7U-7D<19^,!"/XTY0N"G+=7
M#,L0OW.-X#B^@JJU7,2A&@U:*KV),`T=#T`"::V,<Y44=0+!T=*M<E[G?<N]
M^I9[]2WWZEON55&=ON5>?<N]^I9[M9DAO]N#[M^V;Z$"0+G/CR^F'!\GW*$Y
MW#I8$BN)--_3%/72W1>O\/8,5K\'J\/=?QH6QCT^W#3MU!O&:Y;BP_#^(LB>
MKF/R-7L;R;^-Y)T8R3LR;'L;NA]SZ.Y(I;^-U2W&ZKX/SNF8D?6&BY2P#=7H
M_/6G#$4WR2[)RBS,\3/.,<IXYPI%Z4@&%;K?BAQ$Z/C(Y,X.#N(SX,;E(`7[
M/N?P_63?P`#2.@TX3-F<$X2^@VH6_6M;'9U^('<H)$F(8]0R\H$`72<(MH<L
MHJKLPQ0QH99RA#HX5(,[C.J^#XMF89@BYBO^O4/1Y[J]]#Z/AO6#(I,H/=%&
M[2&4*3#<4\+W?J.;3&"V)FF.?ZLNUBU2M,;;=>_4@0:/()V#@&>R\#7QV7$P
M#=3,]T"[SSVU2'&([G#V[WT2*LZK66#Z7E8P(?UDP:WKJ^,`&Z"5R:5"M\YL
M7R*J=H@+5])_QT7OQ!+Q-UIQ!]DZ+/4-`!#+9/%MX+'C0!RFF.]Y@-H]4B?7
M?W<%!49<CY\5Q)-%M):7CC2V5JAD<ZG3!13O'Z68+V])LKJEO5!4&O=7%$?7
M)/VIG^-*AZ<>:<-X)@MM$Y\=::0-T\SWG$KJ'(@_)2D*8OQ;[[*."2LX<V63
M=;+HM_#@<1J!GH)CWJT=ZB&\D*P27/9JEY4!_%>^(:2[:]LRTLFB6\-#QT&S
M7*%1[P0+KH87%T3GQ1&Y11S4"YG]HQA2JMUY#`'59`$(\\MQL"?4Q>J&[T'2
MI=]DV39(0C1?EK?GZ12U3MU-^X-[E#[C$&7S]"(.<.]8D!ES/1K69)XL<JV\
M>*3QL::*WM]`WJ]0LC?%V6([2W^8O[+FG+/$:,53KL*%:0A3;W5:SC19^!MY
M[=CKU'+5C.XTNS48?GLX]1A0MWUT]6!`UWFP]<S;-\_J=!FHN+U"QV2\31@Y
M43V^%A!-%KH@KQQI="U0I8:GM\]TU$_%T2%5ZPG<#D!59)TG^?IDDP4IT#/'
M@:E8F1JH'N=`;6\)M5\V+%(192'9]E-8Z[)Q-P-E;).%MJ'GQM@@E"E70]_?
MO<(D3!'M>RY1^7?#-Q?!!N=!+$X(I,FXSQ$$9IPL_(V]=ZR3>G#UZB9@](:&
MFTU@D2(Z2XCJ5?;Z:8@D*EZGX1X&L1,B;!HP(6-FU]*%,1?\!K[J)>8"*L*'
M-TP!DR/8;HUS^I;/PK(OH\,[=BFT-GGGOEL</.*XB!!*R!O($B)?2Y;W#<#<
M<\.V`RT]QCNH+=C\:6SQ%V.U>IU3^H*2'E/E=2C39`<P1EX[SN`%JEH=S4<X
M_O3V^-?1`6OW7MBAL'J@)\9<&E[K/OK>VWS4>BL>SC99I!MZ[MA;D"KE*MQK
M;<ZX-=BVN]'<:0_#"!LD\<BD[KD/ZM<#II"P4M*F#W'A(0:!_>6%TH%3^A@*
ME;<L;:%^I?2Q\YE%2A_M@GV_7%SOPCV06?CK%J?H?)M1/V59<<]TOF1.JKYT
MKSR8L';V7F&LKO4.IN@D5CX#]06:JC7W86$J^;]DV;.W=6IMED2BXXOZC"*T
M2QBGC'6HOXZ&=(E")G'=,9RG)$0H*IXJYAS/E`%=G[-&N@[GE*!N[+&#85U'
M(]^7A'H-^_Z)I/D#2M?BU^*U>$2!G,\S)6`;>.EHX9NOB__K//VV"\&S%I,P
M7D\?T29^.EZ4EF+:VY.[=AX;=)UET/652;6,0?UZJ!9CJZ1-1B&'5RYW9TJ'
M7+DT%"IO6=I"_5JYM/.9Q<JE=L&^#_KOT*8:$)8Y:5BG69U)NF6'C^:/,5YQ
M.Q`#SEWR"@U.U[H&4V@2&X^!^@%-S<KT%1H:36#1LC%0W%\V7]2F%+?.Z9R^
M_`'1C\4ODBF"OA#.E$%'R(1:PR!^/%3#,%7.^XTLKMT79+TF";PQ<.BEN&_1
M3Q[B8N\<%\TM/7P?Q[36`/:)<;*K%Y2&..MONT+I>6L\?/J)`A?BG6,`5Z"'
MR4*E4\#=#<`N,7-7$F6Z`Q)S"9T5>2T)4X*[M0</U@!,-/,_JWES7O*%Y*B^
M^2*9@O+(.//--MF$,`STQ3%FDNWB3=8*W4)CLQ>2H%%%QAE)3!:-0%\<8]S`
M1:.WF0&:EMV2H+<J)_S.05_U?:*PXUE_#+Q5Y8Z7Q5MPC:W6L9SXX3QG#8(I
M6S00-BU$43'.9HF/GDA,U1>!RT1$!W]Z(B8(40L?'AK%>JJ9I.AV*:(6[94.
MHXL%[^P.A0@_,\/O4,P&'XL@+7T7QRCD[8,8\U>U:<`_H>9@Z[U#M04#O4;-
M]CU,6VB>4F<MO?AW5J0W[Z`>0%E?;Y913@C)<(\<"K-2#49,"GZ`O(6;;1H^
ML0W*)3N`F[\*EL2DM+P,AGW:"2%4QRN'7M`2Z&"4TMNM&&KGJT'/%`UZEFA2
M36%0OQZJK=@J:90PW*5C>E?+)1U=T>CP$A89.>YH^YXG13>71.PO%C:>@Y@%
M%$!C&DI<5>WVXAP]E#>PGR#'\>R+]'T?4-#8S?L(\P[!*[":6V]Q3%0*0:/[
M!2Z$6WYSFU$/I.DKM96E0^IN>FCQ-&>$:AY'`6=B,01J0+D61^\I5#&):.EI
M/EFH_?+-?Q[8>C8/#S>3_;(2;E?)Z#.R^^UF$Q<>"&)F[W5,OMXD2Y*NRPKF
M7^?0Y*J?[(!R.0HX,ZLA@`-+=F[GC&E;K@"CZ+)X76%10/N:I`+L:'`TPI22
M8SS,:**"F+B@`R)8D74H4Q9E<GO!I?E!ZPQO0E5"65X;+3N4+2#EG<?ND8Z&
M-QWP=,]9RPUN@PQ03N_\=$_^M)#%\D@^!"]W:+E-(MGI$A$I%UE=4C^1)35X
M`&1UY7M_FV2_V`_(DMK?NX&D5NUMXDB9?.I!C1QAW(E"2_,=DW7\7@0X^H+Z
M[^=PO^[>0^A\'0U.FM@@*LO:L(%)+]\JZ$@=KS,4O7<>/J%HRY*"?"'%@G(C
M$;TH!&GQU!,_&(]'B#'Q@BF.@&4Y][9%XXA%5NYB%\G`%M7&=O3PE)+MZJEY
MI[KW6IV%B/KE.B,1X_6%6L`B@[BHTR]"-"C>G#,JV;D@N+_T.4\CG`3I:W&&
M,RMV,I+R!-O/.'^ZQ6'QPM(J18B7'LM:3MV1FLOQ![5#.<L0NA;%.Q=F1;;,
MF2W/M$C,WN@X3W&THET,.[L)!*Y:@`*Q,@'^0Q7LGH$Q*BMWO)OJ2G#NKF;6
MUES$099=\&RZ1^$V96]+LY]RW#QH/TNB61BF6[;17(ZNA6`^=($]\!^N0!\;
MRY'<;]VX#J?G>*=NM$<ZMQAMRSSLYR39PD<V`C[E2*;'YR/"]9PQ^$BE5YSW
M*3Q)$E)KYBF[0%+]IS''*)YU;+SF.*.>6:/HK'OBRTY*??K+5(H_0![&48:P
M-B[<)KNF"R#?[?^739<M.@M7V@"D]0*;E'3\XQ0R"TB#[D%Y#UXFLE@LZXAJ
M+3>4COC^M.>'6_I#^8W[J>4C])*C)-IOGK:\1/O9.`A1_"$DZQ)UES@+8Y+1
M@<.7(*=_TD"^/]">1.=!AK-B%+(K\=U8V)RGJR#!OQ5*T$%.1F(<E3`I$JGL
M%)POJV/V0;QSMPC$@\JL$#&0S-%B@)7^>SP]4"2>Q_V<1X<2/X3WN>)'BT_#
M@I,<W/7M4#B(]BQF#J_UH(N\8\7K^^UZ3<?;=-Z'5PE>XI"]:E*^-LZ.+%`O
MA>Q1\;&B2%\500A6$^ZV2L2$XPV89,X7A4`]IGH0!60:[QE>=4420]O;D45<
M4#'$`A8PB2!P'>"T..[](PK8_\M=@+$:PTZ;O8*B5@\AK2I?3CI:R^>I)6KP
M(%J)N2XT;U"-$3U;V^U:5@)KV0K)DVC0=$"S"7!T];)A.WML"E8L-EQL4U8O
MLRQ#1NU;F%A*79KHK)\!Z^Y\J0[KD&FTU.6*6K`1KX:]+K1PHRHE=K[IG#K2
MT*`\@ZM5\B0B1+61TUQ^;)O=^#+:2*!*VKC;>`IBR9EA%>7^H+"8<K1A0#7&
MK--4BFNG\=.^,JLJ$T6=PPAOSZ<&$S[F^4@EA,B!G=D[/2G2J#R:-JPFDXAK
M10;L<W8R[X*L63P?=[5YKUB14W&G4)5%[H)D>5;L=3XRE>OCLH(@-XRP"FJV
MPD8+E6#%SYN*BV+C0-)TG2J2-EKT&PA;9&B/MB.BG98L:%IK-XDH6:9W+9V3
M1&4RDQ5*1EWJE>C4&+8*KEN;\-87K_5XQ\N8`=%3%.;,F'4\Y$(0,X,!L71/
MY]ZGC@[%Y77-LB<1@(IA6I5!NDK].-YAE:XJ[+"C\+@*A'AW8$5./.+Y')YB
MZBBBS2=UA%NQ`UBSQ-P+W3,^LO+*4S[@<CR."8VS3DX%!=YAK>Z9-=Y)KN['
M\0_AW7;3_'3-Z!%T36D0C'_,KNUT`K!#<+BN$-0Z3M<0X/\M]S!EEQ$O4?GW
M3=)O77<DCJ])^C5(NPED#+EWM^0UN<<'51\ZQ-8+D)18VB7XGFJF.M=?O"32
M#4><3W4@:GT:#2VF>"!2X]HXT2RC"%\MV1:!RZ'TD$"<]!(?3@LIBKR.@V'%
MY/;6`,D=12D5HG]MLW)"_$!F451<E@ABEF'D)JDNVM?IHG\.TC1(\D6*63[T
M[KZ7M:!ZC\M"D(\8',QQUGBUT<3W%ZT+YY1-M9E`K#B[]`5]+;[TQ_0:/,W9
MN9K'1R";N,,^QL(*]3U?O<#,LH?1Q*>`20[0'M.X:T=@F(EQ*7<#9_U(5:8$
MCKVRG,M9([/P,@V^7I*OR>ZE0A25;;&\O(&N@Y"=>.@^"S6D2$#TA(N<6G`U
M=.9!8R]<I_$NF>LUA;(-#]L6S&1"(K4'K6%02*OB_"!M9`B-E;V$=LOQHQ.I
M)@S9U0M*0YSU5QI,>`'=`H=W:O%?Y9Z#!GI.X>-E5#")Z(;`5#!#8K1+T#3#
MERKJZB%32P=E'!4#TX^`N4CQ<Y"C!=O"96LR&O%2Q`H(EWW6J45+A7,.&BS[
M95N\^#-"K#3#I)P7$BD=0J41M%1Q4@N3.AHHHZ00D?[N>DK<LS]LW+JP`(^L
M<@&`^"H2,+4H"W+406.M2(/Q'KPZPE*P#<`A$B#!VCF(6^!4%;@-8*ZOC3*(
M*Z`^R5#>3*/:R)]:9%0M+]+"HSI8%B#``V1-+=;KNN^@81^@3-4L/DVL692Q
M8*!VH2D,TB^XW#*&@;>JM[!K*%8Z*OL0>+OQMCL!G6\IX@WK1DE2G)-O^.(2
M/?8RH0TH4N?\DU*DCWW,`9QYG#-12IUV+<>/99YF+."`WHA7MX<8&<:#8E&G
M7U"">`C-M'J#4J-M1C4AF[(PSY;2[Q`S!C72@6M,#L3,@-D`C]G'T&SEH(..
M]WFEU^!T'IUE8S.%IXH;$G*=`J@ARE3A51.@>EHH0ZD,H,[@$]*IL*=IZOQ'
M/P><E]#MA&@,?WE"?(RJ@SCL*$-<GA8UB-UYN*XP=99$]=:_H!'SHBN<JQE5
M(5P^`M/,)</T\Y!B:^BY\RR=6O6R-]#&7IL-#+Z:;=R^7`-"(-1QG<'IO=7E
MPN!6E_>?L/)5>8%[#=287Z-3[_#[&#9MW724KKRC0`UM=QX5E(V_RY^IQ?<H
M?<:AUBZ?D!<PC^?P^@A0&_<<=!;/*;P&IB<70PR1J6"&3.%=PJ89P%03>#UH
M:NF@G+Y+D.D,,"%AG^6Z8\FNMD$L?'#>6HY&=R^0XV-4'<IM1^G^!8K4F/;D
MT@8$S>8"@'M53N'7'H2`72I-"!OK!-F?DJ'8UWF:]&P@^S8O-N",+M%)^2$G
ME_G\/@9L6S<=]MPR7X$:VB/<%#G&N65S<`,$@$XM.P9O<XPJSRQK(UQ;%_6)
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M"LV3FX2J0FDV0?):'!*L[5RP)DIAD><I?MSF[.#@`UD4]:L]5!FT5/#(9:!2
MQWR@"XQ[T.#E$-70;FH`E6'CEX%4]7T]2N2HRCWEL[3AZT-*'4)]R_R01,7_
MXA*AN[6"X9KU0<M6-.X#E>U[$S]&E0S:T`^DL._O$(G<Q:9PPS5@36F*)@F6
MYGLC,W/;H,T&K()-NGS"KHNXL-?8&J"7"Q7=H3QOAU&#3?CBHHC-Q^F3H5.&
MV2,'E<N_FOQ->7#4S?UN.!S-)("2*KH&4FVD*=,JZ@,5JH,ZL:(66,_&QFKU
M8%XG<4`V>\'"ERQEM-U'+?FTXS]%*'[?$F!=%SG"IR[YLMRH^HYNEV0=X.Y"
MN)2F<H:`9OPJEE8D@1DGJ&F>:%;Q`I%N5'A[3_5'M'Y$::>^92251_@DH]6V
MO!()R*1V)7,ELLKE2_)]I8B]-4$2,22$W_>[!]WO[H)!90P0"1PQOJ\@",X#
M<2$!HMT='9/2N@L5'2.!L%&(]/TEQ5D8;M?;F&V;BM8A^'#2Y:NA!>=S&&:&
MQD,A!Q?O^TN)]6F`YAF`?7[D1?!:G'SD(M"$M3[EI\7J+@XM7`"$HEX)XST.
M-PP:[U!.[4;159`F.%GQ<2<GJMPK(G(72R"S@*@1R1KOJ:F#'>P1#;]!_8&7
MG=_`G9VZ<_/X#E6U\C!?]A<J!2?!M'BZZW9RGO$7=T`V$>&"GW1U1R:[M;Q7
MR>0L[WQ_VO/,+?VA_,;]U/(:>LE1$NTO9[7\%KZ&[-&>^`,%>`G12YR%,<FV
M*;K'JP0O<1@D>7U3-GLWW,ULCO1]V2(8:C'5.`0R#7CK7%KB`ZV1\[A_%423
M"V1=@VN\=J97:<34$YT6""JU:(+0TG:/_@QS,'VL=GT19$^S)&)_L7CT',1L
ML&S0L@<:O7#5$9U(!A'7XQ@%\7@#-JYBZ@BAS2=UA%M1`EBSQ-P+G5,PTO**
M(2"\G(E$AD5*-BC-7Q<QC874=&;VIGC0;[Q])H%&@O@`IM_M0"GI1]QC$^BF
M#A0FK"J/N!4NX!5-K-S1#AK*4LN]/9W2)A(Z[A!UP#;,BR,LHX6+EA;4]7>H
M6*Z>A3E^+N\=\L.&-M]N/0W,-^+JH4)'=3BQ$0'UE%OA11\09!`WM<,-6(MR
M==.D](F$GZOU)B:O")VC!"UQSD+OB#.:QJY$41$Y3E&[`Y!<N-3D;*S9@CG'
M&]*P]=1"P6('<4&H1CM-J[H#Q"-;,?50QUC,J-<(=`%"!G-8_QX!4)=B6&2L
MPT1BU$/P@L8+2N4>!M5!&80`E!4>I)2C!1F.5J)``B$5V^I"0(!4%M$RM'?G
M0B2?-6JYW(DTW,^(K-)@\X3#FV1)TG69$F*T[3NT8A'S#FW8Y2LZU!-LE2C(
MZNT#(=EX^Y,=E0`[)W`.@=EN-6IEW1$3FSO[(X(RBAT1B.R)-.Y[%*.0SI/^
MO@U2JE7\ZD(;WRESC9,@"7$0-[12=N"&W!5,M+E'"Q12346Q0H\)XA,7(H9I
ME1-#A[1CB6;I+,1`2YU*E-D^9NC7+15\]3SJ;FM7$='H04%6=Z-"LO%&#QV5
MA&,&%9W`1!=:N[)V"-R^SJA`(+D8%8@E'JV55E_8'RRS+/WE_P%02P,$%```
M``@`9("O0+BK'MC5"@``M5X``!$`'`!C>6-C+3(P,3(P,S,Q+GAS9%54"0`#
M?+:R3WRVLD]U>`L``00E#@``!#D!``#M7-USVD@2?[^J^Q]T?KE<U6&,O<EM
M7$FVL!".Z@"Q""?9I]0@-3"[8D1F1K;9O_YZ1@@$^K#`R1ZXR$.LC^[6=/^Z
M9[I'+=[]\C@+C'O@@H;L_5GC_.+,`.:%/F63]V>1J!'A47KVRX>__^W=/VHU
MP^1`)/C&:&%T@7,:!(89\GG(B40!1JV6$-X"`YZ0MJ/?J12183.)3Y)D`L:7
MSX3YQLU%X\V;K]V+QI+S4?C7PIO"C!B2\`G('IF!F!,/WI]-I9Q?U^O>P@OP
M/#CWPEG]\J)Q>7%UU3@SB)2<CB()[9#/6C`F42!1`?8M(@$=4_!1KP!FP.0&
M0>HV&H*):QS!ZE$/#P_G#U?G(9_@@RX:]2_=CJL'EQ#C6+RG!A93!I3]L2'W
M<<2#1/)57=T>$0$).8=Q(?6;.MY-""OIQ*)9OC1?\KI<S*&.%,"IMV((606>
MD-6V^!21+U=\Z5&_KL<W$U)TK0DA\Q7MF(B1IEW>4!9LU"X:M;4-&4R40Q4:
MYFV=AP&.*R9;C2DHL?N7#AI^#3U]&OH:9>C`S(.TSK3D$=OT%1PU)O2!;EI2
M@'<^">_K>"/'.H\9%UN.O_'V[=NZOGN&(688.L@(8Z'4,:NO)5?G<\K&X?(2
M7E1<UXES#F!L:#G7"O_W9X+.YH'22U^;:I]5$5%+G/_KG,,YCBXA4?"46$JC
MARP"'5H/K;-^<"*"<"\C):,G"@GGP"4%D8JL^G=3RR/!KFHABQ<%!ZV5#^-=
MM4(6RN@A*Q60T:Y*(0L$/U8?)6>(&ACJX&Y@YZ\A>C2MT(O4#-]DOL4DE0L;
M`Y3/M">=&11GPU**U8.31Z\A^W"!_XR:D?"G#]7:'`LS4M+>U;=%;$N/!/@.
M^Z"/MR-YR;TD*>/<"I;JC)O^F,^WO)I`L#\R-R10\[H[!9`Q$AM7RBW?4)9W
MT3BP-+WI]%I6S[5:ZLAU.G:K.<23FV:GV3,MP_UH64/W!$`1`'W"4=4I2(IC
MSZ*Q>?L):%[O`XWQ:N,9_SI!E89J94YG;&-U,8,8HNSE<F@N*T:-.\0_7:N'
ML#AMP^E;@^;01H(3*`6@F.$,M9T"$_0>"A#*HRF'ZVHON$RGVQ]8'Y'._F09
M'<<]P;8!FTG$M!V$#R)&:'U:#L9/NX*AL6BZ'XUVQ_E\PF`S*Z/""T(1<>@1
MB?\[8V<.\1Z(P#SLA@@JG'$_985EKK8[7QFJC3B/6$O%DUYS>#>P-N<]H]E3
MZY5KZP##Z'(17WWK!&L^K&XTFQ&^<,8NG3`LRSV"";;GA1$FQ6S2#P/J88J_
M#6I%KG)(+S.0NG?=;G/PF\+.M6][=MLVFQB?3=-T[GI#NW=K]#%\3=LZ16D!
MG&U"^2<21-`%HL[5%)A!+Y^H'*RK#%CMICTP/C4[=Y;1M9HNQJ)>V4[(Y".#
M<]V<4-]ZG&-B`6H2=#"'YF;$53;=%`*R0%7B*<?MIPQN."OVFW;+L+[TU:H8
MSYG.\*,U,,R[P4`MB$W7/15AA4CB1,<C\#N4C&A`U0[(%C"I.]N([L1;CNSK
M#+(X3P[N,+/IV,T;NV,/[5QP4W=/"!<LBC+T_L`<!7Q5"V#LY68V!53EJ+W)
M+GI#Q_RO2EIT@MI507G*6$K`06//J-1K%L:.&>J4`UA>FE)&6@[3?S(P(31=
M>Q@7;RJHL)90&8G5.Z4C3P32-`Q\X,+Z%E&YR`VB38IR9'[.#Z"/3J=E#=Q_
M&M:O=_;PMQ,@!1L@18B4DY1!\G.\N[Y5<1=M>N2!9;QJ69CJV\/39F)UV$Q4
MX;("=C%=.8!YF_3[`6B8S8YI7)YP+)@/U^6R6HTX\;))?RY-.7XYE?1:B+&2
M<D*E(*,@8JKR`_RC8N:>!'E5<P%5.3+9LEGQZ]>.^B`EZ81.4>&L7S0O^@&)
MW_VBR>9JGLI6RT6$Y1CEE,A+2?\VM*SX+7$B[813/DX#$))'GHPX)MG;V&S>
M+,<C6]AN<)_LGV]_:S8/P@7`#3`<@%2>FYG#<FG*T<@6K(D08RE%!\EI^BJ`
M94@>LX5I?+'<\-D25'.=[)QOYUL()YS,I]3+-@X]052.0[;@7$LY-0U5R'DA
M`$^"_VM$N`0>Y#1V5:,MA^EM-@=>"C-6TM)P&:\B1B*?(L&I["Q\.3@2\"U"
M9:W[O)0X<[\4HL9%%J*5`".6\(*1>%??[CQ>7MGL4-;]R70V#[DT6.:C@-+N
M\?B#@D[H:6F;/=6YC'4(I$BNU-:BSG$,23-G^7@J=,P7C*J0LQ<SUE2C>ZUQ
M66N\V7,X.9WR5<82<+[!M==`2OO8RW#:YE$'ST=FJT&_BADTBSI;?0B@#'&E
M#)$SC.7G&7H<Y9VZS9'0NQ'Q7**:F+]6(X\[H?57"-=X#2L!6\),!1@JA/,(
M,D:*XY:'T3PAQ.E]=F:0I9#W9UA&(#FC04!&JL4Y/H]IL>2CH3_4C_$COER@
M"I7L<Q@#Y^#K/;<.Q?K0USSQ#4"+Z9?L*46KLZ25G84,).&+/=0=DT`4ZCN*
M^T9Q;#@B*O/,$$,ORZQ`%NKLCOG`;W&=16K84#G__E^JGP^C?/4JH&Q."9N`
MS10NFM89?R9<J2%26I92';.NEA>R<$:]`9U,G])XF_99>O]`-5OTGOK`?.&P
M54`ZW*<,Q^=."8>TGE6(CP;@`?B`$S\*WYR)Q$K+E.95B(]&\]68MW3)0SI#
M<C1:JBWE`7A`[\%OZ<VROA;0#GG.LEN)^M!67?5QHA\%X(Q[(5,:#'&6%?@4
MJCI+LTI6I#\T-9L>Y@9"UQD"9]9D[[D?<6^J.DZ&4QS(9&J2.94DZ`!>2_OR
M?NQ'X^>V$)&2XHPWIV*;F2%CH,']3.6T0SW5.-><<$AW0FH3/4/&@21GSS"4
MHY1<?@SOC&\X]2?H\IV0L`H6*F,^1M-DUG4S($*8><JZX$5<]7NI2Y+BT)3:
MO5#J/KYE<Y_^^!^$S#7ECWO8,9I^._0Z%")GK*;IFY!%U<(UPW,\AM`)AC/7
M%2#*2_I\T\M7$<41SM5Q.H6NFY1&F&BXP.]Q@A4.QSB@LWS$JS$>C47Z//0`
ML*(8Q_V)DJ1#6ZD-?IN',^W@RUZ>C4V$?=B/R#I/][SGY'F[L1U:NE=E]$-X
ME#<!1L*.6J?X8K7C'SVYELGU[^T&NZ:Z_N^1B)MTAV'3]W762H(^ZH6Y6)RA
M6N,Q9F2K394^I]ZJR2!.>)\AY,C6BSC"TP6;WC-L<?+0"A_8:EH`/VX`;.-J
MB8]N$T]]5[#87ER>+>[HS1<G$M_/?KO*VYB,XJ3F_QN197Z1+,'6(W"/"O52
MI9(_Y?"]$,?9PR*%C$?E"CB!WA,)??7Z>-V/]Z0G9-E>B"/L;H\BOH-S@RK+
MJTI!19\LU,,^$[6IN./ZG"?@R%PC5:,4>/^V4U3A>$E&R+Q@J<YR<%%1-LLM
MZ[!UH5IQ=LSA.S+XBP#<PR*%C`?G"E7FM^0[C(@$N3O2SY#Q0ESD*0OMPWQP
MKA)7Z-G?&+IC'$A`_]2N#G3"K$=/OV1WF-[D19HY80N]2O8`Z]@A>>R'7#?)
M+']J4XUM&,:_SY4RVU_VQ)?CAJM-^!:,*B=R6;Z#<[ZRI6<`:O20>G=8<<W*
M8_R1S1\_#OE]3%#,^0STO\^B-%/!^N>R/:>5[FHH^'&#>!W:B>U0NWSR/J-,
M_0Y'3J=`189#VSLN'W?>KG%ECH/<+TXU<)BAD,)A+E']'86M:E49#L"3XX[P
MN#T73_\'4$L!`AX#%`````@`9("O0)ENX-]:@@``RVX&`!$`&````````0``
M`*2!`````&-Y8V,M,C`Q,C`S,S$N>&UL550%``-\MK)/=7@+``$$)0X```0Y
M`0``4$L!`AX#%`````@`9("O0$`5\7$-#P``F<\``!4`&````````0```*2!
MI8(``&-Y8V,M,C`Q,C`S,S%?8V%L+GAM;%54!0`#?+:R3W5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`&2`KT`\IM@X.1P``!.]`0`5`!@```````$```"D
M@0&2``!C>6-C+3(P,3(P,S,Q7V1E9BYX;6Q55`4``WRVLD]U>`L``00E#@``
M!#D!``!02P$"'@,4````"`!D@*]`W042>NAC``"HN@4`%0`8```````!````
MI(&)K@``8WEC8RTR,#$R,#,S,5]L86(N>&UL550%``-\MK)/=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`9("O0$](8AG<)@``)G@"`!4`&````````0``
M`*2!P!(!`&-Y8V,M,C`Q,C`S,S%?<')E+GAM;%54!0`#?+:R3W5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`&2`KT"XJQ[8U0H``+5>```1`!@```````$`
M``"D@>LY`0!C>6-C+3(P,3(P,S,Q+GAS9%54!0`#?+:R3W5X"P`!!"4.```$
:.0$``%!+!08`````!@`&`!H"```+10$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NATURE OF OPERATIONS AND BASIS OF PRESENTATION<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS AND BASIS OF PRESENTATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.&#160;&#160;&#160;&#160; NATURE OF OPERATIONS AND BASIS OF PRESENTATION</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Nature of Operations</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cyclacel Pharmaceuticals,&#160;Inc. (&#8216;&#8216;Cyclacel&#8217;&#8217; or the &#8216;&#8216;Company&#8217;&#8217;) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel&#8217;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cyclacel&#8217;s clinical development priorities are focused on sapacitabine, an orally available, cell cycle modulating nucleoside analogue.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Sapacitabine is being evaluated in the SEAMLESS Phase 3 trial being conducted under a Special Protocol Assessment agreement with the US Food and Drug Administration (&#8220;FDA&#8221;) for the front-line treatment of acute myeloid leukemia in the elderly and in Phase 2 studies for myelodysplastic syndromes, non-small cell lung cancer (&#8220;NSCLC&#8221;) and chronic lymphocytic leukemia.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">We have ongoing clinical programs in development awaiting further data. Once data becomes available and is reviewed, we will determine the feasibility of pursuing further development and/or partnering these assets, including sapacitabine in combination with seliciclib, our second clinical candidate,&#160; and seliciclib in NSCLC and nasopharyngeal cancer (&#8220;NPC&#8221;). In addition, we market directly in the United States Xclair&#174; Cream for radiation dermatitis and Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia. However, these activities generate a small amount of revenues.&#160; As a development stage enterprise, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. We currently anticipate that our cash and cash equivalents of approximately $23.6 million at March&#160;31, 2012 are sufficient to meet our anticipated short-term working capital needs and to fund our on-going sapacitabine clinical trials for at least the next twelve months. However, we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Basis of Presentation</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The condensed consolidated balance sheet as of March&#160;31, 2012, the condensed consolidated statements of operations, comprehensive loss, and cash flows for the three months ended March&#160;31, 2012 and 2011 and the period from August&#160;13, 1996 (inception) to March&#160;31, 2012, and all related disclosures contained in the accompanying notes are unaudited. The condensed consolidated balance sheet as of December&#160;31, 2011 is derived from the audited consolidated financial statements included in the 2011 Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The condensed consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the rules&#160;and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the condensed consolidated balance sheet as of March&#160;31, 2012, and the results of operations, comprehensive loss and cash flows for the three months ended March&#160;31, 2012 and 2011, have been made. The interim results for the three months ended March&#160;31, 2012 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2012 or for any other year. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December&#160;31, 2011, included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the SEC.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Recent Developments</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><u><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Sale of Common Stock and Economic Rights</font></u></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On March&#160;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses involving specified Cyclacel intellectual property and for general corporate purposes.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&#8217;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&#8217;s common stock for the period ending on Wednesday, March&#160;21, 2012. The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional shares or warrants. These collective contractual rights are referred to as &#8220;Economic Rights&#8221;.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">See &#8220;<i>Note 3, Fair Value Measurements&#8221;</i> for further details.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><u><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Preferred Stock Dividend</font></u></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On March&#160;6, 2012, the Company&#8217;s Board of Directors decided not to declare a quarterly cash dividend on the Company&#8217;s 6% Convertible Exchangeable Preferred Stock (&#8220;Preferred Stock&#8221;) with respect to the first quarter of 2012 that would have otherwise been payable on May&#160;1, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Subsequent Developments</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><u><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">NASDAQ Appeal</font></u></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Previously, the Company received a determination letter from NASDAQ, notifying the Company that it had not regained compliance with the minimum closing bid price requirements set forth in Listing Rule&#160;5450(a)(1)&#160;(the &#8220;Rule&#8221;) during the 180 calendar days allowed to regain compliance and that the Company&#8217;s common stock was subject to delisting from the NASDAQ Global Market.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On April&#160;26, 2012, the Company presented its plan to regain compliance with the Rule, which plan included the possibility of effectuating a reverse stock split,&#160;before a NASDAQ Listing Qualifications Panel (the &#8220;Panel&#8221;). On May 15, 2012, the Panel approved the Company&#8217;s plan to regain compliance, and determined to continue the Company&#8217;s listing pursuant to an exception to the Rule&#160;for a maximum of 180 calendar days from the date of the NASDAQ Staff&#8217;s notification, or through September&#160;11, 2012, provided that the Company has evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days prior to such date.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">If the Company is unable to provide evidence of compliance with the Rule, the Company may still transfer its listing to the NASDAQ Capital Market if it meets the initial listing criteria set forth in NASDAQ Marketplace Rule&#160;5505, except for the bid price requirement. In that case, it may have until September&#160;11, 2012 to comply with the minimum bid price requirement. The Company currently meets these initial listing criteria, except for the bid price requirement.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">1,213,142<span></span></td>
        <td class="nump">1,213,142<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">1,213,142<span></span></td>
        <td class="nump">1,213,142<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference value (in dollars)</a></td>
        <td class="nump">$ 13,890,476<span></span></td>
        <td class="nump">$ 13,708,505<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">58,993,414<span></span></td>
        <td class="nump">54,220,458<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">58,993,414<span></span></td>
        <td class="nump">54,220,458<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 15, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Cyclacel Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001130166<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">59,003,301<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EI6AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">188 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration and research and development revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
        <td class="nump">161<span></span></td>
        <td class="nump">192<span></span></td>
        <td class="nump">3,182<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,648<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump">161<span></span></td>
        <td class="nump">192<span></span></td>
        <td class="nump">9,930<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump">94<span></span></td>
        <td class="nump">106<span></span></td>
        <td class="nump">1,846<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">1,347<span></span></td>
        <td class="nump">3,080<span></span></td>
        <td class="nump">187,146<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">1,996<span></span></td>
        <td class="nump">1,806<span></span></td>
        <td class="nump">91,483<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,934<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Restructuring costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,634<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
        <td class="nump">3,437<span></span></td>
        <td class="nump">4,992<span></span></td>
        <td class="nump">291,043<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(3,276)<span></span></td>
        <td class="num">(4,800)<span></span></td>
        <td class="num">(281,113)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with aborted 2004 IPO</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,550)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PaymentUnderGuarantee', window );">Payment under guarantee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,652)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ChangeInValuationOfEconomicRights', window );">Change in valuation of Economic Rights</a></td>
        <td class="num">(56)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(56)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in valuation of other liabilities measured at fair value</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">78<span></span></td>
        <td class="nump">6,413<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (losses)/gains</a></td>
        <td class="nump">114<span></span></td>
        <td class="num">(68)<span></span></td>
        <td class="num">(4,259)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">6<span></span></td>
        <td class="nump">11<span></span></td>
        <td class="nump">13,731<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,677)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="nump">47<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">153<span></span></td>
        <td class="nump">21<span></span></td>
        <td class="nump">5,997<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes</a></td>
        <td class="num">(3,123)<span></span></td>
        <td class="num">(4,779)<span></span></td>
        <td class="num">(275,116)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="nump">168<span></span></td>
        <td class="nump">191<span></span></td>
        <td class="nump">18,612<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(2,955)<span></span></td>
        <td class="num">(4,588)<span></span></td>
        <td class="num">(256,504)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DividendsOnPreferredOrdinaryShares', window );">Dividends on preferred ordinary shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(38,123)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_RedeemablePreferredStocksDividends', window );">Deemed dividend on convertible exchangeable preferred shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,515)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DividendsPreferredStocks', window );">Dividend on convertible exchangeable preferred shares</a></td>
        <td class="num">(182)<span></span></td>
        <td class="num">(182)<span></span></td>
        <td class="num">(3,839)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
        <td class="num">$ (3,137)<span></span></td>
        <td class="num">$ (4,770)<span></span></td>
        <td class="num">$ (301,981)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - Basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.10)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
        <td class="nump">54,761,620<span></span></td>
        <td class="nump">46,572,180<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ChangeInValuationOfEconomicRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the change in the valuation of economic rights during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_ChangeInValuationOfEconomicRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DividendsOnPreferredOrdinaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Dividends on preferred ordinary shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DividendsOnPreferredOrdinaryShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DividendsPreferredStocks">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of dividends declared in the period to preferred shareholders even if not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_DividendsPreferredStocks</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PaymentUnderGuarantee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow form a repayment of an unsecured loan facility agreement with the Scottish Enterprise having terms of repayment due if the Company significantly reduced its Scottish research operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PaymentUnderGuarantee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_RedeemablePreferredStocksDividends">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of dividends deemed declared in the period to preferred shareholders as a result of the preferred shares being converted into common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_RedeemablePreferredStocksDividends</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Chapter 4<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings in the period, comprised of costs associated with restructuring activities not otherwise specified in the taxonomy pursuant to a duly authorized plan, excluding a discontinued operation as defined by generally accepted accounting principles. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, but excludes costs associated with the retirement of a long-lived asset and severance costs associated with established compensation plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherRestructuringCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for loan and debt issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Paragraph 5A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK BASED COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6.&#160;&#160;&#160;&#160; STOCK BASED COMPENSATION</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March&#160;31, 2011 and 2012 as shown in the following table:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.75in; WIDTH: 80%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="80%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 33.12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="33%" colspan="3">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">For&#160;the&#160;three&#160;months<br />
ended&#160;March&#160;31,</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2011</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 33.12%; PADDING-TOP: 0in" valign="bottom" width="33%" colspan="3">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">($000s)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Research and development </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">50</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 15.02%; PADDING-TOP: 0in" valign="bottom" width="15%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">General and administrative </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">201</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="15%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">85</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 62.48%; PADDING-TOP: 0in" valign="bottom" width="62%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Stock-based compensation costs before income taxes </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="15%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">251</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 3.12%; PADDING-TOP: 0in" valign="bottom" width="3%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 15.02%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="15%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">102</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.26%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">At the Company&#8217;s annual shareholder meeting on May&#160;14, 2008, the stockholders approved and amended the number of shares reserved under the 2006 Plan to 5,200,000 shares of the Company&#8217;s common stock, up from 3,000,000 shares. The awards granted under the 2006 Plan have a maximum maturity of 10&#160;years and generally vest over a four-year period from the date of grant.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">A summary of activity for the options under the Company&#8217;s 2006 Plan for the three months ended March&#160;31, 2012 is as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Options</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Weighted<br />
Average<br />
Exercise&#160;Price</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
&#160;Term&#160;(years)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Aggregate<br />
Intrinsic<br />
Value</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">(in&#160;$000s)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Options outstanding at December&#160;31, 2011</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,515,741</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.73</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">140</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Granted </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Exercised </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">77,062</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Expired </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Cancelled / forfeited </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Options outstanding at March&#160;31, 2012 </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,438,679</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.80</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6.18</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">233</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Unvested at March&#160;31, 2012</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">556,177</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.72</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8.59</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 41%; PADDING-TOP: 0in" valign="bottom" width="41%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Vested and exercisable at March&#160;31, 2012 </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,882,502</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4.20</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">5.71</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">232</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding), vest ratably over four years, with 1/4 of the award vesting one year from the date of grant and 1/48 of the award vesting each month thereafter.&#160; However, certain awards made to executive officers vest over three to five years, depending on the terms of their employment with the Company. In addition, recent awards made to rank-in-file employees vest ratably over three to four years, with 1/36 to 1/48 of the award vesting each month.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company estimates grant date fair value for stock option awards using an option-pricing model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. This analysis is evaluated quarterly and the forfeiture rate adjusted as necessary.&#160; Ultimately, the actual expense recognized over the requisite service period is based on only those shares that vest.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company estimates the expected term of stock option awards using past history of early exercise behavior and expectations about future behavior. Starting with the December&#160;2010 annual grants to the Company&#8217;s employees, the Company relied exclusively on its historical volatility as an input to the option pricing model as the Company&#8217;s management believes that this rate will be representative of future volatility over the expected term of the options.&#160; Prior to December&#160;2010, because the Company had been publicly traded for a limited period, the expected volatility assumption was based on the historical volatility of peer companies over the expected term of the option awards.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Estimates of pre-vesting option forfeitures are based on the Company&#8217;s experience. For outstanding options, the Company uses a forfeiture rate of 0 &#8212; 50% depending on when and to whom the options are granted. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and may impact the amount of compensation expense to be recognized in future periods.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">There were no options granted during either of the three month periods ending March&#160;31, 2011 and 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">During the three months ended March&#160;31, 2011, 5,131 stock options were exercised resulting in approximately $2,000 of cash proceeds to the Company.&#160; During the three months ended March&#160;31, 2012, there were 77,062 stock options exercised totaling approximately $34,000 in proceeds. As the Company presently has tax loss carry forwards from prior periods and expects to incur tax losses during the year ended December&#160;31, 2012, the Company is not able to benefit from the deduction for exercised stock options in the current reporting period.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Restricted Stock</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In November&#160;2008, the Company issued 50,000 shares of restricted common stock to an employee subject to certain forfeiture provisions. Specifically, one quarter of the award vests one year from the date of grant and 1/48 of the award effectively vests each month thereafter.&#160; This restricted stock grant was accounted for at fair value at the date of grant and an expense is recognized during the vesting term. Summarized information for the restricted stock grant for the three months ended March&#160;31, 2012 is as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="86%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="bottom" width="56%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Restricted&#160;Stock</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Weighted&#160;Average&#160;Grant<br />
Date&#160;Value&#160;Per&#160;Share</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Non-vested at December&#160;31, 2011</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">11,450</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="21%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Vested</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(3,126</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 56.16%; PADDING-TOP: 0in" valign="top" width="56%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Non-vested at March&#160;31, 2012</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.84%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8,324</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Restricted Stock Units</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In November&#160;2008 and December&#160;2011, respectively, the Company issued 91,700 and 238,000 restricted stock units to senior executives.&#160; Each unit entitles the holder to receive a share of the Company&#8217;s common stock.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">During the first quarter of 2012, the Company issued approximately 86,000 restricted stock units to employees as part of its annual grant.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The 2008 grants vest over four years and the 2011 and 2012 grants vest over three years.&#160; A restricted stock unit grant is accounted for at fair value at the date of grant which is equivalent to the market price of a share of the Company&#8217;s common stock, and an expense is recognized over the vesting term. Summarized information for restricted stock grants for the three months ended March&#160;31, 2012 is as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 86.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="86%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="bottom" width="51%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Restricted&#160;Stock&#160;Units</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 23.08%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="23%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Weighted&#160;Average&#160;Grant<br />
Date&#160;Value&#160;Per&#160;Share</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Non-vested at December&#160;31, 2011</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="18%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">255,175</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 21.58%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="21%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.80</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Granted</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 18.46%; PADDING-TOP: 0in" valign="bottom" width="18%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">85,974</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.55</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Vested</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="18%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(4,689</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0.375pt; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">)</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 51.54%; PADDING-TOP: 0in" valign="top" width="51%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Non-vested at March&#160;31, 2011</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 18.46%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="18%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">336,460</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.88%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.5%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 21.58%; PADDING-TOP: 0in" valign="bottom" width="21%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.74</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.16%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">5.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Accrued and other current liabilities consisted of the following:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.2in; WIDTH: 94.66%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="94%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">December&#160;31,<br />
2011</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,<br />
2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 28%; PADDING-TOP: 0in" valign="bottom" width="28%" colspan="3">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">($000s)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Accrued research and development</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.68%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,471</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12.68%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,334</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other current liabilities </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,193</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,170</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 68.3%; PADDING-TOP: 0in" valign="bottom" width="68%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,664</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.64%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.68%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,504</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.06%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">COMMITMENTS AND CONTINGENCIES</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Licensing Agreements</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of product employing the technology or falling under claims of patent applications.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine, its lead drug candidate, the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee and certain past reimbursements have been paid and, as a result of the SEAMLESS trial entering Phase 3 during the first quarter of 2011, a milestone payment of $1.6 million was paid in April&#160;2011. A further $10.0 million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones and the Company&#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six months&#8217; notice, or upon twelve months&#8217; notice after a launch of a sapacitabine-based product.&#160; The license also may be terminated by either party for material default. Effective July&#160;11, 2011, the license agreement was amended to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September&#160;2011, and releases the Company from all claims and liability of any kind arising under such provision. The amendment further provides that the royalty rate due from the Company to Daiichi Sankyo on future net sales of sapacitabine be increased between 1.25% and 1.50% depending on the level of net sales of sapacitabine realized.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In connection with the asset acquisition of ALIGN on October&#160;5, 2007, the Company acquired distribution rights for the exclusive rights to sell and distribute three products in the United States. Each of the agreements covering the three products expires in June&#160;2015, after which the Company has no rights to distribute these products. The Company has a minimum purchase obligation equivalent to the value of product purchased in the previous year.&#160; For the year ended December&#160;31, 2012 this equates to $0.2 million.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Legal proceedings</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On April&#160;27, 2010, the Company was served with a complaint filed by Celgene Corporation in the United States District Court for the District of Delaware seeking a declaratory judgment that four of the Company&#8217;s own patents (claiming the use of romidepsin injection in T-cell lymphomas) are invalid and not infringed by Celgene&#8217;s products, but directly involve the use and administration of Celgene&#8217;s ISTODAX&#174; (romidepsin for injection) product. On June&#160;17, 2010, the Company filed its answer and counterclaims to the declaratory judgment complaint. The Company has filed counterclaims charging Celgene with infringement of each of its four patents and seeking damages for Celgene&#8217;s infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene&#8217;s ISTODAX&#174; (romidepsin for injection) product.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">A Scheduling Order was entered February&#160;2, 2012, at which time the court set the following significant dates: March&#160;22, 2012 (amendment of pleadings/joinder of parties); September&#160;24, 2012 (teleconference with the court exploring possibility of Alternative Dispute Resolution); March&#160;14, 2013 (claim construction hearing); August&#160;14, 2013 (summary judgment briefing); and June&#160;2, 2014 (7 day jury trial start date). Discovery is currently ongoing.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8.&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Preferred stock</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">As of March&#160;31, 2012, there were 1,213,142 shares of Preferred Stock issued and outstanding at an issue price of $10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August&#160;and November, commencing February&#160;1, 2005. Any dividends must be declared by the Company&#8217;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of $10 per share, plus accrued and unpaid dividends.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s shares of common stock at a conversion rate of approximately 0.42553 shares of common stock for each share of Preferred Stock based on a price of $23.50. The Company has reserved 516,228 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at March&#160;31, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">During 2010, 833,671 shares of Preferred Stock were converted into 1,655,599 shares of the Company&#8217;s common stock. Since inception through March&#160;31, 2012, holders have voluntarily converted 1,776,858 shares of Preferred Stock into common stock. The converted shares of Preferred Stock have been retired and canceled and shall upon cancellation be restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#8217;s common stock has exceeded $35.25, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&#160;24, 2011.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">From November&#160;6, 2007, the Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption prices per share stated below, plus an amount equal to accrued and unpaid dividends up to the date of redemption:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 20pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.1in; WIDTH: 90.68%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Year from November&#160;1, 2011 to October&#160;31, 2012</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10.18</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Year from November&#160;1, 2012 to October&#160;31, 2013</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10.12</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Year from November&#160;1, 2013 to October&#160;31, 2014</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10.06</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 82.92%; PADDING-TOP: 0in" valign="bottom" width="82%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">November&#160;1, 2014 and thereafter</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.74%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.44%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 11.8%; PADDING-TOP: 0in" valign="bottom" width="11%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10.00</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s 6% Convertible Subordinated Debentures (&#8220;Debentures&#8221;) at the rate of $10 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have terms substantially similar to those of the Preferred Stock.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On March&#160;6, 2012, the Company&#8217;s Board of Directors decided not to declare a quarterly cash dividend on the Company&#8217;s 6% Convertible Exchangeable Preferred Stock (&#8220;Preferred Stock&#8221;) with respect to the first quarter of 2012 that would have otherwise been payable on May&#160;1, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><b><i><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Common Stock</font></i></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">March&#160;2012 Sale of Common Stock and Economic Rights</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On March&#160;22, 2012, the Company entered into a purchase agreement with certain existing institutional stockholders, raising approximately $2.9 million of proceeds, net of certain fees and expenses. The proceeds from the financing will be used to fund ongoing litigation-related expenses on certain intellectual property and for general corporate purposes.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&#8217;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&#8217;s common stock for the period ending on Wednesday, March&#160;21, 2012. In addition to the common stock, investors received contractual rights to receive cash equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap.&#160; In certain defined situations, the Company may have to issue either additional shares or warrants.&#160; The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">See <i>Note 3, Fair Value Measurements</i> for further details.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Common Stock Warrants</font></i></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The following table summarizes information about warrants outstanding at March&#160;31, 2012:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 54.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Issued&#160;in&#160;Connection&#160;With&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Expiration</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1">Date</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Common&#160;Shares</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1">Issuable</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Weighted</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1">Average</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1"><br /></font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt" size="1">Exercise</font></b></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Price</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 54.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="54%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">April&#160;2006 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2,571,429</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7.00</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">February&#160;2007 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2014</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,062,412</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8.44</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">December&#160;2007 CEFF</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">100,000</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.40</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">July&#160;2009 Series&#160;II stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2014</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">692,256</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.00</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">January&#160;2010 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">712,500</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.26</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">January&#160;2010 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">705,000</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2.85</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">October&#160;2010 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 13%; PADDING-TOP: 0in" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4,161,595</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.92</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">July&#160;2011 stock issuance</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3,808,823</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.36</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 10.7%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="10%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 54.5%; PADDING-TOP: 0in" valign="bottom" width="54%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">13,814,015</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.3%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 10.7%; PADDING-TOP: 0in" valign="bottom" width="10%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.28</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">There were no exercises of warrants during the three months ended March&#160;31, 2011 and 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">188 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (2,947)<span></span></td>
        <td class="num">$ (4,611)<span></span></td>
        <td class="nump">$ 256,439<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.25in; TEXT-INDENT: -0.25in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8.5pt" size="1">&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">PREPAID EXPENSES AND OTHER CURRENT ASSETS</font></b></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.25in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Prepaid expenses and other current assets consist of the following:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">December&#160;31,<br />
2011</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">March&#160;31,<br />
2012</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 26.5%; PADDING-TOP: 0in" valign="bottom" width="26%" colspan="3">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">($000s)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Research and development tax credit receivable </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">541</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">734</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Prepayments </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">321</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">278</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Accounts receivable </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">116</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">152</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Deposits </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">13</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 12%; PADDING-TOP: 0in" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">153</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Other current assets </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">209</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">106</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 70%; PADDING-TOP: 0in" valign="bottom" width="70%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total prepaid expenses and other current assets </font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,200</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.5%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1,423</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represent as Prepaid Expenses and Other Current Assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cycc_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>125</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheet</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/BalanceSheetParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementOfIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/StatementOfComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0040 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/CashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1010 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>NATURE OF OPERATIONS AND BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1030 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1040 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1050 - Disclosure - ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureAccruedLiabilitiesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1060 - Disclosure - STOCK BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1070 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1080 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 0030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 0040 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>cycc-20120331.xml</File>
    <File>cycc-20120331.xsd</File>
    <File>cycc-20120331_cal.xml</File>
    <File>cycc-20120331_def.xml</File>
    <File>cycc-20120331_lab.xml</File>
    <File>cycc-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
